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ABSTRACT 
It has long been recognized that Ca2+ acts as a second messenger to regulate diverse crucial 
cellular processes in response to external stimuli. The discovery of the parathyroid Ca2+-sensing 
receptor (CaSR) has established a new paradigm of Ca2+ signaling as a first messenger. The 
CaSR regulates the calcium homeostasis in the human body via sensing fluctuations in the 
extracellular Ca2+ concentration. Naturally occurring mutations in the CaSR could result in 
abnormal receptor responses toward [Ca2+]o which causes inherited Ca2+ regulation disorders.  L-
amino acids have been found to stereoselectively interact with the CaSR thus coupling protein 
digestion to receptor activity. In the present study, we use several complementary approaches 
including  imaging [Ca2+]i  response in living cells at the cellular level, measuring metal binding 
affinity, making site-direct mutagenesis, examining conformational changes of purified 
extracellular domains with various  spectroscopic methods,  and using molecular dynamic (MD) 
simulations at the atomic level to provide important insights into the behavior of the receptor in 
both normal and disease statuses. We demonstrated that the molecular connectivity between 
[Ca2+]o–binding sites is responsible for the functional positive homotropic cooperativity in the 
CaSR’s response to [Ca2+]o. Naturally occurring disease mutations near Site 1 disrupted the 
cooperativity. We further identified an L-Phe-binding pocket adjacent to Ca2+-binding Site 1. 
This L-Phe-binding pocket is essential for functional positive heterotropic cooperativity by virtue 
of its having a global impact on all five of the predicted Ca2+-binding sites in the ECD with 
regards to [Ca2+]o-evoked [Ca2+]i signaling. Furthermore, the CaSR’s ECD has been expressed 
using both bacteria without glycosylation and mammalian systems with either complex glycans, 
or high mannose, were characterized using the fluorescence titration spectroscopy, circular 
dichroism technique as well as the NMR spectroscopy to show calcium and Phe directly bind to 
the ECD domain directly and interactively. Moreover, we also demonstrated that intracellular 
trafficking of the CaSR is a complex process, which involves modulation by calmodulin and can 
possibly be affected by different CaSR isoforms when expressing in various cell lines. The 
studies on the isolated proteins will pave the way for future protein crystallization and related 
structural research.  
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CHAPTER 1. INTRODUCTION 
1.1 The role of Ca2+ in mammalian cells 
Before Sydney Ringer serendipitously discovered calcium (Ca2+) to be essential for the 
contraction of isolated hearts in 1883(1), Ca2+  had received little attention for years except the 
recognition that it was an important element for the formation of bone and teeth. After the mid-
20th century, research on Ca2+ has grown at an exponential rate and Ca2+ became a universal 
carrier for biological information(2). Ca2+ controls the matter of life and death as it modulates the 
process of fertilization as well as apoptosis. 
1.1.1 General principles of calcium signaling 
Three major properties of Ca2+ are particularly drawing scientists’ attention: the first is that Ca2+ 
can both play a role as a first and as a second messenger; secondly, Ca2+ can autoregulate itself 
through various signals; finally, its ambivalent nature in which it can control a number of 
essential normal functions of cells and meanwhile could also be a messenger of death(2).  
After thousands of years of evolution, eukaryotic cells managed to maintain a free Ca2+ 
concentration at the level of 10-7 M in the cytoplasm through various ways while they are 
surrounded by an environment containing more than 1 mM free Ca2+ concentration. The low 
level of cytosolic Ca2+ concentration is necessary in order to prevent the precipitation of Ca2+-
phosphate salts and prevent the extra energy that would have to be invested to change it. Those 
various ways are including binding to membrane (acidic) phospholipids, interaction with low 
molecular weight metabolites, formation of new compounds with inorganic ions, and binding to 
specific proteins.  
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The proteins that can interact with Ca2+, and thus regulate the intracellular calcium concentration, 
can be categorized into two major classes: The first class belongs to intrinsic membrane proteins 
which transport Ca2+ across the membrane to maintain cellular Ca2+ homeostasis. The other class 
is soluble proteins. The minority of the latter is Ca2+ buffers, which mainly operate to lower the 
intracellular calcium concentration. The majority of the aforementioned soluble proteins are 
defined as calcium sensors as they have specific functional properties besides their Ca2+ binding 
capability. These types of proteins include: the annexins, gelsolin, C-2 domain proteins as well 
as EF-hand proteins.  
1.1.2 Calcium as a first and a second messenger in cells 
Before the discovery of the calcium sensing receptor, Ca2+ was mainly considered as a crucial 
second messenger that rapidly yet efficiently regulated the intracellular calcium level and 
modulated  extensive molecular signaling components through calcium channels, exchangers as 
well as pumps (3).  
When Ca2+ acts as a second messenger, the Ca2+ signaling network can be summarized as four 
components: A stimulus that induces various signals to mobilize Ca2+, The ON mechanisms that 
introduce Ca2+ into the cytosol, Ca2+ functions as a message transducer and lastly, the OFF 
mechanisms to remove Ca2+ via pumps or exchangers (4). When Ca2+ plays a role as first 
messenger, it is also the stimulus in the first component.   
The Ca2+-mobilizing second messengers are generated when certain stimuli interact with cell 
surface receptors. Inositol-1,4,5-trisphosphate (Ins(1,4,5)P3) (5) is one of them that can bind to 
inositol-1,4,5-trisphosphate receptor (InsP3Rs) and release Ca2+ from the ER. Sphingosine 1-
phosphate (S1P) is another messenger that releases Ca2+ from the ER by engaging a sphingolipid 
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Ca2+ release-mediating protein of the ER (SCaMPER)(6). Cyclic ADP ribose (cADPR) (7) is a 
calcium dependent activator for ryanodine receptors (RYRs).  
While the InsP3Rs and RYRs are related with Ca2+ derived from internal stores, there are other 
mechanisms contributing to the ON mechanisms via controlling the entry of external Ca2+. The 
best-known mechanism is voltage-operated channels (VOCs). When a receptor binds to external 
stimuli such as glutamate, ATP or acetylcholine, the receptor-operated channels (ROCs) will be 
operated. The depletion of internal calcium stores can trigger the store-operated channels (SOCs) 
(8). 
The Ca2+ signal induced by the ON mechanism can then be transferred to cellular responses. 
Those responses recruit numerous Ca2+ binding proteins as Ca2+ buffers and sensors. Troponin C 
(TnC) and calmodulin (CaM) are two calcium sensors that have been extensively studied (4). 
The OFF mechanisms will be initiated when Ca2+ needs to be removed from the system. There 
are various ways the extra Ca2+ can be sequestered. The plasma membrane Ca2+-ATPase (PMCA) 
pumps and Na+/Ca2+ exchangers can transfer intracellular Ca2+ to the extracellular space, the 
sarco-endoplasmic reticulum ATPase (SERCA) pumps, on the other hand, pump Ca2+ back to 
the internal stores (9,10).   
How Ca2+ performs as a first messenger will be elucidated in the following introduction to the 
calcium sensing receptor.  
1.1.3 Endoplasmic reticulum dynamics and calcium signaling 
A number of cellular functions such as synthesis of protein and lipid, protein folding and post-
translational modification as well as maintaining the Ca2+ concentration constant take place in 
the endoplasmic reticulum (ER) (11). The calcium dynamics in the ER influence many cellular 
pathways and ER functions, from gene regulation to cellular level responses, which include: cell 
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differentiation and proliferation, apoptosis, from embryo development to the tissue level such as 
muscle contraction and relaxation; even learning and memory, membrane excitability and energy 
metabolism (12). 
 
As mentioned in 1.1.2, the InsP3R and RyR (13,14) control the extruding of calcium from ER 
while SERCA replenishes the calcium store. Besides these “in” and “out” regulations, the Ca2+ 
buffering system in the ER and resident chaperons control the free Ca2+ concentration in the 
range of 50-500 M (15-17) although the total [Ca2+]ER is in the mM range. A number of ER-
located chaperones have been identified that buffer Ca2+ including calreticulin, glucose-regulated 
protein 94 (Grp94), immunoglobulin binding protein (Grp78) (11), the family of PDI-like ER 
resident proteins (18), calsequestrin (19), and reticulocalbins (11). Some of these chaperones 
have weak affinity but high capacity, PDI-like proteins, while some of them have high affinity 
but low capacity, such as Grp94. Proteins with very high affinity (Kd=1M), for example 
reticulocalbins, are considered to play a role in maintaining certain structures or participating in 
specific protein-protein interactions.  
 
In addition to proteins locally regulating the [Ca2+]ER within the calcium store organelle, ER also 
communicates with the plasma membrane for Ca2+ signaling regulation through the machinery 
named as store-operated Ca2+ channel (SOC) (20). In many cell types, the inwardly rectifying 
current is called ICRAC characterizing as highly Ca2+ selective, non-voltage gated current (20). 
The identification stromal-interacting molecule (STIM1) connects the ER, cytoplasm, and the 
Orai1 protein resident in the lumen of ER which provides reasonable explanation for the 
mechanism of SOC (21-23). 
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Normally, the [Ca2+]ER is controlled at 50-400 M, which is suitable for protein and lipid 
synthesis as well as protein posttranslational modification (11). Severe consequences will occur 
if the [Ca2+]ER is sustained and prolonged at a low level (below 20 M ) such as disrupted protein 
synthesis, accumulation of unfolded proteins, even cell apoptosis (11). On the other hand, the 
overload of [Ca2+]ER stress also has negative impacts on ER function and cellular signaling 
leading to congenital problems (11).  
 
1.1.4 Spatiotemporal aspects of Ca2+ signaling 
Although Ca2+ is considered as a universal signal for the regulation of cells, it could be toxic to 
cells if it stays at an excessively high concentration. A pulsatile manner of Ca2+ signals has 
evolved to prevent such toxicity.  
Two major mechanisms are involved in the production of the temporal Ca2+ signals that would 
further lead to more complex downstream signaling. The first one happens in skeletal and 
cardiac cells when the Ca2+ signal pulses are produced on demand as the cells respond to 
periodic stimulation that leads to membrane depolarization. This kind of signal can be observed 
in muscle cells when they contract and also in nerve terminals when neurotransmitters are 
released upon a brief localized pulse of Ca2+ (Calcium: A Matter of Life or Death p496). The 
second type appears as an oscillation when the cells receive a continuous stimulation over a 
period of time. The rhythmical Ca2+ signal has a wide range of frequencies that are tightly related 
to a variety of cellular responses. The details of which will be discussed in the next paragraph.  
The types of oscillations can be categorized by the oscillatory activity: membrane oscillators and 
cytosolic oscillators.  The membrane oscillators are usually the results of K+ outward currents 
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inducing depolarization and the PMCA (plasma membrane Ca2+ ATPase) activity. The action 
potentials that are set up by membrane oscillators provide rhythmical pacemaker activity that 
would be responsible for processes such as cardiac contraction, neuronal activity, secretion, etc. 
(24,25). The other type, the cytosolic oscillators, cause the periodic release of internal Ca2+ and 
their mechanism depends on various intracellular stores. For agonist triggered cytosolic Ca2+ 
oscillation, the InP3/Ca2+ signaling pathway, which requires the participation of endoplasmic 
reticulum, plays a crucial role in activating the oscillation. This second type of regulation has 
drawn more attention to researchers since the oscillation frequencies have a large range that 
varies with the type of stimulation and encode specific information regulating diverse cellular 
processes. Various hormones and transmitters can induce repetitive cytosolic Ca2+ spikes in 
hepatocytes in the range of 1-10 min (26-28) and this physiological process is modulated by 
phorbol esters (29), protein kinase inhibitors (30), extracellular Ca2+ (27,28,31), Na+, and K+ 
(27,31). Ca2+ oscillations are also responsible for initiating embryonic development in both 
mammalian and ascidian oocytes (32-34).  In 2001, Pasti et al. demonstrated that [Ca2+]i 
oscillations could cause a pulsatile release of glutamate and the calcium signal could be mediated 
by activation of AMPA/mGluRs (35). Airway epithelial cells utilize the Ca2+ oscillations to 
control ciliary beat frequency as a response to ATP (36). Figure 1.1 shows a summary of the 
cytosolic oscillation frequencies and their related biological functions.               
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Figure 1.1 Biological Processes Regulated By [Ca2+]i oscillations. 
The cytosolic oscillators would cause the periodic release of internal Ca2+ (termed [Ca2+]i 
oscillation) and their mechanisms depend on various intracellular stores. The oscillation 
frequencies have a large range varying with the type of stimulation and encoding specific 
information to diverse cellular processes from fast reactions, such as hypertropy, to slow 
physiological responses like Interleukin production (37).  
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1.2 The structure and function of Calcium sensing receptor (CaSR)  
1.2.1 The discovery of CaSR 
It has been well known that the serum Ca2+ concentration can regulate the secretion of 
parathyroid hormone (PTH). In 1993, Dr. Edward M. Brown cloned the receptor that is primarily 
responsible for this type of regulation from bovine parathyroid gland (38). The receptor was 
given the name “calcium sensing receptor” (CaSR/CaR). The previously observed cytosolic 
calcium changes in parathyroid cells, as well as in other in vitro expression systems, was 
triggered by serum calcium concentration change and is greatly attributed to the function of 
CaSR (39,40). A unique characteristic of CaSR is the high cooperativity of Ca2+ dependent 
activation, which tightly controls the secretion of parathyroid hormone when the receptor is 
exposed to serum Ca2+ concentrations within its responsive range (38). The CaSRs expressed in 
various species are highly conserved (Appendix D), indicating the biological importance of this 
receptor in regulating physiological functions among living organisms.  
 
1.2.2 Biological roles of CaSR 
The major function of the CaSR is to maintain calcium homeostasis through balancing the 
ingestion and absorption of calcium from the gastrointestinal tract, excretion of calcium by the 
urinary system and the breakdown and formation of bone (41,42) (Figure 1.2). The CaSR is 
mainly expressed in the parathyroid and thyroid glands, as well as in other tissues mentioned 
above. The CaSR regulates PTH secretion from parathyroid glands and calcitonin secretion from 
thyroidal C-cells upon detecting variations in the calcium concentration in the extracellular fluid 
(41). 
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Fgirue 1.2 Systematic regulation of Ca2+ homeostasis in human body. 
 
Two major circulating hormones (PTH and CT) regulate Ca2+ homeostasis via several 
primary organs. If the Ca2+ level is too low, PTH is released from parathyroid gland. It 
then stimulates Ca2+ uptake from intestines, increases the rate of Ca2+ release from bone 
and the rate of Ca2+ reabsorption in urinary system. If the Ca2+ level is too high, the 
opposite regulation will occur to control the blood Ca2+ level. Thus, the blood Ca2+ is 
strictly maintained between 1.1-1.4 mM. 
 
Moreover, CaSR has its specific role in different tissues. As mentioned in the last section, the 
CaSR was first discovered in parathyroid cells. The main function of the receptor is to mediate 
the negative feedback of PTH secretion upon the stimulation of various agonists (38). Most of 
the CaSR expressed in parathyroid cells is located in caveolae, where a significant number of 
signaling molecules, as well as scaffolding proteins, reside (43). Similarly, one of the critical 
Homeostatsis:
Blood Ca2+ level (10mg/100mL)
Ca2+ reabsorption
from urine
Ca2+ deposition 
in bone
Ca2+ uptake in 
intestines
Ca2+ uptake in 
intestines
Ca2+ reabsorption
from urine
Ca2+ deposition 
in bone
C cell in 
thyroid glands
Calcitonin
secretion
PT glands
PTH Release
Ca2+ level too high
Ca2+ level too low Ca2+ level rise
Ca2+ level decrease
10 
 
roles the CaSR expressed in the kidney plays is maintaining calcium homeostasis (44). However, 
the CaSR present at different parts of the nephron (e.g. the proximal tubule, thick ascending limb, 
etc.) may have specific functions (45,46). 
 
The CaSR is also found in the gastrointestinal tract, including the esophagus, stomach, small 
intestine, and colon (47,48). The activity of CaSR has been reported to be associated with 
increased phosphorylation of ERK, intracellular calcium mobilization, secretion of IL-8, gastric 
acid (49-51) and cell proliferation and differentiation (52,53).  
 
The CaSR has been identified in bone, demonstrated by various techniques (54). Both 
osteoblastic cell line MC3t3-E1 and osteoclasts are reported to express the CaSR. The receptor is 
involved in osteoblasts proliferation likely via JNK signaling (55,56) and participates in both 
differentiation and apotosis of osteoclasts through the PLC pathway (57). The CaSR stimulation 
is also believed to be inhibiting bone resorbing activity of osteoclasts (58).        
 
Experiments using immunocytochemistry showed that the CaSR is widely distributed in the 
central nervous system with quite a diverse pattern (59). In the neuron system, the CaSR is also 
forming heterodimers with other family C GPCRs (60,61).  It has been proposed that the CaSR 
may play a crucial role in regulating currents which mediates the bursting of action potentials 
and the following depolarization (62). The CaSR in the hippocampus has been reported to 
regulate both Ca2+-permeable, nonselective cation channels as well as Ca2+-activated K+ 
channels (59,63,64).   
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The CaSR is also detected in cardiac tissue by various techniques including RT-PCR, 
immunohistochemistry, etc. (65). A few pathological processes have been found to be associated 
with an increased expression level of the CaSR, for instance the angiotensin II induced cardiac 
hypertrophy (66), hypoxic-reoxygenation treated cardia myocytes, etc. (67).  
1.2.3 The structure of the Calcium Sensing Receptor (CaSR) 
The CaSR comprises four major parts in terms of its structure: a large N-terminal extracellular 
domain (ECD), a cysteine-rich domain, a seven transmembrane domain and the intracellular C-
terminal (Figure 1.2). The major function of the CaSR is regulating the calcium concentration in 
the human blood.  
 
Figure 1.3 The modeled structure of Ca2+-sensing receptor. 
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The modeled CaSR extracellular domain (ECD) is based on mGluR1 (pdb: 1EWT). A 
number of agonist and antagonists interact with the large ECD that forms a Venus Fly 
Trap (VFT) structure. The seven transmembrane domain is linked with the ECD via a Cys-
rich domain.  The C-terminal domain is involved in the interaction with intracellular target 
proteins (68). 
 
Members in the family C GPCR proteins possess signature large N-terminal ECDs. The low but 
significant amino acid sequence similarity between the GPCR family C and a group of bacterial 
periplasmic amino acid-binding proteins suggest evolutionary relevance. Indeed, the crystal 
structure of the ECD of rat metabotropic glutamate receptor (mGluR1) showed a bi-lobed 
Venus-flytrap-like structure (VFT) which is fully consistent with the structure of the bacterial 
periplasmic amino acid-binding proteins, switching between “open” and “closed” conformational 
status upon releasing or binding their endogenous agonists(69). The alignment of the amino acid 
sequence of the CaSR ECD (AA36-AA513) with mGluRs and the bacterial periplasmic amino 
acid-binding proteins results in a proposed VFT model of CaSR ECD with the N-terminal lobe I 
connecting with C-terminal lobe II(70). However, the alignment also shows four segments in 
lobe I that do not align with the bacterial periplasmic amino acid-binding protein resulting in 
four unstructured loops (I~IV) (71). Only a large part of loop III (from residues 365-385) could 
be deleted without reducing the activity of CaSR while truncation in the other four loops resulted 
in a low surface expression of the receptor (71).  
The VFT structure of mGluR1 forms a homodimers as verified by 3D structure of rat mGluR1 
VFT. The intermolecular disulfide requires a conserved cysteine in loop 2, and the equivalent 
residues in the CaSR are C129 and C131 (70,72). Experiments carrying out mutagenesis of the 
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two cysteines suggested that disruption resulted in failure to form disulfide bonds, but did not 
affect the formation of dimer (73). Other cysteines in the ECD of CaSR including C60–C101, 
C358–C395 and C437–C449 form three intramolecular disulfides,  which are critical for CaSR 
expression and activity(74). 
 
All members of the GPCR family C have a conserved nine-cysteine structure at the end of the C-
terminal domain of the ECD and before the seven transmembrane domains except the GABAB 
receptor (75). For CaSR, the region possesses about 84 residues. Mutations on any of the nine 
Cys to Ser dramatically impair the surface expression and the function of CaSR. Deletion of this 
Cys-rich domain results in the abrogation of CaSR activity.   
 
The CaSR contains a seven transmembrane domain (7TM) similar to the other proteins in the 
GPCR superfamily. It is believed that agonist binding to GPCRs will lead to conformational 
changes of the 7TM -helices, further inducing alterations in intracellular loops as well as the C-
terminal domain, thereby triggering the downstream signaling pathways. The crystal structure of 
rhodopsin (a GPCR Family A protein) with 7TM domain has been reported. However, caution is 
extremely needed when extrapolating the CaSR 7TM structure from rhodopsin as proteins from 
family C share low sequence identity with proteins from family A. The 6 prolines in the 
transmembrane domain are important to maintaining the kinks in the transmembrane helices. 
Mutations of some prolines (P748R, P823A) (76,77) impair receptor function.  
 
The intracellular domain of the CaSR contains 216 amino acids that do not show high 
conservation among species (78). Two regions in this intracellular tail are homologous between 
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species: one from 863-925 located at the proximal of C-tail which is pivotal in surface 
expression; the other from 960-984 which is involved in interacting downstream proteins (79-81). 
Three potential protein kinase C (PKC) phosphorylation sites are present in the intracellular 
domain: T888, S895 and S915 are involved in regulating the receptor activity (82). Especially, 
T888 plays significant role in the PKC regulation as a negative modulator of CaSR function.  
 
Along with the PKC phosphorylation sites, two other residues participate in protein kinase A 
phosphorylation: S899 and S900, but studies on these two sites indicate minor effect of PKA 
phosphorylation in the modulation of CaSR (83). 
1.2.4 Contribution of glycosylation to CaSR  function 
The attachment of sugar residues on a protein is considered to be the most complicated co- or 
posttranslational modification (84). The glycosylation process is regulated by factors that vary 
greatly among cell types and species (85). Mature carbohydrate units can be assembled on 
protein via numerous delicate glycosylation routes and the resultant glycoproteins are secreted 
out of the cells or become cellular components, including membranes, cytoplasm, or nucleus etc.  
A varity of carbohydrate-peptide linkages have been found among glycoproteins in nearly all 
living organisms, ranging from bacteria to eukaryotes (85). Those linkages involve 13 different 
monosaccharides and 8 amino acid types and the glycopeptide bonds can be further categorized 
in five distinct groups shown in Figure 1.3(85). One of the common forms of glycopeptides 
bonds is N-linked glycosylation. This modification is the result of a complex process of 
trimming and remodeling of the oligosaccharide that takes place in the endoplasmic reticulum 
(ER) and Golgi as illustrated in Figure 1.4 (86). The synthesis of various glycopeptides bonds 
takes place within different subcellular organelles (85).  
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Figure 1.4 Glycan-protein linkages reported in nature. 
(Updated and redrawn, with permission of Oxford University Press, from Spiro R.G. 
2002. Glycobiology. 12: 43R–56R.) Diagrammatic representation of the five distinct types 
of sugar-peptide bonds that have been identified in nature.  (Ara) arabinose; (Rha) 
rhamnose; (FucNAc) N-acetylfucosamine (2-acetamido-2,6-dideoxy-D-galactose); (Bac) 
bacillosamine (2,4-diamino-2,4,6-trideoxy-D-glucose); (Pse) pseudaminic acid (5,7-
diacetamido-3,5,7,9-tetradeoxy-L-glycero-L-manno-nonulosonic acid); (Hyl) hydroxylysine; 
(Hyp) hydroxyproline; (C-term) carboxy-terminal amino acid residue. Glypiation is the 
process by which a glycosylphosphatidylinositol (GPI) anchor is added to a protein. For 
other details, including anomeric linkages, please see the Spiro (2002) review cited above. 
 
Endoglycosidases can be categorized into two major types: one for deglycosylation of 
asparagine-linked (N-linked) oligosaccharides; the other for O-linked oligosaccharides. 
Endolycosidases F(1,2,3), Endoglycosidases H (Endo H) and peptide-N4-(N-acetyl-beta-
glucosaminyl) asparagine amidase (PNGase) cleave N-linked glycosylation. O-Glycosidase 
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cleaves O-linked glycosylation. Among the first category, Endoglycosidases F1, F2, and F3 are 
more suitable for removing the glycans of native protein due to their low sensitivity to protein 
conformation while PNGase F prefers to work on denatured protein. Both Endo F1 and Endo H 
can cleave asparagine-linked oligosaccharides, however, the later does not cleave sulfated high-
mannose form (i.e. containing 5~9 mannose). 
(http://www.sigmaaldrich.com/technicaldocuments/articles/biology/glycobiology/endoglycosidas
es.html). The differences between the endoglycosidases are summarized in Figure 1.5.  
 
 
 
 
  
Figure 1.5 Schematic representation of the generation of N-linked glycosylation. 
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N-linked oligosaccharide modification takes place in the ER and Golgi. Following glucose 
trimming in the ER, high mannose glycans are available for further processing and 
trimming by glycosidase and mannosidases to yield high-mannose, hybrid and complex 
glycan structures.  
 
 
Figure 1.6 Schematic representation of different endoglycosidases  
 
CaSR isolated from pcDNA CaSR transfected human embryonic kidney (HEK293) cells 
exhibited similar expression patterns as the CaSR proteins identified from parathyroid cells (87). 
The western blot results of CaSR extracted from HEK293 cells showed several immunoreactive 
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bands using antibodies specific for the CaSR. The minor band at 120 kDa corresponds to the 
nonglycosylated form of the protein, the major band at 140 kDa stands for the high mannose 
form while another major band at 160 kDa represents the complex carbohydrates form of CaSR 
(87,88). Additional bands at higher molecular mass (350 kDa) corresponds to the dimeric form 
of the receptor. The CaSR that is expressed on the cell membrane is mature receptor that only 
account for a small portion of the protein (89).  
 
The sequon N-X-S/T is a general position at which N-Linked glycosylation can occur (90). X 
can be any amino acid but not proline. The glycosylation process is completely blocked if P is at 
the presence of X position. On the other hand, W, D, E and L at position X leads to inefficient 
glycosylation (90). The CaSR ECD contains 11 potential N-Linked glycosylation sites and 9 of 
them (N90, N130, N261, N287, N446, N468, N488, N541, N594) are highly conserved in 
different species including rat (44), chicken (91), rabbit (45) and bovine (38). The other 2 (N386, 
N400) are conserved in chicken, rabbit and human (88) . A mutagenesis study revealed that 
N386, N400 and N594 are not efficiently glycosylated in CaSR since the replacement of those 
sites with glutamine does not lead to the alteration of receptor mass or mobility as shown from 
western blot, whereas, disruption of other N sites would causes a decrease in  receptor mass.  
 
The protein folding, intracellular trafficking, protein secretion as well as cell surface expression 
of glycoproteins are significantly related with their carbohydrate moieties (92,93). The 
carbohydrate group also plays a crucial role in protein conformation, enzymatic activity and 
other structural functions. As K.Ray et al. reported, the cell surface expression of CaSR was 
disrupted if as few as three glycosylation sites were mutated to glutamine (88). Substitution of 
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the first five glycosylation sites with Q significantly decreased the surface expression of CaSR 
(>50%) compared with other mutants. A CaSR functional study using a PI hydrolysis assay 
further indicated that the mutants that exhibited impaired glycosylation had their responses to 
extracellular calcium correlated with their surface expression. The maximum responses to 
calcium were significantly reduced, while the EC50 of the dose response curve did not look 
altered as judged from the figure, though the authors did not use it as one of the parameters. 
After compensating for reduction of the surface expression level using higher DNA transfection 
amount, the calcium-stimulated PI hydrolysis among the mutants were comparable with the wild 
type.  
 
1.2.5 CaSR induced intracellular calcium oscillation and  signaling 
 
The CaSR activators can be defined into several groups: Ca2+ and polycations which interact 
with the Venus Fly Trap (VFT) domain (94-96) and transmembrane region(97,98) ERK; L-
amino acids (12), which bind to the VFT domain; phenylalkylamine type-II calcimimetics whose 
binding pockets located at transmembrane helices VI and VII (98-100). Upon stimulation with 
Ca2+ or other polycations, a number of intracellular signal transduction pathways will be 
activated.  
 
Among them, the phosphoinositide-specific phospholipase C (PI-PLC) and extracellular –signal-
regulated kinases (ERK1/2) have been widely applied to the investigation of CaSR activity 
(101,102). In 1998, McNeil et al first reported that in rat fibroblasts the activation of CaSR could 
increase c-SRC kinase activity as well as the extracellular signal-regulated kinase 1/mitogen-
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activated protein kinase activity and the non-functional mutation R796W inhibited both of the 
two kinases. Their results linked the activation of the SRC and ERK1 pathway to the modulation 
of proliferation in different cell types by extracellular calcium  (103). One year later, Hoff et al 
found that, a gain-of-function mutation T151M could enhance ERK1/2 and Jun-N-terminal 
kinase/stress-activated (JNK/SAPK) pathway at the presence of a physiological extracellular 
calcium concentration (104). Later on, the ERK1/2 activity has been widely investigated in a 
number of cells with expression of calcium sensing receptor including ovarian surface epithelial 
cells (105), proximal tubular OK cells (106), Madin-Darby canine kidney cells (107), prostate 
cancer cells (108), colon carcinoma cells (109), cytokine-stimulated adult human astrocytes 
(110), rat neonatal ventricular cardiomyocytes (111), Xenopus melanotrope cells(112), osteoblast 
(113),etc. The ERK1/2 activity has also been utilized to identify CaSR interacting proteins, for 
instance, filamin A (114), 14-3-3 (115), etc. 
 
Studies on how the L-amino acids or other type II calcimimetics affect these two major signal 
pathways were conducted in different labs. It is known that those allosteric modulators require a 
threshold calcium level or other agonists to active CaSR (100). However, the effect of amino 
acids on calcium dependent PI-PLC activation is negligible(116). On the other hand, L-Phe 
induced a significant enhancement on the extracellular calcium triggered ERK1/2 activity (100). 
It has been reported that the aromatic side chain amino acids (L-Phe and L-Trp) could enhance 
[Ca2+]o stimulated intracellular calcium change, while the effect of L-Phe on ERK1/2 signal were 
comparatively small. Thus it has been suggested that dietary protein intake could fine tune 
cellular responses to the calcium change.  
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As constant exposure to serum Ca2+ would chronically activate CaSR followed by activation of 
numerous cellular functions, several key questions need to be addressed, including how single 
cells that expressing CaSR can adapt to such chronic exposure and what are the kinetic features 
of intracellular Ca2+ response to alterations in extracellular Ca2+. In 2001, the heterologous 
expression system using human embryonic kidney 293 cells was utilized to explore those 
fundamental mechanisms by Gerda E.Breitwieser. Her group reported several major findings:  1, 
steady-state intracellular Ca2+ concentration change was observed in CaSR expressing cells when 
they are exposed to steady-state perturbations of the extracellular Ca2+ concentration (i.e. 
stepwise increases of extracellular Ca2+ concentration ); 2, small changes in extracellular Ca2+ 
could induce intracellular calcium oscillation and the oscillation frequency was constant over the 
range of 2.5~5 mM [Ca2+]o; 3, thapsigargin-sensitive intracellular Ca2+ stores contributed to the 
formation of intracellular Ca2+ oscillations; 4, staurosporine, a broad-specificity protein kinase 
inhibitor (inhibit protein kinases A, C, myosin light chain kinase and calmodulin kinase) did not 
affect the oscillation frequency but increased the number of oscillating cells (117).   
 
Further study of the regulation of intracellular Ca2+ oscillation was carried out by Enrique 
Rozengurt’s group. Previous models explained [Ca2+]i oscillations occurring following GPCR 
activation by resorting to  negative feedback effects of protein kinase C (PKC) on the production 
of Ins(1,4,5)P3 or the [Ca2+]i regulation on the Ins(1,4,5)P3 receptor. His group found that the 
observed [Ca2+]i oscillation triggered by changes in extracellular [Ca2+] in HEK293 cells 
expressing CaSR was also modulated by PKC since addition of PKC specific inhibitor 
significantly decrease the number of oscillatory cells and converted the intracellular responses to 
transient, non-oscillatory response.  PKC activators could reduce the oscillatory frequency but 
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didn’t eliminate the oscillations. Their study also demonstrated that the PKC phosphorylation 
site at T888 of CaSR played crucial role in the negative feedback of [Ca2+]i oscillations.  
 
As early as 2000, Conigrave et.al found that CaSR activity could also be regulated by aromatic 
amino acids since they shifted  the [Ca2+]o-[Ca2+]i response curve and lowed the EC50(118). In 
2002, the aromatic amino acid induced [Ca2+]i oscillations in CaSR-transfected HEK293 cells 
was further analyzed by Young et. al. (119). The [Ca2+]i oscillation induced by L-Phe or L-Trp 
required a normal physiological range of [Ca2+]o (1.8 mM in their study). The average oscillation 
frequency was 1/min which was much lower than [Ca2+]o induced [Ca2+]i oscillations (~ 4/min). 
The two different patterns, specifically sinusoidal response induced by [Ca2+]o and transient 
baseline calcium response elicited by amino acids, allow the CaSR to differentiate which agonist 
was interacting with the receptor.   
 
The mechanisms of [Ca2+]i oscillation triggered by extracellular calcium and amino acids are 
considered to be different according to the studies from Dr.Rozengurt’s group(116,120) as well 
as Dr.Breitwieser’s group(121). By tracking intracellular signaling markers tagged with 
fluorescent proteins, including GFP-PHD (pleckstrin homology domain of PLC-1linked with 
GFP in order to detect Ins(1,4,5)P3), PKC-YFP (for the indirect measurement of [Ca2+]i), and 
PKD-RFP (sensing the generation of DAG), it was found that GFP-PHD and PKC-YFP 
oscillatory translocated  to the membrane after stimulation by high [Ca2+]o and PKD-RFP was 
translocated to membrane. It was demonstrated that CaSR mediated activation of Gq and PI-PLC 
(116).In contrast, [Ca2+]i change stimulated by phenylalanine did not redistribute the location of 
either GFP-PHD OR PKD-RFP, but PKC-YFP exhibited cyclically redistributed pattern.  
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An intact actin cytoskeleton system including the small GTP binding protein RhoA which 
facilitates actin cytoskeleton organization(122), and filamin A, which is linked to the actin 
cytoskeleton as a scaffold protein (123) was found to be involved in phenylalanine induced 
oscillation(116) but not extracellular calcium induced [Ca2+]i change. Besides, heterotrimeric G-
protein subunits G12/13 participated in the phenylalanine regulated oscillations, but it is Gq 
that mediates the [Ca2+]o induced oscillation (116). Since HEK-293 cells express TRPC1 
channels (124), it is also suggested by studying of thrombin-mediated Ca2+ entry in endothelial 
cells (125) that the [Ca2+]i influx stimulated by phenylalanine could due to activation of RhoA, 
which further caused the translocation of Ins(1,4,5)P3 receptors and TRPC1 channels to the cell 
membrane.  
Phenylalkylamine allosteric regulators of CaSR could also change the [Ca2+]i oscillation patterns 
(126).  
 
1.2.6 Proteins interacting with CaSR 
In addition to heterotrimeric G proteins, the CaSR needs to recruit a number of other proteins to 
ensure the net work is fully functional. Recently, a few of these proteins have been identified 
using yeast two-hybrid system and/or coimmunoprecipitation studies. The absence of these 
proteins would influence the CaSR signaling. 
Filamin A has been demonstrated to interact with the C-terminal of the CaSR in 2001 by two 
individual groups (80,81). Later study using truncation and deletion mutants revealed that the 
binding happened in a two -strands region from amino acid 962 to 981 of the CaSR. Blocking 
the interaction between Filamin A and CaSR attenuated CaSR-induced ERK activity(80). The 
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binding of the two proteins also exhibited importance in the CaSR-mediated Rho signaling 
(116,127) as well as the JNK activation (128). Studies in a cell line deficient in filamin A 
suggested Filamin A might protect the CaSR from degradation(114). 
Potassium channels Kir4.2 and Kir4.1 have been reported to colocalize with CaSR in HEK293 
cells stably expressing the CaSR and in endogenous rat kidney tissues respectively(129). 
However, how and whether their function can be regulated by the CaSR still needs to be 
elucidated. It is possible that Filamin A may act as a bridge that links the CaSR and either Kir4.1 
or Kir4.2.  
The region between amino acids 880-900 of the CaSR has been identified to interact with the 
region 660-838 of an E3 ubiquitin ligase, dorfin (130). The overexpression of dorfin is believed 
to increase the ubiquitination of the CaSR, resulting an accelerated degradation process (130).  
Associated molecule with SH3 domain of STAM (AMSH) is an ubiquitin isopeptidase that 
regulates the sorting of the receptor EGFR (131). The CaSR C-tail region from 895-1075 was 
found to bind with AMSH(132). Increasing the AMSH expression level or stimulating the CaSR 
with calcium could reduce the CaSR expression in HEK293 cells transfected with these two 
proteins (132,133).                                                                                                                                                     
-Arrestins play an important role in modulating the desensitization and internalization of 
GPCRs through collaborating with G protein receptor kinases (GRK) (134).  Overexpression of 
-Arrestins negatively regulates the inositol phosphate signaling via CaSR in HEK 293 cells.  A 
PKC inhibitor or mutation on the CaSR PKC phosphorylation sites reduces the effect of  
overexpressing -Arrestins. 
RAMP is short for receptor activity-modifying protein which has been reported to influence 
receptor trafficking, glycosylation as well as second messenger production(135). Experiments in 
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COS7 cells demonstrated that RAMP1 and RAMP3 can increase the surface expression of 
transfected CaSR, but not RAMP2 (136). Moreover, RAMP3 had greater influence on 
modulating the receptor surface expression.   
1.2.7 Trafficking of the CaSR in cells 
Like many other GPCRs, the trafficking of the CaSR is a complex process that involves 
interacting with various proteins to determine the final destination of the receptor. Once 
synthesized at the endoplasmic reticulum (ER), those improperly folded CaSR will fail the 
quality control and be lead towards the proteasome for degradation. Receptors passing the 
quality control will traffic to plasma membrane or other cellular compartments via interaction 
with chaperone and small GTP-binding proteins (137-140).  
Several proteins interact with CaSR while the receptor exits from the ER, including p24A 
(transmembrane emp24 domain trafficking protein 2(TMED2))(141); small GTP-binding protein 
Sar1(142); receptor-activity-modifying proteins (RAMPs)(136); Rab1(143); calmodulin (CaM) 
(82); 14-3-3(144) and Dorfin (130).  p24A binds predominantly with immature form of CaSR 
and cycles between the ER, the ER-Golgi intermediate compartment(ERGIC) as well as the cis-
Golgi membranes (145,146). Through its interaction with p24A, the stability of CaSR and the 
plasma membrane targeting will be increased possibly via inceasing total cellular CaSR(141). 
Sar1 is another protein that is required in releasing the receptor from the ER (141,142). RAMPs 
and Rab1 are small GTP-binding proteins that localize to the cytoplasmic face of organellar 
membranes. Both of them are found to facilitate CaSR trafficking from ER to Golgi (136,143).  
The 14-3-3 is predicted to interact with the arginine-rich domain of CaSR (890RRxxxxRKR898) 
and may lead to the retention of CaSR in the ER (115,144,147). There is also a calmodulin 
binding site in the C-tail of CaSR comprising residues 874-895 (148). However, the function of 
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CaM still needs to be revealed. It is reported that CaM binds to both immature and mature forms 
of CaSR suggesting its role in modulating anterograde trafficking (82). On the other hand, CaM 
may stabilize the surface receptor on the cell membrane (148). 
Its interactions with different proteins contributes to the sub cellular localization of CaSRs. The 
association of intracellular loops 1 and 3 with caveolins keeps the CaSR highly enriched in 
invaginations of plasma membrane called caveolae in certain type of cells, like parathyroid chief 
cells and cardiac myocytes (43,149-151). Filamin A, an adaptor protein, has also been identified 
to interact with the C-terminal of CaSR, targeting the receptor to sites of Rho activity 
(116,127,152). The CaSR also interacts with integrins, the latter may contribute to the regulation 
of cell migration(153).  
The surface expressed CaSRs may undergo endocytosis initiated with phosphorylation by G 
protein coupled receptor kinase (GRKs) or protein kinase C(154,155), involving -arrestins and 
facilitated by Rab7, Rab11a and adaptor protein-2 (AP2)(133,156,157). The endocytosed 
receptors are either recycled to the cell membrane contributing to the receptor resensitization or 
translocated to the lysosomes for degradation (158,159).  
There are two mechanisms that CaSR can utilize to get degraded. One is mediated by the activity 
of E3 ubiquitin ligase family member dorfin. CaSR will be targeted to proteasome after being 
ubiquitinated by dorfin (160). CaSR can also be degraded in lysosomes. A deubiquitinating 
enzyme specific for k63-likages (AMSH which is short for associated molecule with the SH3 
domain of STAM) has been reported to be involved in the process(133). Moreover, the PEST-
like sequence in the C-tail of CaSR, which are rich in proline, glutamine, serine and threonine, 
can also lead the receptor to lysosome (157).  
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In the continuous presence of agonist stimulation, those secretory pathways as well as the 
endocytosis mechanisms mentioned above work collaboratively (Figure 1.7), causing a net 
increase in the plasma membrane expressed CaSR. This phenomenon was named Agonist-
Driven Insertional Signaling (ADIS)(144). However, a number of questions raised by the ADIS 
mechanism remained to be explored.   
1.2.8 Disease associated CaSR mutations 
 
The discovery of CaSR and its role in maintaining physiological calcium level led to the 
identification of disorders of calcium homeostasis that are related to abnormal CaSR activity. 
There are more than 100 mutations of the CaSR that have been catalogued in the online database 
at http://www.casrdb.mcgill.ca/. They are the primary attribution for the CaSR related disorders. 
Autoimmune antibodies against the CaSR are another cause for the receptor dysfunction (161).  
Mutations of the CaSR may lead to an inactive receptor or an overactive receptor. The former 
includes cases of familial hypocalciuric hypercalcemia, which is a calcium disorder associated 
with dominant negative activity of the mutant CaSR (162) as well as a more serious disorder 
known as neonatal severe hyperparathyroidism (NSHPT) due to inactivating mutations in both 
copies of the CaSR gene (161). NSHPT can cause severe hypercalcemia, multiple fractures, 
neurodevelopmental disorders and even death. The latter includes autosomal dominant 
hypocalcemia (ADH) (163) and Bartter syndrome type V (164). Patients with ADH usually do 
not show symptoms but have mild reductions in calcium concentration in the blood. Patients 
with Bartter syndrome type V show symptoms like hypokalemic metabolic alkalosis and 
hyperaldosteronism along with hypocalcemia (164). 
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Figure 1.7 The trafficking of CaSR. 
 
Illustrated are the primary compartments during the trafficking of CaSR. The major 
players are highlighted next to the subcellular organelles where they are expected to 
interact with CaSR. Abbreviations: AP-2, adaptor protein-2; CaM 
calmodulin; ER, endoplasmic reticulum; FLNA, filamin A; GRKs, G protein coupled 
receptor kinases; RAMPs, receptor activity modifying proteins; VCP/p97, valosin-
containing protein. 
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1.3 Physiological condition of the amino acids concentration and the reational for the 
dosage used in this study 
In biological systems, free L-amino acids are essential molecules since they not only serve as the 
building blocks of protein but are also the metabolic precursors of crucial substances that serve 
as ligands for receptors (165). Evidence for the presence of amino acid sensing mechanisms in 
various studies, e.g., regulating insulin secretion from pancreatic B cells, hepatic autophagy, etc., 
suggest the widespread existence of amino acid sensors, although the identities of these amino 
acid sensors are in many cases unknown.  These findings highlight amino acid-dependent control 
of cellular signal transduction pathways. Fluctuation of the plasma levels of amino acids can, 
therefore, regulate the rate of hormone synthesis and secretion as well as Ca2+ metabolism, 
among other processes (165). CaSR is present throughout the gastrointestinal tract (41,166), 
including in gastrin-secreting antral G cells and cholecystokinin-secreting l cells, both of which 
are known to be activated by both [Ca2+]o and aromatic amino acids (166). L-amino acids, 
especially aromatic amino acids, are known to enhance the sensitivity of CaSR to [Ca2+]o, which 
could be one potential explanation for how dietary protein modulates [Ca2+]o homeostasis in 
normal individuals as well as in patients with chronic renal failure (165,167).  
 
The amino acids concentration in plasma before and after meal is listed in Table 1.1. All of them 
are within the range of M. Even after steak meal, the peak value for certain amino acids (e.g. 
Gly) is around 0.5 mM (168). However, the reported EC50 for L-Phe was 3.5 mM as measured 
by intracellular calcium readout from CaSR transfected HEK293 cells (118). The discripency for 
the phenomena relies on the fact that in physiological conditions, the receptors are stimulated by 
a mixture of amino acids, small peptides as well as proteins instead a single amino acid. In fact, 
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small peptides, for instance, -glutathione and its variants, have smaller EC50s (in the range of 
M) compared with L-Phe or L-Trp (Table 1.2).   
 
Table 1.1 Plasma amino acid concentrations before and during intravenous amino acid 
infusion and after oral steak meal  
Mean (±SE) plasma amino acid concentrations of phenylalanine, tryptophan, glycine, 
alanine, and histidine before (basal) and in response to intravenous infusion of each 
individual amino acid and after the steak meal. Each amino acid was infused in 125 ml for 
1 h in increasing stepwise manner; doses of Phe, Gly, Ala, and His were 0.0125, 0.025, 0.05, 
and 0.1 M, respectively, and doses of Trp were 0.005, 0.01, 0.02, and 0.04 M. The steak 
meal contained 49 g protein and 405 kcal. (Table adopted from J.Clin. Invest.Vol 71. pg. 
1254-1262, 1983. ) 
 
Amino acid 
infused IV 
Basal 0-60 min 61-120 min 121-180 min 181-240 min Steak meal 
M 
Phe 51±5 68±8 90±7* 103±14* 198±37* 85±7 
Trp 49±5 66±6 97±8* 140±16* 244±38* 94±9 
Gly 283±50 291±49 315±50* 417±75* 559±98 386±53 
Ala 316±16 345±15 353±25 326±10 365±31 549±50 
His 80±14 104±8 130±10 172±19 316±25 100±11 
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Table 1.2 Potencies of -glutamyl peptides for Ca2+i mobilization in CaR-expressing HEK-
293 cells  
 
HEK-293 cells that stably express the CaR were loaded with fura-2AM and assayed for 
receptor-dependent intracellular Ca2+ mobilization by microfluorimetry. The data were 
obtained from cells perifused with physiological saline solution in the presence of 2.5 mM 
Ca2+o. In accompanying experiments, the EC50 for L-Phe was 1.1 ±0.5 mM (n =4).(Table 
adopted from JBC vol 286, no. 11, pp. 8786–8797, March 18, 2011) 
 
-Glutamyl peptide EC50 for peptide (M) 
S-Methylglutathione 1.7 ± 0.5 (n= 4) 
Glutathione 3.9 ± 0.7 (n = 4) 
-Glu-Cys 4.7 ± 0.9 (n =3) 
-Glu-Ala 4.8 ± 0.7 (n =3) 
 
 
 
Conigrave et.al. have investigated the physiological relevance of their in vitro findings regarding 
to the amino acid concentration. They mixed 20 common L-amino acids at similar concentration 
comparing to those present in fasting human plasma and showed that the mixture could 
reproduce the effects of high concentrations of single amino acids (Table 1.3). These findings 
suggest that the CaSR sensing L-amino acid is a universal property and amino acid composition 
of human plasma has a pronounced effect on the activity of CaSR compared to single amino acid 
(118).   
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Table 1.3 Effect of L-amino acids on the potency of Ca2+ ions as agonists of the Ca2+ 
receptor.   
Data are shown ± SEM. All experiments were performed at pH 7.4. ∆ EC50 is defined as 
control minus experimental. Unpaired t tests performed on the data set (individual amino 
acids vs. control) yielded the following results: L-His, L-Phe, L-Trp, L-Tyr, L-Cys, and L-
Thr, P ≤ 0.0001; L-Ala, P ≤ 0.0002; L-Asn, L-Gln, L-Ser, and L-Glu, P ≤  0.01; Gly, L-
Pro, L-Val, L-Met, L-Asp, P < 0.05; L-Lys, P = 0.05; L-Ile, P = 0.31; and L-Leu, P = 0.95. 
(Data adopted from 2000 PNAS vol.97 no.9 pg 4814-4819) 
 
 
Amino acid (10 mM) EC50 for Ca2+ (n) ∆EC50 for Ca2+ (n) 
L-His 2.4 ± 0.1 (4) 1.9 ± 0.2 (4) 
L-Phe 2.5 ± 0.1 (7) 1.8 ± 0.2 (7) 
L-Tyr 2.5 ± 0.2 (3) 1.8 ± 0.2 (3) 
L-Trp 2.6 ± 0.3 (3) 1.6 ± 0.2 (3) 
L-Cys 2.8 ± 0.1 (5) 1.6 ± 0.1 (5) 
L-Ala 2.9 ± 0.3 (3) 1.4 ± 0.04 (3) 
L-Thr 3.0 ± 0.1 (3) 1.1 ± 0.3 (3) 
L-Asn 3.1 ± 0.2 (3) 1.1 ± 0.2 (3) 
L-Gln 3.2 ± 0.2 (3) 1.0 ± 0.2 (3) 
L-Ser 3.3 ± 0.2 (3) 1.0 ± 0.2 (3) 
L-Glu 3.5 ± 0.2 (3) 0.9 ± 0.1 (3) 
L-Pro 3.6 ± 0.3 (3) 0.6 ± 0.2 (3) 
L-Val 3.6 ± 0.3 (3) 0.6 ± 0.2 (3) 
L-Met 3.6 ± 0.3 (3) 0.6 ± 0.1 (3) 
L-Asp 3.7 ± 0.2 (3) 0.6 ± 0.3 (3) 
L-Lys 3.7 ± 0.1 (3) 0.6 ± 0.2 (3) 
L-Arg 3.7 ± 0.1 (3) 0.5 ± 0.3 (3) 
L-IlE 3.9 ± 0.5 (3) 0.3 ± 0.1 (3) 
L-Leu 4.2 ± 0.3 (3) 0.6 ± 0.2 (3) 
Control 4.2 ± 0.1 (10) 0 ± 0  
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Our lab utilized computational algorithms HADDOCK to dock amino acids into the CaSR ECD 
and comparied the binding energies among them (Figure 1.8 ). Similarly, the calculated binding 
energe correlated well with in vitro studies reported by Conigrave’s group.  
 
 
 Figure 1.8 Calculated binding energy for single amino acids docking into the CaSR ECD 
using HADDOCK.  
 The blue bars show the amin acid that has a calculated binding energy level correlated 
well with expectation estimated from in vitro experiments. The orange bars show the 
discrepancy.  
 
The metabolism of both Ca2+ and amin acids shall be re-appraised in the context of protein 
ingestion and dietary supplements since L-amino acid and Ca2+ can potentiate the sensing 
capability by CaSR for each other. It is also emphasized by Conigrave et. al. that the CaSR 
should be reassessed as a potential target of aromatic L-amino acids under certain toxic 
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metabolic conditions. For instance, the CaSR expressed in the CNS might be involved in 
contributing to the elevated levels of L-Phe in phenylkeonuria or in hepatic encephalopathy 
(118).  
 
1.4 Challenges in studying the membrane protein with weak metal binding affinities 
The challenges in studying the Calcium-sensing-receptor are multifaceted:  
First, the CaSR belongs to membrane proteins, so the challenges associated with membrane 
proteins may also occur to the CaSR. Membrane proteins are difficult to separate from the cells 
due to their hydrophobic transmembrane domain. The heating process may cause the aggregation 
of the 7TM region and thus reduce the solubility of the protein.  
 
Although X-ray crystallography has been used as one of the major tools to study the structure of 
proteins, application of this technique to the crystallization of glycosylated proteins exhibits its 
own limitations. Like other glycosylated proteins, the complex form of the glycans on the CaSR 
can prevent the crystallization of this protein because the chemical and conformational 
heterogeneity of the glycoproteins usually inhibit crystallization.  
 
Due to the limitation of the conditions for crystallization as well as the fast on and off rate of 
Ca2+ when its interaction belongs to weak binding, even some proteins have their crystal 
structure solved like mGluR1, the detection of Ca2+-binding sites in those protein may be still 
elusive. Moreover, the selectivity of the CaSR for different amino acids is not clear and the 
interaction between amino acids and the CaSR are relatively weak (in mM range).  
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Currently, methods for direct measurement of Ca2+ and amino acid binding to the CaSR have not 
yet been well established, nor are there methods for directly monitoring ligand induced 
conformational changes of the proteins. Approaches for addressing these questions rely on 
indirect measurements of calcium-induced intracellular signaling changes in living cells or 
utilizing the Fluorescence Resonance Energy Transfer (FRET) assay for monitoring ligand 
generated fluorescence changes in isolated proteins.  
Last but not least, the large size of the protein (extracellular domain 612 amino acids; whole 
protein 1078 amino acids) as well as the fact that the CaSR function as a dimer contribute to the 
difficulties in studying the protein, especially when it possesses a high Hill coefficient which 
suggests possible multiple binding sites for ligands.  
1.5 Approaches and strategies 
1.4.1 Prediction of Ca2+-binding sites in proteins and computational simulation 
Previous studies on the known Ca2+-binding sites from thousands of proteins with X-ray 
structures show that Ca2+ binding sites usually forms pentagonal or octahedral bipyramidal 
geometry (169) composed by 4-7 oxygen atoms from ligand residues. The preference of the 
residues in a Ca2+ binding sites falls into the following category: Acidic residues (-COOH) > 
H2O> main chain carbonyl > Asn > Ser > Thr > Tyr. There are restrictions on forming certain 
geometries of Ca2+ binding pockets as the distances between Ca2+ and coordinating oxygen 
atoms are within the range of 2.3~2.6 Å and the average Ca-O-C angle has been reported to be 
93~160°. Two major types of Ca2+-binding sites---continuous and discontinuous---are defined 
based on whether a short, contiguous primary sequence can form a pocket to chelated Ca2+. The 
residues composing discontinuous Ca2+-binding sites may be separated in protein sequence but 
might be close enough to form a pocket in three dimensional structures.  Our lab has developed a 
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series of algorithms, including GG, MUG (169), MUGC (170) etc. to predict Ca2+-binding sites 
from discontinuous protein sequences utilizing their 3D structures or modeled structures.  While 
GG algorithm focused on the geometric information of oxygen composition from a protein 
structure, MUG and MUGC further define calcium center and second shell carbon atoms to 
minimize the false positive and false negative results. Having a high performance with 90% site 
sensitivity and 80% site selectivity (171), these approaches have been used to explore the Ca2+-
binding sites in modeled CaSR structure(68,172).  Following the initial grafting  and subdomain 
approaches to verify the Ca2+ binding sites on CaSR, the immediate need is to characterize the 
cooperativity among those Ca2+-binding sites and how they could be modulated by other 
allosteric modulators.  
1.4.2 Computational docking and molecular dynamic simulation 
Molecular docking utilize computational algorithms to calculate the preferred orientation of one 
molecule to another when the two form a stable complex(173). Since the interaction between 
proteins and their ligands plays a crucial role in signal transduction, docking is considered as a 
useful tool to predict the binding orientation of a ligand and its target protein. A scoring function 
is generally used in docking programs as an attempt to approximate the standard chemical 
potentials of the system (174). AutoDock Vina developed in Dr. Olson’s group, is a new 
program for molecular docking. Using a sophisticated gradient optimization approach in its local 
optimization procedure and the multithreading step, AutoDock Vina exhibits fast execution 
capability and improved accuracy (174). AutoDock Vina has been widely used in biologically 
relevant research, including studies probing the target moleculars for GPCR proteins (174). 
Using this strategy, we are able to predict the L-Phenylalanine binding pocket, and further 
investigate how this positive allosteric modulator regulates the function of CaSR.   
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Molecular dynamics (MD) simulation provides an approach complementary to the experiments 
in live cells for understanding biomolecular structure, dynamics, and function. The crystal 
structures of mGluR1, a GPCR family C member, with both the ligand-free form and agonist 
loaded forms available in the Protein Data Bank (PDB) [PDB entries: 1EWT, 1EWK (175), and 
1ISR(176) ] are considered to be employed as a template in the simulation due to their similarity 
in structure with that of the CaSR.  
1.4.3 Using Ca2+ sensors to monitor intracellular calcium signaling 
Monitoring the effects of Ca2+on numerous cellular processes is an essential step for 
understanding the complex intracellular signaling pathways regulated by Ca2+. Several endeavors 
have been made to investigate this problem, characterizing as two major categories: Ca2+-binding 
dyes and genetically-encoded fluorescent proteins (177). Fura-2 is one of the representative Ca2+ 
binding dyes that have been widely applied in many studies. Its advantages, such as high 
spatiotemporal resolution, good photostability and easy cell membrane permeability via its 
acetoxymethyl ester has enabled Fura-2 to become one of the most popular cytosolic Ca2+ 
indicators. However, the drawbacks of these dyes are also apparent since they can not be targeted 
to subcellular compartments, and the exogenous buffer they introduce during the dye mixing 
process may perturb endogenous Ca2+ signaling. Moreover, their sensitivity might be reduced in 
thick tissues and intact organisms (178). On the other hand, the protein-based Ca2+ sensors can 
be specifically targeted to various organelles in various cell types with grafted signal peptides 
(179). Aequorin, the first generation of the protein based Ca2+-sensor, has a wide dynamic range 
and weak Ca2+ binding affinity, but the requirement for cofactors in order to be applied in living 
cell imaging has limited its application (180). The second generation was based on the 
fluorescence resonance energy transfer (FRET) between calmodulin and its binding peptide M13 
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linked to two fluorescent proteins (181,182). The disadvantage of the FRET based Ca2+ 
indicators are mainly two folds: the linker between the donor and acceptor might disrupt the 
endogenous signaling net; and quantitative analysis might be hindered by the distances and 
orientation of the FRET pair (179,183,184). Our lab has developed a Ca2+ sensor named 
“CATCHER” based on the enhanced green fluorescence protein (EGFP). It can target to the 
endoplasmic reticulum (ER) and its weak Ca2+ binding capability as well as the minimum 
perturbation of the endogenous signaling pathways provides a new way to explore calcium 
changes in sub-cellular compartments (185).  
1.4.4 Expression and purification of the extracellular domain of CaSR 
Various studies including protein structure and function analysis, protein-protein interaction 
verification, antibody generation and gene regulation exploration, rely on recombinant protein 
expression technology. Hitherto, six host systems have been used for protein expression, namely 
cell-free expression, bacterial expression, yeast expression, algal expression, insect expression 
and mammalian expression. Among these, the bacterial, insect and mammalian systems are 
widely employed in the study of GPCR proteins. Each system has its own advantages and 
challenges. The bacterial expression system is best known for its low cost, simple culture 
conditions and that it can easily be scaled up to generate large amounts of protein. However, it 
also faces problems like protein solubility, minimal posttranslational modification and is less 
tolerant to mammalian proteins. On the contrary, the mammalian expression system only 
generates limited amounts of proteins and the demanding culture conditions usually make the 
procedure too costly. Nevertheless, mammalian expression systems produce the highest level of 
correct post-translational modification, and it is more suitable to generate functional human 
proteins. Our lab routinely utilizes a variety of E.Coli strains to express engineered proteins.  The 
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grafted proteins and the subdomain constructs of CaSR have been successfully expressed in 
bacteria system (68,172). Meanwhile, our collaborator Dr. Kelley Moremen in the University of 
Georgia has abundant experience of expressing mammalian proteins in suspension culture 
systems using mammalian cells (HEK293F). It will be worthwhile to study how the proteins 
expressed from two different systems will vary in various biophysical characteristics (Invitrogen). 
1.4.5 Monitoring intracellular signaling pathways using immunoassays 
Immunoassays have been widely applied in the exploration of the intracellular molecular 
signaling networks. They rely on the interaction between a certain antibody and a specific 
macromolecule or low molecular weight signaling molecule. The other key feature of 
immunoassays is that they provide a way to quantify the signal in response to the binding. This 
feature requires a detectable label to be linked to the antibodies. The linked label either can emit 
radiation, have a color change during the reaction, produce fluorescence, or can be induced to 
generate light though chemiluminescence detection. Three immunoassays were used in this 
project: Western Blot, immunocytochemistry (ICC) and ELISA. The Western Blot technique 
utilizes chemiluminescent substrate for alkaline phosphatase (AP) to generate detectable signals. 
Those signals can be measured quantitatively by comparing them with an internal control protein 
such as glyceraldehyde 3-phosphate dehydrogenase (GAPDH). The secondary antibody for ICC 
is conjugated with a fluorescent dye that can be excited at various wavelengths and emits lights 
within a certain measurable range. On the other hand, the secondary antibody for the ELISA 
assay is conjugated with horseradish peroxidase (HRP) which interacts with the substrate 
tetramethylbenzidine (TMB) and subsequently generates detectable signals. Those assays can be 
useful for “visualizing” molecules that play crucial roles in intracellular signaling networks.  
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1.6 Major questions to be addressed in this dissertation  
Several major questions need to be addressed in this dissertation: 
1, How CaSR functional cooperativity is regulation by extracellular binding of Ca2+ and amino 
acids?  
2. How the disease associated CaSR mutants can affect the functional cooperativity mediated by 
Ca2+ and amino acids? 
3. How can we determine the binding of Ca2+ and L-Phe to the CaSR ECDs and detect the 
potential conformational change induced by the interaction?.  
4. How the multifunctional intermediate messenger protein--- CaM regulates the CaSR 
trafficking and signaling?  
5. How ER Ca2+ signaling regulates CaSR functional cooperativity via modulation of receptor 
surface expression? 
 
1.7 The objectives and overview of this dissertation 
The overall goal of this research is to understand the mechanisms of how CaSR integrates the 
Ca2+-mediated signaling and to probe the molecular basis for diseases resulting from alterations 
in Ca2+ homeostasis. We will reach the goal via following 5 aims to addressing the above five 
major questions.  
A. Chapter 1 is to overview the background of calcium signaling and calcium sensing 
receptor.  
B. Chapter 2 is to describe methods and materials used in this study. 
C.  Chapter 3 is to understand the regulation of CaSR functional cooperativity by 
extracellular binding of Ca2+ and amino acids  
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A1.Predict Ca2+ and L-Phe binding sites using computational algorithms  
In order to predict the Ca2+ binding sites and potential L-Phe binding site in the ECD, a modeled 
structure of CaSR was generated based on the known structure of mGluR1　. GG (171) and 
MetalFinder (68,186), computational algorithms developed in our lab based on utilizing 
geometric characteristics of Ca2+ binding sites in proteins to identify the Ca2+ binding pockets in 
ECD. And the L-Phe binding site will be predicted based on the results of molecular dynamic 
simulation on the CaSR ECD docked with L-Phe. .  
 A2 Verify predicted Ca2+ binding pockets and L-Phe binding site by monitoring the intracellular 
calcium concentration in HEK293 cells transiently transfected with wild type CaSR and its 
variants using single cell fluorimetric imaging with or without the presence of L-Phe.  
To study the effect of each site-specific Ca2+ binding site on the function of CaSR, the negatively 
charged residues, mainly Glu and Asp, will be mutated into non-charged residues like Ile or Ala. 
To confirm the L-Phe binding site, the site-directed mutagenesis strategy was applied. One of the 
methods to study the effect of calcium binding sites on the function of CaSR is monitoring the 
intracellular calcium release in mammalian cells. The WT CaSR and its mutants will be 
transfected into HEK 293 cells and heterogeneously expressed. The intracellular calcium 
concentration changes will be recorded with the aid of a ratiometric Fura-2 based method upon 
stepwise increased in extracellular Ca2+. By comparing the responses of WT CaSR and its 
mutants, the function of mutated calcium binding sites might be revealed. The effect of L-Phe on 
WT CaSR as well as the mutants was measured by performing the assays described above.  
 
D. Chapter 3 and 4 are to understand how the disease associated CaSR mutants can affect 
the functional cooperativity mediated by Ca2+ and amino acids. 
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By collaborating with Prof. Thakker’s group at University of Oxford, we will analyze how the 
disease related mutations can affect the function of CaSR and how L-Phe can modulate the 
receptor activity.   
 
E. Cahpter 6 and 7 are aimed to probe the Ca2+ and L-Phe binding affinity, cooperativity, 
and related conformational change of wild type ECD and its mutants by various 
biophysical methods.  
First, we expressed and purified the ECD and disease-related mutants and variants, which were 
shown to play important role in intracellular calcium responses using bacteria and mammalian 
expression systems. The native conformation of the bacterial expressed protein was compared to 
the mammalian expressed protein using by immunoblotting technique and metal binding FRET 
assay.  
Second. The secondary structures of the purified proteins were verified using circular dichroism. 
Moreover, the agonist induced conformational changes were measured using tryptophan spectral 
and ANS binding assays.  Next, the Tb3+ -FRET assay was applied to study the metal binding 
capability of those proteins. Furthermore, the Ca2+-binding affinities were indirectly acquired 
using a Ca2+ competition assay, in which Ca2+ is gradually added to compete with the bound Tb3+.  
 
F. Chapter 8 is to study the mechanism of receptor internalization upon the stimulation of 
extracellular calcium .  
The regulation of cytosolic Ca2+ signaling and cell surface expression of the receptor by 
calmodulin binding to the calcium-sensing receptor's proximal C-terminus was investigated in 
this proposal. The hypothesis to be tested was that extracellular activation triggers the Ca2+-
43 
 
dependent association of CaM the C-terminus of CaSR in regulating cell surface expression of 
the receptor and the PKC activity. We will 1) measure the cellular interaction between CaR and 
CaM  and the effect of CaM binding on the phosphorylation at T888 by PKC; 2), investigate the 
[Ca2+]i oscillation and trafficking changes using CaSR variants with mutations of the calcium 
and amino acid-binding sites and disease associated mutants and CaM variants with altered 
calcium binding affinity. 
 
G. Chapter 9 is to investigate how the CaSR regulate its functional cooperativity by 
modulation of surface expression via [Ca2+]ER signaling.  
We will use the ER calcium probe developed in our lab --- CatchER as well as the commercial 
available ratiometric dye Mag-Fura 2 to investigate how [Ca2+]ER regulates the expression of the 
receptor. We will utilize the real-time imaging system to calibrate [Ca2+]ER and the surface 
expression of CaSR will be analyzed using multiple immunoassays (e.g. western blot, 
immunofluorescence staining).  
 
H. Chapter 10 summarizes major conlusions and the significance of this project.  
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CHAPTER 2. MATERIALS AND METHODS 
2.1 Computational prediction of Ca2+-binding sites in the ECD of CaSR 
The structure of the extracellular domain of CaSR (residues 25-530) was modeled based on the 
crystal structure of mGluR1 (1EWT, 1EWK and 1ISR), and the potential Ca2+-binding sites in 
the CaSR ECD were predicted using MetalFinder (68,187). 
2.2 Computational prediction of L-Phe-binding pocket in the ECD of CaSR 
The Prediction of the L-Phe-binding site was performed by AutoDock-Vina (174). In brief, the 
docking center and grid box of the model structure and the rotatable bonds of L-Phe were 
defined by AutoDock tools-1.5.4. The resultant L-Phe coordinates were combined back to the 
pdb file of the model structure for input into the Ligand-Protein Contacts & Contacts of 
Structural Units (LPC/CSU) server to analyze interatomic contacts between the ligand and 
receptor (188). The residues within 5 Å around L-Phe were considered as L-Phe-binding residues. 
 
2.3 Computational simulation of CaSR and its mutants 
2.3.1 MD simulation and correlation analysis using Amber. 
MD simulation provides an approach complementary to the experiments in live cells for 
understanding biomolecular structure, dynamics, and function. The initial coordinates for all the 
simulations were taken from a 2.20 Å resolution x-ray crystal structure of mGluR1 with PDB ID 
1EWK (175). The AMBER 10 suite of programs (189) was used to carry out all of the 
simulations in an explicit TIP3P water model (190), using the modified version of the all-atom 
Cornell et. al.(191) force field and the re-optimized dihedral parameters for the peptide ω-bond 
(192). An initial 2 ns simulation was performed using NOE restraint during the equilibration in 
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order to reorient the side chains residues in the Ca2+-binding site, but no restraints were used 
during the actual simulation. A total of three MD simulations were carried out for 50 ns each on 
apo-form and ligand (Ca2+ and L-Phe) loaded forms. During the simulations, an integration time 
step of 0.002 ps was used to solve the Newton’s equation of motion. The long-range electrostatic 
interactions were calculated using Particle Mesh Ewald method (193) and a cutoff of 9.0 Å was 
applied for non-bonded interactions. All bonds involving hydrogen atoms were restrained using 
the SHAKE algorithm (194). The simulations were carried out at a temperature of 300 K and a 
pressure of 1 bar. A Langevin thermostat was used to regulate the temperature with a collision 
frequency of 1.0 ps-1. The trajectories were saved every 500 steps (1ps). The trajectories were 
analyzed using the ptraj module in Amber 10. 
2.3.2 Accelerated Molecular Dynamics Simulation.  
 
Accelerated MD (aMD) was carried out on the free CaSR ECD using the RaMD method  (195) 
implemented in a pmemd module of AMBER on the rotatable torsion. A boost energy, E, of 
2000kcal/mol was added to the average dihedral energy and a tuning parameter, α, of 200 
kcal/mol was used. The dual boost was also applied to accelerate the diffusive and solvent 
dynamics as previously described  (196).  The simulation conditions were similar to that of the 
normal MD simulations above. Principal Component Analysis was carried out on the trajectories 
using the ptraj module in AMBER. The directions of the eigenvectors for the slowest modes 
were visualized using the Interactive Essential Dynamics (IED) plugin  (197). 
2.3.3 Docking Studies of Phe, Asp, and Glutathione. 
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The binding energies for the ligands were calculated using an ensemble-docking method and 
Autodock vina (198). The ensemble of conformations of CaSR was generated using molecular 
dynamics simulations as described above. Gasteiger charges were assigned to the ligands and 
CaSR using the Autodock ADT program. The ligands were flexible during docking to each 
conformation of CaSR using the following parameters: the grid spacing was 1.0 Å; the box size 
was 25 Å in each dimension, and the center of the box was chosen as the center of the active site 
of CaSR, with a large enough space to sample all possible ligand conformations within the box. 
The maximum number of binding modes saved was set to 10. The conformation with the lowest 
binding energy was used and assumed to be the best binder. Distributions of the binding energies 
for each ligand were calculated based on the lowest binding energy of each ligand to each 
conformation in the ensemble of CaSR conformations. 
2.3.4 Principal Component Analysis (PCA) 
 
Using the ptraj module of AMBER 10, the Principal Component Analysis (199,200) was 
performed on all the atoms of the residues that are 5 Å away from Site 1 of CaSR ECD. The 
covariance matrix of the x, y, and z coordinates of all the atoms obtained from each snapshot of 
the combined trajectories of the ligand-free CaSR ECD, the Ca2+-loaded form, the form loaded 
with only L-Phe, and the form loaded with both Ca2+ and L-Phe were calculated. The covariance 
matrix was further diagonalized to produce orthonormal eigenvectors and their corresponding 
eigenvalues, ranked on the basis of their corresponding variances. The first three eigenvectors, 
the Principal Components, which contributed the majority of all the atomic fluctuations, were 
used to project the conformational space onto them, i.e., along two dimensions. 
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2.4 Plasmid construction and protein engineering 
 2.4.1 L-Phe binding site related mutation construction 
All of the full length CaSR mutants were generated by site-directed mutagenesis based on the 
sequence of the human CaSR-pcDNA (a gift from Dr. Edward Brown from Brigham and 
Women’s Hospital, Boston). Site-directed mutagenesis was performed using the QuikChangeTM 
kit (Stratagene, Cedar Creek, TX) according to the manufacturer’s instructions. Briefly, a pair of 
complementary primers of 27–35 bases was designed for generating each mutant with the 
mutation placed at the middle of the primers. The template human CaSR in pcDNA3.1(+) was 
amplified using Pfu DNA polymerase (Stratagene) with these primers for 16 cycles in a PCR 
instrument (TECHNE). After digestion of the template DNA with DpnI (New England Biolabs), 
the amplified mutant DNA was transformed into XL10-Gold Ultracompetent cells. All the DNA 
sequences were verified by Genewiz (www.genewiz.com). 
2.4.2 Disease related mutation construction 
All of the full length CaSR mutants were generated by site-directed mutagenesis based on the 
sequence of the human CaSR-pEGFP (a gift from Dr. Rajesh Thakker from Oxford Centre for 
Diabetes, Endocrinology and Metabolism) as well as human CaSR-pcDNA. Site-directed 
mutagenesis was performed using the QuikChangeTM kit (Stratagene, Cedar Creek, TX) 
according to the manufacturer’s instructions as mentioned above. 
2.4.3 ECD construction and its mutants 
For engineering of the hCaSR-ECD, the sequence Tyr20-Phe612 was cloned from CaSR-pCDNA 
3.1(+) by standard PCR methods using 5’ primer (CCGGAATTCTACGGGCCAGACCAGCG 
AGCCCAA) and 3’ primer (CCCAAGCTTTTAAAAGGGCTCCGTCCACGACAGAAACT). 
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The cloned sequence was then inserted into the plasmid pXLG between restriction enzymatic 
sites EcoRI and HindIII. The engineered protein contains a transmembrane signal (MRLLTALF 
AYFIVALILAFSVSAKS) followed by His-tag at N-terminal. The sequences were verified 
through the GENEWIZ Company (www.genewiz.com).  
For engineering of the bCaSR-ECD, the ECD CaSR sequence, Met1-Phe 612 was amplified from 
CaSR-pCDNA 3.1(+) (2009 Nancy 27) and was further subcloned into the pRSET-A vector 
between the BamHI and EcoRI restriction sites. 
2.4.4 Furin tag construction and its mutants 
For engineering of the Furin-CaSR-ECD, the furin cleavage site (ARRRKKRGLDV) was 
inserted immediately after the FLAG tag in the pcDNA-CaSR plasmid by standard PCR methods 
using 5’ primer (AAGCGAGGCTTGGACGTCACCTTTCTGAGAGGTCACGAAGAAAGT 
GGC) and 3’primer (CTTTCGTCGTCGTGCCTTGTCATCGTCATCCTTGTAGTCCACAGG). 
The sequences were verified through the GENEWIZ Company (www.genewiz.com). All 
mutations on the Furin site containing construct were introduced using site-directed mutagenesis 
via the QuikChangeTM kit (Stratagene, Cedar Creek, TX) according to the manufacturer’s 
instructions as described above. 
2.4.5 Construction of the Filamin A interaction region deletion mutant CaSR.  
Deletion of the Filamin A interaction region was carried out on the pcDNA-CaSR plasmid. ∆860 
refers to the deletion of the whole CaSR C-terminal after residue 860. ∆907-999 refers to the 
deletion of the region between residue 907 and 999. ∆971 refers to a construct in which the 
region between residue 971 and 1032 was deleted. All constructs were generated using standard 
PCR methods.  
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2.5 Protein expression and purification 
2.5.1 CaSR ECD expression in bacteria system 
The bacterial expression was carried out in Escherichia coli Rosetta-gamiTM pLysS cells in LB 
medium with 100 mg/L of ampicillin with an initial temperature of 37°C. Isopropyl--D-
thiogalacto-pyranoside (IPTG) at 300 M was added when the absorbance at 600 nm reached 
0.4~0.5 to induce protein expression for overnight expression at 27C.  The cells were collected 
by centrifugation at 5000 rpm for 30 min and the cell pellets were lysed using a cell disruptor. 
After separating the mixture by centrifugation at 17000 rpm for 15 min, the supernatant was 
filtered via a 0.45 M filter and further applied to a HisPrep HP column (GE Healthcare) and the 
protein was purified using AKTA FPLC (GE Healthcare). The bacterial CaSR-ECD 
concentrations were determined using absorbance at 280 nm with an extinction coefficient of 
110,300 M-1 cm-1.  
 
2.5.2 CaSR ECD expression in mammalian system 
One liter of Freestyle™ 293 Expression Medium (Life Technologies) was used for HEK293F or 
Lec1 mutant HEK293 F cell culture. Cells were transfected with pXLG-hCaSR-ECD plasmid 
using the polyethylenimine (PEI) method when the cell density achieved 8x105. The hCaSR-
ECD was secreted into the culture media. When the cell density reached 5x106 cell/mL, the 
media was collected by centrifugation 3 times at 1500xg for 10 min each. The supernatant was 
diluted with dilution buffer (Tris NaCl pH=8.0) at a ratio of 1:3 and further filtered through a 
0.45 m filter (Millipore, Billerica, MA). The filtered medium was applied to a 16/10 HisPrep 
HP column (GE Healthcare) pre-equilibrated with Buffer A (Tris 50 mM, NaCl, 150 mM, 
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Imidazole 20 mM) and a linear segmented gradient of 0–100% Buffer B (50 mM Tris, 500 mM 
sodium chloride, and 500 mM imidazole, pH 7.4) was run using FPLC to elute the protein.  The 
hCaSR-ECD concentrations were determined using Bio-Rad protein assay.  
 
2.6 Isotopic labeling of ECD CaSR 
2.6.1 15N labeled CaSR-ECD from bacterial system 
For isotopic labeling (15N-13C-2D), 15NH4Cl and 13C glucose were supplemented as the sole 
source of nitrogen and carbon for bacteria growth in the minimal medium (K2HPO4 45 mM, 
KH2PO4 32 mM, Fe(NH4)2(SO4)2·6H2O 20 M, MgSO4·7H2O 0.25mM, glucose 27.7 mM, 
NH4Cl 9 mM). Escherichia coli Tuner™ strain in minimal medium with 100 mg/L of ampicillin 
was cultured at 37°C at the beginning. Isopropyl--D-thiogalacto-pyranoside (IPTG) at 300 
M was added when the A600 reached 0.6 to induce protein expression for overnight expression 
at 27°C.  The cells were collected by centrifugation at 5000 rpm for 30 min. The cell lysate was 
applied to a HisPrep HP column (GE Healthcare) and protein was purified using AKTA FPLC 
(GE Healthcare). The bCaSR-ECD concentrations were determined using absorption at 280 nm 
with extinction coefficients of 110,300 M-1 cm-1.  
 
2.6.2 13C Methylation labeling of ECD CaSR 
The dimethylation of lysine was performed by reacting with formaldehyde under reducing 
conditions at 4°C for 16 h. The reaction was optimized to allow complete dimethylation. The 
formaldehyde was added twice together with DMAB for reductive methylation. For each time, 
the mole ratio of formaldehyde and Lys was 3:1 and the ratio of DMAB to formaldehyde was 3:1. 
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The time interval between the two additions was 3 hours. The mono-methylated peak can be 
easily differentiated because the chemical shift is in the range of 30-35 ppm while the 
dimethylated lysine has peaks in the range of 42-48 ppm. 
2.6.3 15N labeled CaSR-ECD from mammalian system 
Four~six liters of customized Freestyle™ 293 Expression Medium (Life Technologies) was used 
for HEK293F cell culture. The normal L-Phe supplement in this medium was substituted by N15 
labeled L-Phe. Cells were transfected with pXLG-hCaSR-ECD plasmid using the 
polyethylenimine (PEI) method when the cell density reached 8x10^5. The protocol for purifying 
the mammalian expressed protein was the same as purification for the non-labeled mammalian 
CaSR ECD.  
 
2.7 Circular dichroism spectroscopy 
The circular dichroism spectra were recorded from 190 to 260 nm on a Jasco-810 
spectropolarimeter purged with N2 and equipped with a temperature control system CTC-345. 
Spectral and temperature dependent measurements were performed at a bandwidth of 2 nm using 
a U-type quartz cell of path length 0.1 mm with protein concentrations ranging from 8 to 10 M 
in 10 mM Tris-HCl, pH 7.4. Five spectra were recorded at a scan rate of 50 nm/min and response 
time of 1s. The continuous temperature dependence of the ellipticity at 222 nm was measured 
using a scan rate of 50 C/h and a delay time of 100 s. The cuvette was sealed with parafilm to 
prevent solvent evaporation. 
The spectra were deconvoluted using the selcon method after subtracting the spectrum of the 
buffer as the blank and the CD data was depicted in units of molar ellipticity per residue. The 
melting curve was fitted using equation “∆S =∆Smax/(1 + e(Tm-T)/k)” to obtain the thermal 
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transition point, where ∆S and ∆Smax are the signal changes at each data point and final point, Tm 
and T are the transition temperature and experimental temperature, respectively. k is a transition 
rate that defines how fast the temperature-induced change occurs, which is represented by the 
slope of the transition phase in the fitting curve, a smaller k results in a sharper transition (201).  
 
2.8 Fluorescence spectroscopy 
2.8.1 Intrinsic tryptophan fluorescence 
A PTI lifetime fluorimeter was used to record the fluorescence spectra at room temperature using 
a 1 cm path length cell. Intrinsic tryptophan emission spectra were recorded from 300 to 400 nm 
with the excitation wavelength at 282 nm. The slit widths were set at 1~4 nm for excitation and 
3~8 nm for emission respectively. The calcium titration was performed in 10 mM Tris with the 
protein concentration of 1.5~2.0M at pH 7.4 by adding known amount of CaCl2.  
2.8.2 Tb3+-FRET assay 
For the Tyr/Trp-sensitized Tb3+ fluorescence energy transfer (Tb3+-FRET) assay, protein samples 
(1.5~2.0M) were in 20 mM PIPES-10 mM KCl at pH 6.8. The emission spectra was collected 
from 500~600 nm with the excitation at 282 nm. The slit widths for excitation and emission were 
set at 1 nm and 3 nm, respectively. Secondary Rayleigh scattering was circumvented by using a 
glass filter with a cutoff of 320 nm. The Tb3+ titration was performed by adding various volumes 
of Tb3+ stock solutions (1 mM) stepwise into the cuvettes. The Ca2+ -Tb3+ competition 
experiments were performed in solutions containing 30~50 M Tb3+ and 2 M proteins as the 
starting point. The stock solution of 100 mM ~1 M CaCl2 with the same concentration of Tb3+ 
was gradually added into the mixture. The background fluorescence intensity was subtracted 
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using logarithmic fitting and the Tb3+ binding affinity of the protein was calculated by fitting 
normalized fluorescence intensity data using the Hill equation 
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ΔS is the total signal change in the equation, Kd is the apparent binding affinity, n is the Hill 
coefficient, and [M] is the free metal concentration.  
The Ca2+ competition data was first analyzed to derive the apparent dissociation constant by 
Equation 1. By assuming that the samples were saturated with Tb3+at the starting point of the 
competition, the Ca2+-binding affinity is further obtained by using the equation, 
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where Kd,Ca and Kd,Tb are the dissociation constants of Ca2+ and Tb3+, respectively. Kapp is the 
apparent dissociation constant. 
 
2.8.3 ANS-binding measurement 
For the ANS (8-anilino-1-naphthalenesulfonic acid) binding assay, protein samples were 
incubated with 40 M ANS in 50 mM Tris-HCl and 100 mM KCl (pH 7.4) with either 5 mM 
EGTA or 3 mM Ca2+ at room temperature for 1 h prior to measurement. The excitation 
wavelength was set at 370 nm, and the emission spectra was acquired from 400 to 600 nm. For 
the Ca2+ titration, the protein concentration was 1.5 M and the Ca2+ concentration was varied 
from 0 to 30 mM in 20 mM Tris- HCl and 50 mM KCl (pH 7.4). 
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2.8.4 Measurement of [Ca2+]i in cell population by fluorimetry 
The [Ca2+]i responses of wild type CaSR and its mutants were measured as described by Huang, 
et al. (68). Briefly, CaSR-transfected HEK293 cells were grown on 13.5 × 20 mm coverslips. 
After the cells reached 90% confluence, they were loaded by incubation with 4 μM Fura-2 AM 
in 20 mM HEPES, containing 125 mM NaCl, 5 mM KCl, 1.25 mM CaCl2, 1 mM MgCl2, 1 mM 
NaH2PO4, 1% glucose, and 1% BSA (pH 7.4) for 1 h at 37oC and then washed once with 20 mM 
HEPES, pH 7.4, containing 125 mM NaCl, 5 mM KCl, 0.5 mM CaCl2, 0.5 mM MgCl2, 1% 
glucose, and 1% BSA (bath buffer). The coverslips with transfected Fura-2-loaded HEK293 cells 
were placed diagonally in 3 ml quartz cuvettes containing bath buffer. The fluorescence spectra 
at 510 nm were measured during stepwise increases in [Ca2+]o with alternating excitation at 340 
or 380 nm. The ratio of the intensities of the emitted light at 510 nm when excited at 340 or 380 
nm was used to monitor changes in [Ca2+]i. The EC50 and Hill constants were fitted using the Hill 
equation 
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   (Eq. 2.3) where ΔS is the total signal change in the equation.  
 
2.9 Nuclear magnetic resonance (NMR) spectroscopy 
NMR spectra were collected on a 900 MHz NMR spectrometer. Two-dimensional total 
correlation spectra were collected using a heteronuclear single quantum coherence spectroscopy 
pulse sequence with an isotropic mixing time of 75 ms at 37oC. The spectrum width was 13.3 
ppm at both dimensions with a complex data point of 4096 at the first dimension and 400 
increments at the second dimension. Two dimensional (15N,1H)-heteronuclear single quantum 
correlation (HSQC) NMR spectra were collected with 4096 complex data points at the 1H 
dimension and 128 increments at the 15N dimension. Samples contained the protein at 10 mM 
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Tris buffer, 10% D2O at pH 7.4. All of the NMR data was processed using FELIX (Accelrys) on 
a Silicon Graphicscomputer. 
2.10 Cell culture and transfection 
For measuring cytosolic free [Ca2+], HEK293 cells were seeded on 22 × 40 mm coverslips in 60 
mm culture dishes and cultured in 5% CO2 at 37oC in High Glucose Dulbecco’s modified 
Eagle’s medium (DMEM) (Invitrogen) containing 10% fetal bovine serum with 100 μg/ml 
penicillin-streptomycin. For fluorimetric assays, the cells were grown on 13.5×20 mm coverslips 
that were placed in 6-well plates one day before the transfection. CaSR-pcDNA and its mutants 
were transfected using Lipofectamine 2000TM (Invitrogen) according to the manufacturer’s 
instructions. Cells were incubated for 48 h in high glucose DMEM after transfection.  
 
2.11 Measurement of [Ca2+]i responses in single cells 
Measurement of intracellular free Ca2+ was assessed as described by Huang, et al.(148). Briefly, 
wild type CaSR or its mutants were transiently transfected into HEK293 cells grown on 
coverslips and cultured for 48 h. The cells were subsequently loaded for 15 min using 4 μM 
Fura-2 AM in 2 mL physiological saline buffer (10 mM HEPES, 140 mM NaCl, 5 mM KCl, 1.0 
mM MgCl2, 1 mM CaCl2 and pH 7.4). The coverslips were mounted in a bath chamber on the 
stage of a Leica DM6000 fluorescence microscope. The cells were alternately illuminated with 
340 or 380 nm light, and the fluorescence at an emission wavelength 510 nm was recorded in 
real time as the concentration of extracellular Ca2+ was increased in a stepwise manner in the 
presence or absence of 5 mM L-Phe. The ratio of the emitted fluorescence intensities resulting 
from excitation at both wavelengths was utilized as a surrogate for changes in [Ca2+]i and was 
further plotted and analyzed as a function of [Ca2+]o. All experiments were performed at room 
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temperature. The signals from 30 to 60 single cells were recorded for each measurement. 
Oscillations were identified as three successive fluctuations in [Ca2+]i after the initial peak.  
 
2.12 Immunoassays 
2.12.1 Western Blot 
2.12.1.1 Detection of membrane protein 
The transfected cells grown on 60 mm plates were washed with PBS and lysed with 10 mM Tris-
Cl (pH 7.4), 150 mM NaCl, 0.5% Nonidet P-40, 2 mM EDTA, 1 mM EGTA, and 1X protease 
inhibitor cocktail on ice for 30 min. Cell debris was removed by centrifugation at 10,000 rpm for 
10 min at 4 °C. The supernatants were denatured in SDS sample buffer (60 mM Tris-HCl, 2% 
SDS, 10% glycerol, 5% -mercaptoethanol, 0.1% bromphenol blue) at 55°C for 10 min under 
reducing conditions and subjected to 7.5% SDS-PAGE. The proteins resolved by SDS-PAGE 
were subsequently electrotransferred to a nitrocellulose membrane (Thermo Scientific). The 
membrane was blocked using 2% non-fat milk (Bio-Rad). The CaSR on the blot was detected by 
incubation with a 1:3000 dilution of monoclonal anti-CaR antibody (ADD, Abcam) followed by 
horseradish peroxidase-conjugated, goat anti-mouse secondary antibody. CaSR was visualized 
with an enhanced chemiluminescence detection reagent according to the manufacturer's 
instructions (Pierce Biotechnology). 
2.12.1.2 ERK activity detection 
Thirty-six hours post transfection of monolayers of HEK293 cells with CaSR or its mutants, cells 
were incubated in serum-free high glucose DMEM medium supplemented with 0.2% w/v BSA at 
37oC overnight. On the following day, cells were first incubated with HBSS for 30 min, followed 
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by stimulation with varying levels of CaCl2 (0-20 mM) with or without L-Phe (5 mM) for 10 min. 
At the end of the [Ca2+]o stimulation, cells were lysed with RIPA lysis buffer (Millipore, CA, 
USA). In total, 150 g aliquots of lysate protein were loaded into either a 12.5% SDS-gel or a 
4%-12.5% gradient gel for PAGE and analyzed by western blotting with an anti-phospho-p44/42 
ERK polyclonal antibody (Cell signaling Technology, Beverly, MA, USA) diluted (1:2000). A 
chemiluminescent method (AP Conjugate Substrate Kit) was employed to detect the phospo-
p44/42 proteins. Quantitative analysis of the results was performed using ImageJ software 
(National Institutes of Health). The responses were normalized to the maximal effect observed 
with [Ca2+]o alone. The EC50 of [Ca2+]o-dependent responses was calculated by fitting the [Ca2+]o 
concentration-response curves with the Hill equation 
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 where ΔS is the total signal 
change in the equation, Kd is the apparent binding affinity, n is the Hill coefficient, and [M] is 
the free metal concentration.  
 
2.12.2 Immunofluorescence staining 
2.12.2.1 Immunostaining of membrane protein 
CaSR-transfected HEK293 cells were grown on poly(L-lysine)-coated glass coverslips for 
immunofluorescence microscopy. After treatment with polyoxymethylene for 15 minutes, non-
specific antigens on the cells were blocked by incubating with 2% BSA/PBS at 37°C for 1 hr. 
Anti-CaSR, mouse monoclonal antibody, ADD, was diluted 1:3000 in 1% BSA/PBS and 
incubated with the coverslips overnight at 4°C. Cells were then washed with PBS for 10 minutes 
at room temperature before incubating with a 1:3000 dilution of a FITC-labeled goat anti-mouse 
IgG antibody (Invitrogen) at 37°C for 1 hr. Coverslips were then washed with PBS followed by 
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incubation with 0.1% Triton X-100 for 15 minutes. Cells were further stained with propidium 
iodide (PI) (0.5 μg/mL) for 15 minutes at room temperature before they were mounted with anti-
fade reagent (Invitrogen). Assessment of plasma membrane staining was carried out using a 63× 
objective (Zeiss 700). 
2.12.2.2 ADIS experiment 
HEK293 cells were transfected with WT CaSR and variant mutations. After 48 hours, cells were 
first incubated with rabbit anti-flag monoclonal antibody for 1 hour at 4 oC, then stimulated with 
various levels of CaCl2 (0-20 mM) for 10 min (37 oC). Cells were subsequently fixed with 3.7% 
formaldehyde for 15 mins at room temperature and labeled with mouse anti-Flag monoclonal 
antibody for 1 hour (room temperature). Cells were further permeabilized with 0.2% triton x-100 
for 5 mins and stained with goat anti-rabbit Alexa488 and goat anti-mouse Alexa 568 conjugated 
secondary antibodies. Images were collected on Zeiss LSM700 confocal microscope (Carl Zeiss, 
Germany).  
2.12.3 Immunoprecipitation 
2.12.3.1 Biotin assay 
HEK293 cells transfected with different CaSR mutants were incubated with 30 μg/ml disulfide-
cleavable biotin for 30 min at 4°C. Cells were subsequently washed with TBS and incubated in 
Ca2+-free DMEM at 37°C for 15 min. Cells were washed three times with TBS and stimulated 
with buffers containing various [Ca2+]o for 10 minutes. Next, additional calcium was removed by 
washing with TBS and the cells were incubated with reducing buffer (containing 50 mM 
glutathione, 75 mM NaCl, 75 mM NaOH, and 1% FBS) for 20 min at 4°C. Iodoactaminde (50 
mM with 1% BSA in PBS) was added to quench residual unreacted glutathione. Cells were 
washed three times with TBS and lysed in lysate buffer (10 mM Tris-HCl (pH 7.4), 150 mM 
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NaCl, 0.5% Nonidet P-40, 1% Triton-X100 and a 1×protease inhibitor cocktail (EDTA-Free; 
Roche)). CaSR was subsequently immunoprecipitated with anti-FLAG M2 antibody and protein 
A agarose. Samples were denatured in 2× sample loading buffer and subjected to SDS-PAGE. 
Biotinylated CaSR was visualized using Vectastain ABC immunoperoxidase reagent (Vector 
Laboratories, Burlingame, CA). 
 
2.12.3.2 Pull-down assay 
HEK293 cells were lysed 48 hours after transient transfection with the wild type CaSR or its 
truncated constructs. The lysis buffer contains 20 mM Tris-HCl (pH 7.4), 100 mM NaCl, 1% 
Triton-X100. The supernatant of the cell lysates (total about 0.4mg of protein) were collected 
and incubated with 5 μl of anti-flag monoclonal antibodies (Sigma) for half an hour at 4 ºC.  
About 30 μl of the protein A-agarose (Santa Cruz Biotechnology, Inc) was subsequently added, 
and the mixture was gently rotated for overnight at 4 ºC. After washing three times with the 
respective buffers, the agarose beads were finally resuspended in 45 μl 2X SDS sample buffer 
and heated at 42°C for 15 min and subjected to 7.5% SDS-PAGE. The standard western-blotting 
procedure was performed to detect the CaSR, filamin or CaM using anti-FLAG antibody (Sigma) 
and agarose A.   
 
2.12.4 IP-1 ELISA assay 
HEK293 cells were seeded in 24-well plates at 3 x 105 cells per well in 500 l of culture medium. 
After transfection with WT CaSR, or its various mutants, cells were further cultured for 24 hours 
at 37C. Cell monolayers were first washed with Ringer’s buffer without calcium (121 mM NaCl, 
2.4 mM K2HPO4, 0.4 mM KH2PO4, 10 mM HEPES, 5.5 mM glucose, 1.2 mM MgCl2) and then 
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incubated for 1 hour at 37C in stimulation buffer (140 mM NaCl, 5 mM KCl, 10 mM LiCl2, 
0.55 mM MgCl2, 10 mM HEPES) containing varying concentrations of CaCl2.   After treatment, 
cells were lysed for 30 min at 37C with 50 l of 2.5% IP1 ELISA Kit Lysis Reagent (CIS Bio 
International, Gif-sur-Yvette, France). The accumulation of IP1 was measured using an 
immunoassay based on competition between free IP1 and horseradish peroxidase (HRP) 
conjugated IP1 for binding to monoclonal anti-IP1 antibody. The results for IP1 were expressed 
as percentage inhibition of IP1-HRP binding = [1-IP1-HRP binding in stimulated cells/IP1-HRP 
binding in unstimulated cells] x 100.   
 
 
Figure 2.1 Schematic representation of IP1 competition assay.  
IP-One ELISA is a competitive immunoassay which uses IP1-HRP and an anti-IP1 
monoclonal antibody. The kit comes with 96-well microplates pre-coated with an anti-
mouse antibody. Cells are stimulated in the presence of LiCl, causing the accumulation of 
IP1 upon receptor activation. The protocol consists of two steps following cell stimulation: 
H
R
PIP1
IP1
H
R
PIP1
IP1-HRP conjugateGoat anti-mouse IgG Anti IP1 Mab
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addition of ELISA components and addition of TMB, the HRP substrate. The HRP 
reaction is stopped and the optical density (OD) read at 450nm 
(http://www.htrf.com/usa/ip-one-elisa-assay). 
 
2.13 Lectin Agarose Binding Assay 
The ECD containing fractions after His-tag purification were mixed with 30 L of RCA-1 lectin 
agarose (Vector Lab, Burlingame, CA) for overnight incubation at 4Ԩ followed by a washing 
step with PBS. The ECD protein was eluted using 0.2 M galactose. The elution fractions were 
analyzed by Western blot, using an anti-flag antibody. 
2.14 Deglycosylation reactions 
Triton X-100 was added to heat- and SDS-denatured, purified ECD protein (20 g) at a final 
concentration of 2% before the protein was subjected to the PNGaseF deglycosylation procedure. 
Around 1.4 units of PNGase F were added per microgram of purified protein and incubated for 2 
h at 37Ԩ. The samples subjected to deglycosylation were further analyzed by Western blot using 
an anti–flag antibody. For Endo F1 enzyme treatment, purified Lec1-hCaSR-ECD protein was 
directly taken from FPLC fraction and incubated with Endo F1 at mass ratio 1:3 in 10 mM Tris 
buffer, pH 7.4 for overnight incubation at 4 Ԩ.	 
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CHAPTER 3. IDENTIFICATION OF AN L PHENYLALANINE BINDING SITE 
ENHANCING THE COOPERATIVE RESPONSES OF THE CALCIUM SENSING 
RECEPTOR TO CALCIUM 
3.1 Introduction 
 It has long been recognized that Ca2+ acts as a second messenger that is released from 
intracellular stores and/or taken up from the extracellular environment in response to external 
stimuli to regulate diverse cellular processes. The discovery of the parathyroid Ca2+-sensing 
receptor (CaSR) by Brown et al. has established a new paradigm of Ca2+ signaling (38). In 
addition to its known role as a second messenger, extracellular Ca2+ can function as a first 
messenger by CaSR-mediated triggering of multiple intracellular signaling pathways, including 
activation of phospholipases C, A2, and D, and various mitogen-activated protein kinases 
(MAPKs), as well as inhibition of cAMP production (121,202-206). This receptor is present in 
the key tissues involved in [Ca2+]o homeostasis (e.g., parathyroid, kidney, bone) and diverse 
other non-homeostatic tissues (e.g., brain, skin, etc.) (41,49,101,207). CaSR consists of a large 
N-terminal extracellular domain (ECD) (~600 residues) folded into a Venus Fly Trap (VFT) 
motif, followed by a 7-pass transmembrane region (7TM) and a cytosolic C-terminus. The ECD 
has been shown to play an important role in the cooperative response of the CaSR to [Ca2+]o. 
Elevations in [Ca2+]o activate the CaSR, evoking increases in the intracellular Ca2+ concentration 
([Ca2+]i), producing [Ca2+]i oscillations, modulating the rate of parathyroid hormone (PTH) 
secretion, and regulating gene expression (24,119,121,126). The pattern of [Ca2+]i oscillations is 
one of the most important signatures reflecting the state of CaSR activity.  
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 More than two hundred naturally-occurring mutations have been identified in the CaSR 
that either inactivate the receptor (reducing sensitivity to [Ca2+]o), leading to familial 
hypocalciuric hypercalcemia (FHH) or neonatal severe hyperparathyroidism (NSHPT), or 
activate it (increasing sensitivity to [Ca2+]o), thereby causing autosomal dominant 
hypoparathyroidism (ADH) (208-210). Several of these naturally-occurring mutations of CaSR 
exhibit altered functional cooperativity (208).  
 
  Functional cooperativity of CaSR (i.e., based on biological activity determined using 
functional assays rather than a direct binding assay), particularly the positive homotropic 
cooperative response to [Ca2+]o, is essential for the receptor’s ability to respond over a narrow 
physiological range of [Ca2+]o (1.1-1.3 mM). CaSR has an estimated Hill coefficient of 3-4 for its 
regulation of processes such as activating intracellular Ca2+ signaling and inhibiting PTH release. 
Under physiological conditions, L-amino acids, especially aromatic amino acids (e.g., L-Phe), as 
well as short aliphatic and small polar amino acids (211), are able to potentiate the high [Ca2+]o–
elicited activation of the CaSR by decreasing the EC50 values required for [Ca2+]o-evoked [Ca2+]i 
responses and its functional cooperativity (118,212). The levels of amino acids in human serum 
are close to those activating the CaSR in vitro (118,213) and can further enhance functional 
cooperativity via positive heterotropic cooperativity. Recently, several groups have reported that 
the CaSR in cells within the lumen of the gastrointestinal (GI) tract is activated by L-Phe and 
other amino acids, which have long been recognized as activators of key digestive processes. 
Hence, the CaSR enables the GI tract to monitor events relevant to both mineral ion and 
protein/amino acid metabolism in addition to the CaSR’s sensing capability in blood and other 
extracellular fluids (118,166,214). Glutathione and its -glutamylpeptides also allosterically 
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modulate the CaSR at a site similar to the L-amino acid-binding pocket but with over 1,000-fold 
higher potencies (212,215). Thus, CaSR is essential for monitoring and integrating information 
from both mineral ions/nutrients/polyamines in blood and related extracellular fluids. 
Nevertheless, we still lack a thorough understanding of the molecular mechanisms by which 
CaSR is activated by [Ca2+]o and amino acids, which, in turn, regulate CaSR functional 
cooperativity. In addition, in a clinical setting, the molecular basis for the alterations in this 
cooperativity caused by disease-associated mutations is largely unknown due to the lack of 
knowledge of this receptor’s structure and its weak binding affinities for [Ca2+]o and amino acids 
(68,126,172,208).  
 
      In the present study, we use two complementary approaches--monitoring [Ca2+]i  
oscillations in living cells and molecular dynamic (MD) simulations--to provide important 
insights into how the CaSR functions and the behavior of the receptor at the atomic level. We 
first demonstrate that the molecular connectivity between [Ca2+]o–binding sites that is encoded 
within the key Ca2+-binding Site 1 in the hinge region of the CaSR’s ECD is responsible for the 
functional positive homotropic cooperativity in the CaSR’s response to [Ca2+]o. We further 
identify an L-Phe-binding pocket adjacent to Ca2+-binding Site 1. We show that this L-Phe-
binding pocket is essential for functional positive heterotropic cooperativity by virtue of its 
having a marked impact on all five of the predicted Ca2+-binding sites in the ECD with regard to 
[Ca2+]o-evoked [Ca2+]i signaling. Furthermore, with molecular dynamics (MD) simulations we 
show that the motions of Ca2+-binding Site 1 are correlated with those of the other predicted 
Ca2+-binding sites. Finally, the dynamic communication of L-Phe at its predicted binding site in 
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the hinge region with the CaSR’s Ca2+–binding sites globally enhances cooperative activation of 
the receptor in response to alterations in [Ca2+]o.  
 
3.2 Results 
3.2.1 Molecular connectivity among predicted calcium-binding sites is required for functional 
cooperativity of CaSR  
  It has been documented that in several regions of the CaSR and mGluRs, the amino acid 
residues are highly conserved (216). Those conserved elements provide a structural framework 
for the modeling of the CaSR ECD. Among all the available crystal structures of the mGluRs, 
studies on mGluR1 give concrete structural information about ligand-free as well as various 
ligand-bound forms of the receptor. Moreover, CaSR and mGluR1 share similar signaling 
pathways and can form heterodimers either in vivo or in vitro (61). Thus, the crystal structures of 
mGluR1 were employed for modeling the CaSR ECD. By using our own computational 
algorithms, we previously identified five putative Ca2+-binding sites in the modeled CaSR ECD 
(Figure 3.1) (68,169,172). Among those, Site 1 is located in the hinge region of the two 
subdomains in the VFT motif. Among 34 newly found naturally-occurring missense mutations 
within the ECD, 18 are located within 10 Å of one or more of the predicted Ca2+-binding sites 
(208). Interestingly, a few disease-associated human mutations severely alter the functional 
cooperativity of CaSR (161) . 
 
  Functional positive homotropic cooperativity here refers to [Ca2+]o-induced changes in 
CaSR activity that can be ascribed to interactions between the five predicted Ca2+-binding sites, 
which are located in different regions of the ECD (217-219). To understand the observed 
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cooperativity and the origin of changes in cooperativity caused by disease-associated mutations 
at the atomic level, we have carried out MD simulations on the modeled CaSR ECD to predict 
correlated motions. MD simulation provides an approach complementary to experiments in live 
cells for understanding biomolecular structure, dynamics, and function (220). We calculated the 
cross-correlation coefficients of each residue with all of the other residues of the CaSR ECD 
from the simulations. Figure 3.1 (lower-right panel) shows the normalized correlation matrix 
map of both negative (blue) and positive (red) correlated motions between each pair of residues 
that indicate movements in the opposite direction or in the same direction, respectively. Positive 
correlations occur between groups of residues if they are within the same domain or directly 
interact with each other. Figure. 3.1 shows strong correlations amongst residues from S169 to 
A324. Notably, the negative correlation motions between residues K47-L125 and residues S240-
A300 suggest that the two lobes undergo a dynamic change similar to that of mGluR1 upon 
interactions with its ligands. Closer analysis indicates that residues involved in Ca2+-binding Site 
1 exhibit negative correlations with residues in Sites 2, 3, 4 and 5 (Table 3.1).  
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Figure 3.1 Delineating the molecular connectivity associated with functional positive 
homotropic and positive heterotropic cooperativity of the CaSR’s ECD by molecular 
modeling of L-Phe- and Ca2+-binding sites.  
The hinge region is defined as locations near calcium binding site 1. Upper Left corner: The 
location of the predicted calcium binding site 1 and the potential residues involved in the L-Phe 
interaction. Residues in cyan: residues which are both involved in calcium and L-Phe interaction. 
Residues in purple: residues are predicted to interact with L-Phe 
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Table 3.1 Analysis of correlated motions of WT CaSR model structure.  
 Residue Pairs 
Negative 
Correlation 
S170 (Site 1): D398 (Site 5) 
D190 (Site 1): S244 (Site 2) 
D190 (Site 1): D248 (Site 2) 
E297 (Site 1): D248 (Site 2) 
D190 (Site 1): Q253 (Site 2) 
E297 (Site 1): Q253 (Site 3) 
E218 (Site 1): E350 (Site 4) 
E297 (Site 1): E378 (Site 5) 
Positive 
Correlation 
E224 (Site 3): E228 (Site 3) 
E228 (Site 3): E229 (Site 3) 
S244 (Site 2): D248 (Site 2) 
S244 (Site 2): Q253 (Site 2) 
E350 (Site 4): E353 (Site 4) 
E354 (Site 4): E353 (Site 4) 
E378 (Site 5): E379 (Site 5) 
D398 (Site 5): E399 (Site 5) 
 
The cross-correlation coefficients of each residue to all of the other residues of the modeled 
CaSR ECD structure after docking with calcium were calculated from the simulation. The 
strongest positive correlation of a residue with itself is given the value 1; the strongest 
negative correlation between two residues is given the value -1. A cut off at > 0.7 and < -0.4 
is considered as a strong correlation between residues. Strongly correlated residues in 
predicted calcium-binding sites are listed in the table.  
 
 
  We then predicted a putative amino acid-binding site in the modeled CaSR based on its 
sequence homology to mGluR1 and its ligand-loaded form using AutoDock-Vina (174). As 
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shown in Figure 3.1 (upper-left panel), this potential amino acid-binding pocket, formed by 
residues K47, L51, W70, T145, G146, S169, S170, I187, Y218, S272, H413 and R415, partially 
overlaps Ca2+-binding Site 1 in the modeled CaSR ECD. Its predicted location is consistent with 
previous functional studies, suggesting important roles for S170 and T145 in amino acid-
potentiated intracellular calcium responses (221-223). This L-Phe-binding site is also located 
within the hinge region of the ECD of CaSR with a relatively localized configuration. Other 
Ca2+-binding Sites (Sites 2-5) are more than 10 Å away from the L-Phe-binding site.(172). This 
partial colocalization of the predicted Ca2+- and amino acid-binding sites at the hinge domain in 
the ECD of the CaSR is also observed in other members of the family C GPCRs, including 
mGluRs and taste receptors, which share some degree of sequence similarity Figure 3.2a 
(38,96,101,204,209,224,225). The calculated binding free energy of CaSR for various ligands (in 
the order of glutathione>L-Phe>L-Asp) is in excellent agreement with previous reported 
experimental results obtained by determining the EC50 of intracellular Ca2+ responses to the same 
ligands Figure 3.2b (118).  
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Figure 3.2 Sequence alignment and binding energy calculations based on the modeled 
structure of CaSR ECD. 
(a) Sequence alignment of the orthosteric binding site for Glu in mGluR1 with CaSR and 
ten other GPCRs of family C. Residues involved in the predicted CaSR Ca2+-binding Site 1 
are labeled at the top and corresponding residues in other group members are highlighted 
in yellow. (b) The binding energies were calculated after molecular dynamics simulations. 
Red line: CaSR-ECD docking with glutathione (GLUT); Black line: CaSR-ECD docking 
with phenylalanine (PHE); Blue line: CaSR-ECD docking with aspartic acid (ASP). 
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        We define functional positive heterotropic cooperativity as that which occurs when the 
functional positive cooperative effect of interaction with one ligand (e.g., Ca2+) affects the 
functional response resulting from interaction of a different ligand with the protein (e.g., an 
aromatic amino acid) (226). This term can be applied in the case of CaSR when it simultaneously 
senses Ca2+ and L-Phe. We have also observed greater correlated motions among the multiple 
Ca2+-binding sites after docking both Ca2+ and L-Phe compared with docking of L-Phe alone to 
the ECD domain of the CaSR (Figure 3.3). Taking these results together, we propose that there is 
molecular connectivity centered at predicted calcium-binding Site 1 that plays an essential role in 
regulating the correlated motions among the multiple Ca2+-binding sites. Further communication 
of this site with the amino acid-binding site is likely to mediate functional heterotropic 
cooperativity of CaSR-mediated signaling, as shown later.   
 
Figure 3.3 The correlation map of the modeled CaSR ECD structure with the L-Phe-loaded 
form, calcium-loaded form and the form loaded with both calcium and L-Phe.  
The cross correlation matrices show the movements of residues during MD simulation. 
Positive values (in red) show residues moving in the same direction while negative values 
(in blue) indicate residues moving away from one another. 
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3.2.2 Functional positive homotropic cooperativity among Ca2+-binding sites.  
Given that it is not readily feasible to perform radioligand binding assays on CaSR due to its low 
affinities for its ligands, especially Ca2+ (e.g., mM Kd) as well as difficulty in purification of 
CaSR, we monitored intracellular calcium  ([Ca2+] i) responses using both a cuvette population 
assay and by monitoring [Ca2+]i oscillations using single cell imaging to determine functional 
cooperativity of CaSR. HEK293 cells transfected with WT CaSR exhibited sigmoidal 
concentration response curves for the [Ca2+]i responses (as monitored by changes in the ratio of 
fluorescence at 510 nm when excited at 340 or 380 nm) elicited by changes in [Ca2+]o with a Hill 
coefficient of 3.0 ± 0.1 and a EC50 of 2.9 ± 0.2 mM, suggesting strong positive homotropic 
cooperativity within its five predicted Ca2+-binding sites. The sensitivity to agonist was assessed 
using the [Ca2+]o at which cells began to show [Ca2+]i oscillations and the frequency of the 
oscillations at the respective levels of [Ca2+]o at which more than 50% of the cells started to 
oscillate. 
To seek the key determinants underlying the observed functional positive homotropic 
cooperativity, mutations were introduced into the various predicted Ca2+-binding sites of the 
CaSR by site-directed mutagenesis, which resulted in impaired Ca2+-sensing with altered 
oscillation patterns in single cell studies and higher EC50 values compared with WT CaSR in 
population studies (Figure 3.4, 3.5) (Table 3.2 & 3.3). Such population studies were also reported 
in our previous studies (68,172).  Results from western blot and immunocytochemistry utilizing 
immunofluorescence to detect the CaSR indicated essentially equivalent expression of WT CaSR 
and its variants on the cell surface (Figure 3.6). As shown in Figure 3.4a, the level of [Ca2+]o 
required to initiate oscillations in mutant E297I at predicted Ca2+-binding Site 1 or D215I at Site 
2 increased markedly from 3.0 ± 0.1 mM to 17.0 ± 0.4 mM and 13.9 ± 0.2 mM, respectively, 
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(p<0.05). Correlating well with these results, the two mutants had significantly impaired 
responses to [Ca2+]o in the population assay with increased EC50 values (Table 3.3). The Hill 
coefficients in Table 3.3 & Figure 3.4b indicate that the cooperativity among the various Ca2+-
binding sites was impaired by mutating each of them separately. Strikingly, removal of Ca2+-
binding ligand residues, such as E297I and Y218Q at Site 1, converted the single process for 
functional activation of the WT CaSR by [Ca2+]o to biphasic functional processes, suggesting 
that the underlying cooperative binding mechanism had been substantially perturbed Figure 
3.4b&Figure 3.7d. 
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Figure 3.4 Intracellular Ca2+ responses of CaSR mutants involving various Ca2+-binding 
sites following simulation with increases in [Ca2+]o.  
a. Statistical analysis of the starting points for [Ca2+]i oscillation in HEK-293 cells 
transfected with WT, E297I or D215I , respectively. The [Ca2+]o was recorded at the level of 
[Ca2+]i at which single cells began to oscillate. Around 30~60 cells were analyzed and 
further plotted as a bar chart. b. Population assays of WT and Ca2+-binding site-related 
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mutations. HEK293 cells transfected with CaSR or its mutants were loaded with Fura-2 
AM. The intracellular Ca2+ level was assessed by monitoring emission at 510 nm with 
excitation alternately at 340 or 380 nm as described previously(148). The [Ca2+]i changes in 
the transfected cells were monitored using fluorimetry during stepwise increases in [Ca2+]o. 
The [Ca2+]i responses at various levels of [Ca2+]o were plotted and further fitted using the 
Hill equation.  
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Figure 3.5 Individual cellular responses of mutants in calcium-binding sites to the indicated 
increments of [Ca2+]o in the presence or absence of L-Phe.  
(a) Representative intracellular calcium response from a single cell. Fura-2 loaded HEK293 
cells expressing CaSRs with mutations in calcium-binding sites were prepared for single 
cell experiments. In each experiment, with or without 5 mM L-Phe in non-calcium-
containing Ringer’s buffer, stepwise increases in [Ca2+]o in non-calcium containing 
Ringer’s buffer, in the presence or absence of L-Phe, were carried out until [Ca2+]i reached 
a plateau (up to 30 mM). At least 30 cells were analyzed for each mutant. (b) Statistical 
analysis of the [Ca2+]o at which CaSR-transfected single HEK293 cells started to oscillate. 
Empty bar: in the absence of L-Phe; Black bar: in the presence of 5 mM L-Phe. (c) The 
frequency distribution of the oscillation patterns in single cells was investigated as 
described before. For experiments without L-Phe, the peaks per minute were recorded at 
the level of [Ca2+]o at which the majority of cells (>50%) started to oscillate; for 
experiments with 5.0 mM L-Phe, the frequency was analyzed at the same  [Ca2+]o that was 
used in the absence of L-Phe. Specifically, the frequency of oscillations observed with 
mutant E353I was analyzed at 5.0 mM [Ca2+]o; for D398A/E399I it was investigated at 10.0 
mM  [Ca2+]o  and  E224I it was studied at 4 mM [Ca2+]o. Empty bar: in the absence of L-
Phe; black bar: in the presence of 5 mM L-Phe. 
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Table 3.2 Summary of individual cellular responses to the indicated increments of [Ca2+]o in HEK293 cells transiently 
transfected with WT CaSR or mutations in the indicated Ca2+-binding sites. 
Predicted 
Sites Residues Mutants 
Starting Point (mM) Ending Point (mM) Frequency 
w/o L-Phe w  L-Phe w/o L-Phe w  L-Phe w/o L-Phe w  L-Phe 
WT  WT 3.0 ± 0.1 2.0 ± 0.2b 6.4 ± 0.3 4.3 ± 0.2 1.5 ± 0.1 2.2 ± 0.2b 
Site 1 S147, S170,D190, Y218, E297 E297I 17.0 ± 0.4
a 7.3 ± 0.2b N/A N/A 1.6 ± 0.1 2.9 ± 0.1b 
Site 2 D215, L242, S244, D248, Q253 D215I 13.9 ± 0.2
a 6.7 ± 0.3b N/A 17.7 ± 0.3 1.8 ± 0.1 2.5 ± 0.2b 
Site 3 E224, E228, E229, E231, E232 E224I 5.0 ± 0.2
a 3.2 ± 0.1b 16.8 ± 0.3 11.0 ± 0.1b 1.4 ± 0.2 2.2 ± 0.1b 
Site 4 E350, E353, E354, N386, S388 E353I 3.4 ± 0.1
a 2.4 ± 0.1b 10.8 ± 0.2 4.9 ± 0.2b 1.2 ± 0.2 2.0 ± 0.2b 
Site 5 E378,E379, T396,  D398, E399 
D398A 
/E399I 9.3 ± 0.1
a 5.5 ± 0.2b N/A N/A 1.4 ± 0.2 2.2 ± 0.2b 
 
The average [Ca2+]o was recorded at which [Ca2+]i oscillations started or terminated. Values are means ± S.E. N/A= not 
available. a indicates significance with respect to wild type CaSR without L-Phe, p <0.05; b indicates significance with respect 
to the corresponding experiment in the same mutant without L-Phe, p <0.05. 
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Table 3.3 Summary of EC50 values and Hill coefficients predicted using Hill equation for the WT and mutant CaSRs. 
Sites Mutants 
Response at 30 mM [Ca2+] EC50[Ca2+]o Hill Coefficient 
w/o L-Phe w  L-Phe w/o L-Phe w  L-Phe w/o L-Phe w  L-Phe
WT  100.0 ± 2.0 104.6± 2.9 2.9 ± 0.2  1.9 ± 0.2b 3.0 ± 0.1 4.0 ± 0.4b 
Site 1 E297I 78.0 ± 6.9a 132.8 ± 1.9b 
Phase 1: 
3.2 ± 0.4 
7.4 ± 0.6b 
Phase 1: 
2.8 ± 0.2 
4.2 ± 0.3b Phase 2: 
17.8 ± 0.5 
Phase 2: 
3.5 ± 0.1 
Site 2 D215I 88.0 ± 2.5a 147.5 ± 6.0b 14.7 ± 1.9a 9.0 ± 0.5b 2.0 ± 0.2a 2.8 ± 0.3b 
Site 3 E224I 83.2 ± 5.2a 104.2 ± 4.5b 5.3 ± 0.4a 3.1 ± 0.1b 1.9 ± 0.1a 4.3 ± 0.2b 
Site 4 E353I 80.7 ± 1.6a 88.9 ± 1.8b 4.0 ± 0.1a 2.6 ± 0.1b 2.3 ± 0.1a 3.6 ± 0.1b 
Site 5 D398A/E399I 80.9 ± 7.0a 78.3 ± 6.5 4.7 ± 0.7a  3.3 ± 0.1a 2.4 ± 0.1a 3.6 ± 0.4b 
 
HEK293 cells were transiently transfected with the WT CaSR or CaSRs with mutations in Ca2+-binding sites, and after 48 h 
the cells were loaded with fura-2 as described under “Materials and Methods”. The cells on glass coverslips were then 
transferred into the cuvette for measurement of [Ca2+]i by fluorimetry and exposed to various increases in [Ca2+]o in the 
absence or presence of 5 mM L-Phe. The data were obtained from three experiments for each construct. The maximum 
response for each mutant was subtracted from the baseline and normalized to the maximal cumulative [Ca2+]i response of the 
WT receptor. Curve-fitting was performed using the Hill equation. a indicates significance with respect to wild type CaSR in 
the absence of L-Phe, p < 0.05; b indicates significance with respect to the corresponding mutants in the absence of L-Phe, p < 
0.05. 
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Figure 3.6 Expression of WT CaSR and its mutants in HEK293 cells.  
 
(a) Western blot analyses of CaSR and its mutants in transiently transfected HEK293 cells. 
40 g of total protein from cellular lysates were subjected to 8.5% SDS-PAGE. Three 
characteristic bands are shown in the upper panel, including the top band representing the 
dimeric receptor, the middle band showing mature glycosylated CaSR monomer (150 kDa), 
and the lowest band indicating immature glycosylated CaSR monomer (130 kDa). The non-
glycosylated CaSR monomer form is about 110 kDa. (b) Quantification of the expression of 
WT CaSR and its mutants in HEK293 cells. All the bands are shown, including the one 
indicating dimeric receptor, mature glycosylated monomer and the one showing immature 
CaSR monomer. The internal control GAPDH was used to standardize CaSR expression 
and the mutants were further normalized to the WT CaSR expression. (c) 
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Immunofluorescence analyses of surface expressed WT CaSR and its mutants in HEK293 
cells. Immunostaining was done with anti-CaSR monoclonal antibody ADD (227), and 
detection was carried out with Alex Fluor 488-conjugated, goat anti-mouse secondary 
antibody. Red, PI staining of cell nuclei; Green, CaSR. Equivalent expression of WT CaSR 
as well as its variants on the cell surface suggests that the difference in the Ca2+-sensing 
capabilities among the WT and mutant receptors are due to perturbation of the cell surface 
receptors’ functions, rather than, for example, impaired trafficking of the receptor proteins 
to the cell surface. 
 
 
3.2.3 Functional positive heterotropic cooperativity contributed by the identified L-Phe-binding 
site. 
Figure. 3.7a shows the effect of 5 mM L-Phe on the [Ca2+]i responses at different levels of 
[Ca2+]o in HEK293 cells transiently transfected with the WT CaSR or its variants with mutations 
around the predicted L-Phe-sensing site. L-Phe lowered the threshold for [Ca2+]o–induced 
oscillations in the WT CaSR from 3.0 ± 0.1 mM to 2.0 ± 0.2 mM, about a 1.5-fold shift (Figure 
3.7b, Table 3.2). Concurrently, L-Phe also increased the oscillation frequency from 1.5 ± 0.1 to 
2.2 ± 0.2 peaks/min (p<0.05) in the presence of 3.0 mM [Ca2+]o in the single cell assay (Figure 
3.7b). Meanwhile, L-Phe produced functional positive heterotropic cooperativity of the receptor, 
as it facilitated the response of the WT CaSR to [Ca2+]o by significantly decreasing the EC50 from 
2.9 ± 0.2 mM to 1.9 ± 0.2 mM (p<0.05) and increasing the Hill coefficient from 3.0 to 4.0 in the 
cell population assay (Figure 3.7b, Table 3.3).  
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         We then performed detailed analyses to understand the role of residues in the modeled L-
Phe-binding site in the functional positive heterotropic cooperativity contributed by L-Phe 
(Figure 3.7, Table 3.4). Five out of 12 residues located within 5 Å of the modeled L-Phe-binding 
site exhibited impaired L-Phe-sensing ability. Mutants L51A and S170T exhibited impaired L-
Phe-sensing capability as indicated by the absence of any change in the starting point (Figure 
3.7b) as well as constant oscillatory frequencies (~1.7 and 1.4 peaks/min) in the presence of L-
Phe (Figure 3.7c), while they maintained relatively unaltered calcium-sensing functions. 
Consistent with the single cell assay results, cell population studies revealed that the EC50 values 
of L51A, S170T and Y218Q remained the same with or without L-Phe (Figure 3.7d). The effect 
of S170T on the sensing of L-Phe has previously been reported by Zhang et. al. in a cell 
population assay (221). Addition of 5 mM L-Phe lowered the [Ca2+]o required to initiate 
oscillations in cells transfected with mutations S272A or T145A but failed to increase the 
oscillatory frequency at 2.5 mM [Ca2+]o (the level at which the majority of the cells began to 
oscillate), nor did it reduce the EC50 (Table 3.4, Figure 3.8). Y218 is predicted to be involved in 
binding of both L-Phe in its binding pocket and of Ca2+ in Site 1. Indeed, the mutation Y218Q 
largely disrupted the functional positive homotropic cooperativity with transformation of the 
single cooperative response to [Ca2+]o of the WT CaSR to a biphasic process in the cell 
population assay. Y218Q also exhibited less sensitivity to [Ca2+]o, as [Ca2+]i oscillations did not 
start until [Ca2+]o was increased to more than 10 mM, reflecting its role in this Ca2+-binding site. 
Of note, however, addition of 5 mM L-Phe failed to restore the calcium sensitivity of this mutant 
as manifested by an unchanged oscillation pattern. An oscillatory frequency of ~1.5 peaks/min 
was observed at 20 mM [Ca2+]o both with and without L-Phe for this mutant. In contrast, 
mutations such as K47A, Y63I, W70L, G146A, I162A, S169A, I187A, H413L, and R415A did 
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not abrogate the positive allosteric effect of 5 mM L-Phe (Table 3.5). Taken together, these 
results suggest that residues located at the predicted L-Phe-binding site, including L51, T145, 
S170, S272, and Y218, play key roles in sensing L-Phe.   
 
 
Figure 3.7 Functional studies of receptors with mutations in L-Phe-binding site in HEK293 
cells.  
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(a). Representative oscillation pattern from a single cell. Each experiment with or without 5 
mM L-Phe began in Ca2+-free Ringer’s buffer followed by stepwise increases in [Ca2+]o 
until [Ca2+]i reached a plateau (up to 30 mM [Ca2+]o). (b). The pattern of [Ca2+]i responses 
in each cell (minimum of 30 cells) was analyzed, and the [Ca2+]o at which individual cells 
started to oscillate was recorded and plotted as a bar chart. (c). The frequency of the 
oscillation patterns of the individual cells was investigated. For experiments without L-Phe, 
the peaks per minute were recorded at the level of [Ca2+]o at which the majority of the cells 
(>50%) started oscillating; while for experiments with 5 mM L-Phe, the frequency was 
analyzed at the same levels of [Ca2+]o as in the corresponding experiments carried out 
without L-Phe. (d). Population assay for [Ca2+]i responses of HEK293 cells transiently 
overexpressing WT CaSR or CaSR mutants L51A or Y218Q using Fura-2 AM during 
stepwise increases in [Ca2+]o from 0.5 to 30 mM. The ratio of the intensity of light emitted 
at 510 nm upon excitation with 340 or 380 nm was normalized to its maximum response. 
The [Ca2+]o concentration response curves were fitted using the Hill equation.  
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Table 3.4 Summary of cellular responses of HEK293 cells transiently transfected with WT CaSR or mutants in the predicted 
L-Phe-binding site. 
Mutant Starting Point (mM) 
Frequency 
(Peaks/Min) EC50 (mM) Hill Number 
w/o L-Phe w  L-Phe w/o L-Phe w  L-Phe w/o L-Phe w  L-Phe w/o L-Phe w  L-Phe 
WT 3.0 ± 0.1 2.0 ± 0.2b 1.5 ± 0.1 2.2 ± 0.2b 2.9 ± 0.1 1.8 ± 0.2b 3.2 ± 0.3 4.1 ± 0.1b 
L51A 2.9 ± 0.1 2.8 ± 0.1 1.7 ± 0.1 1.8 ± 0.1 3.5 ± 0.2 3.2 ± 0.1 2.4 ± 0.1 2.8 ± 0.2 
T145A 2.8 ± 0.1 2.4 ± 0.2b 1.7 ± 0.3 1.8 ± 0.2 3.0 ± 0.1 3.0 ± 0.1 3.3 ± 0.3 3.7 ± 0.4 
S170T 2.1 ± 0.2a 2.0 ± 0.1 1.5 ± 0.1 1.4 ± 0.2 2.7 ± 0.2 2.9 ± 0.1 2.4 ± 0.3 2.2 ± 0.1 
Y218Q 17.7± 1.0a 16.7 ± 2.2 1.5 ± 0.1 1.6 ± 0.1 
Phase 1: 
3.7 ± 0.4 
Phase 1: 
3.6 ± 0.2 
Phase 1: 
3.8 ± 1.0 
Phase 1: 
3.9 ± 0.4 
Phase 2: 
27.1 ± 0.8 
Phase 2: 
24.6 ± 0.5 
Phase 2: 
3.4 ± 0.5 
Phase 2: 
2.8 ± 0.8 
S272A 2.7 ± 0.2 2.1 ± 0.1b 2.3 ± 0.1 2.4 ± 0.1 2.4 ± 0.1 2.2 ± 0.1 1.9 ± 0.1 3.0 ± 0.1 
The average [Ca2+]o at which cells started to exhibit [Ca2+]i oscillations was recorded for WT or each mutant CaSR. For the 
oscillation frequency in the absence of L-Phe, peaks per minute were measured at the level of [Ca2+]o at which more than 50% 
cells started to oscillate; when L-Phe was added, frequencies were recorded at the same [Ca2+]o as their counterparts without 
L-Phe. Specifically, the frequencies of WT and L51A was measured at 3.0 mM [Ca2+]o S272A, T145A, and S170T were 
measured at 2.5 mM [Ca2+]o; and Y218Q was analyzed at 15.0 mM [Ca2+]o. Values are means ± S.E. EC50 and Hill numbers 
obtained from the cell population assay by fitting plots using the Hill equation. a significant difference between mutant 
receptor and WT CaSR without L-Phe, p<0.05; b significant difference between cases without L-Phe and with 5 mM L-Phe, 
p<0.05.
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Figure 3.8 Individual cellular responses of mutants in the L-Phe-sensitive site to the 
indicated increments of [Ca2+]o in the presence or absence of L-Phe.  
 
HEK-293 cells transfected with wild type CaSR or mutants were loaded with Fura-2 AM 
for 15 min. Each experiment with or without 5 mM L-Phe began in the same non-calcium-
containing Ringer’s buffer followed by stepwise increases in [Ca2+]o until [Ca2+]i  reached a 
plateau (up to 30 mM) as monitored by changes in the ratio of light emitted at 510 nm 
following excitation at 340 or 380 nm. At least 30 cells were analyzed for mutants S272A 
and T145A. Representative cellular responses from a single cell are shown. 
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Table 3.5 Summary of cellular responses from HEK293 cells transiently transfected with WT CaSR or mutants in the 
predicted L-Phe-sensing site.  
The intracellular calcium responses of HEK293 cells transiently overexpressing WT CaSR or various mutants were measured 
using Fura-2AM during stepwise increases in [Ca2+]o. The pattern of [Ca2+]i responses in each cell (minimum of 30 cells) was 
analyzed, and the [Ca2+]o at which individual cells started to oscillate was recorded. For experiments without L-Phe, the peaks 
per minute were recorded at the level of [Ca2+]o at which the majority of the cells (>50%) started oscillating; while for 
experiments with 5 mM L-Phe, the frequency was analyzed at the same levels of [Ca2+]o as in the corresponding experiments 
carried out without L-Phe. Specifically, WT, K47A, G146A, S169A and H413L were measured at 3.0 mM [Ca2+]o; Y63I and 
R415A were measured at 3.5 mM [Ca2+]o; I187A was measured at 10.0 mM [Ca2+]o;  and W70L and I162A were measured at 
12.5 mM [Ca2+]o.  The average fluorescence intensity ratio at each increase in the level of [Ca2+]o was plotted against [Ca2+]o 
and fitted using the Hill equation, which gave EC50 and Hill numbers. Values are means ± S.E.  
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Mutant Starting Point (mM) 
Frequency 
(Peaks/Min) EC50 (mM) Hill Number 
w/o L-Phe w  L-Phe w/o L-Phe w  L-Phe w/o L-Phe w  L-Phe w/o L-Phe w  L-Phe 
WT 3.0 ± 0.1 2.0 ± 0.2b 1.5 ± 0.1 2.2 ± 0.2b 2.9 ± 0.1 1.8 ± 0.2b 3.2 ± 0.3 4.1 ± 0.1b 
K47A 2.4 ± 0.1a 1.9 ± 0.1b 1.6 ± 0.1 2.8 ± 0.2b 2.5 ± 0.1 1.7 ± 0.1b 3.0 ± 0.1 3.6 ± 0.2b 
Y63I 3.3 ± 0.2 2.4 ± 0.2b 1.6 ± 0.2 2.0 ± 0.2b   2.8 ± 0.2  1.7 ± 0.1b 3.0 ± 0.1  3.6 ± 0.2b   
W70L 13.9 ± 1.0a 9.2 ± 0.3b 2.7 ± 0.2 3.1 ± 0.2b 8.2 ± 0.3  7.8 ± 0.1 1.8 ± 0.1 3.7 ± 0.2b 
G146A 2.5 ± 0.1a 1.9 ± 0.1b 2.0 ± 0.1 2.9 ± 0.2b 2.6 ± 0.1 1.9 ± 0.1b 2.5 ± 0.1 3.3 ± 0.1 
I162A 13.0 ± 1.2a 9.6 ± 0.3b 1.4 ± 0.1 2.5 ± 0.2b 7.9 ± 0.4 11.3 ± 0.1 2.0 ± 0.1 1.5 ± 0.1 
S169A 3.0 ± 0.2 2.3 ± 0.1b 1.6 ± 0.1 2.3 ± 0.2b 3.2 ± 0.2 2.2 ± 0.1b 3.3 ± 0.1 3.9 ± 0.1 
I187A 8.1 ± 0.4a 3.4 ± 0.1b 1.8 ± 0.1 N/A 9.0 ± 0.3 3.4 ± 0.1b  1.6 ± 0.1 2.6 ± 0.1b 
H413L 2.8 ± 0.2  1.4 ± 0.1b 1.3 ± 0.1 2.1 ± 0.1b 3.4 ± 0.2 2.1 ± 0.1b 3.4 ± 0.2 3.6 ± 0.1 
R415A 3.5 ± 0.3 2.8 ± 0.2 b 1.8± 0.2 2.6 ± 0.3b 3.0 ± 0.2 2.5 ± 0.1b   2.9 ± 0.2 3.4± 0.1b 
 
a significant difference between mutant receptor and WT CaSR without L-Phe, p < 0.05; b significant difference between cases without 
L-Phe and with 5 mM L-Phe, p<0.05
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3.2.4 Global functional positive heterotropic cooperative tuning by L-Phe of the positive 
homotropic cooperative response of CaSR to [Ca2+]o.  
The sensing of L-Phe at the hinge region adjacent to Site 1 has marked global effects on the five 
predicted Ca2+-binding sites predicted earlier that are spread over several different locations in 
the CaSR’s ECD. Interestingly, addition of 5 mM L-Phe significantly rescued the [Ca2+]i 
responses of the two mutants, E297I and D215I, in Sites 1 and 2, respectively, that exhibited 
disrupted cooperativity. Notably, L-Phe converted the biphasic Ca2+-response curve for E297I 
back to a uniphasic curve (Figure 3.9). Figure 3.9 shows that their starting points for [Ca2+]o-
initiated oscillations were reduced from 17.0 ± 0.4 mM to 7.3 ± 0.2 mM (E297I) and from 13.9 ± 
0.2 mM to 6.7 ± 0.3 mM (D215I), respectively, in the presence of L-Phe (Table 1). Both of the 
mutants exhibited more than 2-fold-shifts in their starting points in the presence of L-Phe. The 
frequencies of their oscillations increased to more than 2 peaks/min in both cases compared to 
their respective frequencies without L-Phe (Figure 3.9c and Table 3.2). Similarly, addition of L-
Phe decreased their EC50s in the cell population assay (Table 3.3).  
    
 Mutant E224I at Site 3 exhibited increases in the [Ca2+]o required to initiate [Ca2+]i 
oscillations but manifested smaller changes (from 3.0 ± 0.1 mM to 5.0 ± 0.2 mM [Ca2+]o 
(P<0.05), compared with the previous two mutants. Moreover, its elevated EC50 obtained in the 
population study correlated well with results from the single cell study (Table 3.2&3.3) 
suggesting an impaired ability of this mutant to sense [Ca2+]o. But addition of L-Phe not only 
significantly decreased the level of [Ca2+]o required for initiating oscillations but also increased 
the oscillation frequency measured at the same level of [Ca2+]o. Furthermore, the population 
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assay showed that the EC50 was reduced and the maximum response was rescued by 5 mM L-
Phe.  
         
 
Figure 3.9 [Ca2+]i responses of receptors with mutations in the Ca2+-binding sites 
stimulated by increasing [Ca2+]o in the presence or absence of 5 mM L-Phe.  
(a). [Ca2+]i was monitored in mutants E297I and D215I in the absence or presence of L-Phe. 
[Ca2+]o was increased stepwise up to 30 mM or until [Ca2+]i reached a plateau. (b). 
Statistical analysis of the [Ca2+]o at which CaSR-transfected single HEK293 cells started to 
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exhibit [Ca2+]i oscillations. (c). In the single cell experiments, the frequency of the 
oscillation patterns was investigated in more than 30 cells. For experiments without L-Phe, 
the peaks per minute were recorded at the level of [Ca2+]o at which the majority of the cells 
(>50%) started to oscillate, while for experiments with 5 mM L-Phe, the frequency was 
analyzed at the same level of [Ca2+]o that was utilized in the absence of L-Phe. Empty bar: 
in the absence of L-Phe; Black bar: in the presence of 5 mM L-Phe. (d). Population assay 
for [Ca2+]i responses of HEK293 cells transiently transfected with CaSRs with mutanted 
Ca2+-binding site-related using Fura-2 AM to measure [Ca2+]i during stepwise increases in 
[Ca2+]o from 0.5 to 30 mM. [Ca2+]i responses were then fitted using the Hill equation.  
 
 
 E353 is predicted to be a [Ca2+]o-binding residue in Site 4 in lobe 2, while D398 and 
E399 are part of Site 5 (172). Table 3.3 and Figure 3.5 show that removal of these negatively 
charged residues at Sites 4 and 5 increased the level of [Ca2+]o required to initiate [Ca2+]i 
oscillations and also their EC50s. L-Phe at 5 mM enhanced these mutants’ sensitivities to [Ca2+]o 
toward, albeit not to normal and decreased their EC50s. Therefore, as shown in Table 3.3, 
mutations not only in those predicted Ca2+-binding residues adjacent to the potential L-Phe-
binding site (e.g., in Sites 1 and 2) exhibited L-Phe-induced increases in their sensitivities to 
[Ca2+]o as well as in their Hill coefficients, but also other in [Ca2+]o-binding residues in sites  
farther away from the hinge region. These results support the concept that there are global 
functional positive heterotropic cooperative interactions between L-Phe and the bindings sites for 
[Ca2+]o in the CaSR ECD. 
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3.2.5 The ensemble of conformations of calcium- and L-Phe-loaded CaSR ECD is 
distinguishable from the non-loaded form.  
To provide a more detailed description of the CaSR’s mechanism of action, , including the 
interactions between the binding sites for [Ca2+]o and L-Phe at the atomic level, we analyzed the 
trajectories of molecular dynamics simulations using principal component analysis (PCA), which 
separates out the protein motions into principal modes ranked according to their relative 
contributions(199). Projection of the trajectories of the different states of CaSR onto the first 
three modes that accounted for the majority of the total fluctuations is shown in Figure 3.10. The 
conformations sampled by the Ca2+-free and L-Phe-free forms of the CaSR are distinctly 
different from those sampled by the Ca2+-loaded and Ca2+- and L-Phe-loaded forms of the 
receptor. Interestingly, the conformations of the L-Phe-loaded and the free form of CaSR are 
essentially indistinguishable as can be seen in Figure 3.10a. The results suggest that [Ca2+]o shifts 
the population of conformational ensembles of CaSR to a semi-active ensemble that can 
subsequently be shifted to an ensemble of more active conformations upon interaction of the 
receptor with L-Phe. These results are consistent with the experiments described above and 
suggest that the unbound CaSR does not respond to L-Phe alone, because L-Phe cannot 
effectively shift the inactive conformations to an active ensemble of conformations. The above 
results do not rule out the role of conformational selection, which implies the existence of all 
relevant active and inactive conformations of the receptor before binding, in the mechanism of 
activation of CaSR, but clearly indicate that the ensembles of active and inactive conformations 
are distinctly different. Moreover [Ca2+]o alone and/or [Ca2+]o and L-Phe together are required to 
shift the population, in agreement with previously well documented experimental results that L-
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Phe could not activate CaSR at sub-threshold levels of [Ca2+]o (below about 1.0 mM in CaSR-
transfected HEK-293 cells) (165). 
Based on all the results described above, we propose a model to illustrate the possible 
mechanism by which Ca2+ and L-Phe regulate the function of the CaSR mainly through the 
molecular connectivity encoded at the hinge region of the ECD of the protein. Our model (Figure 
3.10b) suggests that a local conformational change upon interaction of the CaSR with L-Phe 
might affect the overall conformation of the receptor, thereby influencing the cooperativity 
between multiple Ca2+-binding sites and enhancing the receptor’s overall response to Ca2+.  
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Figure 3.10 Principal component analysis (PCA) of CaSR ECD with experimental data 
suggesting a model for the mechanism underlying activation of the CaSR by extracellular 
Ca2+ and L-Phe.  
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(a). Principal component analysis (PCA) of CaSR ECD. The trajectories of the molecular 
dynamics simulations were analyzed using principal component analysis (PCA), which 
separates out the motions of the CaSR ECD into principal modes ranked according to their 
relative contributions. The first three principal modes were included in the present study to 
analyze four different states of the protein: Ligand-free (black), presence of L-Phe-only 
(Green), presence of Ca2+-only (Red) or presence of both Ca2+ and L-Phe (Blue). (b). Model 
for the mechanism underlying the activation of the CaSR by extracellular Ca2+ and L-Phe. 
Ca2+ and L-Phe modulate the activity as well as the cooperativity of CaSR. Higher [Ca2+]o, 
around 3.0 mM, could change the conformation of CaSR into an active form (second stair 
level) in a positive homotropic cooperative manner (as indicated by the change of the color 
of the Ca2+-binding sites from yellow to orange) and further trigger [Ca2+]i oscillations. L-
Phe binds to the hinge region between Lobe 1 and Lobe 2, modulating the receptor together 
with Ca2+ in a positive heterotropic cooperative way (as indicated by the change in the color 
from orange to red).  This could produce a conformation of the receptor that is a “super-
activated” form (third stair level), associated with a higher frequency of [Ca2+]i oscillations 
and a reduced EC50. CaSR mutants (lower activity stair level), especially those containing 
mutations close to the hinge region between lobe 1 (LB1) and lobe 2 (LB2), could cause a 
disruption of the cooperativity among the various Ca2+-binding sites (lower activity second 
stair level). The impaired receptor function and the cross talk between Ca2+-binding sites 
can be rescued, at least in part, by introducing L-Phe into the extracellular buffer. Red 
Arrow: receptor activity. 
 
 
95 
 
 
Figure 3.11 Docking Glutathione into the CaSR ECD. 
Glutathione was docked into the CaSR ECD using Audodock Vina. The listed residue 
numbers are the real sequence residue number minus 24. Yellow highilighted residues are 
overlapping with Phe binding sites; Blue highlighted residues are predicted to interact with 
Glutathione only.  
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Figure 3.12 Docking Aspartate into the CaSR ECD. 
 
Aspartate was docked into the CaSR ECD using Audodock Vina. The listed residue 
numbers are the real sequence residue number minus 24. Yellow highilighted residues are 
overlapping with Phe binding sites; Blue highlighted residues are predicted to interact with 
Aspartate only.  
 
3.3 Discussion 
Several major barriers have hampered our understanding of the long-standing question of how 
the CaSR integrates its activation by two different classes of nutrients, divalent cations and 
amino acids as well as, to regulate the functional cooperativity of the receptor and the alterations 
of this cooperativity caused by naturally occurring mutations in human diseases. These include 
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“invisible” binding pockets for these two key physiological agonists of the CaSR, namely Ca2+ 
and amino acids, challenges in obtaining structural information associated with membrane 
proteins, and the lack of direct binding methods for determining the mechanisms underlying the 
cooperative activation of the CaSR by Ca2+ and amino acids (118,126,228). To overcome these 
limitations, we have applied several computer algorithms and grafting approaches for identifying 
and predicting Ca2+-binding sites in proteins and we have verified the intrinsic Ca2+-binding 
capabilities of predicted Ca2+-binding sites in the CaSR and mGluR1α (68,124,172,229). 
Our studies,  shown in Figures. 3.1, 3.4 and 3.7 suggest that mutations in Ca2+-binding Site 1, 
such as E2971 and Y218Q, not only disrupt the CaSR’s Ca2+-sensing capacity but also have an 
impact on the positive homotropic cooperative interactions of Ca2+ with the other Ca2+-binding 
sites. Such biphasic behavior with a large disruption of cooperativity, is very similar to our 
previously reported metal-binding concentration response curves of subdomain 1 and its variants 
with increases in [Ca2+]o (172). Subdomain 1 of CaSR contains a protein sequence encompassing 
Ca2+-binding Sites 1, 2 and 3, but without Ca2+-binding Sites 4 and 5. It also exhibits both a 
strong and a weak metal-binding component. This strong metal-binding process can be removed 
by further mutating Site 1 (E297I). In contrast, mutations at Sites 2 and 3 have less impact on the 
first binding process (172). These molecular dynamics simulation studies carried out here are 
consistent with the experimental results showing that residues located within Site 1 have strong 
correlated motions with other residues in Sites 2, 3, 4 and 5 (Table 3.1). These results suggest 
that the dynamics of Site 1 is intricately coupled to those of the other binding sites; therefore, any 
changes in the dynamics of Site 1 could affect that of the other sites. The observation of this 
molecular connectivity and its relationship to positive cooperativity from the molecular 
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dynamics simulations provide a description at the atomic level of the crosstalk between the 
different sites of the CaSR suggested by the experimental results in live cells. 
 
 Here, we have also computationally identified an L-Phe-binding pocket formed by 
residues L51, S170, T145, Y218 and S272, which is adjacent to and partially overlaps the key 
Ca2+-binding Site 1 at the hinge region of the Venus Fly Trap (VFT) of the CaSR. This Ca2+-
binding Site is also conserved in other family C GPCRs, including the mGluR1 VFT (Figure 3.1) 
(96,175,229). Y218 is involved in sensing both Ca2+ and L-Phe. The aromatic ring from residue 
Y218 could form delocalized pi bonds with the side chain of L-Phe and the hydrophobic 
interaction between L51 and L-Phe would further stabilize this interaction. Mutating S170 might 
interfere with hydrogen-bonding of the ligated amino acid to the -amino group of S170 based 
on the structure of mGluR1(223). S170T has been reported by several groups to interfere with 
the CaSR’s L-Phe-sensing ability(221,223). Consideration of the crystal structure of the 
glutamate-bound form of mGluR1 (175), together with our docking analysis, implies that 
residues T145 and S272 may not directly participate in the interaction with L-Phe but could 
possibly interact with L-Phe by ligation of water molecules, which is a relatively weaker type of 
interaction.  
 
We have observed in this study essentially equivalent expression of WT CaSR and its variants on 
the cell surface (Figure 3.6). These lines of evidence suggest that the difference in the Ca2+-
sensing capacities among the WT and mutant receptors are due to perturbation of the cell surface 
receptors’ functions, rather than, for example, impaired trafficking of the receptor proteins to the 
cell surface. L-Phe restored the [Ca2+]i responses of the tested mutants located in all five 
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predicted Ca2+-binding sites, and it had more dramatic rescuing effects on mutants E297I and 
D215I compared with the other mutants (Figure 3.9). Thus, the importance of the hinge region, 
where L-Phe likely interacts with the CaSR ECD, is once again highlighted, although we only 
used [Ca2+]i responses as a read out, and the results could possibly differ if other second 
messenger pathways were examined.  
 
 The PCA results suggest that the need for Ca2+ in initially activating CaSR, as suggested 
by the experiments, is related to shifting the ensemble of conformations of CaSR from inactive 
states to active states. The activity of the Ca2+-loaded form of CaSR is then further enhanced by 
the binding of L-Phe, which produces additional changes in the ensembles of conformations of 
CaSR. Therefore, the global modulation of receptor activity by Ca2+ and L-Phe might be 
explained by a combination of an induced fit and population shift models (230) in which the 
receptor’s overall structure could vary in the equilibrium distributions of conformations of the 
receptor that can interchange dynamically in the absence of Ca2+ and L-Phe . Our experimental 
results suggest that binding of Ca2+ at its various sites is associated with motions of these sites 
that are highly correlated with one another. Consequently, the shift in the ensemble of 
conformations of CaSR induced by the initial binding of Ca2+ at Site 1 will alter the equilibrium 
population of the unbound conformations of other Ca2+-binding sites due to their crosstalk with 
Site 1. The binding of Ca2+ to Site 1 and the subsequent interaction of CaSR with L-Phe can 
further shift the conformations of the ECD from one part of the free energy landscape to another 
in such a way that Ca2+-binding to other sites is more readily favorable. Our findings here also 
enhance our understanding of the role of Ca2+ in modulating key Ca2+-binding proteins such as 
calmodulin to mediate signal transduction via correlated motions among their multiple Ca2+-
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binding sites, thereby generating cooperative responses with critical biological consequences 
(231,232).  
 
The CaSR’s co-activation by these two classes of ligands may be particularly important in the 
gastrointestinal tract, where high concentrations of amino acids resulting from protein digestion 
ensure activation of the CaSR and its stimulation of digestive processes even when there are 
relatively low levels of [Ca2+]o. Moreover, as reported in clinical studies, there are 33 disease-
related mutations near Ca2+-binding Site 1 associated with receptor activation or inactivation and, 
in some cases, with reduced cooperativity (208). Our work suggests that it is likely that such 
mutations disrupt the molecular connectivity encoded in the receptor and provide a better 
understanding of the molecular basis of some of the CaSR-related clinical disorders. Our finding 
of the capacity of L-Phe to rescue disease-linked mutations suggests the possibility of rescuing 
such mutant receptors using calcimimetics of various types as pharmacotherapy, thereby 
increasing cell surface expression or intrinsic activity of the mutant CaSRs. These results, 
therefore,  provide insights into key factors regulating the receptor’s overall activity, which could 
lay the foundation for a new generation of therapeutics. 
 
 In addition to the Ca2+-sensing receptor, [Ca2+]o regulates 14 of the other members of the 
family C G protein-coupled receptors (GPCRs), including the metabotropic glutamate receptors 
(mGluR), -aminobutyric acid GABAB receptors and receptors for pheromones, amino acids and 
sweet substances (38,96,101,204,209,224,225,233).The observed molecular connectivity 
centered at predicted calcium-binding Site 1 of the CaSR, which is adjacent to an amino acid-
binding pocket at the hinge region of the receptor, may be shared by other members of the family 
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C GPCRs (234,235). Besides the strong conservation of the predicted calcium-binding site 1 and 
amino acid-binding pocket, several lines of evidence support this suggestion (Figure 3.2) 
(68,96,172,236). We have predicted a Ca2+-binding site partially sharing the Glu-binding site in 
the ECD of mGluR1α, and both of these agonists co-activate the receptor (229). A Ca2+-binding 
pocket was proposed to be present in the ligand-binding site of the GABAB receptor (225). Many 
animals and humans can detect the taste of calcium via a calcium taste receptor that is modulated 
by an allosteric mechanism (237). 
 
         In summary, our present study provides a mechanistic view of the interplay among 
extracellular Ca2+, amino acids and the CaSR via molecular connectivity that modulates the 
positive homotropic and heterotropic cooperativity of CaSR-mediated intracellular Ca2+ 
signaling. The positive cooperative co-activation of the CaSR by Ca2+ and L-Phe and the 
importance of the positive homotropic and heterotropic cooperativity, respectively, exhibited by 
the two agonists may be further extended to other members of the family C GPCRs to facilitate 
an understanding of the molecular basis for related human disorders and the development of new 
therapeutic strategies. 
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CHAPTER 4. IDENTIFICATION OF 71 CALCIUM-SENSING RECEPTOR 
MUTATIONS IN HYPERCALCAEMIC AND HYPOCALCAEMIC PATIENTS: 
EVIDENCE FOR CLUSTERING OF EXTRACELLULAR DOMAIN MUTATIONS AT 
CALCIUM BINDING SITES 
4.1 Introduction 
The human calcium sensing receptor (CaSR) is a 1078 amino-acid cell-surface protein (Figure. 
4.1) that is expressed predominantly in the parathyroids and kidneys, where it regulates PTH 
secretion and renal calcium (Ca2+) reabsorption appropriate to the prevailing extracellular Ca2+ 
concentration ([Ca2+]o) (38,238). The CaSR is a member of family C of the superfamily of G-
protein coupled receptors (GPCRs) that includes the metabotropic glutamate receptors, 
vomeronasal pheromone receptors V2R, taste receptors TAS1R, and the gamma-amino butyric 
acid (GABA-B) receptors (239). The CaSR consists of a 612 amino-acid extracellular domain 
(ECD) that is critical for co-translational processing (240), receptor dimerisation (241), binding 
ligands (95,234,242), and transmitting activation signals through the 7 transmembrane domains 
(TMDs), which comprises residues 613 to 862, and the intracellular domain (ICD), which 
comprises residues 863 to 1078 (Figure 4.1) (243). Ligand binding by the CaSR ECD results in 
the activation of multiple signalling cascades including Gq/11-protein dependent stimulation of 
phospholipase C (PLC) activity, causing accumulation of inositol 1,4,5-triphosphate (IP3) and a 
rapid increase of cytosolic calcium ([Ca2+]i) concentrations (101). These intracellular events 
mediate a decrease in the rate of PTH secretion from the parathyroid chief cell and a reduction in 
renal tubular Ca2+ reabsorption, as illustrated by CaSR mutations which result in alterations in 
plasma calcium and urinary calcium excretion. For example, inactivating (i.e. loss-of-function) 
CaSR mutations result in familial hypocalciuric hypercalcaemia (FHH) and neonatal severe 
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primary hyperparathyroidism (NSHPT) (161,238); whereas activating (i.e. gain-of-function) 
CaSR mutations result in autosomal dominant hypocalcaemia with hypercalciuria (ADHH) (244). 
In addition, CaSR mutations have been reported to be associated with primary 
hyperparathyroidism (PHPT) and a form of Bartter syndrome, designated type V, in rare patients 
(164,245). Moreover, in vitro studies which have functionally expressed these mutant CaSRs and 
determined their dose–response curves and the [Ca2+]o needed to produce a half-maximal (EC50) 
response in total [Ca2+]i, have demonstrated that the inactivating CaSR mutations associated with 
FHH, PHPT and NSHPT result in a rightward shift of the dose–response curve and a 
significantly higher EC50; whereas the activating CaSR mutations associated with ADHH and 
Bartter syndrome type V result in a leftward shift of the dose–response curve and a significantly 
lower EC50 when compared to the wild-type CaSR (87,246). The identification of these disease-
causing CaSR mutations has highlighted the importance of the ECD for CaSR function, as many 
mutations (i.e. 40%) which result in FHH, NSHPT or ADHH cluster in the first 300 ECD 
residues (163).  
 The CaSR ECD three-dimensional structure has been deduced based on its homology to 
the metabotropic glutamate receptor type 1 (mGluR1) whose crystal structure has been 
determined (175). The CaSR ECD is considered to adopt a bilobed venus flytrap conformation. 
The venus flytrap domain (VFTD), comprises residues 20 to 540, and consists of amino- and 
carboxyl-terminal regions that are designated lobe 1 (residues 20 to 205 and residues 324 to 477) 
and lobe 2 (residues 206 to 323 and residues 478 to 540), respectively (175). These lobes form a 
large cleft, and consist of alpha helices and beta sheets that are connected by multiple loops 
(175). The CaSR ECD has been proposed to be the major region for Ca2+ binding (68,172), and 
an analysis of the common structural properties of Ca2+ binding sites in proteins, as well as 
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studies of a CaSR model, has identified 5 putative Ca2+ binding sites (calcium binding sites-1 to -
5) within the CaSR VFTD (68,172).  This is consistent with the finding that the CaSR has a Hill 
coefficient of around 3 (87) and binds Ca2+ in a cooperative manner. These 5 calcium binding 
sitess are located at flexible loops or helical domains near the protein surface and consist of 
clusters of negatively charged or neutral amino acids (68,172). Calcium binding sites-1, which is 
the principal site, is located in the cleft between lobes 1 and 2 (172). To further define these 
structure-function relationships of the CaSR ECD, we undertook studies to characterise 
additional CaSR mutations in patients with FHH, NSHPT and ADHH and assessed the 
functional consequences of those that would increase understanding of the ECD residues within 
the VFTD and their relationship to the 5 Calcium binding sitess. 
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Figure 4.1 Schematic representation of the location of the 72 CaSR variants.  
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The CaSR comprises an extracellular domain (ECD), which is formed by residues 1-612; 
seven transmembrane domains (TMDs) formed by residues 613 to 862; and an intracellular 
domain (ICD), formed by residues 863 to 1078. Every 50th amino acid is indicated. The 612 
amino acid ECD is consists of the following: an N-terminal signal peptide (amino acids 1-
19); a venus fly trap domain (VFTD) (amino acids 20-540); a nine cysteine domain (NCD) 
(amino acids 542-598); and a peptide linker (PL) (amino acids 599-612) that connects the 
ECD to the TMD. The residues involved in forming the 5 VFTD Ca2+ binding sites (CaBSs) 
are indicated by asterisks. The number preceding the asterisk indicates the respective 
Calcium binding sites. The 72 CaSR variants reported in this study (Table 1) are shown in 
black. The amino acid change is detailed above the mutated residue. The bracketed letter 
following the amino acid change indicates whether this variant was identified in a patient 
with FHH (F), NSHPT (N), ADHH (A), or in both FHH and ADHH (A/F). Boxes indicate 
the mutations associated with either loss- or gain of function at codons 173 and 221. The 
location of the splice site mutation (Table 1), which is predicted to lead to either a 2 amino 
acid missense peptide followed by a stop at codon 167, or an in-frame deletion of exon 4 is 
shown as S.S. The location of the previously reported Pro339Thr mutation (245) in relation 
to calcium binding sites-4 residues is also shown. 
4.2 Results 
4.2.1 Overview of CaSR abnormalities and variants 
 
         DNA sequence analysis of the entire 3,236 bp coding region and 12 intron-exon boundaries 
of the CASR in the 290 unrelated probands revealed the occurrence of a CASR sequence 
abnormality in 82 patients (Table 4.1), thereby representing a 28% CaSR variant detection rate in 
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this group of patients with hypercalcaemia and hypocalcaemia. Seven abnormalities (Pro55Leu, 
Arg172Gly, Arg220Pro, Arg227Gln, Glu250Lys, Leu461Pro, Lys831Thr) occurred in more than 
one patient thereby giving a total of 72 abnormalities (Table 4.1). The absence of all of these 
DNA sequence abnormalities in 110 alleles from 55 unrelated normal individuals indicated that 
these abnormalities were mutations or rare polymorphisms. Fifty-five CaSR abnormalities were 
found in the 224 hypercalcaemic patients, representing a 25% detection rate, and 45 of these 
CaSR abnormalities were in FHH patients and 10 were in NSHPT patients (Figure. 4.2) The 
remaining 27 abnormalities of the CaSR were found in the 66 hypocalcaemic patients, 
representing a 41% detection rate, thereby confirming ADHH as the aetiology for the 
hypocalcaemia. Amongst the 72 different CaSR abnormalities, 30 (42%) had not been reported 
in previous studies, and the remaining 42 (58%) had been reported to occur in other, presumably 
unrelated patients (247). One variant (Glu250Lys) was found to occur in FHH and ADHH 
patients, raising the possibility that this may be a polymorphic variant. Indeed, in vitro functional 
expression studies demonstrated that the Glu250Lys variant represented a functionally neutral 
polymorphism (Figure 4.3). Forty-five different CaSR mutations (63%) affected ECD residues 
(Figure 4.1), while 22 (31%) mutations affected TMD residues and 4 (6%) mutations affected 
ICD residues (Table 4.1). An analysis of the location of FHH, NSHPT and ADHH mutations 
identified in this study, revealed that the majority (> 50%) of mutations associated with these 
hyper- and hypocalcaemic disorders were located in the ECD (Figure 4.4A), and a similar 
analysis of the 200 different previously reported CaSR mutations (248) also revealed that > 50% 
of the abnormalities associated with such disorders were located in the ECD (Figure 4.4A). The 
phenotypic features of FHH, NSHPT and ADHH in patients with CaSR mutations were similar 
to those patients without CaSR mutations (data not shown), thereby indicating that phenotypic 
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features alone are unlikely to be useful predictors for the presence or absence of a CaSR 
mutation. 
 
Table 4.1 Details of 82 CaSR abnormalities/variants identified in patients with FHH (n = 
45), NSHPT (n = 10), and ADHH (n = 27). 
 
Disorder Codon Nucleotide Base Amino Exon Location 
FHH       
 25 c.73 CGATG ArgStop 2 ECD 
 55 c.164 CCGCT ProLeuc 2 ECD 
 55 c.164 CCGCT ProLeuc 2 ECD 
 55 c.164 CCGCT ProLeuc 2 ECD 
 55 c.164 CCGCT ProLeuc 2 ECD 
 55 c.164 CCGCT ProLeuc 2 ECD 
 69 c.205 CGCTG ArgCysd 3 ECD 
 138 c.413 ACGAT ThrMet 3 ECD 
 158 c.473 GGGGA GlyGlud 3 ECD 
 161 c.482 TACTG Tyr Cys 3 ECD 
 163 c.488 CCCCG Pro Arg 3 ECD 
 S.S. c.493-1 agaa -d, e IVS2f ECD 
 172 c.515 AGAGG ArgGlyc 4 ECD 
 172 c.515 AGAGG ArgGlyc 4 ECD 
 174 c.521 CTCCG LeuArg 4 ECD 
 185 c.554 CGACA ArgGln 4 ECD 
 208 c.624 TGGTG TrpCysd 4 ECD 
 208 c.623 TGGTC TrpSer 4 ECD 
 218 c.652 TATCA TyrHisd 4 ECD 
 220 c.658 CGGTG ArgTrp 4 ECD 
 220 c.659 CGGCC ArgProc 4 ECD 
 220 c.659 CGGCC ArgProc 4 ECD 
 221 c.662 CCGCA ProGln 4 ECD 
 227 c.681 CGACA ArgGlnc 4 ECD 
 227 c.681 CGACA ArgGlnc 4 ECD 
 236 c.706 TGCGG CysGlyd 4 ECD 
 250 c.748 GAAAA GluLysg 4 ECD 
 296 c.887 AGCAA SerAsn 4 ECD 
 461 c.1382 CTGCC LeuProc, 5 ECD 
 461 c.1382 CTGCC LeuProc, 5 ECD 
 544 c.1631 CGACA ArgGlnd 6 ECD 
 553 c.1657 GGGAG GlyArg 6 ECD 
 573 c.1718 TATTG TyrCysd 6 ECD 
 612 c.1836 TTTTT- Phe d, h 7 ECD 
 645 c.1934 GCCGA AlaAspd 7 TMD 
 701 c.2102 CGTCC ArgProd 7 TMD 
 748 c.2243 CCCCT ProLeu 7 TMD 
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 748 c.2243 CCCCG ProArg 7 TMD 
 752 c.2255 CGCTG ArgCysd 7 TMD 
 778 c.2332 GGCCG GlyArgd 7 TMD 
 791 c.2371 GCCCC AlaProd 7 TMD 
 798 c.2392 CCGAC ProThr 7 TMD 
 798 c.2393 CCGCT ProLeud 7 TMD 
 816 c.2446 ATCAC IleThrd 7 TMD 
 885 c.2654 GCTGA AlaAspd 7 ICD 
NSHPT       
 25 c.73 CGATG ArgStop 2 ECD 
 60 c.179 TGTTT CysPhe j 2 ECD 
 164 c.490 CAGTA GlnStop i 3 ECD 
 190 c.570 GATGA Asp d, i, k 4 ECD 
 212 c.635 ATTAG IleSer i 4 ECD 
 220 c.658 CGGTG ArgTrp i 4 ECD 
 392 c.1174 CGATG ArgStop 4 ECD 
 680 c.2038 CGCTG ArgCys j 7 TMD 
Disorder Codon Nucleotide Base Amino Exon Location 
NSHPT       
 768 c.2303 GGCGT GlyVald, 7 TMD 
 886 c.2656 CGGTG ArgTrp i 7 ICD 
ADHH       
 104 c.310 GTTAT ValIled 3 ECD 
 116 c.346 GCTCC AlaPro 3 ECD 
 127 c.380 GAGGG GluGly 3 ECD 
 131 c.391 TGCAG CysSerd 3 ECD 
 131 c.392 TGCTA CysTyr 3 ECD 
 151 c.452 ACGAT ThrMet 3 ECD 
 173 c.517 CTCTT LeuPhed 4 ECD 
 221 c.662 CCGCT ProLeu 4 ECD 
 228 c.682 GAGAA GluLys 4 ECD 
 241 c.721 GAAAA GluLys 4 ECD 
 250 c.748 GAAAA GluLysg 4 ECD 
 419 c.1256 AATAG AsnSer 4 ECD 
 604 c.1810 GAGAA GluLys 7 ECD 
 610 c.1829 GAGGG GluGly 7 ECD 
 767 c.2299 GAGCA GluGlnd 7 TMD 
 767 c.2299 GAGAA GluLys 7 TMD 
 800 c.2399 AACAC AsnThrd 7 TMD 
 824 c.2470 GCCCC AlaProd 7 TMD 
 828 c.2483 ACCAA ThrAsn 7 TMD 
 831 c.2492 AAGAC LysThrc, 7 TMD 
 831 c.2492 AAGAC LysThrc, 7 TMD 
 832 c.2495 TTTTC PheSer 7 TMD 
 837 c.2511 GAGGA GluAspd 7 TMD 
 843 c.2528 GCAGA AlaGlu 7 TMD 
 845 c.2534 AGCAA SerAsn 7 TMD 
 883 c.2648 GTGAT ValMetd 7 ICD 
 910 c.2730 CCTC-T Pro d, l 7 ICD 
 
110 
 
a Nucleotide is numbered in relation to CaSR cDNA reference sequence (GenBank 
accession number NM_000388) whereby nucleotide +1 corresponds to the A of the ATG – 
translation initiation codon; b ECD, extracellular domain; TMD, transmembrane domain; 
ICD, intracellular domain; c recurrent mutation; d novel mutation; e predicted to abolish 
acceptor splice site (S.S.) and lead to either a 2 amino acid missense peptide followed by a 
stop at codon 167, or an in-frame deletion of exon 4; f IVS, intervening sequence; g 
demonstrated to be a functionally neutral polymorphism (Fig. 3); h  deletion/frameshift, 13 
missense peptide followed by a stop at codon 626; i homozygous mutation; j compound 
heterozygous mutation; k deletion/frameshift, 65 amino acid missense peptide followed by a 
stop at codon 256; l deletion/frameshift, 27 amino acid missense peptide followed by a stop 
at codon 938. 
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Figure 4.2 Detection of a CaSR mutation in exon 2 in a family with neonatal severe 
primary hyperparathyroidism (NSHPT).   
A, DNA sequence analysis of the affected individual (II.1) revealed a C to T transition at 
codon 25, thus altering the wild-type (WT) sequence CGA, encoding an arginine to the 
mutant (m) sequence TGA, which is a termination (Stop) codon. This nonsense mutation 
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also resulted in the loss of the wild-type Cac8I restriction enzyme (GCN/NGC), and this 
facilitated the confirmation of the mutation. B, PCR amplification and Cac8I digestion 
would result in two products of 186 and 114 bp from the wild-type (WT) sequence, but a 
300 bp band would be expected from the mutant (m) sequence as is illustrated in the 
restriction map. This Arg25stop mutation was demonstrated to be homozygous in the 
siblings affected with NSHPT (individuals II.1 and II.2), while their consanguineous 
parents were both heterozygous for this mutation.  The absence of this Arg25stop mutation 
in 110 alleles from 55 unrelated normal individuals (N1-N3 shown) indicates that it is not a 
common DNA sequence polymorphism. Individuals are represented as: male (squares), 
female (circles), unaffected (open circle), affected with NSHPT (filled symbols), affected 
with hypercalcaemia (half filled square). 
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Figure 4.3 Functional expression of wild-type and variant codon 173, 221 and 250 CaSRs in 
transfected HEK293 cells.  
The [Ca2+]o-evoked increases in [Ca2+]i were measured in HEK293 cells that had been 
transiently transfected with wild-type (WT) or variant codon 173,  221 and 250  CaSRs 
(Wild-type sequences - Leu173 (L173), Pro221 (P221) and Glu250 (E250); variant 
sequences – Phe173 (F173), Pro173 (P173), Leu221(L221), Gln221 (Q221) and Lys250 
(K250).  A, The mutant (m) CaSRs, F173, which occurred in an ADHH kindred (Table 1), 
and P173, which occurred in an FHH kindred, resulted in a leftward and rightward shift of 
the concentration-response curve, respectively, when compared to that of the wild-type 
CaSR. Thus, the EC50 values of the mutant CaSRs F173 and P173 were significantly (p < 
0.001) lower and higher, respectively when compared to that of the wild-type CaSR. These 
findings indicate that the mutant CaSRs F173 and P173 result in a gain-of-function and a 
loss-of-function of the CaSR, respectively, and this is consistent with their associated 
phenotypes of ADHH and FHH in man. B, The mutant CaSRs, L221, which occurred in an 
ADHH kindred (Table 1), and Q221, which occurred in an FHH kindred, resulted in a 
leftward and rightward shift of the concentration-response curve, respectively, when 
compared to that of the wild-type CaSR. Thus, the EC50 values of the mutant CaSRs L221 
and Q221 were significantly (p < 0.01) lower and higher, respectively when compared to 
that of the wild-type CaSR. These findings indicate that the mutant CaSRs L221 and Q221 
result in a gain-of-function and a loss-of-function of the CaSR, respectively, and this is 
consistent with their associated phenotypes of ADHH and FHH in man; C, The variant 
CaSR, K250, which occurred in both ADHH and FHH kindreds, did not significantly alter 
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the EC50 or concentration-response curve when compared to that of the wild-type CaSR. 
These findings indicate that K250 is a functionally neutral polymorphism (poly) and not a 
pathogenic mutation.   
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Figure 4.4 Analysis of CaSR mutations by disease association, location and type of 
mutation.  
A, frequencies of ECD, TMD and ICD CaSR mutations in FHH, NSHPT and ADHH 
patients observed in this study (n = 71), and in an analysis of 200 previously reported CaSR 
mutations. The majority (>50%) of mutations associated with FHH, NSHPT and ADHH in 
this study and amongst the previously reported CaSR mutations were located in the ECD. 
Significant differences between this study and the previously reported mutations (248) 
were not observed. In addition, no significant differences in the location of mutations were 
observed between FHH, NSHPT and ADHH. B, frequencies of missense, truncating and 
deletion/insertion CaSR mutations in FHH, NSHPT and ADHH patients observed in this 
study (n = 71) and in an analysis of 200 previously reported CaSR mutations. Greater than 
90% of mutations associated with FHH and ADHH were missense substitutions. However, 
NSHPT was associated with a significantly (p < 0.05) higher proportion of nonsense and 
frameshift mutations when compared to either FHH or ADHH. No significant difference in 
the frequency of mutation types was observed between this study and all the previously 
reported mutations (248). 
 
4.2.2 NSHPT is associated with a high proportion of truncating CaSR mutations  
 
          Four of the ten NSHPT associated CaSR mutations (40%) were nonsense or frameshift 
mutations that were predicted to lead to a truncated CaSR (Table 4.1, Figure 4.2). This high 
proportion of truncating mutations in NSHPT differed significantly (p = 0.01) from that of FHH, 
of which three (6%) mutations were predicted to lead to a truncated CaSR (Table 1, Figure 4.4B). 
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An analysis of previously reported NSHPT mutations also revealed a high proportion of 
truncating mutations, with >40% being nonsense or frameshift mutations (Figure 4.4B), and this 
differed significantly (p < 0.01) from the previously reported FHH mutations, of which 20% 
were predicted to be truncating (Figure 4.4B). All of the 10 mutations found in NSHPT patients 
occurred in the homozygous (n=8) or compound heterozygous (n=2) state. The truncating 
mutation located closest to the CaSR N-terminus in this study was a homozygous Arg25Stop 
mutation that was present in two neonatal siblings who both presented with NSHPT and serum 
calcium concentrations > 4.0 mmol/l (Figure 4.2). Restriction endonuclease analysis revealed 
that the consanguineous parents were both heterozygous for the Arg25Stop mutation (Figure 4.2). 
The homozygous Arg25Stop mutation was predicted to lead to a peptide that was truncated six 
amino acids after the signal peptide cleavage site, and hence was not suitable for in vitro 
expression and functional characterisation.  
4.2.3 Functional characterisation of CaSR variants at codons 173, 221 and 250 detected in FHH 
and ADHH patients  
         Our DNA sequence analysis of the CASR revealed that variants that would be consistent 
with missense mutations at codons 173, 221 and 250 were associated with both FHH and ADHH 
(Table 4.1, Figure 4.1). Thus, at codon 173, we identified a Leu173Phe variant associated with 
ADHH, while, a Leu173Pro variant has been previously reported in association with FHH (249); 
at codon 221, we identified Pro221Gln and Pro221Leu variants that were associated with FHH 
and ADHH, respectively; at codon 250 we identified a Glu250Lys variant in a FHH proband and 
an ADHH proband, and therefore the pathogenic nature of this mutation was uncertain. To 
investigate the functional effects of these variants at codons 173, 221 and 250 we transiently 
transfected wild-type and variant pEGFP-CaSRs into HEK293 cells and assessed the [Ca2+]i 
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responses to changes in [Ca2+]o. Expression of both monomeric and dimeric forms of the wild-
type and variant EGFP-CaSRs was confirmed by Western blot analysis (data not shown). An 
analysis of the response curves of the wild-type and variant CaSRs (Figure 4.3) revealed that the 
Leu173Phe and Pro221Leu variant CaSRs lead to a leftward shift in the concentration–response 
curves and significantly (p < 0.01) reduced EC50 values (Leu173Phe versus wild-type = 1.8 ± 
0.07 mM versus 2.49 ± 0.06 mM; and Pro221Leu versus wild-type = 0.87 ± 0.15 mM versus 
2.74 ± 0.29 mM); and the Leu173Pro and Pro221Gln mutant CaSRs lead to a rightward shift of 
the concentration–response curve and significantly (p < 0.01) raised EC50 values (Leu173Pro 
versus wild-type = 11.0 ± 0.92 mM versus 2.49 ± 0.06 mM; and Pro221Leu versus wild-type = 
4.3 ± 0.18 mM versus 2.74 ± 0.29 mM). In contrast, an analysis of the concentration-response 
curve and EC50 of the Glu250Lys CaSR variant (Figure 4.3) revealed this not to significantly 
differ (p = NS) from that of the wild-type receptor (Glu250Lys versus wild-type = 2.56 ± 0.02 
mM versus 2.49 ± 0.06 mM). Thus, the Glu250Lys missense substitution, which involved 
substitution of the negatively charged Glu residue for a positively charged Lys residue, did not 
alter CaSR function and therefore likely represents a functionally neutral polymorphism. 
However, the Leu173Phe and Pro221Leu mutations, which involved substitutions of a non-polar 
residue for another non-polar residue, led to a gain of CaSR function; while the Leu173Pro, 
which involved substitution of a non-polar residue for another non-polar residue, and Pro221Gln, 
which involved substitution of the non-polar Pro for a polar Gln, mutations were associated with 
a loss of CaSR function. This represents a very unusual situation whereby mutations of a residue 
can result in two opposing functional effects on CaSR responses, such that it appears that the 
residues at codons 173 and 221 when mutated act as “toggles” which either activate or inactivate 
the CaSR.  
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4.2.4 Three dimensional modelling of VFTD mutations  
 
        The two “toggle” residues at Leu173 and Pro221, which are associated with FHH and 
ADHH, are located in the VFTD (Figure 4.1). Moreover, another 30 CaSR missense mutations 
identified by our study (Table 4.1) and 93 mutations identified by previous studies (248), i.e. 47% 
and 47% of all the CaSR mutations, are also located in the VFTD (Figure 4.1). We therefore 
performed homology modelling of the VFTD to determine its three dimensional structure and the 
functional relationships between the VFTD 5 calcium binding sitess and the 34 mutations that 
included the Leu173Phe, Leu173Pro, Pro221Gln and Pro221Leu mutations (Figure 4.5). This 
revealed that: nine of the mutated residues represented by 12 mutations (Thr151Met, Arg172Gly 
Leu173Phe, Leu173Pro, Leu174Arg, Arg185Gln, Tyr218His Arg220Pro, Arg220Trp, 
Pro221Leu, Pro221Gln and Ser296Asn) were located in the cleft between lobes 1 and 2 that 
contained calcium binding sites-1 (Figure 4.5A); two mutations (Ile212Ser and Glu241Lys) were 
adjacent to site 2 (Figure 4.5B); and six residues represented by eight mutations (Arg172Gly, 
Trp208Cys, Trp208Ser, Pro221Leu, Pro221Gln, Arg227Gln, Glu228Lys and Cys236Gly) were 
located within or near to the alpha helix that contained site 3 (Figure 4.5C), with three of these 
(Arg172Gly, Pro221Leu, Pro221Gln) also being in close proximity to site 1. None of the VFTD 
mutations in our study were present at either calcium binding sites-4 or -5, whereas, a Pro339Thr 
CaSR mutation, that we have previously reported in association with primary 
hyperparathyroidism in adulthood (245), was shown by our analysis to be located in a short 
flexible loop that is linked to an alpha helix containing calcium binding sites-4 Ca2+ binding 
residues (Figure 4.5D). Thus, 18 of the 34 CaSR missense mutations (i.e. > 50%) characterised 
by our study were located near one or more s, with the majority (> 50%) of Calcium binding 
119 
 
sites mutations located at site 1 (Table 4.2). A further analysis of the 93 previously reported 
missense mutations (248) located within the CaSR VFTD revealed that 42 (27 from FHH 
patients, 5 from NSHPT patients, and 10 from ADHH patients) mutations (i.e. 45%) were 
predicted to be located at or near one or more of the 5 VFTD calcium binding sitescalcium 
binding sites (Table 4.2) with >50% located at calcium binding sites -1; these findings are in 
agreement with our observations of the 71 CaSR mutations (Table 4.1 and 4.2). In addition, FHH 
calcium binding sitesCalcium binding sites mutations most commonly involved the substitution 
of an Arginine residue, indicating a key role for this residue in Ca2+ binding, whereas, the 
majority of ADHH mutations clustering around calcium binding sitesCalcium binding sites 
involved the loss of a glutamate residue, thereby highlighting a role for glutamate in Ca2+ 
binding (Figure 4.1). A detailed homology modelling analysis of the locations of residues 173 
and 221 at the VTFD cleft, revealed that both of these amino acid residues are situated at the 
entrance to calcium binding sitesCalcium binding sites-1 at the cleft region (Figure 4.5F), and 
hence mutations of these residues would be predicted to influence the entry and binding of Ca2+ 
into the VTFD cleft binding site. This location is consistent with the “toggle” role that these 
residues were found to have in the functional expression studies (Figure 4.3) and in their clinical 
phenotypic expression in being associated with both FHH and ADHH (Table 4.1). 
4.3 Discussion  
We report, 71 different CaSR mutations that have been identified in 80 patients with 
FHH, NSHPT and ADHH (Table 4.1, Figure 4.1). The majority (>50%) of these CaSR mutations 
are missense substitutions located within the ECD (Figure 4.1 and Figure 4.4). These and other 
previously reported disease-causing mutations have highlighted the importance of the ECD in 
CaSR function. The ECD has key roles in co-translational processing of the CaSR (240), 
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receptor dimerisation (241), binding different ligands that include Ca2+ and amino acids 
(95,234,242), and transmitting activation signals to the TMD and ICD (243). The CaSR ECD has 
a bilobed VFTD that is predicted to contain 5 calcium binding sitescalcium binding sites, which 
are located at flexible loops or helical regions close to the protein surface (172). The presence of 
these multiple binding regions explains the ability of the CaSR to bind Ca2+ in a cooperative 
fashion. Homology modelling of the 34 missense mutations (Table 4.1, Figure 4.1) characterised 
by our study and which affect VFTD residues revealed that >50% of these mutations are situated 
within 10 Å of one or more calcium binding sitess (Figure 4.5). Thus, our study of disease-
causing mutations emphasises the key role of the extracellular VFTD in binding Ca2+. The 
VFTD calcium binding sitess have been previously demonstrated to exhibit differing affinities 
for Ca2+ (172). In particular, VFTD calcium binding sites-2 to -5, when compared to calcium 
binding sites-1 exhibit a lower affinity for Ca2+, and are considered to be involved only in 
binding Ca2+ in hypercalcaemic states (172). Given the auxiliary role of sites outside the VFTD 
cleft, in Ca2+ binding, mutations at these calcium binding sites would be expected to induce a 
milder alteration in CaSR function than calcium binding sites-1 mutations. Homology modelling 
in this study revealed that a Pro339Thr mutation (245) was situated in the proximity of Ca2+ 
binding site 4 that is located in lobe 1. Consistent with binding sites outside the VFTD cleft 
having a minor role in Ca2+ binding, the Pro339Thr mutation has been reported to lead to a mild 
loss of function and was associated with normocalcaemia in the heterozygous state (245).  
Over 70% of these calcium binding sites CaSR mutations are associated with FHH or 
NSHPT (Figure 4.1), and it therefore seems likely that the residues, which are within the VFTD 
either participate in the binding of Ca2+, or indirectly enhance this process. Interestingly, the 
most commonly mutated residue within the VFTD was found to be arginine, which is able to 
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form multiple hydrogen bonds to carbonyl groups of the peptide backbone and be involved in 
maintaining tertiary protein structure (250). Mutated arginine residues were located at calcium 
binding sites-1 and -3, and of the 23 arginine residues, which comprise 4% of the VFTD residues, 
5 (i.e. 22%) were involved in mutations that resulted in FHH or NSHPT, but not ADHH. This 
observation was confirmed by our analysis of the previously reported 200 different CaSR 
mutations (248) which revealed the occurrence of mutations at 30% of the VFTD arginine 
residues that were associated with FHH or NSHPT, and never ADHH. Hence it is possible that 
the arginine residues located at calcium binding sites-1 and -3 (Figure 4.5) promote CaSR 
activation by providing a favourable VFTD conformation for Ca2+ binding. In contrast, 2 out of 5 
(i.e. 40%) of the ADHH associated CaSR mutations in this study and 6 out of 10 (i.e. 60%) of 
the previously reported ADHH mutations located near to a calcium binding sites involved the 
substitution of a glutamate residue (Table 4.1). The mechanism of CaSR activation associated 
with the loss of a glutamate binding site residue may involve a reduction in the overall negative 
charge of that binding site, leading to a reduced repulsion between binding site residues that 
facilitates Ca2+ binding (172).  
Our identification and functional characterisation of mutations involving codons 173 and 
221, which are located at the entrance to the VFTD cleft, and lead to either loss- or gain of CaSR 
function, help to illustrate further the important role of this region. Indeed, the VFTD cleft is the 
principal region for the binding of orthosteric ligands such as Ca2+ and amino acids, and it has 
been previously demonstrated that this site has the greatest binding affinity for Ca2+ and 
facilitates the cooperative binding of Ca2+ to the other four calcium binding sitess (172). Such a 
role for the VFTD cleft is consistent with many of the VFTD mutations being located near to this 
critical region and the observation that mutations of Glu297, which is located in the calcium 
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binding sites-1 and VFTD cleft, are also associated with opposing effects on CaSR function (96). 
Our analysis of the mutations at Leu173 predicted that the introduction of a mutant 
phenylalanine residue would enhance CaSR activation by increasing the area of interaction with 
Ca2+ at the VTFD cleft. The importance of phenylalanine for Ca2+ binding by the CaSR has 
previously been demonstrated by studies of Phe270, which is required to complete the 
coordination sphere for Ca2+ at calcium binding sites-1 (96). The introduction of the mutant 
Pro173 residue was predicted to disrupt an alpha helix at calcium binding sites-1 and thereby 
result in a loss of CaSR function. This alpha helix is adjacent to Ser170, which is directly 
involved in Ca2+ coordination, and loss of this secondary structure at calcium binding sites-1 
may reduce the proximity of Ser170 to Ca2+. The predicted derangement of the architecture of 
calcium binding sites-1, in the mutant Pro173 receptor, is in keeping with the severe loss of 
function observed in our in vitro studies of this mutant receptor (Figure 4.3). Our analysis 
mutations at Pro221 predicted that the activating Leu221 mutation would enhance Ca2+ entry into 
calcium binding sites-1 due to the substitution of the rigid side chain of the wild-type proline 
residue at the entrance to the VFTD cleft with the more flexible leucine side chain. In contrast, 
the side chain of the mutant glutamine residue, associated with the Gln221 mutation, would be 
predicted to extend across the entrance of calcium binding sites-1, thereby impairing ligand entry 
and leading to a loss of CaSR function. 
The value of undertaking such functional characterisation studies is demonstrated by our 
analysis of the Glu250Lys variant. The Glu250Lys variant has previously been reported by 
several studies to be a causative mutation in patients with FHH and PHPT (251,252), and is also 
listed in the calcium sensing receptor database (CASRdb) (248) as a recurrent mutation. The 
finding of this Glu250Lys variant in both FHH and ADHH patients in our study (Table 4.1), 
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suggested that this variant, which involves an evolutionary conserved Glu250 residue, may not 
be a mutation but instead a functionally neutral polymorphism. We therefore undertook a 
functional characterisation of the wilde-type CaSR and Glu250Lys CaSRs which demonstrated 
that they each had an EC50 that was similar (Figure 4.3), thereby indicating that Glu250Lys was 
not a CaSR mutation but instead a polymorphism. Thus, our finding emphasises the value of 
undertaking functional characterisation of CaSR variants, which is not generally performed 
because of time and cost constraints. Instead variants are considered to be pathogenic mutations 
on the basis of co-segregation with the disease, absence in a panel of normal individuals, and 
alteration of an evolutionary conserved residue. Our findings indicate that this approach should 
be used with caution for recurrent variants and especially if they are observed in FHH and 
ADHH patients. Indeed, such variants should be evaluated by a functional assay as they may 
represent functionally neutral polymorphisms.  
The NSHPT mutations described in this study included an Arg25Stop mutation (Figure 
4.2) which represents the most N-terminal truncating mutation described to date. The mutant 
25Stop allele would be predicted to produce a transcript that would undergo nonsense mediated 
decay (162), or result in the expression of a non-functional peptide that comprises the 19 amino 
acid signal peptide and an additional 6 amino acids. However, the Arg25Stop CaSR mutation 
was associated with severe hypercalcaemia in the homozygous state, while the heterozygous 
affected parents had differing phenotypes, with the mother being normocalcaemic and the father 
having mild hypercalcaemia. This finding of hypercalcaemia in the heterozygous father suggests 
that the effects of the 25Stop mutant CaSR maybe due to haploinsufficiency rather than a 
dominant-negative action on receptor dimerisation as previously reported (162,246,253). Indeed, 
such an effect due to CaSR haploinsufficiency would be consistent with the observations in Casr 
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+/- mice, which have an ~50% reduction in CaSR protein expression, and exhibit mild (i.e. ~ 10%) 
increases in serum calcium concentrations (227). Thus, it seems likely in the Casr +/- mice and in 
humans with heterozygous null CaSR mutations that the hypercalcaemia results from a reduction 
in the expression of the wild-type receptor from the normal allele, consistent with a gene dosage 
effect or haploinsufficiency. The disparity in the phenotypes of individuals with the same CaSR 
mutation as observed in the hypercalcaemic father and normocalcaemic mother (Figure 4.2), 
which has been previously reported (254,255), may be due to the differences in genetic 
background and gene modifiers. 
Mutations of the CaSR gene were not identified in >70% of the probands, and the 
phenotypes of these patients without CaSR mutations were similar to those with CaSR mutations. 
Therefore it seems likely that other mutations involving the non-coding regions of the CaSR, or 
mutations involving other mediators of calcium regulation may underlie the hyper- and 
hypocalcaemic phenotypes of these patients. Indeed, the occurrence of such genetic 
heterogeneity is supported by the identification of two other FHH loci located on chromosome 
19p and 19q13 (256-258). 
In conclusion, our study reports 71 CaSR mutations identified in patients with FHH, 
NSHPT or ADHH, and demonstrates the value of functional characterisation studies by showing 
that the Glu250Lys variant, which had been previously considered to be a recurrent mutation, is 
instead a functionally neutral polymorphism. Our study also highlights that NSHPT is associated 
with a high proportion of truncating CaSR mutations, such as Arg25Stop, which is one of the 
most N-terminal truncating mutations described to date, and that haploinsufficiency of the CaSR 
may have a role in the etiology of NSHPT. Furthermore, our results reveal that missense 
mutations of the CaSR ECD cluster at multiple calcium binding sites, and particularly in the 
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vicinity of the cleft region formed by the two lobes of the VFTD. Indeed, mutations of residues 
173 and 221, located at the entrance to the VFTD cleft, were demonstrated to have opposing 
effects on receptor function and likely influence receptor function through their effects on the 
entry and binding of Ca2+ in the cleft region. Thus, our findings, which help to further elucidate 
the structure-function relationships of the CaSR extracellular domain, provide support for the 
VFTD cleft in having a major role in the binding of extracellular Ca2+ and regulation of CaSR 
function. 
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CHAPTER 5. DISEASE-ASSOCIATED “TOGGLE” MUTATIONS ON THE CALCIUM-
SENSING RECEPTOR CHANGE THE CA2+ AND L-PHE REGULATED FUNCTIONAL 
COOPERATIVITY 
5.1 Introduction 
          The human calcium (Ca2+)-sensing receptor (CaSR) is a seven transmembrane G protein-
coupled receptor (GPCR) that is expressed at the highest levels in the parathyroid glands and 
kidneys (38). The principal role of CaSR is to sense alterations of the extracellular calcium 
concentration ([Ca2+]o) and to maintain [Ca2+]o homeostasis by regulating parathyroid hormone 
(PTH) secretion as well as renal Ca2+  reabsorption.  Like other members of family C in the 
GPCR superfamily, including the metabotropic glutamate receptors, the V2R vomeronasal 
pheromone receptors, the TAS1R taste receptors, and the gamma-amino butyric acid (GABA-B) 
receptors (241), CaSR possesses a large extracellular domain (ECD) consisting of more than 600 
amino acids (95).  Ca2+, as the principal physiological agonist for CaSR, is thought to bind to the 
ECD resulting in activation of phospholipase C (PLC), with an attendant accumulation of 
inositol 1,4,5-triphosphate (IP3) followed by a resultant increase in the cytosolic calcium ([Ca2+]i) 
concentration (101).  
           The downstream signaling pathways triggered by CaSR generally involve the interactions 
of intracellular loops 2 and 3 of the receptor with heterotrimeric G-proteins, including Gq/11, Gi/o 
and G12/13 (259). The Gq/11 proteins are linked to receptor-mediated activation of phospholipase-
C which plays critical roles in Ca2+o-mediated  PTH secretion. The Gi/o proteins inhibit adenylyl 
cyclase, while the G12/13 proteins have been shown to activate monomeric G-proteins, for 
instance, Rho (259). Studies have shown that CaSR stimulates phosphorylation and concomitant 
activation of the extracellular signal-regulated kinases (ERK1/2) through both a pertussis toxin-
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sensitive pathway involving Gi protein as well as a pertussis toxin-insensitive pathway utilizing 
Gq/11. ERK1/2 are known to modulate many cellular processes, including cell proliferation, 
differentiation, apoptosis, oncogenic transformation as well as enzymatic activity (260,261).  
 
          In biological systems, free L-amino acids are essential molecules since they not only serve 
as the building blocks of protein but are also the metabolic precursors of crucial substances that 
serve as ligands for receptors (165). Evidence for the presence of amino acid sensing 
mechanisms in various studies, e.g.,regulating  insulin secretion from pancreatic beta cells, 
hepatic autophagy, etc., suggest the widespread existence of amino acid sensors, although the 
identities of these amino acid sensors are in many cases unknown.  These findings highlight 
amino acid-dependent control of cellular signal transduction pathways. Fluctuation of the plasma 
levels of amino acids can, therefore, regulate the rate of hormone synthesis and secretion as well 
as Ca2+ metabolism, among other processes (165). CaSR is present throughout the 
gastrointestinal tract (41,166), including in gastrin-secreting antral G cells and cholecystokinin-
secreting l cells, both of which are known to be activated by both [Ca2+]o and aromatic amino 
acids (166). L-amino acids, especially aromatic amino acids, are known to enhance the 
sensitivity of CaSR to [Ca2+]o, which could be one potential explanation for how dietary protein 
modulates [Ca2+]o homeostasis in normal individuals as well as in patients with chronic renal 
failure (165,167).  
               
            Mutations of the CaSR can perturb intracellular signaling events (e.g., intracellular 
calcium response) and disrupt the regulation of PTH secretion from the parathyroid chief cells 
and of Ca2+ reabsorption in the renal tubule. Mutations that inactivate (i.e., cause loss-of-function) 
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CaSR result in familial hypocalciuric hypercalcemia (FHH) and neonatal severe primary 
hyperparathyroidism (NSHPT) (161,240) by producing a rightward shift in the CaSR’s 
concentration–response curve, with a significantly higher EC50 in in vitro studies. On the other 
hand, activating mutations of the CaSR lead to autosomal dominant hypocalcemia with 
hypercalciuria (ADHH) (245), and produce a leftward shift of the concentration–response curve 
and lower EC50 (163). These mutations, including the four studied here and described below that 
involve the two “toggle” residues, L173 and P221, where mutations of the same residue can 
either activate or inactivate the CaSR, serve as a rich source of structure-function information 
and have provided important insights into how the receptor functions. 
             Molecular dynamics (MD) simulation provides an approach complementary to the 
experiments in live cells for understanding biomolecular structure, dynamics and function (220) 
and computational modeling of the GPCR 3D structures have become increasingly indispensable 
tools for studying these receptors as well as discovery of the drugs which effect their behavior. 
Using our previously reported computational algorithm, we have predicted five potential Ca2+-
binding sites in the CaSR ECD based on the charge distribution on the surface of the Venus 
flytrap (VFT) domain  and on the known structural properties of Ca2+-binding sites (68,172). The 
CaSR ECD was modeled from the known structure of the ECD of metabotropic glutamate 
receptor type 1  (mGluR1) (175),Ca2+-binding site 1 in the CaSR ECD is located in the hinge 
region between lobes 1 and 2, and is proposed to be the principle site for Ca2+-binding during 
receptor activation. Moreover, the putative L-Phe binding site is also predicted to be located 
nearby in the hinge region (221). Interestingly, among 34 identified ECD missense mutations in 
patients with FHH, NSHPT and ADHH, 18 are located within 10 Å of one or more of the 
predicted Ca2+-binding sites, particularly site 1(208). Four disease-related mutations involving 
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residues 173 and 221, which are located at the entrance to the Ca2+-binding site in the VFT cleft, 
have been identified. Two of these are activating mutations (L173F, P221L) and two are 
inactivating mutations (L173P, P221Q). These four so-called “toggle” mutations, defined as 
mutations involving the same residue that lead to opposite effects on receptor function, are near 
Ca2+-binding site 1 in our predicted ECD model structure, thereby highlighting the importance of 
these residues for entry and binding of Ca2+ by the CaSR ECD. (161).  
             In the present studies, we extended Dr.Hannan’s studies to investigate whether residues 
L173 and P221 are important for the CaSR’s positive homotropic cooperativity and for the 
coupling of the receptor to several intracellular signaling cascades. We also utilized these four 
mutations to further probe the structure-function relationships of the CaSR as they relate to the 
activation of the CaSR by Ca2+ and L-Phe and how L-Phe interacts with Ca2+ to modulate 
intracellular signaling. These results provide important insights into how Ca2+ and L-Phe interact 
at their respective binding sites in the cleft of the VFT. 
5.2 Results 
5.2.1 The disease-related mutations show altered [Ca2+]i oscillation patterns compared with WT 
CaSR.  
           The two residues involved in the four disease-associated mutations (L173, P221) are 
located in the hinge region near predicted calcium-binding site 1, which is between lobes 1 and 2 
as shown in Figure 4.1a. The immunostaining results suggest that all of these mutant CaSRs can 
be expressed at the cell membrane (Figure 5.1b). We investigated the impact of these four 
disease-associated mutations on [Ca2+]o-induced changes in [Ca2+]i to examine their effects on 
the pattern of [Ca2+]i oscillations, apparent affinity and positive homotropic cooperativity of the 
CaSR (Figure 5.1c).  Three parameters were employed to analyze the [Ca2+]i oscillation patterns: 
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the starting point, which refers to the [Ca2+]o at which a given cell starts to show at least three 
continuous, sequential peaks; the ending point, which considers the [Ca2+]o at which the [Ca2+]i 
reaches to a plateau, and the frequency, which is defined as the number of peaks of [Ca2+]i per 
minute. A stepwise increase in [Ca2+]o induced oscillations in [Ca2+]i in some HEK293 cells 
transfected with WT CaSR (Figure 5.2, WT). Frequency distribution showed that about 53% of 
the cells showing oscillatory responses started to show [Ca2+]i oscillations at 2.5 mM [Ca2+]o 
(Figure 5.3a). The frequency of oscillations at 2.5 mM [Ca2+]o in these cells exhibited a normal 
distribution with an average frequency in the range of 1.0~1.5 peaks/min (Figure 5.3b). About 50% 
of the oscillatory cells reached a [Ca2+]i plateau at 2.5 mM [Ca2+]o (Figure 5.3c). The gain-of-
function mutations have an impact on the responsiveness of the cells to changes of [Ca2+]o. This 
behavior was reflected in the following ways: firstly, the majority of the cells, 54% for L173F 
and 40% for P221L, started to oscillate at lower levels of [Ca2+]o, 1.5 mM and 2.0 mM, 
respectively, than observed with the WT CaSR. Secondly, the average frequencies at 2.5 mM 
[Ca2+]o increased to 1.7 ± 0.1 peaks/min (p<0.05) and 1.6 ± 0.1  peaks/min, respectively (Table 
4.1). The majority of the cells transfected with the gain-of-function mutations had oscillations 
ending points at lower [Ca2+]o level (≤ 3.0 mM) than for WT CaSR. Conversely, the loss-of-
function mutations had opposite effects on the respective oscillation patterns and apparent 
affinities. The majority of cells transfected with the mutant containing P221Q did not oscillate 
until [Ca2+]o reached 4.0 mM, and the threshold for [Ca2+]i oscillations in  the cells transfected 
with L173P was even higher at 15.0 mM. It was difficult to compare the [Ca2+]i oscillation 
frequencies of these two mutants at any given level of [Ca2+]o, because they responded to 
changes in [Ca2+]o over a substantially different range. Therefore, the frequencies were measured 
at the individual EC50s of their [Ca2+]o- concentration response curves. Notably, these two 
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mutations also disrupted the cooperativity of the receptor as reflected by the decreased Hill 
number (P221Q) or an alteration of the monophasic [Ca2+]o-induced [Ca2+]i concentration 
response curve to a biphasic one (L173P) (Table 4.1).  
 
Figure 5.1 The disease-related mutations are located in the hinge region near Ca2+-binding 
site 1.  
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(a), The model structure of the CaSR ECD, which was based on the mGluR1 crystal 
structure (PDB entry: 1ISR) was generated using MODELER 9v4 and Swiss-Model. The 
global view of the ECD is shown in the left panel. Spheres highlighted in red: Ca2+; residues 
involved in predicted Ca2+-binding sites: purple. L-phenylalanine (in yellow) was 
positioned at the hinge region between the two lobes by Autodock vina. Right panel: A 
zoomed in view of the site 1 Ca2+-binding pocket. Labels highlighted in black represent 
residues involved in the Ca2+-binding site 1; residues with disease-related mutations are 
highlighted in purple. ( b). Surface expression of CaSR and its four disease related toggle 
mutants. Green: anti-flag staining of the surface expressed CaSR. (c). Illustrated are 
intracellular responses induced by Ca2+-and L-Phe, and the principle underlying the IP1 
accumulation assay. The addition of Li+ impeded the degradation of IP1.  
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Figure 5.2 Functional studies of disease-related CaSR mutations in HEK293 cells.  
Representative oscillation pattern from a single cell. HEK-293 cells transiently transfected 
with CaSR or one of its mutants were loaded with Fura-2 AM for 15 min. [Ca2+]i was 
assessed by monitoring emission at 510 nm with excitation alternately at 340 or 380 nm as 
described in methods. Each experiment was carried out with or without 5 mM L-Phe began 
in Ca2+-free Ringer’s buffer (10 mM HEPES, 140 mM NaCl, 5 mM KCl, and 1.0 mM 
MgCl2, pH 7.4), which was followed by stepwise increases in [Ca2+]o until [Ca2+]i reached a 
plateau (up to 30 mM [Ca2+]o).  
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Figure 5.3 The frequency distribution of the starting points, frequencies and the ending 
points extracted from  the [Ca2+]i oscillation patterns in HEK293 cells transfected with 
CaSR or its mutants.  
(a). Frequency distribution of the starting points of [Ca2+]i oscillations in HEK-293 cells 
transfected with WT CaSR, or the L173F, L173P, P221L or P221Q mutants, respectively,  
in the presence or absence of L-Phe. [Ca2+]o was recorded at the point when single cells 
started to oscillate. Around 30~60 cells were analyzed and further plotted as a bar chart. 
(b). The frequencies of the individual cell oscillation patterns were investigated. For 
experiments without L-Phe, the peaks per minute were recorded at the level of [Ca2+]o at 
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which the majority of the cells (>50%) started oscillating. Specifically, for the gain-of-
function mutants, the peaks per minute were recorded at 2.5 mM [Ca2+]o ; while for loss-of-
function mutants, the frequency was analyzed at their individual EC50s calculated from the 
concentration response curves for [Ca2+]o.  For experiments with 5.0 mM L-Phe, the 
frequency was analyzed at the same EC50s for [Ca2+]o that were used in the absence of L-
Phe. Empty bar: in the absence of L-Phe; black bar: in the presence of 5 mM L-Phe. (c). 
Frequency distributions of the ending points for [Ca2+]i oscillations.  
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Table 5.1 Summary of [Ca2+]o-evoked [Ca2+]i concentration response data in HEK293 cells transiently transfected with WT 
CaSR and its mutants.  
The cells were exposed to stepwise increases in [Ca2+]o in the absence or presence of 5 mM L-Phe. For WT, L173F and P221L, 
the frequency were recorded at 2.5 mM [Ca2+]o, while for L173P, the frequency was measured at 15.0 mM [Ca2+]o; and for 
P221Q the frequency at 5.0 mM [Ca2+]o was chosen for comparison. The WT oscillation frequency measured at 3.0 mM [Ca2+]o 
is indicated by the brackets. Curve-fitting was performed using the Hill equation. The data were obtained from three 
experiments for each construct.# indicates significance with respect to wild type CaSR in the absence of L-Phe, p < 0.05; * 
indicates significance with respect to the corresponding mutants in the absence of L-Phe, p < 0.05. 
Mutants 
EC50[Ca2+]o Hill coefficient Frequency 
w/o L-Phe with 5 mM L-Phe w/o L-Phe with 5 mM L-Phe w/o L-Phe with 5 mM L-Phe
   WT 3.0 ± 0.2 1.9 ± 0.3* 3.7 ± 0.3 5.0 ± 0.7* 1.3 ± 0.1 2.1± 0.1* 
L173F 1.9± 0.2# 1.6 ± 0.1 3.3 ± 0.1 3.7 ± 0.3 1.7 ± 0.1# 1.9 ± 0.1 
P221L 2.0 ± 0.1# 1.7 ± 0.1 3.2 ± 0.2 2.8 ± 0.2 1.6 ± 0.1# 1.8 ± 0.2 
L173P 
(Phase 1) 3.8± 0.3 3.1 ± 0.2 3.3 ± 0.6 2.5 ± 0.2 
1.3 ± 0.1 1.8 ± 0.2* 
L173P 
(Phase 2) 13.0± 0.3 12.2 ± 0.2* 3.6 ± 0.4 5.8 ± 0.3 
P221Q 5.2 ± 0.4# 3.7 ± 0.4* 2.4 ± 0.4* 4.1 ± 0.7* 1.5 ± 0.1 2.2± 0.1* 
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5.2.2 L-Phe selectively potentiates the [Ca2+]o-evoked [Ca2+]i responses among the four mutants. 
             Since the potential L-Phe binding pocket, similar to that for Ca2+, is also located in the 
cleft of the VFT (Figure 5.1), we next assessed the impact of L-Phe on [Ca2+]o–induced changes 
in [Ca2+]i in order to study the interactions between the functional effects of [Ca2+]o and L-Phe 
and the impact of the four mutations. For the majority of HEK293 cells transfected with the WT 
CaSR, [Ca2+]i oscillations began at 2.0 mM [Ca2+]o and ended at 3.0 mM [Ca2+]o in the presence 
of 5 mM L-Phe, and the oscillation frequency at 2.5 mM [Ca2+]o increased to 2.1 ± 0.1 peaks/min, 
which was significantly higher than the 1.3 ± 0.1  peaks/min observed in the absence of L-Phe 
(Figure 5.3). As shown in Figure 5.3, this allosteric activator exhibited different effects among 
the four mutant receptors. For the gain-of-function mutations (L173F, P221L), L-Phe lowered 
the threshold for the initiation and the termination of [Ca2+]i oscillations, but barely increased 
their frequency at 2.5 mM [Ca2+]o (Figure 5.3 middle panel & Figure 5.3 right panel).  In terms 
of the loss-of-function mutants, cells transfected with mutant L173P started oscillating at 10.0 
mM [Ca2+]o in the presence of 5.0 mM L-Phe and in most cells the [Ca2+]i oscillations stopped at 
25.0 mM [Ca2+]o; in contrast, without L-Phe, 80% of the cells were still oscillating at 30 mM 
[Ca2+]o. Regarding the effect of L-Phe on the frequency parameter, the level of [Ca2+]o at which 
the majority of the cells (>50%) started to oscillate in the absence of L-Phe was chosen to assess 
the influence of the amino acid. The L173P mutant had a frequency of 1.8 ± 0.2 peaks/min at 
15.0 mM [Ca2+]o in the presence of L-Phe, which was significantly higher than the rate in the 
absence of this allosteric agonist observed at the same level of [Ca2+]o (1.3 ± 0.1) (Figure 5.3b & 
Table 5.1). For the P221Q mutant, the threshold for  initiation of [Ca2+]i oscillations decreased 
from 5.0 mM to 3.5 mM [Ca2+]o, while the ending point also decreased in the presence of L-Phe, 
There was an increase in oscillation frequency for this mutant from 1.6 ± 0.1 peaks/min to 2.2 ± 
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0.1 peaks/min with L-Phe at 5.0 mM [Ca2+]o.  
 
             To evaluate the impact of the mutations on the apparent affinities and the cooperativity 
of the responses of the receptor to [Ca2+]o and L-Phe, the averaged [Ca2+]i response at each level 
of [Ca2+]o were plotted to construct [Ca2+]o concentration-response curves for [Ca2+]I as shown in 
Figure 5.4. L-Phe shifted the sigmoid curve to the left producing a lower EC50 for the [Ca2+]o-
evoked increase in [Ca2+]i in WT CaSR-transfected HEK293 cells as well as in cells transfected 
with the P221Q mutant. Interestingly, although considered an inactivating mutation, L-Phe did 
not left-shift the activation of the CaSR mutant L173P by [Ca2+]o to the same extent that it did 
with the other loss-of-function mutant, P221Q, potentially because of the proximity of this 
residue to the binding site for L-Phe, which might interfere with L-Phe binding. The disruption 
of the positive homotropic cooperativity induced by [Ca2+]o as a result of the Leu to Pro change, 
which was reflected as a biphasic concentration response curve, was also not corrected by the 
addition of L-Phe (Table 4.1). Meanwhile, the addition of L-Phe barely further left-shifted the 
concentration-response curves of the two gain-of-function CaSR mutants (p>0.05).  
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Figure 5.4  L-Phe modulates the [Ca2+]o concentration response curves for [Ca2+]o in CaSR-
transfected HEK293 cells.  
The [Ca2+]i responses of HEK293 cells transiently overexpressing WT CaSR or disease-
related mutations were measured using Fura-2AM during stepwise increases in [Ca2+]o 
from 0.5 to 30 mM with or without L-Phe as above. The ratio of light emitted at 510 nm 
upon alternate excitation with 340 or 380 nm was normalized to its maximum response. 
And the [Ca2+]i responses at various [Ca2+]o were plotted and further fitted using the Hill 
equation. Open circle: in the absence of L-Phe; Closed circles: in the presence of 5 mM L-
Phe. 
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5.2.3 L-Phenylalanine potentiates [Ca2+]o-induced IP1 accumulation. 
              To determine whether the functional impact of the four mutations on [Ca2+]i extended to 
other functional read-outs, we examined the effects of [Ca2+]o and L-Phe on the activation of 
PLC as assessed by IP1 accumulation and, in the following section, on ERK activity. Activation 
of the Gq/11 pathway by GPCRs activates phospholipase C (PLC), causing accumulation of 
inositol phosphates (IPs) (101). The responses to [Ca2+]o in the absence and presence of L-Phe in 
cells transiently transfected with WT CaSR or the four mutants were assessed by measuring the 
accumulation of intracellular IP1 (Figure 5.5). The EC50 for the stimulation of IP1 accumulation 
was 2.9 ± 0.3 mM for the WT CaSR, which agrees well with the EC50 calculated from the [Ca2+]i 
responses (3.0 ± 0.2). The addition of 5 mM L-Phe significantly elevated the level of IP1 
accumulation at 2.0 and 3.0 mM [Ca2+]o resulting in a left-shifted [Ca2+]o-IP1 concentration 
response curve. In contrast, the two gain-of-function mutants, L173F and P221L, showed higher 
levels of IP1 accumulation at 1.0, 2.0 and 3.0 mM [Ca2+]o compared with the WT CaSR, leading 
to lower EC50s for the IP1 responses (1.3 ± 0.1 and  1.1 ± 0.1 respectively) (Table 4.2). On the 
other hand, the loss-of-function mutations, L173P and P221Q, exhibited impaired [Ca2+]o–
stimulated IP1 accumulation as the EC50s for the [Ca2+]o-IP1 concentration response curves were 
higher than with WT  (10.8 ± 1.9 and 6.5 ± 0.4 respectively, vs. 2.9 ± 0.3 mM for the WT CaSR). 
In the presence of L-Phe, the EC50 was reduced to 4.3 ± 0.1 (p<0.05) in the case of P221Q. 8.9 ± 
1.7 (p>0.05) in the case of L173P. On the contrary, L-Phe failed to reduce the EC50 of L173P 
significantly. The EC50s of the IP1 responses for the two receptors with activating mutations, 
L173F and P221L, were not altered by L-Phe either. The outcome of IP1 experiments were 
consistent, therefore, with the [Ca2+]o experiments in terms of EC50. However, it seems that the 
alteration in the [Ca2+]o oscillation pattern for L173P was not dramatic enough to change the 
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overall population response. 
 
Figure 5.5. L-Phenylalanine potentiates [Ca2+]o-induced IP1 accumulation.  
IP accumulation was measured in the IP-One ELISA Kit as detailed in Methods. Changes 
in IP1 accumulation were measured in response to [Ca2+]o at 0, 1.0, 2.0, 3.0, 5.0 and 7.5 mM 
in HEK293 cells transfected with WT CaSR, or with mutant L173F or P221L.  For mutant 
L173P, IP1 accumulation was measured at 0, 3.0, 5.0, 7.5, 10.0, 15.0, 20.0 and 25.0 mM 
[Ca2+]o; for mutant P221L, the IP1 responses to [Ca2+]o at 0, 3.0, 5.0, 7.5, 10.0, 15.0 mM 
[Ca2+]o were recorded. The IP1 response-[Ca2+]o concentration responses were fitted using 
Hill equation as mentioned in method.   
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Table 5.2 Summary of EC50s from experiments measuring IP1 accumulation and ERK1/2 
phosphorylation.  
 
HEK293 cells were transiently transfected with the WT CaSR or disease-associated CaSR 
mutants. Cells were then treated with various levels of [Ca2+]o. The EC50s of the IP1-[Ca2+]o 
concentration responses and the ERK1/2 phosphorylation activity-[Ca2+]o concentration 
responses were obtained from curve fitting using the Hill equation as described in Methods. 
# indicates significance with respect to wild type CaSR, p < 0.05; * indicates significance 
with respect to the corresponding mutants in the absence of L-Phe, p < 0.05. 
 
 
 
5.2.4 The ERK1/2 responses of the WT and mutants CaSRs correlate with their [Ca2+]i responses 
to [Ca2+]o. 
            In order to understand the effects of the “toggled” mutations on the function of the CaSR 
and its downstream signal pathways (Figure 5.1c) as well as to explore whether L-Phe can 
Mutants 
EC50 (IP1-Elisa) EC50 (ERK1/2 activity) 
Without L-Phe       With L-Phe Without L-Phe       With L-Phe 
WT 3.0 ± 0.2 2.0 ± 0.1* 3.0 ± 0.1 1.9 ± 0.1* 
L173F 1.2 ± 0.1# 1.0 ± 0.1 2.7 ± 0.1# 1.6 ± 0.1* 
P221L 1.1 ± 0.1# 0.9 ± 0.1 2.2 ± 0.3# 1.7 ± 0.2 
L173P 10.7 ± 1.0# 9.0 ± 0.9 14.9 ± 1.0# 13.5 ± 0.8 
P221Q 6.1 ± 0.3# 4.5 ± 0.4* 11.9 ± 0.3# 9.5 ± 0.4* 
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regulate these mutants as suggested by the computer simulation results, we further analyzed 
[Ca2+]i oscillation patterns induced by [Ca2+]o in HEK293 cells transfected with those mutations.  
             Exposure of WT CaSR-transfected HEK293 cells to increasing concentrations of [Ca2+]o 
in the range of 0.0-~2.0 mM for 10 minutes had little effect on the phosphorylation of p44/42 
ERK. Greater increases of [Ca2+]o resulted in the accumulation of p44/42 ERK, which exhibited 
a maximum response at 8.0 mM [Ca2+]o. In the presence L-Phe, the ERK1/2 activity was 
enhanced. As shown in Figure 5.6 and Table 5.2, the amount of phosphorylated ERK1/2 was 
increased significantly at 2.0 mM [Ca2+]o compared with that observed at the same level of  
[Ca2+]o  in the absence of L-Phe. The ERK1/2 activity in the presence of L-Phe reached a 
maximum at 4.0 mM [Ca2+]o. For the activating mutation, L173F, the phosphorylated ERK1/2 
signal could be detected at 2.0 mM [Ca2+]o which was in line with its enhanced  intracellular 
calcium response compared to WT CaSR. However, although L-Phe didn’t significantly shift the 
[Ca2+]o triggered [Ca2+]i response curve, it enhanced the phosphorylation of ERK1/2 even at 
physiological [Ca2+]o concentrations in the mutant L173F. The maximum ERK1/2 activity in cells 
transfected with the L173F mutant was achieved at 3.0 mM [Ca2+]o with 5.0 mM L-Phe. The 
mutation P221L enhanced ERK1/2 activity in the transfected cells, which approached a maximum 
at 3.0 mM [Ca2+]o .The addition of L-Phe failed to activate the ERK1/2 signaling at lower levels 
of [Ca2+]o, but the maximal p-ERK1/2 activity was enhanced ~15% in the presence of L-Phe. On 
the other hand, the ERK1/2 responses of the loss-of-function mutants, L173P and P221Q, 
correlated with the patterns observed for [Ca2+]i  oscillations, as the phosphorylation of ERK1/2 
started at 10.0 mM and 3.0 mM [Ca2+]o, respectively, similar to the initiation of [Ca2+]i 
oscillations.  The addition of 5 mM L-Phe shifted the [Ca2+]o-stimulated p-ERK1/2 concentration 
response curves of mutant P221Q to the left but had little influence on the rescue of the mutant 
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L173P activity.  
 
 
Figure 5.6 L-Phe potentiates [Ca2+]o-activated ERK signaling in CaSR-transfected HEK293 
cells.  
HEK-293 cells transfected with WT CaSR or its mutants were incubated in serum-free 
high glucose MEM medium containing 0.2% BSA overnight. Cells were washed with HBSS 
and then incubated in the presence of various Ca2+ concentrations (0.0-~25.0mM) in the 
absence or presence of 5 mM L-phenylalanine for 10 min at 37 C. The incubations were 
stopped by exposure to the lysis buffer and processed for SDS/PAGE and Western blotting 
as described in the Methods. The western blot results were further quantified using Image 
J. All [Ca2+]o-concentration response curves were normalized to the maximum response in 
each individual experiment. The Hill equation was employed to fit the data. Solid dots: 
with L-Phe; Empty dots: [Ca2+]o only.  
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5.2.5 CaSR mutants exhibit different sensitivities to L-Phe 
To determine whether the four mutations impacted the apparent affinity of the receptor for L-Phe, 
concentration responses for L-Phe at physiological calcium levels of 1.5 mM [Ca2+]o and 2.5 mM 
[Ca2+]o (intermediate levels of [Ca2+]o at which the two gain-of-function mutants are not 
desensitized based on their responses to [Ca2+]o) were compared among cells transfected with 
different CaSR mutants. Figure 5.7 shows that at 1.5 mM [Ca2+]o mutant L173F has a higher 
sensitivity (EC50 = 2.9 ± 0.1) than WT and the other mutants. On the contrary, the loss-of-
function mutant L173P shows a lower sensitivity (EC50 = 5.5 ± 0.3 mM) to L-Phe compared to 
the other mutants. P221L and P221Q do not show any differences from WT at this level of 
[Ca2+]o. When analyzing the sensitivity to L-Phe at their respective EC50s for [Ca2+]o, P221Q 
exhibited a reduced EC50 of the [L-Phe] response (2.5 ± 0.2 mM, p<0.05) while L173P remained 
a similar sensitivity to L-Phe (4.9 ± 0.5 mM, p>0.05) (Figure 5.7, Table 5.3).  
 
In order to explore how the four mutants have such different sensitivities to L-Phe, the solvent 
accessibility at the hinge region has been analyzed.  As shown in Figure 5.8, mutation L173F, 
P221L and P221Q barely altered the surface potential at the predicted site of entry to the L-Phe 
binding site, which is formed by residues S170, S169, and T145 (221,223); however, the 
mutation from leucine to proline at position 173 contributes significantly to the clustering of 
positive charges in the cleft between lobe 1 and lobe 2.On the other hand, the mutation also 
decreased the original distance between residue L173 and one of the critical calcium binding site 
ligand residues, Y218 from 10.8 Å to 8.7 Å (in the holo form) and from 14.2 Å to 12.2 Å (in the 
apo form), which might make it more difficult for a hydrophobic amino acid to enter into its 
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binding site.  
 
 
 
Figure 5.7 Sensitivity of various CaSR mutants to L-Phe in HEK293 cells.  
(a). HEK-293 cells transfected with CaSR or its mutants were loaded with Fura-2 AM for 
15 min. The intracellular Ca2+ level was assessed by monitoring emission at 510 nm with 
excitation alternately at 340 or 380 nm using fluorescence microscopy as above. Each 
experiment started with 1.5 mM mM Ca2+ followed by stepwise increases in the level of L-
Phe (up to 12.0 mM) while [Ca2+]o maintained at 1.5 mM.  (b). The sensitivity of P221Q to 
L-Phe at 5.0 mM [Ca2+]o. The [Ca2+]i signal was measured using Frua-2 AM as mentioned 
above. The experiment was carried out in the presence of 5.0 mM [Ca2+]o while increasing 
the L-Phe concentration. (c). The sensitivity of  L173P to L-Phe was monitored in the 
presence of 15.0 mM [Ca2+]o. 
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Table 5.3 Summary of EC50s of concentration-response curves for L-Phe at different 
[Ca2+]o.  
Mutants EC50 (at 1.5 mM [Ca2+]o) 
WT 3.7 ± 0.4 
L173F 3.2 ± 0.2 
P221L 4.3 ± 0.3 
L173P 5.5 ± 0.3#    (4.9 ± 0.5) 
P221Q 4.5 ± 0.4     (2.5 ± 0.2*) 
 
 
The [Ca2+]i  responses of HEK-293 cells transfected with CaSR or its mutants upon 
stepwise increases of L-Phe in the presence of 1.5 mM [Ca2+]o were recorded. For L173P 
and P221Q, the L-Phe-induced [Ca2+]i  change were also measured in the presence of high 
[Ca2+]o corresponding to their EC50 values for [Ca2+]o, specifically 15.0 mM [Ca2+]o for 
mutant L173P and 5.0 mM for P221Q. The results are shown in brackets. The EC50s were 
calculated from the concentration-response curves fitted using the Hill equation. # indicates 
significance with respect to wild type CaSR, p < 0.05; * indicates significance with respect 
to the corresponding mutants in the presence of 1.5 mM [Ca2+]o, p < 0.05. 
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Figure 5.8 Surface potential of the hinge region in the extracellular domain of CaSR.  
The zoomed in view of the cleft between lobe1 and lobe2 of WT CaSR or its mutants was 
depicted using pymol. Upper panel: using the apo form of the CaSR models; Lower panel: 
using the holo form of the CaSR models. Residues involving the “toggle” disease mutations 
are labeled in black. Negative potentials are shown in red, and positive potentials are 
shown in blue.    
 
 
 
5.2.6 The protein correlation profiling of the disease-related mutations as assessed by molecular 
dynamic simulations.  
             Since it has been reported that 18 out of 34 newly found naturally-occurring missense 
mutations on the ECD are within 10 Å of one or more of the predicted Ca2+-binding sites (208), 
and a few disease-associated human mutations severely affect the functional cooperativity of 
CaSR (161), an investigation on the mechanisms of the cooperativity alterations induced by 
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mutations as well as allosteric modulators is highly desirable. Molecular dynamic simulation 
provides an approach complementary to in vitro experiments for understanding biomolecular 
structure, dynamics, and function (220). To obtain additional insights into the impacts of these 
various mutations on the structure and function of the CaSR, we carried out molecular dynamics 
simulations, as shown in Figure 5.9. The correlation map in Figure 5.9 illustrates the protein 
motions predicted using such simulations. The X- and Y-axes correspond to residue numbers of 
the CaSR ECD minus 24 (in order to align with the structure of mGluR1). In the WT model, site 
1 is shown to have strong correlated motions with sites 2, 3 and 4, which are shown in blue for 
negative correlations ( motions between each pair of residues taking place in the opposite 
direction) and red for positive correlations (movements in the same direction) (Figure 5.9). The 
correlation maps of the gain-of-function mutations, L173F and P221L, exhibited dramatic 
increases in the regions with either blue or red color indicating an enhancement of correlated 
motions between the respective residues in these two mutants (Figure 5.9). A closer analysis of 
the correlated motions of L173F and P221L revealed that the negative correlations between Site 
1 and Site 3 and between Site 1 and Site 2 observed in the WT correlation map became positive 
correlations in the gain-of-function mutants indicating that the mutations might have profound 
impacts on the dynamic properties of the CaSR-ECD. Moreover, greater correlated motions were 
observed among residues 344-454, among residues 24-124, and between these two groups of 
residues. Especially for P221L, strong negative correlations between lobe 1 and lobe 2 are 
observed as indicated by the abundant blue area between residues 200-300 and residues 24-170. 
On the other hand, the loss-of-function mutations, L173P and P221Q, exhibit weaker correlated 
motions compared to the WT CaSR (Figure 5.9). 
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            Since L-Phe is considered as one of the positive allosteric modulators to the CaSR, we 
investigated whether L-Phe can change the dynamic features of these mutants. The introduction 
of L-Phe and calcium to the simulation system dramatically changed the correlated  motions of 
WT (data not shown) and mutant L173F, P221L and P221Q, but had less effect on the 
correlation map of L173P (Figure 5.9). These results suggested that the allosteric modulator may 
have biased influences on changing the correlation motions among these mutants. 
 
  
 
Figure 5.9 The correlation map of the modeled WT and mutant CaSR ECD structure.   
The correlation map is depicted based on molecular dynamics (MD) simulations for 50 ns. 
The X axis and Y axis are residue numbers of CaSR ECD sequences minus twenty four. 
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The strongest negative correlation is given the value -1 while the strongest positive 
correlation is defined as +1. Residues that have the strongest negative correlated motions 
are shown in blue, while those involved in positive correlated motions are shown in red. 
Green stands for no apparent correlated motion between the two residues.   
 
 
 
            Principal component analysis (PCA) was also applied to the four mutations and the WT 
CaSR as well based on the trajectories of molecular dynamics simulations in order to predict the 
effect that L-Phe could have on the CaSRs at the atomic level. PCA separates out the protein 
motions into principal modes ranked according to their relative contributions (199).Projection of 
the trajectories of the CaSR mutants in both the apo form (upper panel) and the holo form (lower 
panel) onto the first three modes that accounted for the majority of the total fluctuations is shown 
in Figure 5.10. In the Ca2+-free and L-Phe-free forms, the conformations of the CaSR mutants 
sampled are similar to those of the WT CaSR. However, in the L-Phe and Ca2+-loaded forms, the 
conformations of the CaSR mutant L173P is essentially distinguishable from other mutants and 
WT CaSR (Figure 5.10). The results suggest that Ca2+ and L-Phe might shift the population of 
conformational ensembles of mutant L173P in a different way compared with WT or the other 
three mutants.  
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Figure 5.10 Principal component analysis (PCA) of the wild type and mutant CaSR ECDs.   
 
The trajectories of the molecular dynamics simulations were analyzed using principal 
component analysis (PCA), which separates out the motions of different CaSR ECD 
mutants into principal modes ranked according to their relative contributions. The first 
three principal modes were included in the present study to analyze two different states of 
the protein: upper: apo form; lower: holo form. Different colors stands for each individual 
CaSR or its mutants: WT (black), L173F(Green), L173P (Red), P221L (Magenta), P221Q 
(Blue). 
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5.3 Discussion 
The loss-of-function mutations impaired the functional cooperativity of the CaSR 
           We have reported 71 CaSR mutations identified in 220 patients with previously 
undiagnosed hyper- or hypocalcemic disorders. More than 50% of the mutations are located 
within 10 angstroms of our predicted Ca2+-binding sites (208). The hinge region is considered to 
be crucial in terms of the CaSR’s sensing of its agonists (e.g., polyvalent cations and amino acids) 
(68,212). Notably, 12 mutations can be mapped in the vicinity of the major Ca2+-binding site 1, 
which is in the hinge region between lobes 1 and 2, linking other four potential calcium binding 
sites. Thus, mutations near Ca2+-binding site 1 possibly influence the whole receptor’s functional 
cooperativity (68,212).  
          By analyzing the changes in [Ca2+]i  in individual HEK293 cell elicited by increasing 
[Ca2+]o, the impact of the ’toggle’ mutations on the function of CaSR has been further evaluated. 
The in vitro study showed that the L173F and P221L mutations enhance the sensitivity of the 
CaSR to [Ca2+]o compared to the WT receptor, but barely change the cooperativity of the 
receptor, while the L173P and P221Q mutations render a less cooperative receptor with impaired 
capability to sense [Ca2+]o. 
 
Disease related mutations change the [Ca2+]o elicited [Ca2+]i oscillation pattern and 
intracellular signaling.  
            Oscillations have been postulated to be the result of complex responses from multiple 
signaling pathways. Since the [Ca2+]o-triggered [Ca2+]i oscillation pattern is believed to be 
modulated by the activity of phosphoinositide pathway (262) as well as a negative feedback loop 
involving the inhibitory effect of  protein kinase C (PKC) on IP3 production (263), the 
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downstream intracellular signaling responses (such as the production of IP1 and the activity of 
ERK1/2,which will be discussed later) can be reflected in the oscillation patterns associated with 
the different disease-related mutations. Although most research focusing on the relationship 
between intracellular calcium mobilization and CaSR activation has utilized CaSR expressed 
heterologously in HEK293 cells, CaSR-induced [Ca2+]i oscillations have been found in cells with 
endogenously expressed CaSR, for instance in parathyroid cells (264), bovine anterior pituitary 
cells (265), opossum kidney (OK) cells (106) and medullary thyroid carcinoma cells (266). 
Oscillations in [Ca2+]i have been reported  not only to modulate the rate of parathyroid hormone 
(PTH) secretion, but also to regulate gene expression (24,119,126,130). The pattern of [Ca2+]i 
oscillations is thus one of the most important signatures reflecting the state of CaSR activity. As 
[Ca2+]o is increased, the [Ca2+]i oscillations reach a plateau in CaSR-transfected cells as the 
desensitization process occurs and/or there is depletion of [Ca2+]i stores. Although the loss-of-
function mutation L173P still oscillated at 30.0 mM [Ca2+]o, considering the elevated and broad 
range of its sensitivity to [Ca2+]o it is possible that a plateau would be reached at even higher 
levels of [Ca2+]o.        
             The studies of the accumulation IP1 (a metabolite of IP3) and the ERK pathways in 
HEK293 cells transfected with the various CaSR mutants conveyed two messages: Firstly, the 
mutations caused changes in the patterns of [Ca2+]i oscillations that at least partially involve 
activation of the Gq/11 pathway. The changes in the accumulation of IP1 upon stimulation with 
various concentrations of [Ca2+]o correlated well with the patterns of [Ca2+]i oscillations. 
Secondly, stimulation of the ERK1/2 activity in CaSR transfected HEK293 cells has been reported 
to involve PKC-mediated as well as a PTX-sensitive, tyrosine kinase-dependent pathways (260). 
Although it is believed that the carboxyl terminus of the protein is involved in the activation of 
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MAPK signaling by interacting with the scaffold protein filamin A(80,81), the data showed that 
that alterations in the extracellular domain can also affect the ERK cascade which is in 
agreement with previous studies(267). Since all the mutations presented similar levels of 
expression on the membrane (Figure 5.1b), these downstream signaling changes may at least 
partially be contributed by the disruption of cooperativity among different calcium binding sites 
introduced by different mutations. On the other hand, the gain-of-function mutations may 
increase the stability the receptor as suggested by other studies (268). 
 
L-Phe induced heterotropic cooperativity rescued CaSR activity 
           We next investigated the effects of the positive allosteric modulator L-Phe on these four 
mutations. The interaction between CaSR and L-Phe has been reported to modulate the G12/13-
RhoA pathway (121); however, L-Phe could also potentially enhance [Ca2+]o-induced alterations 
in intracellular signaling pathways through Gq/11 pathways as reflected by the IP1 accumulation 
assay. The alterations in the oscillation patterns after the introduction of the allosteric activator 
could be the result of the activation of signaling downstream of G12/13 or a combined effect with 
the positive heterotropic cooperativity between the multiple Ca2+ binding sites induced by L-Phe.   
 
           The present study also confirms that the ERK signaling pathway in CaSR-transfected 
HEK293 cells can be modulated not only by [Ca2+]o but also by the positive allosteric modulator, 
L-Phe (100). It should be noted that the ability of L-Phe to enhance the intracellular response 
varied among different mutations. L-Phe enhanced the maximum response of the ERK signaling 
to a greater extent than it altered the apparent affinity in the two gain-of-function mutants, 
although it showed barely any influence on the [Ca2+]o-triggered [Ca2+]i and IP1 responses for 
157 
 
these mutants, which may explain, in part, the dramatic changes in correlated motions from the 
computational simulation results using molecular dynamics. As a signaling messenger further 
downstream than either IP1 or [Ca2+]i, the phosphorylation of ERK1/2 may not merely reflect 
activation of the Gq/11 pathway, but could be contributed to by other G-proteins (e.g., Gi). In 
agreement with the in silico results, L-Phe exhibited less effect on the regulation of the ERK1/2 
pathway in mutant L173P. The predicted L-Phe-binding site has been reported to be located near 
the hinge region between lobe 1 and lobe 2 and to involve residues S169A/S170A/S171A (221). 
L173 is located within 5 Å of this region. The Leu to Pro change could potentially prevent 
generating additional steric effects on the closure of lobe 1 and lobe 2 so that addition of 
exogenous L-Phe is has relatively little impact on the function of the CaSR’s response to changes 
in [Ca2+]o. Meanwhile, the surface electrostatic charge analysis indicated that the mutation could 
cause charge redistribution, leaving the Ca2+ binding pocket slightly more positive, on one hand, 
and reduce the interaction between calcium and its binding site 1. Thus, the hetero-cooperativity 
between the allosteric modulator and calcium binding sites could be disturbed, resulting in the 
lack of a left-shifted concentration-response curve in response to [L-Phe].  
 
Computational studies revealed different behavior of the four mutants though simulation.  
             Based on the known structure of the agonist-bound and apo forms of mGluR1, which is 
in the same family C of the GPCRs as the CaSR, an analogous hinge motion of the CaSR is 
potentially involved in forming the activated form of the latter upon interaction with ligands 
binding to this region. The correlation maps generated from molecular dynamic simulations for 
the model structures of the ECDs of the WT and mutant CaSRs provide a complementary 
approach that is useful to compare the influence of mutations on the interaction networks within 
158 
 
the CaSR ECD. In the current CaSR ECD model structure, it seems that the gain-of-function 
mutations tend to have stronger correlations between the residues than the WT receptor. 
Meanwhile, the loss-of-function mutations showed opposite effects on the correlation maps, 
suggesting a disrupted cooperativity among different calcium binding sites. The simulation 
results revealed limited effects of L-Phe on changing the correlation motions in the mutant 
L173P. Meanwhile it dramatically changed other mutants as well as WT indicating that L-Phe 
may not alter the cooperativity in the same way as the others which have subsequently been 
confirmed by experiment data.   
            The results from PCA could also be an explanation for the biased L-Phe effects. L-Phe 
could not effectively shift the inactive population of conformational ensembles of L173P to an 
active ensemble of conformations as it did to other mutants and WT as well. However, whether 
the  in silico simulations provide a novel method to predict mutational effects on CaSR will 
ultimately require the kind of structural detail available for the mGluRs whose structures have 
been solved. Certainly, the model structure does not take into consideration the possible 
interactions between the ECD and the extracellular loops and/or transmembrane domain as well 
as the intracellular domains. Thus, caution is merited in applying the calculated in silico results 
to those observed with the CaSR in intact cell or in vivo situations. Nevertheless, the predicted 
structural motions may help to identify the mutations or ligands that have increased or 
diminished coupling among specific structural elements within the CaSR ECD. While this type 
of analysis is limited for the moment to the environment of the orthosteric site, this strategy 
could facilitate drug design for modulating the functions of disease-related mutations in the 
CaSR as well as other members of the family C GPCRs 
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            In conclusion, through the analysis of the [Ca2+]i oscillation and the [Ca2+]o and L-Phe 
triggered downstream signaling changes, we found in the present study that the functional 
cooperativity was disrupted in the identified FHH associated CaSR mutations L173P and P221Q 
but not in the ADHH related mutations L173F and P221L. The addition of L-Phe rescued the 
function of P221Q via the introduction of heterotropic cooperativity.  The distinctive correlated 
motions between the gain-of-function mutations and the loss-of-function mutations and potential 
revealed by the molecular dynamic simulations provide insights into the mechanism for the 
disease associated receptor functional alterations.           
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CHAPTER 6.  CHARATERIZE THE BIOPHYSICAL PROPERTIES OF THE 
EXTRACELLULAR DOMAIN OF CALCIUM SENSING RECEPTOR 
6.1 Introduction 
The calcium sensing receptor (CaSR) is a seven transmembrane protein which belongs to family 
C of the G protein-coupled receptor super family (269). The CaSR is named after its major 
function--regulating extracellular calcium homeo stasis in the body—and its predominant 
expression in parathyroid and kidney cells allows this receptor to modulate parathyroid hormone 
(PTH) secretion as well as renal calcium reabsorption (38,41,270,271). The CaSR is also widely 
expressed in other tissues including the gastrointestinal system(165), the central nervous 
system(272), several kinds of cancer tissues etc. where it may play other crucial roles. Besides 
responding to the primary physiological agonist ‘calcium’, the CaSR can also respond to various 
other stimuli, such as other cations (273), amino acids(118,272), polyamines(242), 
polypeptides(274) etc. 
The CaSR is comprised of the three major structural features of GPCR family C: an extracellular 
domain (ECD) which includes residue 20 to 612 (38); a seven-transmembrane domain (613-862) 
(275) and an intracellular tail covers 216 amino acids(276) which bridge the extracellular stimuli 
into intracellular signal pathways. Based on the amino acid homology of the CaSR’s ECD to 
metabotropic glutamate receptor (mGluR), a modeled structure has been proposed for the 
purpose of exploring the biophysical properties of the protein(68). The generated ECD model has 
a bilobed Venus-fly-trap (VFT) structure (68,70), and is proposed to contain five Ca2+-binding 
pockets (68). Among those calcium binding pockets, it has been demonstrated that binding site 1, 
comprising residues Ser 147, Ser 170, Asp190, Tyr218 and Glu297, is critical for binding 
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Ca2+(96). Eleven highly conserved putative N-linked glycosylation sites, Asn-Xaa-Ser/Thr were 
identified in the ECD which are considered to be critical for cell surface expression (88).  
However, due to the lack of biochemical and structural information about the ECD, how 
extracellular stimuli induce conformational changes of the CaSR leading to further intracellular 
downstream responses still remains to be defined. The expression of the CaSR ECD has been 
reported by Goldsmith et. al. (277) and Ryan et. al. (278) using CaSR ECD stably transfected 
HEK293 cell line and insect cells respectively.  Both of the expressed proteins can form dimers 
and are recognized by specific anti-CaSR antibodies. A few biophysical properties of the insect 
cell expressed CaSR-ECD have also been explored in Ryan’s study including the secondary and 
tertiary structure as well as metal-binding properties. Nevertheless, little is known about the 
influence of glycosylation on this protein and the differences of the expressed proteins with 
distinct glycosylation modifications.  
 
UDP-GlcNAc:-D-mannoside-1,2-N-acetylglucosaminyltransferase I (GnTI)1(EC 2.4.1.101) is 
a type II integral membrane protein, localized to medial-Golgi cisternae, and catalyzing the first 
step in the conversion of high mannose N-glycans into complex and hybrid structures (279,280). 
Although the  complex N-glycans are essential for the viability of the developing embryo, as 
mice lacking a functional GnTI gene die before birth (281,282), the complex N-glycans are not 
crucial for viability of cells cultured in vitro as many mutants have been isolated which lack of 
GnTI activity (283,284). One such mutant is the leuco-phytohemagglutinin (L-PHA) resistant 
Lec1 HEK293F cell (285). Due to the deficiency at GnTI, Lec1 cells are unable to synthesize 
complex and hybrid N-glycans and the oligosaccharides will be accumulated in the form of 
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Man5-GlcNAc2-Asn-structures (286). Thus, protein expressed using Lec1 HEK293F cells could 
have a uniform high mannose glycan modification at the surface.  
 
In the present study, the ECD of CaSR was secreted from human CaSR (hCaSR)-ECD 
transiently transfected HEK293F or Lec1 HEK293F cells. The protein was further purified 
through affinity columns. The biophysical properties of the native CaSR ECDs were 
characterized using fluorescence titration spectroscopy, circular dichroism technique as well as 
NMR spectra. Our studies indicate that glycosylation could dramatically alter the protein’s 
thermal stability; meanwhile it also affected the calcium induced conformational changes as well 
as its metal binding capability.  
 
6.2 Results 
6.2.1 The CaSR ECD forms dimer in culture medium 
HEK293F cells or the Lec1 mutant HEK293F cells were transiently transfected with engineered 
hCaSR ECD cDNA (Figure 6.1). The signal peptide at the N-terminal led to the secretion of the 
CaSR ECD into the culture medium. Those His-tagged CaSR ECDs were efficiently separated 
from other proteins with a HisPrep column using an imidazole gradient (Figure 6.2).  The 
fractions containing CaSR ECD were collected and detected by SDS-PAGE under reducing 
conditions (Figure 6.2). Immunoblot was further applied to verify the samples using the specific 
anti-CaSR antibody. As shown in Figure 6.2 (c~e) WT CaSR ECD exhibited a smeared band in 
the range from 100 kDa ~ 130 kDa suggesting various degrees of glycosylation while the Lec1 
mutant hCaSR has one single band with a molecular weight of approximately 95 kDa. The non-
reducing samples of WT CaSR ECD and Lec1 CaSR ECD have molecular weights at around 240 
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kDa and 200 kDa, respectively, corresponding to the calculated dimerization form of the 
receptor’s extracellular domain.      
 
 
Figure 6.1 Schematic representation of extracellular domain of the CaSR. 
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The first 25 amino acids are signal peptide from vector. The arrow indicates the beginning 
of CaSR ECD sequences. The introduced stop codon mutation is immediately after residue 
612, resulting in the secretion of the receptor into the cell culture medium. Putative 
glycosylation sites are hightlighted using branches. Underlined and labeled regions 
represent peptide sequences used to generate peptide-specific monoclonal antibody ADD. 
The loop inserted between D371 and T372 is the engineered Flag-tag.  
 
 
 
Figure 6.2 CaSR ECD protein fractions isolated from cell culture medium using FPLC 
 
(a). HEK293F cells transfected with WT CaSR ECD were continuously cultured for 6 days. 
Then cell culture medium was collected and underwent protein purification procedure 
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using a nickel affinity column. Representative tracing of A280 measured in milli AU for 
protein eluted by imidazole. Inset: Coomassie blue staining of the representative fractions 
from the affinity column separation. The lanes marked “M” are protein molelcular weight 
standards. (b). The same chromatography of protein purification using secreted proteins 
from Lec1 cells transfected with the CaSR ECD.  (c). WT CaSR ECD proteins (50 g) from 
indicated fractions were incubated at 100 °C  in sample dissociation buffer containing -
mercaptoethanol for 5 mins before loading on the SDS gels. (d). the same treatment as (a) 
but with Lec1 CaSR ECD proteins  (e). Left two lanes were loaded with WT/Lec1 CaSR 
ECD incubated at 4°C  for 5 mins in sample dissociation buffer without -mercaptoethanol; 
the right two lanes were loaded with WT/Lec1 CaSR ECD and incubated at 100°C  for 5 
mins with reducing reagent.  
 
6.2.2 The secreted CaSR ECD is stable and glycosylated 
The stability of the purified extracellular domain was further investigated using immunoblot. 
Samples from CaSR ECD aliquots were kept at room temperature continuously for seven days. 
Both the WT CaSR ECD and the Lec1 CaSR ECD was quite stable as no degradation bands 
could be detected by Western blot (Figure 6.3). In order to verify whether the secreted WT CaSR 
ECD is glycosylated or not, Ricinus communis agglutinin I (RcaI) agarose beads, which 
preferentially binds to oligosaccharides, were incubated with the purified protein. A high 
concentration of galactose (200 mM) would compete with the glycoproteins for interaction with 
the lectin agarose beads. Figure 6.4a shows that the WT CaSR ECD was able to interact with the 
RcaI agarose beads which indicate that the protein was glycosylated. N-Glycosidase F, known as 
PNGase F, can cleave between the innermost acetylglucosamine (GlcNAC) and asparagine 
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residues of high mannose, hybrid, and complex oligosaccharides from N-linked glycoproteins 
(287). Treatment with heat and detergent denatured WT CaSR ECD and exposed enzyme 
cleavage sites. As shown in Figure 6.4b, with the presence of N-glycosidase, the molecular 
weight of WT CaSR ECD decreased from ~100 kDa to ~80 kDa. Meanwhile, Endo F1 cleaves 
asparagine-linked or free high mannose and hybrid structures but not complex oligosaccharides, 
leaving a truncated sugar molecule with one N-acetylglucosamine residue on the 
asparagines(288). The Lec1 CaSR ECD showed a lower band on the gel at molecular weight 
around 87 kDa after treatment with Endo F1 (Figure 6.4c), suggesting that the Lec1 CaSR ECD 
has homogenous high mannose form.  
 
 
Figure 6.3 The stability of CaSR ECD at room temperature.  
The purified ECD protein aliquots were incubated in 10 mM Tris buffer (pH 7.2) at room 
temperature for the indicated number of days. Samples were then added with the sample 
dissociation buffer with or without -mercaptoethanol before loading in the gel. R: without 
-mercaptoethanol. (a) WT CaSR ECD; (b)  Lec1 CaSR ECD. 
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Figure 6.4 The secreted ECDs were glycosylated.  
(a.) WT CaSR ECD protein (1.0 mg) was incubated with RCA-1 lectin agarose beads 
overnight at 4Ԩ followed by washing with PBS. Lane 1: Eluted fractions using PBS without 
addition of galactose. Lane 2:  Eluted fractions using PBS containing 200 mM galactose. 
Lane 3: 5 l of the Rca-1 lectin agarose beads after incubating with protein were loaded 
into the gel as a positive control. The elution fractions were further analyzed by 
immunoblot using anti-flag antibody. (b.) Denatured purified WT CaSR ECD (20 g) was 
treated with PNGase F for 2 hours at 37Ԩ. Protein aliquots treated with or without 
PNGase F were loaded in the gel and  further analyzed by Western blot using an anti-flag 
antibody. (c.) The purified Lec1-hCaSR-ECD protein was mixed with Endo F1 at mass 
ratio 1:3 in 10 mM Tris buffer, pH 7.4 for overnight shaking at 4 Ԩ. Samples were detected 
using anti-flag antibody by immunoblot under reducing condition.  
6.2.3 Calcium and glycosylation caused little secondary structure change of the CaSR ECD. 
        In order to analyze the secondary structure of the purified CaSR ECDs, circular dichroism 
measurements were performed. Figure 6.5 shows typical far-UV CD spectra of the proteins. 
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Analysis of all the spectra indicated that the purified WT and Lec1 CaSR ECD shared similar 
secondary structure with  helical content of 52%~58% and -sheet content of 17% ~25%. The 
addition of calcium had caused minimal changes in the spectra of both WT CaSR ECD and Lec1 
CaSR ECD (Table 5.1).   
         The proteins were subjected to stepwise increases in temperatures to assess thermal 
stability. Molar ellipticity was monitored from 4~ 95 C at 222 nm, which is considered to be a 
sensitive position for proteins have >50%  helical structure. As shown in Figure 6.5 (a&b), the 
WT CaSR ECD demonstrated extraordinary thermal stability as the signal at the given 
wavelength did not change. The high mannose form of the CaSR ECD, the Lec1 CaSR ECD, 
showed a rapid disruption of secondary structure at 92C in the absence of Ca2+. In the presence 
of Ca2+, the melting points of the Lec1 CaSR ECD were decreased dramatically to 80C 
possibily due to protein precipitation. However, the calcium induced alterations in melting 
temperature were not observed in the WT CaSR ECD. The heating process resulted in 
irreversible structural changes in the Lec1 CaSR ECD as the high temperatures caused marked 
precipitation of the protein. To determine the enthalpy of the unfolding process for the CaSR 
ECD, the Van’t Hoff equation could be employed for the analysis (289), however, in the present 
study, the precipitation could due to calcium binding induced instability of the protein.  
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Figure 6.5 Circular Dichroism measurement of purified ECD in the presence or absence of 
calcium.  
(a) Far-UV CD spectrum of WT CaSR ECD in 10 mM Tris, pH 7.2 with or without 2.0 mM 
Ca2+, at 25 Ԩ. (b) Far-UV CD spectrum of Lec1 CaSR ECD in 10 mM Tris, pH 7.2 with or 
without 2.0 mM Ca2+, at 25 Ԩ. (c) Temperature dependence of the molar ellipticity at 222 
nm for WT CaSR ECD in 10 mM Tris, pH 7.2. (d) Temperature dependence of the molar 
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ellipticity at 222 nm for Lec1 CaSR ECD in 10 mM Tris, pH 7.2. The addition of calcium 
may also cause the precipitation of Lec1 protein at high temperature, resulting in a 
decrease of the melting temperature.  
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Table 6.1 Secondary structure of CaSR ECDs at 25Ԩ. 
 
-Helix -Strands  Turns Unordered 
 Ca2+(-) Ca2+(+) Ca2+(-) Ca2+(+) Ca2+(-) Ca2+(+) Ca2+(-) Ca2+(+) 
WT 
CaSR 
ECD 
58% ± 1% 55% ± 6%  17% ± 1% 21% ± 4%  6% ± 2% 5% ± 1%  18% ± 4% 15% ± 4% 
Lec1 
CaSR 
ECD 
52% ± 5% 60%  ±4%  25% ± 3% 18% ± 1%  5% ± 1% 7% ± 2%  18% ± 3% 18% ± 3% 
 
The secondary structure contents were estimated according to SELCON and CONTIN algorithms. Numbers in the table 
show the average of secondary structure content of both algorithms.  
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6.2.4 Fluorescence spectra indicate folded structure of the CaSR ECD.  
There are twelve tryptophan (Trp) residues in the ECD, thus, by analyzing the intrinsic 
tryptophan emission spectra from 300 to 400 nm at the excitation wavelength of 282 nm, the Trp 
environment can be monitored. The emission spectrum of free Trp has a peak at around 350 nm. 
The emission peak undergoes a blue-shift if the tryptophan is embedded in a hydrophobic 
environment. All the Trp emission spectra of various types of ECD showed a peak at around 334 
nm, indicating that the proteins retained their native structures (Figure 6.6).  
 
Meanwhile, ANS, a fluorescence probe extensively used for the detection and analysis of protein 
conformational changes, was applied to the study of the two proteins (290). This dye has low 
fluorescence yield when exposed to polar environments, but a blue shift of the emission 
spectrum and an increase of the fluorescence intensity would occur once its fluorophore is 
located in less polar media (291). Compared to the free ANS dye, which has an emission peak at 
around 500 nm, the ANS fluorescence spectra of both the CaSR ECDs underwent a more than 30 
nm blue shift and further exhibited a 10-fold increase in fluorescence intensity (Figure 6.7). The 
fluorescence spectra changes indicate the hydrophobic portion at the protein surface can bind 
with ANS and calcium can induce a conformational change of CaSR ECDs. These results 
correlate well with the Trp spectrum, demonstrating that the purified ECDs, both from WT 
HEK293F cells and Lec1 mutant system, were possibily in their native forms.  
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Figure 6.6 Tryptophan fluorescence titration of CaSR ECDs.  
(a) Trp fluorescence spectra of WT CaSR ECD in the presence of 0 (---) or 5 mM Ca2+ (—). 
(b) Trp fluorescence spectra of Lec1 CaSR ECD in the presence of 0 (---) or 5 mM Ca2+ (—). 
(c) Calcium titration curve of WT CaSR ECD. (d.) Calcium titration curve of Lec1 CaSR 
ECD. 
 
 
174 
 
 
Figure 6.7 Ca2+-induced changes in ANS fluorescence in CaSR ECDs. 
ANS fluorescence spectra of CaSR ECD in the presence (—) or the absence of (---) 5 mM 
Ca2+. The spectrum of ANS alone is shown in gray. The fluorescence intensity at 465 nm 
was recorded and plotted against calcium concentration. The data were further fitted using 
Hill equation. (a) WT CaSR ECD; (b) Lec1 CaSR ECD. 
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6.2.5 Ca2+-induced conformational changes in CaSR ECDs. 
As shown in Figure 6.6 & 6.7, the addition of Ca2+ led to changes in both Trp fluorescence and 
ANS spectrum. Binding to Ca2+ resulted in 2~3 nm blue shift of the emission maxima of the Trp 
fluorescence spectra of both the WT CaSR ECD and the Lec1 CaSR ECD. Futhermore, a 
decrease of 20% in Trp fluorescence intensity in WT CaSR ECD was observed upon the addition 
of saturating amounts of Ca2+, while a 14% decrease in signal was shown in the case of Lec1 
CaSR ECD.  Compared to the calcium induced signal changes of the Trp spectra, the ANS 
intensity alterations upon Ca2+ titrations rendered different patterns for the two proteins. Calcium 
produced an exposure of more hydrophobic regions in the complex oligosaccharides form (WT 
CaSR ECD) as there was a 25% increase in the fluorescence signal. Similar intensity 
enhancements, though to lesser extents (~10%), were detected in Lec1 CaSR ECD.   
 
The calcium induced conformational changes reflected in the Trp spectra were further assessed 
by monitoring the calcium titration processes. As expected, the Kds for mammalian system 
expressed CaSR ECDs were in mM range for WT CaSR ECD 3.5 ± 0.3 mM and for Lec1 CaSR 
ECD 3.2 ± 0.3 mM, respectively. The Hill numbers obtained from the Trp fluorescence spectra 
were 2.6 ± 0.5 for WT CaSR ECD and 2.2 ± 0.2 for Lec1 CaSR ECD, indicating that the two 
proteins may share similar multiple binding processes (Table 5.2). The calcium induced ANS 
spectral alterations were also fitted by the Hill equation. The WT CaSR ECD had a Kd of 3.8 ± 
0.2 mM while the Lec1 CaSR ECD had a Kd value at 3.2 ± 0.1 mM. Their corresponding Hill 
numbers calculated from the Ca2+-ANS titration curves were 2.6 ± 0.4 and 2.3 ± 0.5 respectively.  
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Table 6.2 Summary of dissociation constants and Hill numbers for CaSR ECDs. 
Mutants 
Trp Spectrum ANS Spectrum 
EC50              Hill number EC50                  Hill number 
WT CaSR 
ECD 3.5 ± 0.3 2.6 ± 0.5  3.8 ± 0.2 4.0 ± 0.4 
Lec1 CaSR 
ECD 3.2 ± 0.3 2.2 ± 0.2  3.2 ± 0.1   2.8 ± 0.4 
 
6.2.6 Tb3+ binding process confirmed the weak binding affinity of CaSR ECD  
Considering the potential presence of background Ca2+ in the buffer, which might affect the 
accurate measurement of binding affinity, the metal binding capability of ECDs were further 
analyzed using Tb3+ luminescence resonance energy transfer (Tb3+-LRET). There are 12 Trp 
residues in the CaSR ECDs. According to the model structure of the CaSR ECD, more than 5 of 
the Trp residues are within 15 Å of those potential calcium binding pockets, thus enabling 
aromatic residue-sensitized Tb3+-LRET. Due to their similarities in ionic radii and coordination 
chemistry, Tb3+ has been ubiquitously used to probe Ca2+ binding sites as a trivalent Ca2+ 
analogue. There are several advantages of using Tb3+. Firstly, the spectroscopic properties of 
energy transfer between Tb3+ and the aromatic residues near the binding pockets can facilitate 
the measurements of Kd as well as revealing structural information. Secondly, the higher affinity 
of Tb3+ than Ca2+ also helps to probe the weak Kd values. Last, but not least, the background 
contamination of Tb3+ in the titration system is lower than that of Ca2+. The Tb3+ binding 
processes of the two different proteins turned out to be one binding step instead of a biphasic 
process as observed in the subdomain studies (172). The Tb3+ binding affinity for WT CaSR 
ECD was about 36.6 ± 0.4 M with a Hill number at 1.2 ± 0.1 suggesting a 1:1 binding mode 
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(Figure 6.8). In terms of Lec1 CaSR ECD, the Kd for Tb3+ was 31.8 ± 0.3, which is comparable 
with the WT CaSR ECD. On the other hand, the Ca2+-Tb3+ competition assay suggested apparent 
dissociation constants for the ECDs, from which the binding constants for calcium can be 
deduced (Figure 6.9). The Ca2+ binding dissociation constant calculated from Ca2+-Tb3+ 
competition assay, using equation; 
][
,
,
,
TbK
K
KK
Tbd
Tbd
appCad   , for the WT CaSR ECD and the 
Lec1 CaSR ECD were 3.7 ± 0.2 mM and 2.4 ± 0.2, respectively. This is comparable to the Kd 
calculated from Ca2+ induced changes in native Trp signals as well as the ANS spectra.  
 
Figure 6.8 Tb3+ titration curve of CaSR ECDs.  
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Tb3+ titration curve of purified CaSR ECDs. The buffer for Tb3+ titration consisted of 20 
mM PIPES, 135 mM NaCl, and 10 mM KCl (pH 6.8). The arrow indicates the increase in 
fluorescence. The titration curve was fitted using the Hill equation. (a.) WT CaSR ECD; (b.) 
Lec1 CaSR ECD. 
 
Figure 6.9 Tb3+ competition assay of CaSR ECDs.  
Tb3+-Ca2+ competition assay of purified CaSR ECDs. The buffer for Tb3+ titration 
consisted of 20 mM PIPES, 135 mM NaCl, and 10 mM KCl (pH 6.8). The arrow indicates 
the decrease of the fluorescence with Ca2+ addition. (a) 2.0 M of WT CaSR ECD; (b) 2.0 
M of Lec1 CaSR ECD. 
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Table 6.3 Summary of the Tb3+ FRET assay. 
Mutants 
Tb3+ Titration (M)  Tb3+ Competition (M) 
Kd,Ca (mM)     EC50              Hill 
number  
      EC50 Hill number  
WT CaSR 
ECD 36.6 ± 0.4  1.2 ± 0.1
 
 16.1 ± 0.2  1.8 ± 0.1
  3.7 ± 0.2 
Lec1 CaSR 
ECD 31.8 ± 0.3 1.3 ± 0.2  10.0 ± 0.2  1.6 ± 0.1  2.4 ± 0.2 
 
6.2.7 NMR spectrum revealed calcium induced tertiary structure changes in CaSR ECDs 
Disruptance of chemical shift can be used to monitor the interaction between metals and the 
protein due to the sensitivity of the chemical shifts of protein amides to even dimunative 
conformational changes occurring at the interacting interface. As depicted by Tb3+ binding 
process, as well as the ANS fluorescence, a multiple binding process can be observed in both the 
one-dimensional (1D) (Figure 6.10) and two-dimensional (2D) NMR (Fig. 6.11) when calcium 
was titrated into both 15N L-Phe labeled WT CaSR ECD and 15N L-Phe labeled Lec1 mutant 
CaSR ECD. The chemical shift changes for each protein are shown in Figure 6.11. During the 
titration, a progressive disappearance of the amide signals at 8.05 ppm of the WT CaSR ECD 
was accompanied by the concomitant emergence of a new set of peaks at 7.85 ppm as well as a 
chemical shift between amide signal at 7.95ppm and 8.21ppm which move towards each other 
upon titration of Ca2+ (Figure 6.11 a,b.&c), indicating complex binding states.  
 
The chemical shifts of the peaks were further plotted into calcium response curves as shown in 
Figure 6.11. The calcium induced conformational changes revealed a 1:1 ligand-protein complex 
formation process, Figure 6.11 left panel. In agreement with data from fluorimetric systems, the 
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binding constant was in the millimolar range (1.1 mM). Meanwhile, the analysis on the peaks in 
Figure 6.11c suggested a slow exchange process in which the exchange rate of the bound and 
unbound conformation could not catch up with the amide frequency. The Ca2+-concentration 
response curve indicated a multiple ligand binding process with a Kd at 2.5 mM and a Hill 
number at 2.5. 
 
The Lec1 mutant CaSR ECD with its high mannose form demonstrated a less dispersed 2D 
spectrum after the addition of calcium. A few peaks appeared with the addition of 3 mM calcium 
with characteristics as slow chemical exchanges indicate a strong binding process (Figure 6.12).  
 
 
 
Figure 6.10 Ca2+ titration of CaSR ECD monitored by 1D 1H NMR.  
(a) Ca2+-induced, gradual chemical shift changes in WT CaSR ECD were observed at 
resonances in the main chain amide proton region, such as 7.35 and 8.42 ppm . (b). Ca2+-
induced, gradual chemical shift changes in Lec1 CaSR ECD were observed at resonances in 
the main chain amide proton region, such as 7.40 and 8.40 ppm 
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Figure 6.11  (1H,15N)-HSQC spectra of WT CaSR ECD.  
Left panel: Ca2+-induced chemical shift changes of WT CaSR ECD. Red: WT CaSR ECD 
without addition of Ca2+; Orange: 1 mMCa2+; Yellow: 3 mM Ca2+; Green: 5 mM Ca2+; Cyan: 
10 mM Ca2+. Right panel: Ca2+- chemical shift curves of peak b and peak c in WT CaSR 
ECD fitted by the Hill equation. 
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Figure 6.12 (1H, 15N)-HSQC spectra of Lec1CaSR ECD. 
Ca2+-induced chemical shift changes of Lec1 CaSR ECD. Orange: Lec1 CaSR ECD with 5 
M EGTA; Cyan: Lec1 CaSR ECD with 1 mM Ca2+ 
6.2.8 The binding of L-Phe to the CaSR ECD can be modulated by Ca2+ 
The protein yield of 15N-labeled Lec1 mutant CaSR ECD was much lower compared with 15N-
labeled WT CaSR ECD. Therefore, the application of the heteronuclear single quantum 
coherence (HSQC) NMR to monitor the protein-ligand interaction with the purified 15N-labeled 
Lec1 mutant CaSR ECD will be fraught with pitfalls. Recently, saturation transfer difference 
(STD) NMR has become a popular NMR technique in terms of analyzing protein-ligand 
interactions due to the fact that it detects the signals from the ligands and only small amount of 
nonlabeled proteins or macromolecules are required. As shown in Figure 6.13, the NMR signal 
change from the L-Phe STD spectrum indicated the conformational change of this CaSR positive 
allosteric regulator during the interaction with CaSR ECD (Figure 6.13). This phenomenon 
provides direct evidence to support the earlier hypothesis that L-Phe can bind to the extracellular 
183 
 
domain of CaSR with a Kd at 4.7~6.5 mM (Figure 6.13a&b). Intriguingly, the addition of 2.5 
mM calcium decreased the signal from L-Phe STD spectrum, suggesting the interaction between 
Ca2+ and the receptor may influence the binding between L-Phe and the CaSR ECD (Figure 6.13 
c&d).  
 
Figure 6.13 Monitoring the ligand-protein interaction via STD NMR.  
(a) STD spectrum of L-Phe titration to the CaSR ECD in the absence of Ca2+. The 
increased L-Phe concentration is indicated in the figure. (b) STD spectrum of L-Phe 
titration to the CaSR ECD in the presence of Ca2+. (c) The overlaid 1.0 mM L-Phe STD 
spectra in the presence of Ca2+ (cyan line) and in the absence of Ca2+(red line). (d) The 
intensity of the three major peaks shown in panel c was integrated respectively and further 
plotted against L-Phe concentration. The plots were further fitted by a 1:1 binding 
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equation. The blue line represents the left peak, red for the middle one and black for the 
right one.   
6.3 Discussion 
It has been suggested that the ECD of the mGluRs and CaSR share similar Venus Fly Trap 
structures based on several conserved amino acid regions and predicted secondary structures 
(216). However, there is limited structural and biochemical information available for CaSR due 
to its large molecular weight (~70 kDa as monomer) and heterogeneous glycosylation. In the 
present study, we were able to purify CaSR ECDs from both normal mammalian expression 
systems and the complex N-glycans deficient expression system. In the two systems, the target 
protein was expressed by mammalian cells and was secreted into the cell culture media due to a 
signal peptide at the beginning of the ECD sequence. It is known that CaSR functions as a dimer 
on the surface of the cell membrane. Importantly, the secreted ECD proteins from both the 
complex glycan and the homogenous high mannose form also present in the culture medium as a 
dimer form.  
 
Glycosylation is one of the most important posttranslational modifications occurring in protein 
biosynthesis and secretary pathways. The secreted WT CaSR ECD was well glycosylated as it 
can bind with lectin agarose beads and the treatment with PNGase reduced its molecular weight. 
The Lec1 hCaSR ECD can be further cleaved by Endo F1 but it could not interact with the lectin 
beads. The thermodynamic stability calculations indicate that the stability of a protein may be 
enhanced when a glycan is covalently bound to the protein surface, which can be measured by an 
increase in melting temperature (292). A stabilization by glycosylation has been reported for 
other membrane proteins such as AQP2 mutants (293) and a shaker potassium channel (294). 
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How the glycosylation could affect the biophysical properties of CaSR or other family C GPCR 
proteins has yet to be analyzed. In the present study, the influence of the complexity of 
polysaccharide on the thermal stability of CaSR-ECD is remarkable. The ECD protein with 
heterogeneous saccharides was able to maintain its secondary structure at high temperature (> 
90C). On the other hand, the CaSR ECD with homogenous glycan was comparatively less 
stable. These phenomena would be importantly contributed to the differences of protein tertiary 
structures altered by the post-translational modification since their secondary structures were 
relatively similar.  
 
Calcium, as a predominant agonist for CaSR, is believed to induce conformational changes of the 
receptor to convey the extracellular signal to intracellular messengers. However, the lack of 
evidence to prove such a change makes it worthwhile to analyze alteration of the receptor’s 
biophysical characteristics before and after the Ca2+ binding. One of the biophysical changes on 
CaSR, upon the interaction with Ca2+, is the thermal stability of its ECD. The addition of calcium 
altered the structural stability of CaSR-ECD, resulting in loss of the secondary structure at much 
lower temperatures. Another possible interpretation is the positive charges of the metal 
accelerate the aggregation of the protein at higher temperatures. Different changes in enthalpy 
corresponding to different states, measures a change in the strength of the interactions between 
molecules (295). The enthalpy change of Lec1 CaSR ECD, measured in the present study, is 
comparable to the results from previous subdomain studies in our lab (172), confirming the weak 
binding of Ca2+ to the CaSR ECDs. These lines of evidence are also in line with results from 
tryptophan spectra, as well as the ANS assay, regarding the metal-binding capability.  
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The results in the present study suggested that the full length of WT CaSR ECD has Ca2+ binding 
affinities (3.5~3.7 mM) comparable with the EC50s calculated from CaSR functional assays 
(2.7~3.1 mM). The high mannose form of the CaSR ECD showed similar Ca2+ binding capability 
as the complex N-glycans form. This indicates that the additional post-translational modification 
did not impose large structural changes on the protein. There are twelve tryptophan residues in 
the ECD, among them four are on the molecular surface between lobes 1 and 2. The decrease of 
tryptophan intensity might be explained by a closed form of the receptor resulting from calcium 
binding which could lead to a more imbedded position of those tryptophan residues. On the other 
hand, the signal from the ANS spectrum decreased upon titration with Ca2+ suggesting the 
ligand-induced exposure of more hydrophobic regions of the protein to interact with the ANS 
probe. The Ca2+ induced ANS signal increase of the WT CaSR ECD was larger than with the 
Lec1 CaSR ECD which indicated that the glycans on the WT CaSR ECD might contribute to the 
hydrophobicity changes in the protein triggered by Ca2+.    
 
Functional studies of the CaSR in cells, as well as our previous metal binding studies, using 
grafting approaches have demonstrated that the CaSR has multiple Ca2+-binding sites (87). The 
Hill coefficients of both the WT CaSR ECD and its Lec1 mutant, calculated from calcium 
induced spectrum changes in the current study (2.2~4.0), were also in agreement with the 
multiple Ca2+ binding modes. In our lab’s previous studies, when titrated with Tb3+, CaSR ECD 
subdomain 1, which includes predicted Ca2+ binding site 1, site 2 and site 3, showed biphasic 
binding processes while subdomain 2 (including Ca2+ binding site 2 &3) and subdomain 3 
(including Ca2+ binding site 4 &5) had monophasic responses to Tb3+. However, in the present 
studies, the fitted Tb3+-response curve for the WT and Lec1 CaSR ECD did not show an 
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observable cooperative binding curve. It could possibly be due to the fact that in the grafting 
approaches, the subdomains were not constrained by the additional structural conformations as it 
would be when they are in the intact ECD structure. Concomitantly, the CaSR ECDs had much 
stronger binding affinities for Tb3+ than for Ca2+ with Kds at M range. Thus the differences 
between potentially weak metal-binding sites may not be detected. Moreover, the intensive 
FRET signal between Tb3+ and more than one Trp residues might produce an overall strong 
signal hiding behind the possible cooperativity among these metal binding sites. There are more 
than 30 Phe on the ECD of CaSR, however, limited peak numbers were detected using a 900 
MHz magnet, suggesting similar local environment for multiple Phe residues. Data from NMR 
spectra indicated that the local environment around several Phe residues had been changed 
during the calcium titration process in various ways, supporting that CaSR ECDs may interact 
with calcium cooperatively.  
 
Calcium-induced conformational changes in the intact CaSR ECD were observed in both 
fluorescence and NMR spectra. Such conformational changes are fundamental initial signals for 
activation of the CaSR and transduction of these signals to the cytoplasm, calling on numerous 
downstream molecules that are involved in critical signaling cascades and resulting in the 
regulation of numerous processes, such as the control of parathyroid hormone (PTH) secretion. 
The ligand triggered tertiary structure alterations in the extracellular domain have been observed 
in other GPCR family C members. Kunishima et al. have reported ligand-bound forms and 
unliganded forms of mGluR1, showing alterations in the bi-lobed protomer architecture 
associated with the receptor’s active and resting status through the modulation of the dimeric 
interface by a packed -helical geometry (175). Ligands stabilize the mGluR1 in the active form 
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by maintaining the closed bi-lobed receptor structure as the dominant form in the receptor’s 
dynamic equilibrium between open and closed state. Although the changes from the Trp 
spectrum and the ANS probes may, in a way, support a wrapped form of the CaSR, mutagenesis 
work on the CaSR ECD will still be necessary in order to assign the peaks of the NMR spectra. 
Only by gathering the detailed information about the authentic structural movements of the 
CaSR, will we understand whether correcting the deviations from homeostatic balance is via 
modulating the “open” and “close” form of the CaSR.   
 
Overall, the present study provides further insights into the structure-function relationships for 
the CaSR and should permit further studies to define which are the key residues involving the 
interaction with the ligands for this receptor, including cations, nutrient amino acids, as well as 
antibiotics. This information will be crucial to understanding how CaSR responds to variety of 
stimuli and pave the way for future research works on this and other members in GPCR family C.  
 
 
 
 
 
 
 
 
 
189 
 
CHAPTER 7. COMPARISON OF BIOPHYSICAL CHARATERISTICS OF BACTERIA 
AND MAMMALIAN EXPRESSED CASR ECD   
7.1 Introduction 
       Prokaryotic expression systems have been widely used in scientific research. It is considered 
as one of the most efficient and economic ways to produce proteins. Among various prokaryotic 
expression systems, including Escherichia coli (E.coli), Lactococcus lactis and other bacteria, 
(e.g. Bacillus species) E.coli is the most proficiently explored organisms and has been 
prevalently applied for heterologous expression of proteins (molecular biology and genomics 
pg.191).   
       The advantages of the bacterial expression system are multifaceted. Firstly, bacterial cells 
have simple physiology compared with eukaryotic cells so they are relatively easy to culture. 
Secondly, their short generation time makes them grow and multiply much quicker than 
eukaryotic cells, which is a characteristic favorable to large scale expression of recombinant 
proteins. Moreover, it is inexpensive to culture bacterial cells. Last, but not least, the post-
translational modification in bacteria cells is different with eukaryotic cells, such as 
glycosylation, the most common post-translational modifications.(296). Thus, the bacterial 
expression is widely applied in protein isotopic labeling methods and the produced homogenous 
samples allow structural related studies using NMR. 
        A number of GPCR proteins have been expressed using bacterial systems. Link et. al. have 
expressed two proteins, cannabinoid receptor (CB1) and bradykinin receptor 2 (BR2), in E.Coli 
system using the shake flasks culture method (297). Four GPCRs, namely chemokine receptors 
(hCRs) CCR5, CCR3, CXCR4 and CX3CR1, have been discovered to be involved in HIV-1 
infection, asthma and cancer metastasis. These proteins have recently been purified using a 
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bacterial system for biochemical, biophysical as well as structural studies (298). In 2013, the 
functional N-terminal domain of the T1R3 taste receptor was expressed using an E. coli system 
by Maitrepierre et. al (299). Similar to CaSR, T1R3 taste receptor also belongs to GPCR family 
C, the successful purification of functional T1R3 taste receptor suggested feasibility to express 
CaSR ECD in E. coli.  
 
Along with the advantage in utilizing E.coli, there are also several disadvantages intrinsic to the 
prokaryotic system. First, the expressed proteins may not fold properly and thus lose its 
biological activity. Misfolding of disulfide bonds are one of the frequent errors observed in 
manipulation with prokaryotic expression. Second, the synthesized protein, especially exogenous 
protein, can be toxic to bacteria. Decreasing the bacteria cell number and/or degredation of the 
expressed protein can be the following consequences. Additionally, the lack of post-translational 
modification can work as double-edged sword. Protein expressed from a bacteria system is not 
attached with sugar residues, which may affect its in vitro functional studies  
 
In this chapter, the ECD of CaSR was expressed using a bacteria system (bCaSR) and was 
further purified through affinity columns. The biophysical properties of the native CaSR ECDs 
were characterized using the fluorescence titration spectroscopy, circular dichroism technique as 
well as the NMR spectrum. 
7.2 Results 
7.2.1 Expression of triple labeled and non-labeled CaSR ECD in bacteria system.  
The non-labeled human CaSR ECD was expressed overnight at 30C using the Rosetta-gami 
(DE3) pLys bacteria strain.  Since the Rosetta-gami (DE3)pLys strain does not grow or express 
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well in minimum growth medium, the triple labeled protein was expressed in the Tuner strain. 
Those His-tagged CaSR ECDs were efficiently separated from other proteins with a HisPrep 
column using an imidazole gradient. The fractions containing CaSR ECD were collected and 
revealed by SDS-PAGE under reducing conditions (Figure. 7.1a &b). Immunoblot was further 
applied to verify the samples using specific anti-CaSR antibody. As shown in Figure 7.1 c&d, 
the bacterial expressed CaSR ECD (bCaSR ECD) showed a clear band at around 72 kDa, which 
is close to its predicted molecular weight (70 kDa). Moreover, the bCaSR ECD can not interact 
with Ricinus communis agglutinin I agarose beads, which preferentially binds to 
oligosaccharides, suggesting that the bCaSR ECD has minimal glycosylation modification 
compared with its mammalian expressed counterpart (Figure 7.1 e). Unlike the mammalian 
expressed CaSR ECD, the bCaSR ECD forms high-order polymers instead of dimer under a non-
reducing environment. It is also worthwhile to notice that the bCaSR ECD was less stable when 
compared with ECD expressed from mammalian cells, as there were multiple degradation bands 
below 72 kDa.  
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Figure 7.1 Bacterial expressed CaSR ECD isolated by FPLC is non-glycosylated 
a: WT bCaSR ECD was expressed in Rosetta-gami (DE3) pLys at 30C. The cell pellet was 
collected and the soluble protein was extracted by a cell disruptor. After centrifugation, the 
supernatant fraction of the cell lysate then underwent protein purification procedure using 
a nickel affinity column. Representative tracing of A280 measured in milli AU for protein 
eluted by imidazole. Inset: Coomassie blue staining of the representative fractions from the 
affinity column separation. b: The same chromatography of protein purification using 
triple labeled 15N13C2D WT bCaSR ECD expressed in Tuner at 30C. c: WT bCaSR ECD 
protein (50 g) from indicated fractions were incubated at 100 °C  in sample dissociation 
buffer containing -mercaptoethanol 5 mins before loading on the SDS gels. The band of 
bCaSR ECD was detected using anti-flag antibody. d: the same treatment as (a) but with 
triple labeled bCaSR ECD proteins  e: WT bCaSR ECD protein (0.5 mg) was incubated 
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with RCA-1 lectin agarose beads overnight at 4Ԩ followed by a washing step with PBS. 
Lane 1: Elution fraction from FPLC as input protein. Lane 2:  Elution fraction using PBS 
containing 200 mM galactose. Lane 3: 5 l of the RCA-1 lectin agarose beads after 
incubating with protein were load into the gel. The elution fractions were further analyzed 
by immunoblot using anti-flag antibody. 
 
7.2.2 Fluorescence spectra indicate folded structure of the bCaSR ECD  
 
There are twelve tryptophan (Trp) residues on the bCaSR ECD, thus, by analyzing the intrinsic 
tryptophan emission spectra from 300 to 400 nm at the excitation wavelength of 282 nm, the Trp 
environment can be monitored. The emission spectrum of free Trp has a peak at around 350 nm. 
The emission peak undergoes blue-shift if the tryptophan is embedded in the hydrophobic 
environment. As shown in Figure 7.2, bCaSR ECD showed a peak at around 334 nm indicating 
that the proteins are retained in their native structure (solid line).  
 
Meanwhile, ANS, a fluorescence probe extensively used for the detection and analysis of protein 
conformational changes, was applied to the study of bacterial expressed CaSR ECD in the same 
way as in the application to the mammalian expressed proteins mentioned in Chapter 6. This dye 
has low fluorescence yield when exposed to polar environments, but a blue shift of the emission 
spectrum and an increase of the fluorescence intensity would occur once its fluorophore relocates 
into a less polar media (291). Compared to the free ANS dye, which has an emission peak at 
around 500 nm, the ANS fluorescence spectra of the bCaSR ECDs underwent a more than 30 nm 
blue shift and further exhibited a 10 fold increase in fluorescence intensity (Figure 7.3). The 
194 
 
results from the ANS spectra thus correlates with the Trp spectrum in terms of demonstrating the 
purified ECD from the bacterial system was at least partially folded.  
 
 
Figure 7.2 Tryptophan fluorescence titration of CaSR ECDs.  
Trp fluorescence spectra of WT CaSR ECD in the presence of 0 (---) and 139 M Ca2+ (—). 
 
195 
 
 
Figure 7.3 Ca2+-induced changes in ANS fluorescence in bCaSR ECDs. 
ANS fluorescence spectra of CaSR ECD in the presence (—) or the absence of (---) 1 mM 
Ca2+. The spectrum of ANS alone is shown in gray.  
 
7.2.3 Calcium induced little secondary structure change of the bCaSR ECD. 
 
In order to analyze the secondary structure of the bacterial expressed protein, the far-UV circular 
dichroism measurements were performed as shown in Figure 7.4. Analysis of all the spectra 
indicated that the purified bCaSR ECD shared similar secondary structure with CaSR ECD 
expressed from a mammalian expression system, possessing  helical content of 47%~58% and 
-sheet content of 17% ~27%. The addition of 200 M calcium did not change the spectrum of 
bCaSR ECD significantly (Figure 7.4).   
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The proteins were subjected to step-wise increasing temperatures to measure the thermal stability. 
The molar ellipticity signal was monitored from 4~95 C at 222 nm, which is considered to be a 
sensitive position for proteins that have >50% of the  helical structure. As shown in Figure 7.4, 
the melting point (Tm) of bCaSR ECD is around 80 C in the absence of calcium. Interestingly, 
in the presence of Ca2+, the melting point of bCaSR ECD was dramatically dropped to 55C and 
80C respectively. The heat denaturation is irreversible as the high temperatures lead to the 
formation of precipitation of the bCaSR ECD.  In the presence of 200 M Ca2+, the tendency of 
protein precipitation at lower temperatures was seen.  
 
Figure 7.4 Circular Dichroism measurement of purified ECD in the presence or absence of 
calcium.  
Left panel: Far-UV CD spectrum of bCaSR ECD in 10 mM Tris, pH 7.2 with or without 
200 M Ca2+, at 25 Ԩ. Right panel: Temperature dependence of the molar ellipticity at 222 
nm for bCaSR ECD in 10 mM Tris, pH 7.2. In the presence of 200 M Ca2+, bCaSR ECD 
tended to form precipitants.   
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7.2.4 Metals induced conformational changes in bCaSR ECD 
As shown in Figure 7.2 & 7.3, the addition of Ca2+ leaded to changes in both the Trp 
fluorescence and the ANS spectrum. Binding to Ca2+ resulted in 2~3 nm blue shift of the 
emission maximum on the Trp fluorescence spectrum of the bCaSR ECD. Futhermore, similar to 
mammalian expressed CaSR ECDs, a decrease of 17% in Trp fluorescence intensity in bCaSR 
ECD was observed upon the addition of saturating amounts of Ca2+.  Compared to the calcium 
induced signal changes on the Trp spectra, the ANS intensity alterations upon Ca2+ titrations 
rendered different patterns between the proteins generated from the two expression systems. For 
bCaSR ECD, calcium caused less hydrophobic areas interacting with ANS, resulting in a 34% 
decrease of the fluorescence peak value; on the contrary, it induced exposure of more 
hydrophobic regions in the complex oligosaccharides form (WT hCaSR ECD) as there was a 25% 
increase in the fluorescence signal. Similar intensity enhancements, though to lesser extents 
(~10%), were detected in Lec1 hCaSR ECD (Figure 6.7).   
 
The calcium induced conformational changes reflected in the Trp spectra were further assessed 
by monitoring the calcium titration processes. The calcium titrating bCaSR ECD step could be 
fitted by the Hill equation with a dissociate constant (Kd ) of 0.8 ± 0.2 mM and a Hill coefficient 
of 1.1 ± 0.2, indicating a similar 1:1 binding process as bCaSR ECD (Figure 7.5). Meanwhile, 
the calcium induced ANS spectra alterations were also fitted by the Hill equation. The Kd of 
bCaSR ECD measured via ANS spectra was 0.9 ± 0.2 mM with a Hill coefficient of 1.1± 0.2.  
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Figure 7.5 Ca2+-induced changes in native tryptophan and ANS fluorescence 
 (a.) Left panel: Trp fluorescence spectra of WT bCaSR ECD in the presence of 0.0 (---) 
and 2.0 mM Ca2+ (—). Right panel: Calcium titration curve of WT bCaSR ECD. The 
fluorescence intensity was normalized to the initial read-out when the calcium 
concentration was 0.0 mM and further plotted against calcium concentration. The plot was 
fitted using the Hill equation. (b.) Left panel: ANS fluorescence spectra of CaSR ECD in 
the presence (—) or the absence of (---) 1 mM Ca2+. The spectrum of ANS alone is shown in 
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gray. Right panel: Calcium titration curve of WT bCaSR ECD. Curve was fitted as 
mentioned above.  
 
Considering the potential background Ca2+ in the buffer, which might affect the accurate 
measurement of binding affinity, the metal binding capability of bCaSR ECD was further 
analyzed using Tb3+ luminescence resonance energy transfer (Tb3+-LRET). There are 13 residues 
on the bCaSR ECD and according to the modeled structure of the CaSR ECD, some of the Trp 
residues are within 10 Å of those potential calcium binding pockets, thus enabling the aromatic 
residue-sensitized Tb3+-LRET. Due to their similarities in ionic radii and coordination chemistry, 
Tb3+ has been ubiquitously used to probe Ca2+ binding sites as a trivalent Ca2+ analogue. The 
advantages of using Tb3+ have been elucidated earlier in Chapter 6. The Tb3+ binding processes 
of the bCaSR ECD turned out to be one binding step instead of a biphasic process as observed in 
the subdomain studies (Huang 2009). The Tb3+ binding affinity for bCaSR ECD was about 5.1 ± 
0.3 M with a Hill coefficient of 1.2 ± 0.2 (Figure 7.6). The Ca2+-Tb3+ competition assay gave 
the apparent dissociation constant for the ECD. For bCaSR ECD, the Ca2+ binding dissociation 
constant calculated from Ca2+-Tb3+ competition assay using equation 2 was 38.4 ± 2.2 M 
(Figure 7.7).  
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Figure 7.6  Tb3+ titration curve of bCaSR ECDs.  
Tb3+ titration curve of purified CaSR ECDs. The buffer for Tb3+ titration consisted of 20 
mM PIPES, 10 mM KCl (pH 6.8).The arrow indicates the increase of the fluorescence with 
increasing [Tb3+]. The titration curve was fitted using Hill equation.  
 
 
Figure 7.7 Tb3+ competition assay of CaSR ECDs.  
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Tb3+-Ca2+ competition assay of purified bCaSR ECD. The buffer for Tb3+ titration 
consisted of 20 mM PIPES, 135 mM NaCl, and 10 mM KCl (pH 6.8). The arrow indicates 
the decrease of the fluorescence with increasing [Tb3+].  
 
 
 
 
 
 
 
7.2.5 NMR spectrum revealed calcium induced tertiary structure changes in bCaSR ECD. 
 
The fluctuationsin the chemical shift can be used to monitor the interaction between metals and 
the protein due to the sensitivity of chemical shifts of protein amides to even subtle 
conformational changes occurring at the interacting interface. Figure 7.8 depicts the one-
dimensional (1D) NMR of the N15 labeled bCaSR-ECD expressed from the Tuner strain. The 
proton signal from the aromatic group and side chain HN (chemical shift from 8 ppm~6ppm) 
indicated that the bacterial protein was at least partially folded. However, the large size of the 
protein (72 kDa) may also influence the resolution as well as the dispersion of spectrum.  
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Figure 7.8 1D  1H spectrum of 15N labeled bCaSR ECD. 
The bCaSR ECD was expressed in the Tuner Strain at 25C. The protein sample was 
prepared in 10 mM Tris buffer with pH at 7.4. The NMR spectrum was collected from an 
800 MHz magnet.  
 
The chemical shifts observed in the 2D spectrum of bCaSR-ECD showed a more 
complicated pattern compared with the mammalian expressed ECDs.  The calcium induced 
chemical shift changes suggested multiple binding processes instead of 1:1 binding as 
demonstrated in fluorescence spectroscopy.  As shown in Figure 7.8, the concentration 
bCaSR ECD is constantly maintained at 100 M while the calcium concentration is 
increased stepwise. When the ratio of protein concentration versus [Ca2+] equals 1:4, the 
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spectrum appeared similar as the ratio was 10:1. The spectrum of 1:0 is similar to the one 
with 1: 1 (Figure 7.8). 
 
 
 
 
  
Figure 7.9 (1H,15N)-HSQC spectra of bCaSR ECD with Ca2+ titration.  
15N labeled CaSR ECD was expressed in the Tuner strain at 25C. The sample was initially 
prepared in 10 mM Tris buffer with a pH at 7.2. Calcium was introduced to the system 
stepwise before each scan of the HSQC spectra using a 900 MHz NMR instrument.  
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7.2.6 Optimization for the expression condition of CaSR ECD 
 
Due to the fact that the bacterial expressed CaSR ECD tends to degrade within a short time, 
efforts have been made to optimize the expression conditions using different cell strains, 
temperature, as well as expression time. By collaborating with Dr. Jian Hu from Michigan State 
University, we designed mutations on several cysteine residues and changed the rare codon in 
the human CaSR sequence. The optimized CaSR ECD sequence was then synthesized from the 
Genscript Company. Figure 7.10 shows the sequence alignment of the CaSR among different 
species.  
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-----------------------------MAFYSCCWVLLALTWHTSAYGPDQRAQ---- 27 
-------------------------MNPLTGLVPPLLFLLCLVPHGSAYGPDKRAQ---- 31 
-----------------------------MRFYLYYLVLLGFSSVISTYGPHQRAQ---- 27 
-----------------------------MRLLLYYLTLLGSSYVISTYGPHQRAQ---- 27 
MNFGAGLRTGSRNGNEKWKRMTFCRSSAFCHMFSSTLYLISSMARHAVVLRAGACQLQGR 60 
-------------------------------MIPNTMPVLE------------------- 10 
                               :      ::                     
                                       60 
-------KKGDIILGGLFPIHFGVAAKDQDLKSRPESVECIRYNFRGFRWLQAMIFAIEE 80 
-------KKGDIILGGLFPIHFGVASKDEDLESRPESLECVRYNFRGFRWLQAMIFAIEE 84 
-------KTGDILLGGLFPMHFGVTSKDQDLAARPESTECVRYNFRGFRWLQAMIFAIEE 80 
-------MTGDILLGGLFPLHFGIASKDQDLAARPESTQCVRFNFRGFRWLQAMIFAIEE 80 
FRLNGMYQDGDVILGGLFEAHFFTLFPELTFRTEPAPPYCEIFNMESFQYAQTMAFAINE 120 
-------KKGDIILGGLFSLHDMVEEQSLPFTSHPPKSKCTRFNFRTFRWMQTMIFAIEE 63 
         **::*****  *      .  : :.*    *  :*:. *:: *:* ***:* 
                    101                         129131 
INSSPALLPNLTLGYRIFDTCNTVSKALEATLSFVAQNKIDSLNLDEFCNCSEHIPSTIA 140 
INSSPTLLPNITLGYRIFDTCNTVSKALEATLSFVAQNKIDSLNLDEFCNCSEHMPSTIA 144 
INNSSTLLPNITLGYRIFDTCNTVSKALEATLSFVAQNKIDSLNLDEFCNCTDHIPSTIA 140 
INNSSTLLPNITLGYRIFDTCNTVSKALEATLSFVAQNKIDSLNLDEFCNCTDHIPSTIA 140 
INRNPSLLPNISLGYHLYDNCVMLGMALRAAMSLVSGIEES----FLNLNCTGPPP-IIG 175 
INKEGKLLPNITVGYKIYDSCSTPHQALKAAMELMGGEKSSEVGEKTQRNSTCNES-VPL 122 
** .  ****:::**:::*.*     **.*::.::.  : .        *.:   .     
 
VVGATGSGVSTAVANLLGLFYIPQVSYASSSRLLSNKNQFKSFLRTIPNDEHQATAMADI 200 
VVGATGSGVSTAVANLLGLFHIPQVSYASSSRLLSNKNQYKSFLRTMPNDEHQATGMADI 204 
VVGASGSAVSTAVANLLGLFYIPQISYASSSRLLSNKNQFKSFMRTIPTDEHQATAMADI 200 
VVGAAGSAVSTAVANLLGLFYIPQISYASSSRLLSNKNQYKSFMRTIPTDEYQATAMADI 200 
VVGDPSSTPSIAISSVLGLFRVPIVSHYATCSCLSDRKKYPSFFRTIPSDAFQVRAMIQL 235 
VIGDGGSTQSLVVARFLGVFTVPQISYFSSCACLSDKKQFPAFLRTMPSDFFQVDALVQL 182 
*:*  .*  * .:: .**:* :* :*: ::.  **::::: :*:**:*.* .*. .: :: 
                                   236 
IEYFRWNWVGTIAADDDYGRPGIEKFREEAEERDICIDFSELISQYSDEEEIQHVVEVIQ 260 
IEYFQWNWVGTIAADDDYGRPGIEKFREEAEEREICFDFSELISQYMEEEEIDRVASVIQ 264 
IDYFQWNWVIAVASDDEYGRPGIEKFEKEMEERDICIHLSELISQYFEEWQIQGLVDRIE 260 
IEYFQWNWVIAVASDDEYGRPGIEKFENEMEERDICIHLNELISQYFEDHEIKALVDRIE 260 
ISHFGWTWIGLLYSDDDYGTYAAQSFHQEMQLFGFCIAFSEPLRYDSNPRDIQRLMEVIQ 295 
VKHFGWTWVGVIAGDDAYGRGGANIFANEVTNLGVCIAFHRIIPKNRQQAEILSIISVIR 242 
:.:* *.*:  : .** **  . : * :*     .*: : . :    :  :*  : . *. 
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Figure 7.10 Sequence alignment of CaSR ECD among different species.  
NSTAKVIVVFSSGPDLEPLIKEIVRRNITGKIWLASEAWASSSLIAMPQ-YFHVVGGTIG 319 
NSTARVIVVFSSGPDLEPLIKEIVKRNITGRIWLASEAWASSSLIALPN-FFDVMGGTIG 323 
NSSAKVIVVFASGPDIEPLIKEMVRRNITDRIWLASEAWATTSLIAKPE-YLDVVVGTIG 319 
NSTAKVIVVFASGPDVEPLIKEMVRRNITDRIWLASEAWAISSLVAKPE-YLDVMAGTIG 319 
ASTSTVVVVFSPSTLVIPLMNEVVLQNMTGRQWIASESWATSPVFYTPR-FLPFLGGTLG 354 
LSGAKVILVFAVEQDAAALFDEVQRSELTGIQWLASEAWSTAAVLSTPEKYHNILQGTVG 302 
 * : *::**:      .*:.*:   ::*.  *:***:*: :.:.  *. :  .: **:* 
                                        358 
FALKAGQIPGFREFLKKVHP--RKSVHNGFAKEFWEETFNCHLQEGAKGPLPVDTFLRGH 377 
FALRAGQIPGFREYLRNVNV--KMSNVNGFLKEFWEETFNCHLPS---KSLSSPSSFMGS 378 
FALRAGEIPGFKDFLQEVTP--KKSSHNEFVREFWEETFNCYLED--------SQRLRDS 369 
FALKAGRIPGFREFLQHVQP--KKDSHNEFVREFWEETFNCYLED--------SPRFQES 369 
IAIRRGEIEGLREFLLQLRP-KNDPRNN-MLKIFWENMFGCSF----------------- 395 
FAIQQANIPGLRDFLLRLNPSRSDAQTDPFLVSFWEEVFQCSLGV--------------- 347 
:*:: ..* *::::* .:         : :   ***: * * :                  
                 395                                       437 
EESGDRFSNSSTAFRPLCTGDENISSVETPYIDYTHLRISYNVYLAVYSIAHALQDIYTC 437 
PEDPNRWGNSS-SFRLPCSGKENISSVETPYLDFTHLRISYNVYLAVYSIAYALQDIYSC 437 
E-------NGSTSFRPLCTGEEDIMGAETPYLDYTHLRISYNVYVAVHSIAQALQDILTC 422 
E-------NGSTSFRPLCSGEEDIASVETPYLDYKHLRISYNVYVAVYSIAQALQDILTC 422 
--------ETGPHVKNVCTGQEDLSTTNTPYTDVSELRAANNVYKAVYALAHALHDLMKC 447 
---QTESREKEGESKPPCSGKEDLGNVTNIYSDVSQLRISYNVYKAVYAVAYALKAMKSC 404 
        :     :  *:*.*::  . . * * ..** : *** **:::* **: : .* 
           449                              482 
LPGRGLFTNGSCADIKKVEAWQVLKHLRHLNFTNNMGEQVTFDECGDLVGNYSIINWHLS 497 
TPGKGLFANNSCADIKKVEAWQLLKHLRHLNFTNNMGEQVDFNDSGDLVGNYSIINWHLS 497 
IPGRGLFSNNSCADIKKIEAWQVLKQLRHLNFSNSMGEKVHFDENADPSGNYTIINWHRS 482 
TPGRGLFANNSCADIKKMEAWQVLKQLRHLNYTNSMGEKMRFDENSDMEANYTIINWHRS 482 
EEGKGPFSKNSCAEISNLKPWQLVHYLQKVNFSTRFGDHVSFNKNGDALAIYDVMNWQPG 507 
VKGEGPFFQRSCADPDVIQPWQLLHYLKQVQYLNSFASEIKFDENGDPAAMYDLVNWQMN 464 
  *.* * : ***: . ::.**::: *::::: . :...: *:. .*  . * ::**: . 
 
PEDGSIVFKEVGYYN-VYAKKGERLFINEEKILWSGFSREVPFSN----CSRDCLAGTRK 552 
QEDDSIVFEEVGYYN-VYAKVGERLFINESKILWNGFSREVGAGQEGLGAGQEGLGAGQK 556 
PEDGSVVFEEVGFYN-MRAKRGVQLFIDNTKILWNGYNTEVPFSN----CSEDCEPGTRK 537 
TEDGSVVFEEVGYYN-MHAKRGAKLFIDRTKILWNGYSTEVPFSN----CSEDCEPGTRK 537 
S-DRSIRIHTVGVVS-EELEKGLMLTLDEDAIYWNFETKKPPQSV----CSESCPRGSRR 561 
P-NGKIEFINIGKFDGMTGDVKQKLYIHEDIILWNGNRTRVPLSV----CSTICPPGTRK 519 
  : .: :  :*  .    .    * :..  * *.    .   .     ..     . :: 
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Predicted secondary structures of CaSR are highlighted in colors. Red: Helix structure; 
Blue: Strand. Conserved Cysteines are highlighted in yellow; Green labeled cysteines are 
cysteines unique in the CaSR ECD.  
 
Cysteines are generally considered to be important in the disulfide bond formation and protein 
folding. In order to facilitate the correct protein folding, we mutated non-conservative cysteines 
and cysteines that are involved in intermolecular dimerization to alanines (Figure 7.11). Six 
cysteines involved in three pairs of intramolecular disulfide bonds are kept in the sequence.  
  
Query METABOTROPIC GLUTAMATE RECEPTOR SUBTYPE 1 (PDB: 1EWV)  
Sbjct Human CaSR 
 
 
Query  7    ARMDGDVIIGALFSVHHQPPAE-----KVPER-KCGEIREQY-GIQRVEAMFHTLDKINA  59 
            A+  GD+I+G LF +H    A+       PE  +C  IR  + G + ++AM   +++IN+ 
Sbjct  26   AQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVEC--IRYNFRGFRWLQAMIFAIEEINS  83 
 
Query  60   DPVLLPNITLGSEIRDSCWHSSVALEQSIEFIRDSLISIRDEKDGLNRCLPDGQTLPPGR  119 disordered Cys 
             P LLPN+TLG  I D+C   S ALE ++ F+  + I   +  +  N C    + +P    
Sbjct  84   SPALLPNLTLGYRIFDTCNTVSKALEATLSFVAQNKIDSLNLDEFCN-C---SEHIPS--  137 
 
Query  120  TKKPIAGVIGPGSSSVAIQVQNLLQLFDIPQIAYSATSIDLSDKTLYKYFLRVVPSDTLQ  179 
                   V+G   S V+  V NLL LF IPQ++Y+++S  LS+K  +K FLR +P+D  Q 
Sbjct  138  ----TIAVVGATGSGVSTAVANLLGLFYIPQVSYASSSRLLSNKNQFKSFLRTIPNDEHQ  193 
 
Query  180  ARAMLDIVKRYNWTYVSAVHTEGNYGESGMDAFKELAAQEGLCIAHSDKIYSNAGEKSFD  239 (free Cys) 
            A AM DI++ + W +V  +  + +YG  G++ F+E A +  +CI  S+ I   + E+    
Sbjct  194  ATAMADIIEYFRWNWVGTIAADDDYGRPGIEKFREEAEERDICIDFSELISQYSDEEEIQ  253 
 
Query  240  RLLRKLRERLPKARVVVCFCEGMTVRGLLSAMRRLGVVGEFSLIGSDGWADRDEV-IEGY  298 
             ++  ++     A+V+V F  G  +  L+  + R  + G+  L  S+ WA    + +  Y 
Sbjct  254  HVVEVIQNS--TAKVIVVFSSGPDLEPLIKEIVRRNITGKIWL-ASEAWASSSLIAMPQY  310 
 
Query  299  EVEANGGITIKLQSPEVRSFDDYFLKLRLDTNTRNPWFPEFWQHRFQCRL----------  348 
                 G I   L++ ++  F ++  K+    +  N +  EFW+  F C L           
Sbjct  311  FHVVGGTIGFALKAGQIPGFREFLKKVHPRKSVHNGFAKEFWEETFNCHLQEGAKGPLPV  370 
 
Query  349  ---------PGHLLENPN--FKKVCTGNE---SLEENYVQDSKMGFVIN---AIYAMAHG  391 
                      G    N +  F+ +CTG+E   S+E  Y+  + +    N   A+Y++AH  
Sbjct  371  DTFLRGHEESGDRFSNSSTAFRPLCTGDENISSVETPYIDYTHLRISYNVYLAVYSIAHA  430 
 
Query  392  LQNMHHALCPGH----VGLCDAMKPIDGRKLLDFLIKSSFVGVSGEEVWFDEKGDAPGRY  447 
            LQ+++  L PG      G C  +K ++  ++L  L   +F    GE+V FDE GD  G Y 
Sbjct  431  LQDIYTCL-PGRGLFTNGSCADIKKVEAWQVLKHLRHLNFTNNMGEQVTFDECGDLVGNY  489 
 
Query  448  DIMN  451 
             I+N 
Sbjct  490  SIIN  493 
Non-conserved Cys
May be involved in dimerization, 
but disordered in 1EWV
Mutated into 
Alanine in our 
constructs
208 
 
Figure 7.11 sequence alignment of mGluR1 and the CaSR ECD domain.  
Intramolecular disulfide bonds are labeled with red arrows. Three cysteines that will be 
mutated to alanines are circled in red.  
7.2.7 Problems associated with the CaSR ECD expression using bacterial system.  
One of the problems associated with the CaSR ECD expression using E. Coli is protein 
degradation.  As shown in Figure 7.12, the SDS page on the left indicated a dark band at around 
70 kDa which is corresponding to the calculated CaSR ECD molecular weight. However, there 
are smeared bands at lower molecular weights. Western bloton the right side, shows that the 
smeared bands are at least partially due to the protein degradation. It is also possible that the 
degradation may start during protein expression.  
 
  
 
 
 
 
 
 
Figure 7.12 Protein degradation problem observed during protein expression and 
purification 
Left side: Coomassie blue staining of purified CaSR ECD collected from FPLC fractions. 
Right side: western blot of the same fractions. Protein was blotted using anti-flag antibody 
at 1:3000 dilution.  
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In order to solve the issue, several conditions have been screened for increasing protein stability. 
As shown in Figure 7.13, proteins aliquoted into six conditions started to degrading from Day 1. 
There were no significant differences among these reagents. However, the results on Day 3 
suggested dramatic variation among the six conditions. Caclium free buffer may prevent the 
protein from severe degradation. Meanwhile, the decrease of the pH condition to 4.0 could also 
help in slowing down the degradation process. Other conditions, including addition of protein 
inhibitor (PMSF), mixing with 5% glycerol, as well as 20 M of La3+, help to increase the 
stability of the protein to a certain extent, but not as promising compared to EDTA and an acidic 
environment.  
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Figure 7.13 Stability test of bacteria expressed CaSR ECD 
Aliquots of CaSR ECD samples were prepared in different buffer conditions and incubated 
at room temperature or -20C for upto 5 days. Samples are further loaded onto the SDS 
page gels.   
 
211 
 
 
Although some reagents might be helpful for preventing protein degradation, it would be better if 
the CaSR ECD can be expressed with less degradation bands. Several methods are considered to 
be feasible for dealing with this problem. First, deleting the cysteine rich domain as well as the 
signal peptide at the beginning of CaSR ECD sequence might increase the yield and decrease the 
misfolding of disulfide bonds during protein expression. Second, decreasing the expression 
temerpature to 20 or 16 C can be helpful for the protein folding correctly. Third, we can switch 
to different bacterial strains (e.g.SHuffle). SHuffle have DsbC prokaryotic disulfide bond 
isomerases, which help disulfide bond formation and functions in bacterial cells.  
 
7.2.8 Comparing the bacterial expressed protein with mammalian expressed CaSR ECDs 
As can be seen from those aforementioned results, bCaSR ECD and hCaSR ECDs have few 
similarities in their biophysical studies. First, all of them showed a blue shift from their intrinsic 
Trp spectrum indicating the protein was at least partially in its native form. Second, all of their 
secondary structures are dominanted by -helix (Table 7.1). Third, protein from either of the two 
systems exhibited conformational changes upon their interaction with Ca2+ as well as Tb3+.  
 
Table 7.1 Secondary structure comparison between bCaSR ECD and hCaSR ECD.  
 
  
-Helix -Strands Turns Unordered
Without Ca2+ With Ca2+ Without Ca2+ With Ca2+ Without Ca2+ With Ca2+ Without Ca2+ With Ca2+
bCaSR 47% ± 6% 48%± 1% 27% ± 5% 25%± 2% 7%± 2% 7%± 2% 21%± 1% 21%± 1%
mCaSR-WT 58% ± 1% 55% ± 6% 17% ± 1% 21% ± 4% 6% ± 2% 5% ± 1% 18% ± 4% 15% ± 4%
mCaSR-Lec1 52% ± 5% 60%  ±4% 25% ± 3% 18% ± 1% 5% ± 1% 7% ± 2% 18% ± 3% 18% ± 3%
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Despite the fact that the CaSR ECDs expressed from bacterial and mammalian systems share 
several similiarities, the properties of CaSR ECDs expressed from the two systems have quite a 
few differences. The most apprarent difference is the size of the CaSR ECDs. The bCaSR ECD 
showed a clear band at around 72 kDa; on the other hand, WT hCaSR ECD exhibited a smeared 
band in the range from 100 kDa~130 kDa while the Lec1 mutant hCaSR has one single band 
with a molecular weight of approximately 95 kDa. Under non-reducing conditions, the WT 
hCaSR ECD and Lec1 hCaSR ECD have molecular weight at around 240 kDa and 200 kDa 
respectively, corresponding to the calculated dimerization form of the receptor’s extracellular 
domain. However, the bCaSR ECD forms oligormers (Figure 7.14).  
 
The second difference is the glycosylation pattern and it is one of the major factors that affected 
the thermal stability of the proteins. The melting point (Tm) of bCaSR ECD is around 80 C in 
the absence of calcium. Interestingly, the WT hCaSR ECD demonstrated extraordinary thermal 
stability as the signal at the given wavelength did not change. The high mannose form of the 
hCaSR ECD, the Lec1 hCaSR ECD, showed a rapid disruption of the secondary structure at 
92C (Figure 7.15). 
 
Moreover, the calcium induced conformational changes of the CaSR ECDs expressed from the 
two different systems are dissimilar. For bCaSR ECD, calcium caused less hydrophobic areas 
interacting with ANS, resulting in a 34% decrease of the fluorescence peak value; on the 
contrary, it induced exposure of more hydrophobic regions in the complex oligosaccharide form 
(WT hCaSR ECD) as there was a 25% increase in the fluorescence signal. Similar intensity 
enhancements, though to lesser extents (~10%), were detected in Lec1 hCaSR ECD.   
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Figure 7.14 Bacterial expressed CaSR ECD under reducing and non-reducing condition 
(Data adopted from Ling Wei). Immunoblotting using anti-CaSR antibody ADD shows 
that bCaSR ECD formed oligomers under non-reducing condition (Left lanes).  
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Figure 7.15  The thermal stability of CaSR ECDs from different expression systems.  
Temperature dependence of the molar ellipticity at 222 nm for CaSR ECDs in 10 mM Tris, 
pH 7.2 in the absence of calcium is shown in the figure. Square: bCaSR ECD; Open circle: 
Lec1 hCaSR ECD; Closed circle: WT hCaSR ECD.  
 
Fourth, the binding affinities calculated from the fitting curves for titration experiments with 
bCaSR ECD and hCaSR ECDs are different. The observed Kds of hCaSR ECDs for Ca2+ were in 
the range of mM, however, the Kd of bCaSR ECD for Ca2+ was in M range. It is also 
worthwhile to notice that during the titration of calcium into the buffer containing 2 M bCaSR 
ECD, protein precipitation was observed. This phenomenum may be due to the fact that bCaSR 
ECD has less solubility compared with the hCaSR ECDs, which have glycosylation to increase 
their solubility.  
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7.3 Discussion  
It has been suggested that the ECD of the mGluRs and CaSR share similar Venus Fly Trap 
structure based on several conserved amino acids regions and predicted secondary structures 
(Mei Bai 2004). However, there is limited structural and biochemical information available for 
CaSR due to its large molecular weight (~70 kDa as monomer) and heterogeneous glycosylation. 
Since the amino acid sequence of a protein determines its three-dimensional structure, it is 
worthwhile to utilize the bacterial system to express the CaSR ECD. In the present study, the 
target protein was expressed in the cytosol of bacteria and we were able to purify the bCaSR 
ECD via affinity columns. It is known that CaSR functiona as a dimer on the surface of cell 
membrane, the mammalian secreted ECD proteins, both the complex glycan form and the 
homogenous high mannose form, also present in the culture medium as a dimer form (Chapter 5). 
However, the bacterial expressed ECD forms an oligomer in the non-reducing environment.   
 
Glycosylation is one of the most important posttranslational modifications occurring in protein 
biosynthesis and secretory pathways. As expected, distinctive from the mammalian expression 
system, the bCaSR ECD did not have glycosylation modifications. The thermodynamic 
stabilization calculations indicate that the stability of a protein may be enhanced when a glycan 
is covalently bound to the protein surface, which can be measured as an increase in melting 
temperature (292). The ECD protein with heterogeneous saccharides was able to maintain its 
secondary structure at high temperature (> 90C) (Chapter 5). On the other hand, bCaSR ECD, 
which has no glycosylation modification, was comparatively less stable than its mammalian 
expressed counterparts.  These phenomena may be attributed to the differences of protein tertiary 
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structures altered by the post-translational modification since their secondary structures were 
relatively similar.          
 
Calcium, as a predominant agonist for CaSR, is believed to induce conformational changes of the 
receptor to convey the extracellular signal to intracellular messengers. However, the lack of 
evidence to prove such change makes it worthwhile to analyze the alteration of the receptor’s 
biophysical characteristics before and after the Ca2+ binding. One of the biophysical changes on 
CaSR, upon the interaction with Ca2+, is the thermal stability of its ECD. The addition of calcium 
altered the structural stability of CaSR-ECD, resulting in losing the secondary structure at a 
much lower temperature. Another possible interpretation is the positive charges of the metal 
accelerate the aggregation of the protein at higher temperatures.  
 
The enthalpy change usually measures a change in the strength of the interactions between 
molecules. However, the decreased Tm value of bCaSR ECD as well as Lec1 CaSR ECD, in the 
presence of calcium, indicates that proteins could tend to aggregate with the addition of calcium.  
 
Data from spectroscopy and NMR spectrum indicated that calcium induce conformational 
changes in CaSR ECD. There are fourteen tryptophan residues on the ECD, among them four are 
on the malleolar surface between lobe 1 and 2. The decrease of tryptophan intensity might be 
explained by a close form of receptor resulting from calcium binding which could lead to a more 
imbedded position of those tryptophan residues. However, the Trp spectrum relies on the 
environment surrounding the Trp residues. Since those Trp residues are not only near the 
predicted calcium binding site, but also spread out on the entire ECD, sensitivity to monitor the 
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real binding process can be affected. Interestingly, the decreased ANS signal resulting from 
calcium titration into the bCaSR ECD, revealed the difference between the bacterial expressed 
protein and the mammalian expressed protein.  
In our lab’s previous studies, when titrated with Tb3+, CaSR ECD subdomain 1, which includes 
predicted Ca2+ binding site 1, site 2 and site 3, showed biphasic binding processes while 
subdomain 2 (including Ca2+ binding site 2 &3) and subdomain 3 (including Ca2+ binding site 4 
&5) had monophasic responses to Tb3+. However, in the present studies, bCaSR ECD presented 
a sigmoidal curve, suggesting multiple metal binding sites in the ECD may work coorperatively 
in order to accommodate the extracellular calcium concentration changes.  
Overall, the present study provides further insights into the structure related CaSR functions and 
should permit further studies to define which are the key residues involving the interaction with 
the ligands for this receptor, including cations, nutrient amino acids, as well as antibiotics. This 
information will be crucial to understanding how CaSR responds to a variety of stimuli and will 
pave the way for future research of other members in GPCR family C.  
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CHAPTER 8. CALMODULIN, AN ASSISTANT FOR THE RECEPTOR INSERTION ON 
CELL MEMBRANE.  
8.1 Introduction 
The calcium sensing receptor (CaSR),  which is predominately expressed in the parathyroid 
glands and kidneys, is a major player in sensing fluctuations of the extracellular calcium 
concentration [Ca2+]o and in maintaining calcium homeostasis by regulating parathyroid 
hormone (PTH) secretion as well as renal Ca2+  reabsorption (38). Since 1995 when CaSR was 
found universally in the gastrointestinal tract (41,166) and antral G cells (166), the exploration of 
its physiological function has been extended.  
 
In the digestive system, proteins from dietary intake can be ultimately transformed to free amino 
acids which are essential molecules as they are the metabolic precursors of crucial substances 
which could be ligands for receptors, for instance L-histidine for histamine, L-tryptophan for 5-
hydroxytryptamine (serotonin) , and L-tyrosine for dopamine, catecholamines and thyroid 
hormone (165). Fluctuation of the plasma amino acid level can regulate the rate of hormone 
synthesis and secretion as well as calcium metabolism through the control of cellular signal 
transduction pathways (165). 
 
It has been reported that aromatic amino acids can enhance the sensitivity of CaSR to 
extracellular calcium, which could be one potential explanation for how dietary protein 
modulates calcium homeostasis in normal individuals as well as patients with chronic renal 
failure (165,167). However, the mechanisms by which these two nutrients, calcium and L-Phe, 
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cooperatively regulate the function of the receptor are barely understood, other than the fact that 
they activate the CaSR through Gq/11 and G12/13 respectively(121).  
 
Recently, a novel concept which is termed “agonist-driven insertional signaling” (ADIS) has 
been brought to the field of CaSR signaling by Dr.Breitwieser’s group(144). ADIS is considered 
to be contributing to the high degree of the receptor’s cooperativity as well as lack of 
desensitization(144). The subsequent insertion of additional CaSR upon the activation of plasma 
membrane CaSRs is the fundamental feature of ADIS model. Since ADIS integrates the cell 
signaling with protein trafficking, it would be interesting to analyze whether ADIS contributes to 
the L-Phe modulated CaSR activity.  
 
One of the scaffold proteins that have been reported to interact with the CaSR is filamin (80,81).  
Filamin is ubiquitously expressed as a homodimer which is composed of monomers with 2647 
amino acids forming 24 immune globulin-like repeats, two hinge regions, a dimerization domain 
at the C terminus, and an actin-binding domain at the N terminus (300). Filamin crosslinks actin 
to cell surface receptors, for instance, dopamine D2 receptor (a G protein-coupled 
receptor), the Fc receptor, platelet glycoprotein Ib, 1 and 2 integrins, tissue factor, MAP 
kinases, the tumor necrosis factor receptor-associated factor-2 (TRAF2), Rho GTPases, and 
Smad proteins (301-304). Filamin is also involved in protein trafficking and cycling of proteins 
by interacting with caveolin (305,306). Filamin binds to the c-tail of the CaSR as demonstrated 
by yeast two hybrid assays, and there are two potential interaction regions, one 972-1031, and 
the other 907-997.   
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CaM is a ubiquitously expressed protein in the cytosolic environment. It has been reported that 
the interaction between the CaSR and CaM is essential for maintaining [Ca2+]i oscillations 
triggered by [Ca2+]o(148). The previous study by our lab using a calmodulin binding domain 
(CaMBD) peptide indicated that CaM could interacted with the potential CaMBD at the c-tail of 
the CaSR in 1-8-14 class binding mode and it induced significant changes in the secondary and 
tertiary structure of this region (148). Since it has been reported that CaM can modulate the 
surface expression of other GPCR proteins (307), it is worthwhile to analyze how CaM, as one of 
many proteins that interacting with CaSR (see Chapter 1 for details), can regulate the trafficking 
as well as the function of this particular recpeotr. Calmodulin can stabilize the CaSR by 
interacting with the c-terminal of the receptor, specifically in the region between amino acids 
881-894 (148). Moreover, the presence of calmodulin (CaM) inhibitors can diminish the 
extracellular calcium [Ca2+]o  as well as the L-Phe induced intracellular calcium concentration 
[Ca2+]i change(120). However, how CaM can regulate the the agonist triggered receptor function 
as well as the following downstream signaling pathways is unclear.  
In the present study, we report our observation that in the presence of L-Phe, the ADIS was 
enhanced in HEK293 cells either expressing wild type CaSR or disease related loss-of-function 
mutant CaSR, which possibly contributes to the L-Phe potentiated receptor activity. The deletion 
of potential CaM and filamin interaction regions changed the [Ca2+]i oscillation patterns and 
abolished the L-Phe promoted ADIS. Our findings may provide a novel angle to investigate how 
calcium and L-Phe cooperatively work together to promote the function of the CaSR.  
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8.2 Results 
8.2.1 L-Phe can promote the function of CaSR by working cooperatively with Ca2+. 
In the presence of L-Phe, the [Ca2+]i oscillation pattern was changed as the [Ca2+]i started 
oscillating at lower [Ca2+]o, and a [Ca2+]i plateau required less [Ca2+]o to be reached to (Figure 
8.1a). Next, we utilized immunostaining assay to analyze the Ca2+ triggered ADIS in CaSR 
transfected HEK293 cells with or without the addition of L-Phe. The transfected CaSR has a flag 
tag in the extracellular domain. Cells were first labeled with a rabbit monoclonal FLAG antibody 
to block all plasma membrane FLAG epitopes, followed by stimulation with different calcium 
concentration. Cells were then fixed with formaldehyde and incubated with a mouse monoclonal 
FLAG antibody to identify newly exocytosed receptor. After permeabilization with triton, cells 
were stained with goat anti-rabbit Alexa488 and goat anti-mouse Alexa568 to differentiate the 
original surface CaSR and newly translocated CaSR. The immunostaining assay revealed that the 
agonist driven receptor insertion phenomena induced by [Ca2+]o emerged at 3.0 mM [Ca2+]o with 
the addition of L-Phe instead of 4.0 mM [Ca2+]o without L-Phe (Figure 8.1b). Quantitative 
analysis of the surface receptor intensity using Image J was able to generate an ADIS-[Ca2+]o 
response curve which correlated with their [Ca2+]i change (Figure 8.1c). Meanwhile, the results 
of the biotin-cleavable western blot assay showed that the  CaSR internalization in the presence 
of both L-Phe and Ca2+ compared to Ca2+ only was similar (Figure 8.1d). 
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Figure 8.1 L-Phe and [Ca2+]o influenced the activity and trafficking of CaSR.  
(a.) Representative oscillation pattern from a single HEK-293 cell transfected with WT 
CaSR. The [Ca2+]i was measured using Fura-2AM as described in methods. Each 
experiment was carried out in 0.1% DMSO as W7 solvent control. Cells were first 
submerged in Ca2+-free Ringer’s buffer followed by treatment with various [Ca2+]o buffers 
until [Ca2+]i reached a plateau (up to 8 mM [Ca2+]o) in the presence or absence of 5 mM L-
Phe.(b.) HEK293 cells transiently expressing FLAG-CaSR were labeled with polyclonal 
anti-FLAG antibody (pFLAG) for 1 hour (4°C), then incubated in various [Ca2+]o buffer 
for 10 min (37°C).  Cells were labeled with monoclonal anti-FLAG antibody (mFLAG) for 
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1 hour (room temperature) after fixing with formaldehyde. Cells were permeabilized and 
labeled with goat anti-rabbit Alexa488- and goat anti-mouse Alexa555-conjugated 
secondary antibodies. Incubation in high [Ca2+]o buffer  increased binding of monoclonal 
anti-FLAG antibody (mFLAG) to CaSR, demonstrating ADIS. Images shown are 
representative of N = 25 cells. (c.) Quantitative analysis of ADIS: The fluorescent intensity 
from Alexa555 was measured by Image J which was further divided by the fluorescent 
intensity from Alexa488. The values were calculated for all cells at each indicated [Ca2+]o 
with (grid) or without (blank) L-Phe.(d.) Effects of L-Phe on internalization of the WT 
CaSR. CaSR transfected HEK293 cells were labeled with disulfide-cleavable biotin in 
calcium-free buffer for 30 min, and then stimulated with  various [Ca2+]o for 10 mins. The 
internalized CaSR was immunoprecipitated with the anti-FLAG antibody and detected by 
streptavidin peroxidase. Top panel: Non-cleaved biotin labeled CaSR stands for 
internalized receptor. Lower panel: total CaSR.  
 
8.2.2 L-Phe enhanced the ADIS in inactive CaSR mutants.  
We next examined whether this L-Phe enhanced ADIS existed in the disease related mutations. 
The CaSR L173P and P221Q are two loss-of-function mutants recently reported by Hannan et. al. 
The immunostaining results showed that the translocation of the mutated receptors from 
cytosolic reservoir to cell membrane can also be facilitated by L-Phe (Figure 8.2). Although the 
L-Phe enhanced the ADIS in mutant CaSRs, it did not increase the surface receptor 
internalization as shown in Figure 8.3.  
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Figure 8.2 L-Phe enhanced ADIS in disease related mutants.  
Cells transfected with L173P and P221Q were exposed to various [Ca2+]o for the 
measurement of ADIS as described in Figure 6.1(b). Quantitative analysis of ADIS was 
shown in the scatter plot. The fluorescent intensity from Alexa555 (I555) and Alexa488 (I488) 
was measured by Image J. The ratio of I555/I488 was further plotted against [Ca2+]o and 
normalized to the intensity ratio when [Ca2+]o was at 1.0 mM. Open circle: without L-Phe; 
Closed circle: in the presence of L-Phe. 
 
Figure 8.3 Receptor internalization in disease related mutants.  
CaSR mutants transfected HEK293 cells were labeled with disulfide-cleavable biotin in 
calcium-free buffer for 30 min, and then stimulated with various [Ca2+]o for 10 mins. The 
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internalized CaSR was immunoprecipitated with the anti-FLAG antibody and detected by 
streptavidin peroxidase. 
 
8.2.3 CaM inhibitor W7 affected the trafficking of the CaSRs.  
Previously studies have reported that CaM plays a pivotal role in regulating the traffic of the 
CaSRs (148) and it may also be involved in modulating the L-Phe triggered [Ca2+]i 
oscillation(120). We further investigated whether CaM could also be involved in regulation of 
the ADIS effects. We first incubated the cells with CaM inhibitor W7 followed by monitoring 
the [Ca2+]o induced [Ca2+]i changes using Fura-2 AM in the presence or absence of L-Phe. As 
shown in Figure 8.4, the [Ca2+]i oscillation has gone through dramatic pattern alterations. Most 
cells exhibited transient peaks instead of continuous sinusoidal changes (Figure 8.4a). The 
confocal images suggested the ADIS induced by Ca2+ was still observable (Figure 8.4b); on the 
contrary, the L-Phe enhanced ADIS was abolished. Meanwhile, the ERK activity which once 
could be promoted by L-Phe was also reduced by W7 (Figure 8.4c). The [Ca2+]o induced 
internalization of the receptor had no significant change with the pretreatment of W7 either in the 
presence or the absence of L-Phe (Figure 8.4d). 
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Figure 8.4 W7 reduced the Ca2+ and L-Phe induced ADIS.  
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(a.) Cells were pretreated with 50 M W7 or DMSO for 30 mins. Figures show 
Representative oscillation pattern from a single pretreated WT CaSR transfected HEK-293 
cell with or without L-Phe. Right panel: Statistic analysis of total responded cells. Empty 
bar: DMSO only; Black: with 50 M W7; Red diagonal: with 5 mM L-Phe and DMSO; 
Red solid: with 5 mM L-Phe, DMSO and 50 M W7.  (b.) HEK293 cells transiently 
expressing FLAG-CaSR were first treated with either W7 or DMSO for 30 mins at 37°C. 
Cells were labeled with polyclonal anti-FLAG antibody (pFLAG) for 1 hour (4°C), then 
incubated in various [Ca2+]o buffer with 5 mM L-Phe for 10 min (37°C).  Cells were labeled 
with monoclonal anti-FLAG antibody (mFLAG) for 1 hour (room temperature) after 
fixing with formaldehyde. Cells were permeabilized and labeled with goat anti-rabbit 
Alexa488- and goat anti-mouse Alexa555-conjugated secondary antibodies. Right panel: 
Quantitative analysis of ADIS as described in Fig. 1c. (c.) W7 inhibited [Ca2+]o activated 
ERK phosphorylation in CaSR-transfected HEK293 cells. HEK-293 cells transfected with 
WT CaSR or its mutants were incubated in serum-free high glucose MEM medium 
containing 0.2% BSA overnight. Cells were pretreated with DMSO alone or W7 in DMSO 
for 30 mins, cells were then incubated in various Ca2+ concentrations (0.0-~8.0mM) for 10 
min at 37 C. The incubations were stopped by exposure to the lysate buffer and processed 
for SDS/PAGE and Western blotting as described in the Methods. The western blot results 
were further quantified using Image J. Empty bar: without W7; Black bar: with W7.  (d.) 
Effects of W7 on Ca2+ and L-Phe triggered internalization of the WT CaSR. CaSR 
transfected HEK293 cells were incubated with DMSO or W7 for 30 mins. Cells were then 
labeled with disulfide-cleavable biotin in calcium-free buffer for 30 min, followed by 
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stimulation with various [Ca2+]o for 10 mins. The internalized CaSR was 
immunoprecipitated with the anti-FLAG antibody and detected by streptavidin peroxidase. 
 
8.2.4 Mutations on the CaM interaction region changed the L-Phe enhanced intracellular 
calcium response pattern.  
Since CaM is a ubiquitous molecule that participates in hundreds of intracellular signaling 
pathways, the addition of W7 could affect other signal transductions besides the potential 
disruption of the interaction between CaSR and L-Phe. In order to analyze the specific role of 
CaM in the trafficking of the CaSR, we designed experiments with several CaSR C-tail mutants 
(CaSR F881E/V894E, F881E/T888E, F881E/T888E/V894E) which their binding with CaM are 
believed to be interrupted (148). The [Ca2+]i changes upon the [Ca2+]o stimulation were altered in 
those mutants as shown in Figure 8.5. Majority of the cells transfected with C-tail mutants 
F881E/V894E, F881E/T888E, F881E/T888E/V894E showed transient peaks as their responses 
to the increase of [Ca2+]o. The addition of L-Phe could not change the [Ca2+]i response as the 
way it changed the oscillation patterns in WT CaSR, i.e. starting oscillation at lower [Ca2+]o, 
increasing the [Ca2+]i oscillation frequencies; instead, the [Ca2+]i responded in a special way in 
the presence of L-Phe. Noticeably, the width of each transient peak became wider in the mutant 
F881E/V894E, mutant F881E/T888E and mutant F881E/T888E/V894E as well. Moreover, the 
peak descending rates were also decreased compare to WT CaSR.  
 
Because the CaM CaSR interaction region also includes T888, which is a potential 
phosphorylation site of CaSR, in order to rule out the possibility that mutations at the 
phosphorylation site would complicate the conclusion, single mutation to the residue T888 was 
229 
 
employed for an in depth analysis. As indicated in (Figure 8.5), the T888V mutation, which 
abolished the phosphorylation site, forced the receptor to start oscillating at lower [Ca2+]o 
compared with WT CaSR. However, with L-Phe, the oscillation patterns were changed likely as 
in WT CaSR. Thus, the L-Phe caused peak transformation is more related to CaM other than 
phosphorylation.  
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Figure 8.5 The [Ca2+]i oscillation in cells expressing CaSR with mutations in the CaM 
binding region.  
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Representative oscillation patterns from a single cell. HEK-293 cells transfected with CaSR 
or one of its mutants were loaded with Fura-2 AM for 15 min. The [Ca2+]i was assessed by 
monitoring emission at 510 nm with excitation alternately at 340 or 380 nm as described in 
methods. Each experiment carried out with or without 5 mM L-Phe began in Ca2+-free 
Ringer’s buffer (10 mM HEPES, 140 mM NaCl, 5 mM KCl, and 1.0 mM MgCl2, pH 7.4) 
followed by stepwise increases in [Ca2+]o until [Ca2+]i reached a plateau (up to 10 mM 
[Ca2+]o).  
 
8.2.5 Filamin A is involved in the CaM regulated CaSR trafficking.  
The next question is how CaM could modulate the traffic of the receptor. The C-tail of the CaSR 
has been reported to interact with the cytoskeleton protein, filamin. Truncation of these potential 
binding domains on CaSR led to the weakened interaction with filamin as shown in (Figure 8.6). 
Interestingly, the disruption of the CaSR-filamin interaction also influenced the communication 
between CaM and CaSR. Notice that the molecular weight of CaM shown in the western blot 
results indicated its existence as a dimer form. It is worthwhile to look into the [Ca2+]i oscillation 
pattern in those mutants as well as the ADIS effects. 
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Figure 8.6  Filamin A and CaM interacts with CaSR.  
HEK293 cells expressing FLAG-CaSR or its Filamin truncation mutants (860/ 906-
998/907-999/860971) or CaM truncation mutants (880-894) or CaM interaction 
mutation (3E3) were immunoprecipitated with anti-flag antibody. The input receptor 
(CaSR), Filamin A and CaM were immunoblotted with their specific antibodies 
respectively.  
 
8.3 Discussion 
 
In the present study, we characterized how the interaction between CaSR and CaM could 
transduce the extracellular amino acids triggered signaling into the intracellular environment and 
modulate the trafficking of the receptor. We have demonstrated that the disruption of the CaM 
binding site on the C-tail of CaSR altered the L-Phe and [Ca2+]o cooperatively induced [Ca2+]i 
oscillation patterns in the HEK293 cells transfected with the CaSR. The cross-talk between the 
two proteins and filamin A appear to be critical in the L-Phe enhanced agonist-driven receptor 
insertion signaling.   
 
The addition of L-Phe can potentiate the responses of HEK293 cells transfected with the CaSR 
to the changes of extracellular calcium concentration, characterizing by starting as well as 
terminating [Ca2+]i oscillation at lower [Ca2+]o and an increase in the oscillation frequency at the 
EC50 for [Ca2+]o. The data reported herein suggested that L-Phe also enhanced the [Ca2+]o driven 
receptor insertion while stimulating more surface receptor underwent internalization. The CaSR 
specific allosteric modulator NPS R-568 has been reported to have the similar ADIS(144). Since 
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the L-Phe induced [Ca2+]i change via the CaSR requires a minimum of 1.5 mM [Ca2+]o, the 
potentiated ADIS effect was barely observable when the [Ca2+]o  was in the physiological range. 
This phenomenon was also detected in the disease related mutants and was well correlated with 
their respective [Ca2+]i oscillation patterns, suggesting that both active and inactive receptors 
could be modulated in the similar way as WT CaSR. On the other hand, the L-Phe enhanced 
ADIS was diminished in the mutant L173P, of which the rescue ability of the L-Phe was 
impaired possibly due to the sterically hindering by the Leu to Pro mutation, indicating the 
appropriate interaction between the CaSR and the L-Phe should be crucial in transducing the 
extracellular signaling into the cytosol. Considering the fact that the [Ca2+]i alterations responded 
much faster than the ADIS, the oscillation patterns could be a necessary messenger for the 
regulation the trafficking of the CaSR.     
     
In the present study, we confirmed that not only the application of CaM inhibitor W7 but also the 
mutations on the CaMBD, which interrupted the interaction with CaM could change the [Ca2+]i 
oscillation patterns upon the step wise increase of [Ca2+]o. The reduced ADIS in these CaSR 
mutants suggested a linkage between the two events. The addition of L-Phe failed to rescue the 
[Ca2+]i oscillation as it would to WT CaSR indicating CaM probably involved in the L-Phe 
regulation which is in a way correlated with the findings from Rey et. al. that CaM inhibitors 
impaired the L-Phe induced [Ca2+]i changes(120). Meanwhile, the L-Phe enhanced ADIS was 
also abolished suggesting CaM participates both in the [Ca2+]o stimulated ADIS as well as in the 
L-Phe signaling.  
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Based on the results, a model of the L-Phe enhanced Ca2+ induced ADIS was proposed as 
presented in the schematic figure (Figure 8.7). CaM binds to the CaSR to stabilize the receptor 
during its interaction with agonists. In the presence of Ca2+ the ADIS is predominately regulated 
by 14-3-3 protein (144). The addition of W7 did not completely abolish the transferring of novel 
receptor to the cell membrane. The L-Phe cooperatively regulated the CaSR with Ca2+, 
meanwhile it activated Gi/o signal pathway other than Gq/. CaM is a crucial element in the L-
Phe regulated [Ca2+]i change. The disruption of its interaction with CaSR not only alter the 
[Ca2+]o induced [Ca2+]i oscillation pattern but the [L-Phe] promoted [Ca2+]I responses. CaM may 
participate in the L-Phe enhanced ADIS in a dimer form.  
 
Figure 8.7 Schematic presentation of the L-Phe enhanced ADIS under the modulation of 
CaM  
P
ERKP
P
Ca2+
Ca2+
CaM
CaM
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Phosphorylated CaM forms a dimer and binds to the C-tail of CaSR. The stimulation with 
[Ca2+]o and L-Phe facilitates the phosphorylation of ERK. The later may accelerate the 
opening of cytosolic CaSR reservoir and potentiate the exocytosis.  
 
In the present study, we found that in the presence of L-Phe, the ADIS was enhanced in HEK293 
cells transfected with either wild type CaSR or disease related loss-of-function mutant CaSR. 
Further analysis with the calmodulin (CaM) inhibitor suggested CaM could be involved in 
regulating the L-Phe enhanced ADIS. Studies on the CaSR with mutations at calmodulin binding 
domain which interrupted CaM-CaSR interaction and the CaSR with Filamin A binding domain 
truncation showed that not only the L-Phe induced intracellular calcium[Ca2+]i oscillation was 
altered, but the L-Phe promoted receptor insertion phenomena was abolished. Thus, L-Phe 
possibly regulates the receptor through CaM and Filamin A modulation.  
 
Several experiments still need to be done in order to finalize the story. The interaction between 
Filamin A and the c-tail of CaSR need to be confirmed either using pull down assay or 
immunofluorescence study. Whether Filamin A is truly involved in the CaM modulated CaSR 
trafficking needs to be further investigated. The relationship among CaM stabilized surface 
receptor and  receptor internalization as well as the ADIS might be much clearer with 
bungotoxin linked SEP-CaSR. Our approach will shed light on understanding the mechanisms 
underlying the agonist regulated receptor trafficking for other GPCR family members and will 
provide new strategies for drug designing targeting at various GPCR proteins.  
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CHAPTER 9. PROBING THE CORRELATION BETWEEN THE [Ca2+]ER AND THE 
TRAFFICKING OF CASR 
9.1 Introduction 
The endoplasmic reticulum (ER) is considered as a major storage reservoir and a crucial 
regulator of intracellular Ca2+ as it stores more than 90% of the Ca2+ in the cells, although its 
volume is less than one tenth of the total cell (308-310). ER is also the most important  
suborganelle for global protein maturation, as approximately one third of all open reading frames 
code for proteins that enter the ER in human. A polypeptide starts with translocation across or 
into the ER membrane before its secretory pathway. It will not be transported via the Golgi 
apparatus to the cell surface unless it is folded and modified correctly in the ER. The ER lumen 
has a unique environment for the proper folding of protein, including complex pathways, tons of 
folding factors like Hsp90, Cyp, FKBP, PDI, UGGT etc., quality control, recycling (e.g. ER-to-
Golgi intermediate compartment (ERGIC)), Especially for membrane proteins, which usually 
contain glycosylation sites, the ER provides a good compartment for proper modification such as 
glycosylation and disulfide bond formation to stabilize their conformation before they are 
secreted out  and exposed to extracellular milieu (311). In this case, protein folding and secretion 
can be related with the ER calcium concentration. An accurate way for quantifying the ER Ca2+ 
concentration is thus in great need.  
 
Certain mutations on CaSR can lead to reduced receptor surface expression on the cell 
membrane. The treatment with the CaSR specific positive allosteric modulators can increase its 
surface expression while the negative allosteric modulators have the opposite effects. Since ER is 
one of the major subcellular organelles involving the synthesis, modification and transportation 
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of proteins, it would be worthwhile to test how those allosteric modulators can affect ER, mainly 
focusing on the ER calcium concentration.  
How these allosteric modulators can change the receptor expression level is still obscure. One of 
the hypotheses is that the drug treatment can influence the ER calcium concentration change 
thereby affecting the foldings of the receptors and the following trafficking pathways. 
In order to analyze the ER calcium concentration, an ER targeted calcium sensor should be an 
essential tool  
 
Currently, there are two major generations of ER Ca2+ sensors. The first one is small molecular 
based Ca2+ dye, Mag-fura-2 which can majorly measure Ca2+ concentration in calcium stors (e.g. 
mitochondria or ER) due to its small size and low affinity to Ca2+. The other type is based on 
fluorescent proteins consisting of a Ca2+ regulated protein such as calmodulin or troponin 
C(181,312,313). The advantage of those protein based Ca2+ indicators is that they can target 
subcellular organelles with high spatial and temporal resolution (9). However, they still have 
some limitations during the application in excitable cells (18). Our group has engineered a new 
type of Ca2+ sensors, named CatchER(calcium sensor for detecting high concentration in the ER), 
based on the green fluorescence protein. CatchER has an ER retention sequence KDEL and its 
EGFP based property allows it to have intensity change upon calcium binding. CtachER  meets 
the requirements for a better Ca2+ indicator such as accurate targeting to certain cellular 
compartments, the ability to quantitatively measure the ER Ca2+ concentrationand, fast release 
kinetics, and minimized quenching problems (185). 
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Although CatchER has been successfully applied for detecting the Ca2+ release in mouse muscle 
sarcoplasmic reticulum (SR), the lower temperature requirement for the expression of CatchER 
in HEK293 cells limited its further application, e.g. co-expression with other proteins in cells. 
Our lab further improved this calcium sensor to ensure its chromophore formation at 37 C and 
named it CatchERT. 
 
In the present study, we aim to answer how ER Ca2+ signaling regulates CaSR  functional 
cooperativity via modulation of receptor surface expression. Either CatchER or CatchERT were 
co-transfected with CaSR and the ER calcium concentration changes were monitored using these 
designed calcium sensors after treating with various drugs. We found that the positive allosteric 
modulator NPS R-568 could increased the calcium concentration in ER, while NPS 2134 had 
minimum effect on the ER.   
9.2 Results 
9.2.1 The CaSR allosteric regulators can influence the receptor expression level. 
It has been reported that the not only the addition of proteasome inhibitor e.g. GM132 can 
increase the amount of the CaSR expressed at the cell surface, but also overnight incubation with 
positive allosteric CaSR modulator NPS R-568 can increase the expression of the receptor 
(268). Here we confirmed that the 0.1%DMSO as solvent only treatment did not change the 
expression level of WT CaSR while the negative regulator NPS-2143 down regulated the total 
amount of CaSR and the positive modulator NPS-R568 had the opposite effect.  
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Figure 9.1 Total CaSR expression in HEK293 cells with various treatments.  
After transfection with CaSR for 48 hours, HEK293 cells were treated with 10 M CaSR 
positive allosteric modulator NPS R-568 in 0.1% DMSO or 10 M negative allosteric 
modulator NPS 2143 in 0.1% DMSO or 0.1%DMSO (as solvent control) for 16 hours. Cells 
were collected and lysed in RIPA buffer. The total CaSR was detected by anti-Flag 
antibody. GAPDH was used as internal control.  
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9.2.2 Monitoring the [Ca2+]ER using calcium sensor CatchER. 
In the present study, we coexpressed Catcher and the CaSR in HEK293 cells in order to detect 
the extracellular calcium induced intracellular calcium concentration change as well as the 
corresponding calcium concentration alteration occurring in sub cellular organelles. Because 
CatchER has to be expressed at 30C while the CaSR exhibited best expression at 37C, we used 
two different protocols to optimize the condition for co-expression of the two proteins 
simultaneously. Figure 9.2 shows the first protocol in which cells were initially cultured at 37C 
for 12 hours after transfection followed by 12 hours incubation at 30C. Cells were continued in 
culture for another 4 hours before proceeding to the imaging experiments. The green line 
represents the fluorescent intensity from CatchER while the red line represents the signal from 
Rhod-2, which is a calcium sensing dye to measure the cytosolic calcium concentration, from the 
same single cell. Cells responded to upon the addition of extracellular calcium indicating the 
CaSR had been expressed. However the dynamic range of CatchER is relatively small compared 
with Rhod-2. Figure 9.3 indicated the intracellular responses using the second protocol. 
Apparently the CaSR did not properly fold and express on the cell surface as suggested by 
impaired the intracellular calcium responses. After comparing the two methods, the expression 
with two temperatures was chosen for future measurements.      
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Figure 9.2 Monitoring the [Ca2+]ER using CatchER (first method). 
After co-transfection with CaSR and CatchER, cells were first incubated at 37 C 
overnight then the temperature was reduced to 30C for continuing expression another 12 
hours. Cells were further moved to a 37C incubator for another 4 hours prior to 
experiments. The calcium concentration is indicated above the lined bar. Ionomycin is used 
as ionopore to transport the extracellular calcium to the intracellular enviroment. Red: 
cytosolic calcium changes measured using Rhod-2. Green: signals from CatchER.  
 
 
 
 
 
 
 
 
Figure 9.3 Monitoring the [Ca2+]ER using CatchER (second method). 
After co-transfection with CaSR and CatchER, cell were first incubated at 30 C for 2 days 
then the temperature was increased to 37C for continuing 1 day expression. Red: cytosolic 
calcium changes measured using Rhod-2. Green: signals from CatchER. 
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9.2.3 Measuring the drug induced [Ca2+]ER in CaSR transfected HEK293 cells using CatchER.  
       We next analyzed the intracellular responses upon the treatment with different CaSR 
modulators. HEK293 cells co-transfected with CatchER and CaSR were treated with the CaSR 
positive modulator NPS R-568, the negative modulator NPS 2143 or DMSO as solvent control 
overnight at 37C. As shown in Figure 9.4, 3.0 mM of [Ca2+]o can trigger the increase of 
cytosolic calcium concentration. Some of the cells started to show [Ca2+]i  oscillation (Figure 
9.4B) while some of the cells responded as transient peak of cytosolic [Ca2+] (Figure 9.4A). The 
incubation with 0.1% DMSO barely had any influence on the extracellular induced intracellular 
calcium change. Incubation with NPS 2143 diminished the cytosolic calcium oscillation 
frequency as well as the peak amplitude. On the other hand, NPS R568 had the opposite effect. 
The calcium alterations in the ER were less pulsatile compared with its cytosolic changes. Only a 
sudden decrease of the [Ca2+]ER was able to be detected when cells were exposed to 3.0 mM 
[Ca2+]o and the [Ca2+]ER started to increase when the [Ca2+]o mM dropped to 1.0 mM. 1.5 M of 
ionomycin was introduced as a positive control. The addition of ionomycin induced a [Ca2+]i 
climbing and a similar [Ca2+]ER descending was able to be detected. Although the fluorescence 
quenching phenomenon is quite notable, the overall [Ca2+]ER responses were able to be recorded.  
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Figure 9.4 [Ca2+]ER measurement in HEK293 cells treated with various CaSR allosteric 
modulators.  
Cells were seeded on coverslips and transfected with CatchER T and CaSR simultaneously. 
Cells were continuously cultured for another 48 hours at 37C and further treated with 
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various drugs for 16 hours. After loading with Rhod-2, the coverslip was mounted onto the 
microscope working stage. The chamber was first perfused with 3 mM Ca2+, followed by 
calcium free washing buffer. Then cells were then treated with 1.5 M ionomycin. The 
cytosolic calcium concentration was measured using Rhod-2 (Red), while the [Ca2+]ER was 
analyzed using CatchER-T(Green). A. WT CaSR expressed cells as controls. B. Cells were 
treated with DMSO. C. Cells were incubated with NPS-2143, which is a negative allosteric 
modulator for CaSR. D. Cells were treated with NPS R-568, which positively regulated 
CaSR.  
  
Next, we measured the [Ca2+] in subcellular organelles using Mag-Fura-2 and CatchER. The 
former compartmentalizes in the ER, mitochondria as well as cytoplasm while the latter targets 
to the ER only. The calibration using Mag-fura-2 suggested an increase in the subcellular 
organelles [Ca2+] after incubation with the CaSR positive modulators NPS R-568. Further 
analysis using CatchER showed an increase in the [Ca2+]ER upon the treatment with NPS R-568. 
Other treatments did not have significant influences on the [Ca2+] ER.  
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Figure 9.5 Calibration of ER calcium concentration using Mag-fura 2.  
The [Ca2+]ER was calculated using [Ca2+]i = Kd(F − Fmin)/(Fmax − F) (314) and the results 
from different drug treatments were further normalized to WT. The calcium binding 
constant for Mag-Fura-2 is around 25M.  
 
 
Figure 9.6 Calibration of ER calcium concentration using CatchER.  
The [Ca2+]ER was calculated using [Ca2+]ER = Kd(F − Fmin)/(Fmax − F) The Kd of CatchER 
was  0.18 mM and the results from different drug treatments were further normalized to 
WT.  
 
9.2.4 Insertion of Furin tag in CaSR functional mutants.  
White et.al has categorized CaSR loss-of-function mutants into four types: Class Ia mutants have 
little expression on the plasma membrane regardless of the presence of proteasomal inhibitor 
MG132. They went through the mature glycosylation process and traverse from ER to the Golgi; 
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Class Ib mutants are also not significantly localized to the plasma membrane, but they are 
targeted for degradation from the ER or ER-Golgi intermediate compartment (ERGIC). Class IIa 
can be expressed on the cell membrane without MG132 and their function can be rescued by 
CaSR positive allosteric regulator NPS R-568. Class IIb CaSR mutants can locate on the plasma 
membrane but their function is barely rescued by NPS R-568. Figure 9.7 shows the schematic 
diagram of the four types of mutants. The pro-protein convertase furin cleavage sequence 
“ARRRKKRGLDV” was cloned right behind flag-tag in our pcDNA-CaSR (Figure 9.8). Furin is 
a trans-Golgi network (TGN)-resident type I membrane protease with a catalytic site facing the 
Golgi lumen (Furin at the cutting edge: from protein traffic to embryogenesis and disease.).  
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Figure 9.7 Schematic diagram of the trafficking pathways of the disease related mutants 
(315).  
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Figure 9.8 Schematic diagram of Furi-CaSR constructions.  
A. Furi sequence inserted into pcDNA CaSR. B. Furi sequence inserted into pEGFP CaSR.  
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9.2.5 Analysis of the constructed Furin-CaSR and its mutants 
A few CaSR loss-of-function mutants from each subclass have been selected for the present 
studies. As shown in Figure 9.10, the furin tagged WT CaSR, either constructed in the pcDNA 
plasmid or in the pEGFP plasmid, traversed from ER to Golgi would be cleaved by furin 
resulting in an additional band at 50 kDa in reduced environment on a denatured SDS-page gel. 
P39A and G778D are two inactive mutants that can not traffic to the Golgi, therefore they 
maintained in an intact form. In the absence of -mercaptoethanol, WT Furin-CaSR was still 
able to keep all the fragments together even though it interacted with pro-protein convertase. 
Further analysis of other mutants confirmed this phenomenon (Fig. 8.11) as majority of the 
mutants had an intense western blot band with fragment molecular weight at 50 kDa except for 
L174R which also belongs to class Ib as P39A and G778D.  
 
The pull down experiment using anti-flag antibody revealed similar results compared with the 
experiment directly using cell lysates in terms of the band at 50 kDa (Fig. 8.12). Multiple bands 
are observed under the reducing environment due to the fact that the secondary antibody not only 
recognizes the primary anti-CaSR ADD antibody but also the anti-flag antibody which was used 
to pull down the receptor.   
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Figure 9.9 Schematic illustration of location of CaSR loss-of-function mutations.  
Mutations involved in the present studies are highlighted with frames.CaSR contains 1078 
amino acids. The amino-terminal, ECD is comprised of a VFTD, divided into lobes I 
(horizontal bars) and II (vertical bars), and a CysRD (diagonal bars). The TMD contains 
seven helices (gray boxes). Extra- and intracellular loops and carboxyl terminus are 
white.Yellow: Class Ia, Green: Class IIa, Red: Class Ib, Blue: Class IIb. 
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Figure 9.10 Western blot of Furin-CaSR constructions with or without reducing reagent 
(R). (-G) represent plasmids constructed in pEGFP vectors.  
                                                                                                                                                                                    
 
 
 
 
 
 
Figure 9.11 Western blot of disease related mutations in pcDNA-Furin-CaSR constructs.  
Forty-eight hours after transfected with different mutants, cells were lysated and 
underwent western blot. R: with the addition of reducing reagent (-mercaptoethanol). 
Yellow: Class Ia, Green: Class IIa, Red: Class Ib, Blue: Class IIb. (The clone of R227Q was 
not correct).   
 
 
 
 
 
 
 
Figure 9.12 Pull down assay analysis of disease related mutations in pcDNA-Furin-CaSR 
constructs.  
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Forty-eight hours after transfection with different mutants, cell lysate was co-
immunoprecipitated with anti-flag antibody overnight at 4C. Proteins were further eluted 
from beads with sample buffer and underwent western blot. R: with the addition of 
reducing reagent (-mercaptoethanol). Yellow: Class Ia, Green: Class IIa, Red: Class Ib, 
Blue: Class IIb. 
9.3 Discussion 
How the calcium concentration in the endoplasmic reticulum (ER) change during cytosolic 
calcium oscillation is a question that has puzzled scientists for a long time. The absence of a 
proper ER calcium indicator is one of the major barriers. The development of CatchER enables 
us to monitor the ER calcium concentration change in living cells due to its engineered ER 
targeting peptide and the relative weak binding affinity (0.19 ± 0.02 mM) (185). The fact that we 
only observed a decrease in the [Ca2+]ER during the [Ca2+]i oscillation should not be attributed to 
the failure of dissociation of calcium from CatchER since the koff rate of CatchER is 700 s-1. To 
our knowledge, it is the fastest off-rate of all reported Ca2+ sensors. The [Ca2+]ER is thea 
consequence of the entrance and exit of calcium from the organelle while the cytosolic calcium 
concentration reflects the dynamics calcium change as a result of various membrane pumps and 
calcium inlets. The potential increases of [Ca2+]ER contributed by the presumed SERCA pump 
and other factors may not be dramatic enough to be captured by the ER calcium indicator during 
[Ca2+]i oscillation.  
 
The calibration of the [Ca2+]ER suggested the positive allosteric modulator NPS R-568 can 
increase [Ca2+]ER which is expected as a potential explanation that the addition of the NPS R-568 
can facilitate the expression of the CaSR. Similar findings have been reported by Ong et al on the 
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study of glucocerebrosidase (316). Their group found out that increasing the ER calcium 
concentration can regulate the post-tranlational protein folding pathway which can facilitate the 
chaperone system to fold misfolding-prone enzymes and increase folded protein population.   
 
In the present study, we first documented how the dynamics of [Ca2+]ER changed upon the 
extracellular induced intracellular calcium oscillation. Second, we analyzed the influence of 
CaSR allosteric regulators on the intracellular calcium store. Third, this approach can be applied 
to other receptors located on the cell membrane.  
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CHAPTER 10. MAJOR CONCLUSIONS AND SIGNIFICANCE 
      Overall, these series of studies provide a mechanistic view to understand how CaSR 
integrates the Ca2+ as well as amino acids -mediated signaling and depict the molecular basis for 
diseases associated CaSR mutations resulting in alterations in Ca2+ homeostasis.  We have met 
different challenges, nevertheless, we are able to achieved the goal via addressing the following 
five major questions.  
1, How CaSR functional cooperativity is regulation by extracellular binding of Ca2+ and amino 
acids? 
2. How the disease associated CaSR mutants can affect the functional cooperativity mediated by 
Ca2+ and amino acids? 
3. How can we determine the binding of Ca2+ and L-Phe to the CaSR ECDs and detect the 
potential conformational change induced by the interaction?  
4. How the multifunctional intermediate messenger protein--- CaM regulates the CaSR 
trafficking and signaling? 
5. How ER Ca2+ signaling regulates CaSR functional cooperativity via modulation of receptor 
surface expression? 
 
A. In Chpater 3, we focused on the regulation of CaSR functional cooperativity by 
extracellular binding of Ca2+ and amino acids. 
      Although previous lab members predicted five potential Ca2+ binding sites using 
computational algorithm as well as grafting approaches, how these Ca2+ binding sites are 
correlate with each other in tuning the function of CaSR is still a mystery. Calcium binding sites 
are usually invisible even in determined structures of the ECD such as mGluR1. Combined with 
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the challenge, the lack of direct binding methods for determinging cooperativity in its responses 
to Ca2+ and amino acids and the high off rates of these binding ligands associated with their 
weak binding affinities discourage the structural and functional study of the CaSR.  
       The major findings in the chapter are summarized in the following figure (see Fig. 3.10 for 
details).  
 
       The studies in Chapter 3 are important and novel for several reasons: 
       First, we have documented for the first time the predicted Ca2+-binding site 1 within the 
hinge region of the CaSR’s ECD plays a central role of molecular connectivity in tuning the 
positive cooperativity caused by changes in [Ca2+]o. Second, We also identified a potential L-Phe 
binding pocket in the hinge region of CaSR ECD which plays a key role in regulating the 
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heterotropic cooperativity of CaSR. Third, we were able to demonstrate of the interplay among 
extracellular Ca2+, amino acids and the CaSR via molecular connectivity that modulates the 
positive homotropic and heterotropic cooperativity of CaSR-mediated intracellular Ca2+ 
signaling. The positive cooperative co-activation of the CaSR by Ca2+ and L-Phe and the 
importance of the positive homotropic and heterotropic cooperativity, respectively, exhibited by 
the two agonists may be further extended to other members of the family C GPCRs to facilitate 
an understanding of the molecular basis for related human disorders and the development of new 
therapeutic strategies. 
       
 
B. In Chapter 4 & 5, we analyzed how the disease associated CaSR mutants can affect the 
functional cooperativity mediated by Ca2+ and amino acids. 
       Several naturally occurring mutations in the CaSR are located in the extracellular domain of 
CaSR. However, due to the lack of structure information about this receptor, it is not clear how 
calcium modulates those CaSR mutants as well as the molecular basis of those clinical disorders 
associated with this receptor. By collaborating with Prof. Thakker’s group at University of 
Oxford, we have demonstrated the importance the predicted Ca2+-binding sites play in regulating 
the function of the receptor. Among the thirty-four VFTD missense mutations we have identified, 
18 mutations were located within 10 Angstroms of one or more of the Ca2+ binding sites, 
particularly at the calcium binding site 1, which is the principal site of Ca2+ binding. Moreover, 
our studies strongly suggested that the Ca2+ binding site 1, which is encoded in the VFTD, is the 
key for connecting the other calcium binding sites and regulting the receptor activity. Two 
residues 173 and 221 located at the entrance to the VFTD cleft binding site, were associated with 
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both receptor activation (L173F, P221L) and inactivation (L173P, P221Q), thereby highlighting 
the importance of the molecular connectivity linked by the Ca2+ binding site 1 . We also found 
that the heterotropic cooperativity introduced by L-Phe can be limited by gain-of-function 
mutants.Both in silico and in vivo results indicated that the residue Leu173, which is close to 
residues that are part of the L-Phe-binding pocket, exhibited impaired heterotropic cooperativity 
in the presence of L-Phe.  
       The following schematic figure summarizes our work in Chapter 4 and 5. 
 
257 
 
       These naturally occurring mutations, therefore, may be useful for further probing the 
functions of Ca2+-binding site 1 and the adjacent L-Phe binding site in producing the positive 
cooperative interactions that are critical for the capacity of the CaSR to sense both mineral ions 
and amino acids. Last but not least, our findings may provide key insights into molecular 
mechanisms shared with other members of the class C GPCRs, including metabotropic glutamate 
receptors (mGluRs), GABAB receptors, pheromone receptors, and taste receptors, that are 
regulated by Ca2+o. 
 
C. In Chapter 6 and 7, we have probed the Ca2+ and L-Phe binding affinity, cooperativity, 
and related conformational change of both mammalian and bacteria expressed ECD by 
various biophysical methods.  
      The challenges associated with probing the key question, how CaSR senses the alterations of 
calcium concentration, are multifaceted. First, the full length of CaSR is huge (260 kDa), even 
the extracellular domain of the CaSR is comparably larger (~70 kDa based on sequence only ) 
than most of the proteins that can be expressed and purified using bacterial system (< 60 kDa). In 
order to get the protein within its native conformation, eukaryotic system may be the best choice. 
Second, the multiple glycosylation sites (11) in the ECD can cause difficulties in crystallization. 
Besides, those glycans also introduce structural heterogeneity into the entire system make the 
protein in infavorable condition for structure studies using NMR. Third, despite extensive 
functional studies of CaSR by different groups, how calcium and L-Phe interact with the 
extracellular domain is still under debate due to the lack of structural information. Fourth, the 
direct visualization of interaction of Ca2+ and Phe to the receptor ECD has also been hampered 
by the high off rate associated with weak binding during X-ray crystallography. Last but not least, 
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direct monitoring of such interactions in solution and characterization the biophysical properties 
of the large size protein and collection of structurally related information using spectroscopic 
methods also requires a large amount of homogenous native protein.   
       In these two chapters, we demonstrated our progress in coping with the challenges stated in 
the last paragraph. By collaboration with Dr. Kelley W. Moremen, we expressed and purified the 
CaSR ECD, which was shown to play important role in intracellular calcium responses, using 
bacteria and mammalian expression systems. The native conformation of the bacterial expressed 
protein was compared to the mammalian expressed protein using by immunoblotting technique 
and metal binding FRET assay. The secondary structures of the purified proteins were verified 
using circular dichroism. Using various spectroscopic methods, we have shown that both protein 
variants bind Ca2+ with a to Kd of 3.0~5.0 mM, which were hardly affected by the level of 
glycosylation. We have demonstrated for the first the direct interaction between the CaSR and its 
ligands. The calcium binding induced local conformational changes of the protein can be 
visualized by NMR with both uniformly labeled and specific 15N Phe-labeled ECDs. By utilizing 
the saturation transfer difference (STD) NMR technique, we report for the first time the direct 
interaction between the CaSR ECD and its positive allosteric modulator L-Phe. We further 
demonstrate that L-Phe increases the binding affinity of the CaSR ECD for Ca2+. This current 
study provides valuble molecular basis for studying the connectivity between different calcium 
binding sites. Our findings also present new insights into the mechanism of how Ca2+ and amino 
acids regulate the CaSR and other proteins in the G protein coupled receptors (GPCR) 
superfamily and may pave the way for exploration of the structural properties of CaSR.  
 
259 
 
D. In Chapter 8, we have studied the molecular mechanism underlying receptor trafficking 
upon the interaction with various agonists. 
      Given the fact that the CaSR has low affinity for Ca2+ or allosteric regulators such as amino 
acids, small peptides (in the range from M to mM), structural and functional studies about this 
receptor are mainly through mutagenesis induced changes. And the regulation about the CaSR is 
largely from signaling readouts of intracellular calcium, lipids or mitogen-activated protein 
kinase (MAPK) pathways. The complex and hysterestic regulation of the downstream signaling 
pathways independent of the activated recptors, combined with receptor desensitization, 
contribute to the difficulties to describe the responses exclusively to the CaSR.  Understanding 
the factors that regulate the life cycle of the receptor in the context of physiological condition is 
crucial for developing strategies to regulate CaSR activities.  
      In our previous study, we have demonstrated a CaM-binding domain (CaMBD) located 
within the C terminus of CaSR (residues 871–898) interacting with CaM in a Ca2+-dependent, 
stoichiometric way. Our studies suggest a wrapping around 1–14-like mode of interaction that 
involves global conformational changes in both lobes of CaM with concomitant formation of a 
helical structure in the CaMBD. More importantly, the Ca2+-dependent association between CaM 
and the C terminus of CaSR is critical for maintaining proper responsiveness of intracellular Ca2+ 
responses to changes in extracellular Ca2+ and regulating cell surface expression of the receptor. 
       In chapter 8, we particularly investigated how calmodulin regulates of the CaSR mediated 
cytosolic Ca2+ signaling and the receptor cell surface expression. We found that in the presence 
of L-Phe, the agonist driven insertion signaling (ADIS) was enhanced in HEK293 cells 
transfected with either wild type CaSR or disease related loss-of-function mutant CaSR. Further 
analysis with the calmodulin (CaM) inhibitor suggested CaM could involve in regulating the L-
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Phe enhanced ADIS. Studies on the CaSR with mutations at calmodulin binding domain which 
interrupted CaM-CaSR interaction and the CaSR with Filamin A binding domain truncation 
showed that not only the L-Phe induced intracellular calcium[Ca2+]i oscillation was altered, but 
the L-Phe promoted receptor insertion phenomena was abolished. Thus, L-Phe possibly regulates 
the receptor through CaM and Filamin A modulation. Our working model is summarized in the 
following figure (see Fig. 8.7 for details) 
 
       The significance of the work relyis on the fact that CaM not only interact with the CaSR, but 
also its activity is prevalently involved in the function of other GPCR family members. Since 
GPCRs meet at least a subset of the criteria for the ADIS mechanism, such as a large 
intracellular pre-Golgi pool of receptors, chronic or extended exposure to agonist during receptor 
life cycle, relatively low steady-state plasma membrane amounts of receptor and a CaM binding 
domain at C-tail, our findings may be a relevant regulatory mechanism for other GPCRs, include 
mGluRs, adrenergic, dopamine and cannabinoid receptors etc. 
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E. In Chapter 9, we have investigated the regulation of CaSR functional cooperativity by 
modulation of surface expression via [Ca2+]ER signaling.  
       Ca2+ signaling is one of the most ubiquitous cellular events in living organisms. It regulates 
tremendous amount of biological functions. The endoplasmic reticulum (ER) lumen, which 
occupies less than 10% of cell volume, stores >90% of intracellular Ca2+ and is crucial in 
controlling Ca2+ signaling. Directly monitoring fast ER Ca2+ dynamics in living cells is still a 
new field, and understanding how the ER [Ca2+] can regulate the trafficking of receptors is a 
challenging project.  
        In Chapter 9, we reported that our lab has used the ER calcium probe developed in our lab -
-- CatchER as well as the commercial available ratiometric dye Mag-Fura 2 to investigate how 
[Ca2+]ER regulates the expression of the receptor. The working model is summarized in the 
following schematic diagram.  
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        The significances are in several layers. First, we first documented how the dynamics of 
[Ca2+]ER upon the extracellular induced intracellular calcium oscillation. Second, we analyzed 
the influence of CaSR allosteric regulators on the intracellular calcium store. Third, this 
approach can be applied to other receptors located on the cell membrane.  
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APPENDICES 
Appendix A: EMOC, a Novel Endoplasmic Reticulum Protein that Regulates Cell Growth 
and Ca2+ Store-Operated Entry 
INTRODUCTION 
The endoplasmic reticulum (ER) is a key organelle involved in controlling major cellular 
functions including protein synthesis and modification as well as intracellular Ca2+ homeostasis 
[1, 2]. In recent years, the role of ER in the regulation of intracellular signal transduction is 
beginning to become clear. A number of ER-associated proteins are known to modulate 
intracellular Ca2+ signaling, including, for example, calreticulin, glucose-regulated protein 78 
(Grp78/Bip), 94(Grp94), and calsequestrin [reviewed in 3]. Other types of ER-associated 
proteins are ER-membrane calcium channels; for example, the ER Ca2+ uptake channels, formed 
by sarcoplasmic/ER Ca2+-transporting ATPases (SERCAs), and the Ca2+-releasing channels, 
constituted by the inositol-1,4,5-triphosphate receptor (InsP3R) or ryanodine receptors (RYRs) 
[3].  Many of these proteins are known to regulate several cellular processes including 
proliferation, adhesion, motility, metabolism, differentiation, gene expression and apoptosis [4, 
5]. 
Store-operated calcium (SOC) channels play important roles in regulation of a series of 
distinct cellular processes including cell migration, gene expression, cell growth and apoptosis 
[reviewed in 6, 7]. Store-operated Ca2+ entry (SOCE) is evoked by depletion of Ca2+ from the ER. 
It has been noted that depletion of intracellular calcium store triggers the opening of plasma 
membrane Ca2+ channels that leads to Ca2+ influx [6-8]. Although the phenomenon of SOCE was 
noted many years ago, little is known about proteins that regulate SOCE process. Recent studies 
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have identified two proteins, STIM1 (stromal interaction molecular 1) and Orai1 (also named 
CRACM1) that are believed to work together to regulate SOCE. While STIM1 functions as the 
ER Ca2+ sensor [9-11], Orai1 is an essential pore-forming subunit of the plasma membrane Ca2+ 
release-activated Ca2+ (CRAC) [11-14].  Several lines of evidence suggest that when the ER Ca2+ 
stores are replete, STM1 predominantly localizes in the ER-membrane, however, in the event 
that ER Ca2+ stores are depleted, STIM1 forms oligomers and redistributes to ER-plasma 
membrane junctions as STIM1 clusters (aggregates) [9, 15, 16]. Evidence also suggests that 
STIM1 recruits ORAI1 protein to the regions directly opposite of the STIM1 clusters and 
STIM1-ORAI1 interactions activate ORAI1 channels resulting in Ca2+ influx through the ORAI1 
channels [8, 15, 17-19]. While these findings significantly enhance our understanding of how 
SOCE is regulated, several questions still remain unanswered and warrant further investigations. 
Chief among those are how STIM1 and ORAI1 are regulated and whether other cellular protein(s) 
is/are also involved in the regulation of SOCE process.  
In the present study, we report the characterization of a novel ER membrane protein named 
EMOC (ER Membrane protein Overexpressed in Cancer). Our study shows that EMOC is an 
integral ER membrane protein that harbors two transmembrane domains. Our study also shows 
that EMOC forms oligomers and binds to Ca2+. Importantly, we have also provided evidence that 
EMOC is linked to controlling of cell growth and appears to play a role in regulation of SOCE. 
Thus, our studies indicate EMOC to be another cellular protein involved in the regulation of the 
SOCE process. 
EXPERIMENTAL PROCEDURES 
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Measurements of intracellular calcium concentration: Measurement of intracellular Ca2+ was 
performed as described [39]. Briefly, Hela  and 293T cells with scrambled RNAi or EMOC 
RNAi were seeded on coverslips and further cultured for 48 hrs. The cells on the coverslips were 
subsequently loaded using 4 μM Fura-2 AM in 2 mL physiological saline buffer (10 mM 
HEPES, 140 mM NaCl, 5 mM KCl, 0.55 mM MgCl2, 1 mM CaCl2 and pH 7.4) for 15 mins. 
Then cells were washed with ringer buffer and coverslips were mounted in a bathing chamber on 
the stage of a Leica DM6000 fluorescence microscope. The Fura-2 emission signals at 510 nm 
from cells excited at 340 or 380 nm were recorded in real time during the experiments as 500 nM 
thapsigargin was added and the concentration of extracellular Ca2+ was changed to 2 mM. The 
data representing relative intracellular Ca2+ change were plotted as 340/380 fluorescence ratios. 
 
The Mn2+ Quench Assay:  The Mn2+quench assay was performed as described [9]. In brief, cells 
were seeded on 13.5 × 20 mm coverslips. Before experiments, 4 mM fura-2/AM was loaded into 
cells. After 20 mins, the remaining extracellular Fura-2/AM was washed out with Ringer buffer 
and the coverslips were transferred to a fluorescence cuvette. Before data acquisition, 2 mM 
Mn2+ in HBSS buffer was added to the cuvette. Thapsigargin was added 50 seconds later, and the 
experiment was continued for another 300 seconds. Quenching of Fura-2 fluorescence signal was 
measured at 510 nm with excitation at 360 nm.  
RESULTS 
 
EMOC plays a role in regulation of store-operated calcium influx: Because our results 
indicate that EMOC is an ER-membrane Ca2+-binding protein, next, we examined the effect of 
EMOC on cellular Ca2+ homeostasis. To this end, we employed a lentiviral shRNA-mediated 
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knockdown (KD) approach to deplete EMOC and to determine the effect of EMOC on Ca2+ 
release from ER and on Ca2+ influx after intracellular Ca2+ store depletion. First, we performed 
EMOC knockdown and Figure 8A shows that EMOC expression was sufficiently depleted by the 
lentilvirus-mediated EMOC shRNA. Next, we performed “Ca2+ add-back” experiments, in which 
the ER Ca2+ stores were first depleted by treating cells with thapsigargin (TG) in the absence of 
extracellular Ca2+,   then 2 mM extracellular Ca2+ was added back to trigger intracellular Ca2+ 
depletion-induced store operated calcium (SOC) influx. Ca2+ release from the ER and 
extracellular Ca2+ influx were monitored in whole cell population by Furo-2-based assays. As 
shown in Figure 8B, there was no significant difference in TG-evoked Ca2+ transient (1st peak) 
observed in the EMOC knockdown cells and in control scrambled RNAi cells. These results 
indicate that EMOC may not have a strong effect on ER Ca2+ store and release because when no 
extracellular Ca2+ is added, TG-evoked Ca2+ transient is mainly contributed by Ca2+ released 
from the ER. By contrast, when ER Ca2+ was depleted by TG and extracellular Ca2+ was added, 
the intracellular Ca2+ transient signal (2nd peak) was significantly lower (by 40-60%) in the 
EMOC knocked down cells (Figure 8B). We also similarly performed the “Ca2+ add-back” 
experiments using another cell line 293T, and as shown in Figure 8C and D, EMOC depletion 
also led to a reduced Ca2+ transient signal in EMOC knockdown cells when extracellular Ca2+ 
was added after ER Ca2+ was depleted by TG. These results indicate that the absence of EMOC 
protein significantly alters Ca2+ transient. Because the suppression of Ca2+ signal in the EMOC 
knockdown cells seen in Figure 8 could be due to a mechanism involving a decreased Ca2+ influx 
from the store operated-channel or due to a mechanism that is involved in an accelerated plasma 
membrane Ca2+ extrusion, we performed the Mn2+ quench assays to further differentiate these 
two possible mechanisms. Like Ca2+, Mn2+ can enter cells via the SOC influx channels to form a 
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non-florescence complex with Fura-2. Thus, the Mn2+ quench assay is widely used to investigate 
the regulation of SOC influx [9, 30]. We reasoned that, if EMOC were involved in the regulation 
of SOC influx, we should be able to observe a difference in intracellular Ca2+ transient monitored 
by Fura-2 in cells depleted with the EMOC expression when extracellular Mn2+ was present. As 
shown in Figure 9A&B, Hela EMOC knockdown cells (EMOC RNAi) exhibited significantly 
reduced Mn2+ quench-rate evoked by TG (Figure 9A and B) compared with cells expressing the 
control RNAi (Scr. RNAi).  
In addition, EMOC depletion also has similar effect in influencing SOC influx in 293T cells 
(Fig. 9C&D). Thus, these results indicate that EMOC depletion significantly reduces the rate of 
Mn2+ entrance through the SOC channels and that EMOC plays a role in the regulation of SOC 
influx.  
Interestingly, this behavior of EMOC in regulation of SOC influx appears to be similar to 
that of STIM1 protein, a key SOCE Ca2+ sensor in the ER [9, 10, 31]. Furthermore, EMOC also 
has additional STIM1-like features including, for example, EMOC is an integral ER membrane 
protein that binds to Ca2+ and forms oligomers. Whether EMOC functions in a manner similar to 
STIM1 in regulation of SOCE is an interesting and important issue that remains to be 
investigated.  
In summary, the present studies have characterized a novel ER transmembrane protein, EMOC. 
EMOC protein binds to Ca2+ and regulates Ca2+ homeostasis. Our mechanistic studies also 
indicate that EMOC is involved in the regulation of the store-operated calcium influx. Thus, our 
data suggest EMOC is a new and critical factor, in addition to STIM1 and ORAI1, involved in 
regulating the SOCE process. 
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Figure 8. Depletion of EMOC expression significantly reduces thapsigargin (TG)- and 
extracellular Ca2+-induced transient [Ca2+]i (intracellular Ca2+ concentration) increase. 
A&B, results obtained from Hela cells. C&D, results obtained from 293T cells. For these 
assays, TG (500 nM) was first added to deplete ER-stored Ca2+ in the absence of 
extracellular Ca2+. CaCl2 (2 mM) was introduced after intracellular calcium concentration 
reached to a plateau to trigger calcium influx. The ratio of emission signals at 510 nm from 
cells excited at 340 or 380 nm were recorded in real time respectively for scrambled RNAi 
expressing cells (black line) or for EMOC RNAi expressing cells (red line). For Hela cells 
(A and B), results shown are the average Ca2+ responses of 16 control (Scr. RNAi) and 18 
EMOC-KD (EMOC RNAi) single cells; and for 293T cells, results shown are the average 
response of 46 control (Scr. RNAi) and 14 EMOC KD (EMOC RNAi) single cells. A and C 
are results of one representative experiment performed in Hela cells (A) or 293T cells (C). 
B and D, bar graphs represent averaged Ca2+ influx peak (ΔF340/F380 ratio) ± s.e.m. of 
three-independent experiments in Hela cells (B) or in 293T cells (D). Expression of EMOC 
mRNA in control and EMOC knockdown cells determined by RT-PCR assay is also shown 
(B and D).  
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Fig. 9. EMOC knockdown significantly suppresses the store-operated channel entry 
demonstrated by the Mn2+ quench assay. The Mn2+ quench assay was performed as 
described in the Materials and Methods. A&B, results obtained from Hela cells. C&D, 
results obtained from 293T. The relative Fura-2 fluorescence intensity was measured with 
360 nm excitation as a function of time in the control (Scr. RNAi, black line) and EMOC 
knockdown cells (red line). Mn2+ quench rate (ΔF/F) measured in the scrambled RNAi and 
EMOC RNAi expressing cells in the absence (clear bars) or in the presence of thapsigargin 
(TG) (dark bars). 
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Appendix B: Enhancing Near IR Luminescence of Thiolate Au nanoclusters by Thermo 
Treatments and Heterogeneous Subcellular Distributions 
INTRODUCTION 
 
Soluble gold nanoclusters can be categorized as very small gold nanoparticles. Unlike other 
nanomaterials normally described by size and shape, a definitive chemical composition of Au 
nanoclusters could be elucidated regarding the number of Au atoms forming an Au core and the 
number of chemically bonded molecules on core surface forming a monolayer of stabilizing 
ligands. Novel physicochemical properties distinct from larger Au nanoparticles have been 
discovered, which render the Au nanoclusters broad applications in fundamental research and 
biomedical and energy applications. Of particular relevance to this report is the intrinsic 
photoluminescence in near IR wavelength range from aqueous soluble Au nanoclusters with core 
diameter smaller than 2 nm stabilized by a monolayer of thiolate ligands. The small overall 
dimension makes them biocompatible, readily accessible to subcellular domains and ultimately 
body-clearable, while an emission maximum longer than 650 nm is highly advantageous for cell 
imaging due to drastically reduced background absorption, autofluorescence and other 
interferences. If the quantum efficiency (QE) of the near IR emission could be further enhanced 
and approach the QEs of organic dyes or semiconductor quantum dots, those aforementioned 
advantages of Au nanoclusters will make them superior candidates in studying the dynamic and 
heterogeneous cellular processes for biomedical applications over other counterparts. The 
luminescence properties of Au-thiolate nanoclusters have been studied from fundamental 
perspective and applied for bioimaging applications.1 An optical energy gap between the highest 
occupied and lowest unoccupied orbitals is required to observe appreciable photoluminescence, 
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albeit the emission energy does not match the band gap of the Au nanoclusters in most cases.2, 3 
A large Stokes shift exists between the visible excitation and near IR emission. The observation 
suggests significant energy relaxation that is also supported by the long lifetime at nano to micro 
seconds.4 An upper threshold in core size of 2.2 nm was determined by transient optical 
measurements from hexanethiolate stabilized Au nanoclusters.5, 6 Strong dependence on ligand 
polarity of the luminescence QE was initially reported via the comparisons through ligand 
exchanged and directly synthesized Au nanoclusters.7, 8 Possible charge interactions between 
the Au core and the ligands were further studied on well-defined monodispersed Au25 
nanoclusters.9 Optimization of those parameters leads to enhanced QE of the near IR emission 
(i.e. emission max > 650-700 nm) at ca. 1% for aqueous soluble and ca. 8% for non-aqueous 
soluble Au nanoclusters. To make the near IR emitting Au nanoclusters competitive with organic 
dyes and nanoclusters that display intense visible emissions, further enhancement in QE would 
be favorable. Recently, a synthetic procedure involving heating induced aggregation was 
reported to generate Au nanoclusters displaying bright emission centered at ca. 600 nm.10 For 
the preformed Au nanoclusters, heating in the presence of excess thiols as ligands arguably 
reduced the core size, known as core etching process.11,12 An annealing procedure was 
developed to improve the electrochemical properties of the Au nanoclusters.13 It generally 
adopts milder conditions compared with etching, using limited amount of excess thiols (same as 
those ligands already on the Au nanoclusters) and lower temperatures. The nanomaterials quality 
is improved presumably by the elimination of those less thermodynamically stable species, or by 
the optimization of the thiolate-Au bonding,14-16 or both. Besides the introduction of 
multidentate dithiol ligands to tailor the core-ligand interfaces and particularly the 
luminescence,17-19 we have reported the observation of the individual Au nanoclusters and their 
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distribution inside fixed HeLa cells under confocal microscope via luminescence intensity and 
lifetime imaging.20 Au is FDA approved materials due to its non- or low toxicity. Various Au 
nanoclusters and Au complexes have been used in basic biomedical research and as diagnostic 
and therapeutic tools.21-23 Fundamental understanding regarding the fate of such small 
nanoclusters in cells is rather diffusive.24-29 One of the essential questions related to those 
contradictory reports is whether the nanoclusters could efficiently enter cell and nucleus, and 
what internalization pathway is responsible for the dynamic processes. Apparently, labeling 
nanomaterials with fluorescent probes adds additional variables and complicates the analysis. 
Ex-situ measurements by mass spectrometry, electron microscopy, or sedimentation etc. are less 
capable to capture living cell dynamics and heterogeneity, information essential for living 
subjects.22, 30 This report establishes a universal approach to enhance the near IR luminescence 
of Au nanoclusters with different sizes (less than 2 nm) and different protecting ligand molecules. 
Because the surface chemistry is known to be critical in the nano-bio interactions, a 
generalizable method to enhance the QE of Au nanoclusters with different surface functionalities 
could enable in-situ dynamic cellular studies previously inaccessible. Two types of monothiols, 
mercaptosuccinic acid (MSA) and tiopronin (Tio), were employed to synthesize different Au 
nanoclusters under a variety of conditions. Heating each batch of the purified Au nanoclusters in 
the presence of the corresponding thiols was found to drastically enhance the emission QE by ca. 
5-10 folds. After the incubation with live human embryonic kidney (HEK) cells, confocal 
microscope analysis demonstrates the heterogeneous distribution of Au nanoclusters inside the 
fixed HEK cells. Furthermore, co-distribution with nucleus stain dye reveals their presence 
inside cell nucleus. 
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EXPERIMENTAL SECTION 
 
Confocal Fluorescence Microscopy. Human embryonic kidney 293 (HEK) cells were incubated 
with Au-MSA-PEG at 37 °C in cell culture media over 24 hours. The cells were then washed in 
triplicate with PBS buffer followed by fixation with 4% ice cold 100% methanol in -20 °C for 
5~10 minutes. Subsequently, cells were mounted on glass slides using Prolong Gold Antifade 
reagent with DAPI (P36391; Invitrogen) followed by triplicate washing with PBS prior to 
confocal imaging. 
RESULTS 
 
Confocal Fluorescence Imaging A key concern for the usage of nanomaterials as medicine or 
contrast enhancing agents for diagnostics and therapeutics is the prolonged body retention and 
subsequent potential toxicity. Effective renal clearance has been reported for nanoparticles with 
an overall dimension of 5 nm or smaller combined with proper surface chemistry design.35, 36 
Because the kidneys play a major role in nanoparticles body retention and clearance, in this 
report, the distribution of the luminescent Au nanoclusters in kidney cells is investigated to offer 
fundamental insights at cell and subcellular levels for potential in-vitro and in vivo applications.  
 
The enhanced QE of Au nanoclusters enables direct imaging using commercial confocal 
fluorescence microscope, albeit only a small portion of the emitted photons could be captured by 
the PMT detectors. Heterogeneous subcellular distribution inside individual HEK cells can be 
readily resolved in Figure 6, information inaccessible by ex-situ and ensemble measurements 
such as mass spectrometry, ICP OES. The membrane boundaries of individual HEK cells can be 
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seen under bright field. A fluorescent dye DAPI, widely used to stain DNA due to its high 
binding affinity to A-T, is co-distributed to highlight cell nucleus region. The blue and red 
channels record the shorter wavelength emission from DAPI and the near IR emission from the 
Au nanoclusters respectively. The co-distribution of the Au NCs inside the cells is further 
demonstrated in the two overlay panels. In comparison, Au NCs without heat treatments could 
not be observed in similar imaging studies at comparable dosage. Those treated Au NCs without 
PEGlation, though detectable directly under the PMT detectors, could not be observed inside the 
cells under comparable conditions. 
 
To affirm that the Au NCs are inside cell nucleus, a series of z-stack images are presented in 
panel B (i.e. from the top toward the bottom of the cells). It is obvious that the emissions from 
both DAPI and Au nanoclusters become more intense toward the center of the cell. The features 
strongly suggest that the Au NCs are inside cell and cell nucleus instead of being adsorbed on 
membranes, which would otherwise display ring-like features along the membrane peripheries 
within focus, especially at middle z positions. Further, the Au NCs distribute heterogeneously 
both within individual cells and between different cells: some cells show very low intensity from 
Au NCs both in cytoplasm and in nucleus; some show high intensity in cytoplasm but low in 
nucleus; while other cells have a high intensity both in cytoplasm and nucleus. The more intense 
clustered red emission signals in cytoplasm suggest confinement or enriched Au NCs within 
unidentified organelles, presumably endosomes. 
The kinetics and pathways of the cell internalization of nanomaterials are known to be 
heterogeneous and require more systematic studies.37 Internalization will differ at different 
phases of cell life cycle,38 which could explain the heterogeneous distributions observed. 
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Furthermore, the Au nanoclusters are not functionalized with specific biomarkers, and thus are 
expected to non preferentially distribute inside the cell if internalized. Due to the small 
dimension, passive diffusion is possible across the cell membrane and maybe nucleus 
membrane.26, 28, 37, 39 The kinetics of internalization and sub-cellular distribution of the Au 
NCs at different dosage and other conditions are under further investigation. Regardless, the 
consistent presence of Au nanoclusters at the center of multiple individual cells clearly 
demonstrated that these Au nanoclusters penetrated both the cytoplasm and nucleus of HEK cells 
that enable further cell dynamics and function studies. 
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Figure 6. Confocal images of fixed HEK293 cells. The cells were exposed to 50 μg/mL Au- 
MSA-PEG NCs (60% of original QE prior PEGlation) for 24 hours prior fixture. Panel A: 
clockwise from left: Au-MSA-PEG; Bright field; DAPI; Composite emissions from DAPI 
and Au-MSA-PEG; Composite image of bright field, DAPI and Au-MSA-PEG. The images 
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correspond to frame 10 in panel B. Panel B: Z-stack images of composite emissions from 
DAPI and Au-MSA-PEG. The images were taken in a series of 15-step 1-μm-step-size 
measurements, starting from above the cell (TOP) toward the bottom of the cell. 
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Appendix C: CaSR May Play A Role In Osteoclastogenesis. 
The bone turnover is a process that continuously exists throughout life.  Osteoclasts which are a 
group of cells responsible for bone resorption and osteoblasts which take in charge of bone 
formation work collaboratively to ensure the old bones degradation and the new bones formation 
(317). The bone remodeling process is believed to be initiated by the recruitment of 
monoucleated osteoclast precursors from circulation (318). The osteoclast precursors then fused 
with these cells after them infiltrating the bone lining cell layer, thus forming multinucleated 
osteoclasts(319). The apoptosis of osteoclast ends the phase of resorption but begins the bone 
formation phase by recruiting osteoprogenitor cells to the resorption surface(320).  
 
The skeleton is considered as a major reservoir of calcium and phosphorus. These bone derived 
products attract various cell types to the bone environment (321). For instance, Olszak et al. 
found that Ca2+ promote the migration of peripheral blood monocyte cells (PBMC)(322,323). 
Since Ca2+ can form great concentration gradient in the bone environment (up to 40 
mM)(324,325), it is reasonable to hypothesize Ca2+ is one of the signals that involving the 
physiological and pathological process of bone modeling.  
 
Arthritis is a form of joint disorder due to the inflammation on one or more joints. Osteoarthritis 
is the most common form of arthritis. Patients with arthritis could suffer from constant pain 
located to the joint affected, causing swelling, stiffness and limited movements. The basic 
treatment involves physical therapy and prescription of anti-inflammation drugs. However, only 
a few arthritis-related disorders can be completely cured, most of the rest are chronic conditions. 
It has been reported that the mean serum calcium level are lower in patients with rheumatoid 
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arthritis than health(326). Nevertheless how calcium concentration can affect the disease state is 
barely understood.  
 
 
Calcium sensing receptor can sense the variation of calcium concentration and regulate the 
secretion of the parathyroid hormone (PTH) and calcitonin. By analyzing the receptor’s function 
in RAW264.7 cells, a well established osteoclast precursor model, recent studies have found that 
CaSR are intimately involved in regulating osteoclastic activities(57). Boudot et.al. reported in 
2010 that CaSR could be a possible candidate for the initiation of the basic multicellular units 
(BMU), which is a temporary anatomical structures during the bone remodeling(321).  However, 
little is known about how CaSR plays a role in the process of Arthritis.  
In this study, we analyzed the CaSR expression level in RAW264.7 cells and carried out 
preliminary researches on the differentiation of the CaSR knock down RAW264.7 cells. A few 
tissue samples from mice with or without rheumatoid arthritis were tested with CaSR specific 
antibodies.  
Preliminary Results 
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Figure. C-1 High [Ca2+]o and RANKL could promote the CaSR expression in RAW264.7 
cells. Cells were incubated either in normal [Ca2+]o medium or 4.0 [Ca2+]o  culture medium 
with or without the addition of RANKL. The mRNA was then extracted from those cells 
with various treatments. RT-PCR was performed to analyze the CaSR expression level. 
GAPDH was used as internal control.  
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Figure C-2 High [Ca2+]o and RANKL stimulate the expression of CaSR. Cells were lysated 
in RIPA buffer after incubation in 1.5 mM [Ca2+]o or 4.0 mM [Ca2+]o in the presence or 
absence of  RANKL. Subsequent to membrane transference, the membrane was incubated 
anti-CaSR specific antibody (ADD) or internal control antibody (GAPDH) overnight at 
4C. Upper panel: CaSR; Lower panel: GAPDH.  
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Figure C-3 Immunostaining of CaSR in RAW264.7 cells. A. Brightfield image of control 
group cells. B. Cells were fixed and further stained with anti-CaSR specific antibody 
(ADD). C. Bright field image of cells treated with 100 ng of RANKL for 6 days. D After 
treatment with RANKL for 6 days, cells were fixed and permeabilized with 0.2% 
tritonX100. Red: anti-CaSR antibody staining; Blue: DAPI staining.            
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Figure C-4. The proliferation of RAW264.7 cells in normal and high [Ca2+]o medium. Cells 
were cultured for 5 continuous days in either 1.5 mM [Ca2+]o medium or 4.0 mM [Ca2+]o 
medium. The total cell numbers were determined using a hemocytometer. 
 
Figure C-5. RT-PCR of CaSR knock down in RAW264.7 cells.  
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Figure C-6 CaSR knock down reduced the osteoclasts induced by RANKL. The CaSR 
knock down cells and the control group were subjected with 100ng/L of RANKL for 5 
continuous days. A. Brightfield images of RANKL treated RAW264.7 cells. Red arrows: 
osteoclast like cells. B. Quantitative analysis of the number of osteoclasts after normalized 
to the control group.  
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                  A 
 
                B 
 
Figure C-7 HE Staining of CaSR in physiological and pathological tissue samples. A. Paw 
tissues from normal mouse stained with anti-CaSR antibody (ADD) at 1:1000.  B. Tissues 
from rheumatoid arthritis mouse model stained with the same antibody.  
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Appendix D: Sequence alignment of CaSR in various species 
Rattus          MASYSCCLALLAL-AWHSSAYGPDQRAQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVE 59 
Mus             MAWFGYCLALLAL-TWHSSAYGPDQRAQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVE 59 
Homo            MAFYSCCWVLLAL-TWHTSAYGPDQRAQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVE 59 
Bos             MALYSCCWILLAFSTWCTSAYGPDQRAQKKGDIILGGLFPIHFGVAVKDQDLKSRPESVE 60 
Capra           MALNSCCWILLAFSTWCTSAYGPDQRAQKKGDIILGGLFPIHFGVAAKDQDLKSRPESVE 60 
                **  . *  ***: :* :****************************.************* 
  
Rattus          CIRYNFRGFRWLQAMIFAIEEINSSPSLLPNMTLGYRIFDTCNTVSKALEATLSFVAQNK 119 
Mus             CIRYNFRGFRWLQAMIFAIEEINSSPALLPNMTLGYRIFDTCNTVSKALEATLSFVAQNK 119 
Homo            CIRYNFRGFRWLQAMIFAIEEINSSPALLPNLTLGYRIFDTCNTVSKALEATLSFVAQNK 119 
Bos             CIRYNFRGFRWLQAMIFAIEEINSSPALLPNMTLGYRIFDTCNTVSKALEATLSFVAQNK 120 
Capra           CIRYNFRGFRWLQAMIFAIEEINSSPALLPNMTLGYRIFDTCNTVSKALEATLSFVAQNK 120 
                **************************:****:**************************** 
 
Rattus          IDSLNLDEFCNCSEHIPSTIAVVGATGSGVSTAVANLLGLFYIPQVSYASSSRLLSNKNQ 179 
Mus             IDSLNLDEFCNCSEHIPSTIAVVGATGSGVSTAVANLLGLFYIPQVSYASSSRLLSNKNQ 179 
Homo            IDSLNLDEFCNCSEHIPSTIAVVGATGSGVSTAVANLLGLFYIPQVSYASSSRLLSNKNQ 179 
Bos             IDSLNLDEFCNCSEHIPSTIAVVGATGSGISTAVANLLGLFYIPQVSYASSSRLLSNKNQ 180 
Capra           IDSLNLDEFCNCSEHIPSTIAVVGATGSGISTAVANLLGLFYIPQVSYASSSRLLSNKNQ 180 
                *****************************:****************************** 
 
Rattus          YKSFLRTIPNDEHQATAMADIIEYFRWNWVGTIAADDDYGRPGIEKFREEAEERDICIDF 239 
Mus             FKSFLRTIPNDEHQATAMADIIEYFRWNWVGTIAADDDYGRPGIEKFREEAEERDICIDF 239 
Homo            FKSFLRTIPNDEHQATAMADIIEYFRWNWVGTIAADDDYGRPGIEKFREEAEERDICIDF 239 
Bos             FKSFLRTIPNDEHQATAMADIIEYFRWNWVGTIAADDDYGRPGIEKFREEAEERDICIDF 240 
Capra           FKSFLRTIPNDEHQATAMADIIEYFRWNWVGTIAADDDYGRPGIEKFREEAEERDICIDF 240 
                :*********************************************************** 
 
Rattus          SELISQYSDEEEIQQVVEVIQNSTAKVIVVFSSGPDLEPLIKEIVRRNITGRIWLASEAW 299 
Mus             SELISQYSDEEEIQQVVEVIQNSTAKVIVVFSSGPDLEPLIKEIVRRNITGRIWLASEAW 299 
Homo            SELISQYSDEEEIQHVVEVIQNSTAKVIVVFSSGPDLEPLIKEIVRRNITGKIWLASEAW 299 
Bos             SELISQYSDEEKIQQVVEVIQNSTAKVIVVFSSGPDLEPLIKEIVRRNITGRIWLASEAW 300 
Capra           SELISQYSDEEEIQQVVGVIQNSTAKVIVVFSSGPDLEPLIKEIVRRNITGRIWLASEAW 300 
                ***********:**:** *********************************:******** 
 
Rattus          ASSSLIAMPEYFHVVGGTIGFGLKAGQIPGFREFLQKVHPRKSVHNGFAKEFWEETFNCH 359 
Mus             ASSSLIAMPEYFHVVGGTIGFGLKAGQIPGFREFLQKVHPRKSVHNGFAKEFWEETFNCH 359 
Homo            ASSSLIAMPQYFHVVGGTIGFALKAGQIPGFREFLKKVHPRKSVHNGFAKEFWEETFNCH 359 
Bos             ASSSLIAMPEYFHVVGGTIGFGLKAGQIPGFREFLQKVHPRKSVHNGFAKEFWEETFNCH 360 
Capra           ASSSLIAMPEYFHVVGGTIGFGLKAGQIPGFREFLQKVHPRKSVHNGFAKEFWEETFNCH 360 
                *********:***********.*************:************************ 
 
Rattus          LQEGAKGPLPVDTFVRSHEEGGNRLLNSSTAFRPLCTGDENINSVETPYMDYEHLRISYN 419 
Mus             LQDGAKGPLPVDTFVRSHEEGGNRLLNSSTAFRPLCTGDENINSVETPYMGYEHLRISYN 419 
Homo            LQEGAKGPLPVDTFLRGHEESGDRFSNSSTAFRPLCTGDENISSVETPYIDYTHLRISYN 419 
Bos             LQEGAKGPLPVDTFLRGHEEGGARLSNSPTAFRPLCTGEENISSVETPYMDYTHLRISYN 420 
Capra           LQEGAKGPLPVDTFLRGHEEGGARISNSSTAFRPLCTGEENISSVETPYMDYTHLRISYN 420 
                **:***********:*.***.* *: **.*********:***.******:.* ******* 
 
Rattus          VYLAVYSIAHALQDIYTCLPGRGLFTNGSCADIKKVEAWQVLKHLRHLNFTNNMGEQVTF 479 
Mus             VYLAVYSIAHALQDIYTCLPGRGLFTNGSCADIKKVEAWQVLKHLRHLNFTNNMGEQVTF 479 
Homo            VYLAVYSIAHALQDIYTCLPGRGLFTNGSCADIKKVEAWQVLKHLRHLNFTNNMGEQVTF 479 
Bos             VYLAVYSIAHALQDIYTCIPGRGLFTNGSCADIKKVEAWQVLKHLRHLNFTSNMGEQVTF 480 
Capra           VYLAVYSIAHALQDIYTCIPGRGLFTNGSCADIKKVEAWQVLKHLRHLNFTSNMGEQVTF 480 
                ******************:********************************.******** 
 
Rattus          DECGDLVGNYSIINWHLSPEDGSIVFKEVGYYNVYAKKGERLFINEEKILWSGFSREVPF 539 
Mus             DECGDLVGNYSIINWHLSPEDGSIVFKEVGYYNVYAKKGERLFINEGKILWSGFSREVPF 539 
Homo            DECGDLVGNYSIINWHLSPEDGSIVFKEVGYYNVYAKKGERLFINEEKILWSGFSREVPF 539 
Bos             DECGDLAGNYSIINWHLSPEDGSIVFKEVGYYNVYAKKGERLFINDEKILWSGFSREVPF 540 
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Capra           DECGDLAGNYSIINWHLSPEDGSIVFKEVGYYNVYAKKGERLFINDEKILWSGFSREVPF 540 
                ******.**************************************: ************* 
 
Rattus          SNCSRDCQAGTRKGIIEGEPTCCFECVECPDGEYSGETDASACDKCPDDFWSNENHTSCI 599 
Mus             SNCSRDCQAGTRKGIIEGEPTCCFECVECPDGEYSGETDASACDKCPDDFWSNENYTSCI 599 
Homo            SNCSRDCLAGTRKGIIEGEPTCCFECVECPDGEYSDETDASACNKCPDDFWSNENHTSCI 599 
Bos             SNCSRDCLAGTRKGIIEGEPTCCFECVECPDGEYSDETDASACDKCPDDFWSNENHTSCI 600 
Capra           SNCSRDCLAGTRKGIIEGEPTCCFECVECPDGEYSDETDASACDKCPDDFWSNENHTSCI 600 
                ******* ***************************.*******:***********:**** 
 
Rattus          AKEIEFLAWTEPFGIALTLFAVLGIFLTAFVLGVFIKFRNTPIVKATNRELSYLLLFSLL 659 
Mus             AKEIEFLAWTEPFGIALTLFAVLGIFLTAFVLGVFIKFRNTPIVKATNRELSYLLLFSLL 659 
Homo            AKEIEFLSWTEPFGIALTLFAVLGIFLTAFVLGVFIKFRNTPIVKATNRELSYLLLFSLL 659 
Bos             AKEIEFLSWTEPFGIALTLFAVLGIFLTAFVLGVFIKFRNTPIVKATNRELSYLLLFSLL 660 
Capra           AKEIEFLSWTEPFGIALTLFAVLGIFLTAFVLGVFIKFRNTPIVKATNRELSYLLLFSLL 660 
                *******:**************************************************** 
 
Rattus          CCFSSSLFFIGEPQDWTCRLRQPAFGISFVLCISCILVKTNRVLLVFEAKIPTSFHRKWW 719 
Mus             CCFSSSLFFIGEPQDWTCRLRQPAFGISFVLCISCILVKTNRVLLVFEAKIPTSFHRKWW 719 
Homo            CCFSSSLFFIGEPQDWTCRLRQPAFGISFVLCISCILVKTNRVLLVFEAKIPTSFHRKWW 719 
Bos             CCFSSSLFFIGEPQDWTCRLRQPAFGISFVLCISCILVKTNRVLLVFEAKIPTSFHRKWW 720 
Capra           CCFSSSLFFIGEPQDWTCRLRQPAFGISFVLCISCILVKTNRVLLVFEAKIPTSFHRKWW 720 
                ************************************************************ 
 
Rattus          GLNLQFLLVFLCTFMQILICIIWLYTAPPSSYRNHELEDEIIFITCHEGSLMALGSLIGY 779 
Mus             GLNLQFLLVFLCTFMQIVICIIWLYTAPPSSYRNHELEDEIIFITCHEGSLMALGSLIGY 779 
Homo            GLNLQFLLVFLCTFMQIVICVIWLYTAPPSSYRNQELEDEIIFITCHEGSLMALGFLIGY 779 
Bos             GLNLQFLLVFLCTFMQIVICAIWLNTAPPSSYRNHELEDEIIFITCHEGSLMALGFLIGY 780 
Capra           GLNLQFLLVFLCTFMQIVICAIWLNTAPPSSYRNHELEDEIIFITCHEGSLMALGFLIGY 780 
                *****************:** *** *********:******************** **** 
 
Rattus          TCLLAAICFFFAFKSRKLPENFNEAKFITFSMLIFFIVWISFIPAYASTYGKFVSAVEVI 839 
Mus             TCLLAAICFFFAFKSRKLPENFNEAKFITFSMLIFFIVWISFIPAYASTYGKFVSAVEVI 839 
Homo            TCLLAAICFFFAFKSRKLPENFNEAKFITFSMLIFFIVWISFIPAYASTYGKFVSAVEVI 839 
Bos             TCLLAAICFFFAFKSRKLPENFNEAKFITFSMLIFFIVWISFIPAYASTYGKFVSAVEVI 840 
Capra           TCLLAAICFFFAFKSRKLPENFNEAKFITFSMLIFFIVWISFIPAYASTYGKFVSAVEVI 840 
                ************************************************************ 
 
Rattus          AILAASFGLLACIFFNKVYIILFKPSRNTIEEVRSSTAAHAFKVAARATLRRPNISRKRS 899 
Mus             AILAASFGLLACIFFNKVYIILFKPSRNTIEEVRSSTAAHAFKVAARATLRRPNISRKRS 899 
Homo            AILAASFGLLACIFFNKIYIILFKPSRNTIEEVRCSTAAHAFKVAARATLRRSNVSRKRS 899 
Bos             AILAASFGLLACIFFNKVYIILFKPSRNTIEEVRCSTAAHAFKVAARATLRRSNVSRQRS 900 
Capra           AILAASFGLLACIFFNKVYIILFKPSRNTIEEVRCSTAAHAFKVAARATLRRSNVSRQRS 900 
                *****************:****************.*****************.*:**:** 
 
Rattus          SSLGGSTGSIPSSSISSKSNSEDRFPQ--PERQKQQQPLSLTQQEQQQ---QPLTLHPQQ 954 
Mus             SSLGGSTGSNPSSSISSKSNSEDRFPQ--PERQKQQQPLALTQQEQQQ---QPLTLQPQQ 954 
Homo            SSLGGSTGSTPSSSISSKSNSEDPFPQ--PERQKQQQPLALTQQEQQQ---QPLTL-PQQ 953 
Bos             SSLGGSTGSTPSSSISSKSNSEDPFPQQQPKRQKQPQPLALSPHNAQQPQPRPPSTPQPQ 960 
Capra           SSLGGSTGSTPSSSISSKSNSEDPFPQQQPERQKQPQPLALSPHNAQQPQPRPPSTPQPQ 960 
                ********* ************* ***  *:**** ***:*: :: **   :* :    * 
 
Rattus          QQQPQQPRCKQKVIFGSGTVTFSLSFDEPQKNAMAHRNSMRQNSLEAQRSNDTLGRHQAL 1014 
Mus             QQQPQQPRCKQKVIFGSGTVTFSLSFDEPQKNAMAHRNSMRQNSLEAQKSNDTLNRHQAL 1014 
Homo            QRSQQQPRCKQKVIFGSGTVTFSLSFDEPQKNAMAHRNSTHQNSLEAQKSSDTLTRHQPL 1013 
Bos             PQSQQPPRCKQKVIFGSGTVTFSLSFDEPQKTAVAHRNSTHQTSLEAQKNNDALTKHQAL 1020 
Capra           PQSQQPPRCKQKVIFGSGTVTFSLSFDEPQKSAVAHRNSTHQTSLEAQKNNDALTKHQAL 1020 
                 :. * *************************.*:***** :*.*****:..*:* :**.* 
 
Rattus          LPLQCADADSEMTIQETGLQGPMVGDHQPEMESSDEMSPALVMSTSRSFVISGGGSSVTE 1074 
Mus             LPLQCAEADSEMTIQETGLQGPMVGDHQPEIESPDEMSPALVVSTSRSFVISGGGSSVTE 1074 
Homo            LPLQCGETDLDLTVQETGLQGPVGGDQRPEVEDPEELSPALVVSSSQSFVISGGGSTVTE 1073 
Bos             LPLQCGETDSELTSQETGLQGPVGEDHQLEMEDPEEMSPALVVSNSRSFVISGGGSTVTE 1080 
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Capra           LPLQCGETDSELTAQETGLQGPVSEDHQLEMEDPEEMSPALVVSNSRSFVISGGGSTVTE 1080 
                *****.::* ::* ********:  *:: *:*..:*:*****:*.*:*********:*** 
 
Rattus          NVLHS 1079 
Mus             NILHS 1079 
Homo            NVVNS 1078 
Bos             NMLRS 1085 
Capra           NMLRS 1085 
                *::.* 
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Appendix E: Synergistic Effect 
Simplified concept for synergy: 
Drug A and Drug B are both agonists for Target T.  
Assume: the effect of A only to T equals 1; the effect of B only to T equals 1 
Then combination of the following conditions will be defined accordingly: 
If A + B > 2; Synergism  
If A + B = 2: Additive Effect 
If A + B < 2; Antagonism  
 
For a more detailed description, please see the manual of Calcusyn 
In the present study,  
A= Ca2+ 
B= L-Phe (or other CaSR agonists) 
T=CaSR 
Our readout will be the average [Ca2+]i.  
Procedure: 
First, measure the Calcium (Drug A) only induced receptor activity: 
In the WT CaSR transfected HEK293 cells, Fura-2 AM will be loaded using the aforementioned 
protocol (normal loading). The intracellular calcium readout will be measured using Leica 
microscope.   
Change the [Ca2+]o stepwise from 0.0 mM to 10.0 mM for WT and upto 30.0 mM for inactive 
mutants, and record the ratio of F340/F380. In the current study, the 0.0 mM, 1.0 mM, 2.0 mM, 
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3.0 mM, 4.0 mM, 5.0 mM, 7.5 mM and 10.0 mM were chosen for measuring the Ca2+ dosage-
response  
Second, measure the L-Phe (Drug B) only induced receptor activity: 
Change the [L-Phe]o stepwise from 0.0 mM to 10.0 mM, and record the ratio of F340/F380. In 
the current study, the 0.0 mM, 1.0 mM, 2.0 mM, 3.0 mM, 4.0 mM, 5.0 mM, 6.0 mM, 7.0 mM, 
8.0 mM 9.0 mM and 10.0 mM were chosen for measuring the L-Phe dosage-response.   
For the CaSR project, the activation of L-Phe requires the presence of minimum 1.0 mM Ca2+, 
otherwise, there will be no change for the intracellular calcium readout.  
The basal Ca2+ can be varied among different CaSR mutants. For instance, for analyzing WT 
CaSR, [Ca2+]o was fixed at 2.0 mM while changing the L-Phe concentration; on the other hand, 
7.5 mM of [Ca2+]o was chosen for analyzing the E297I CaSR during the stepwise increase of L-
Phe. The ratio of F340/F380 was recorded for further analysis. The choice of fixed [Ca2+]o is 
depended on the [Ca2+]o of the mutant CaSR to start oscillating.  
Third, measure the combination effect (Drug A & B) induced receptor activity: 
The L-Phe concentration was fixed at either 5.0 mM or 10.0 mM, [Ca2+]o was increased stepwise 
from 0.0 mM to 10.0 mM for WT and from 0.0 mM to 30.0 mM for inactive mutants.  The 
average intracellular calcium change at each level of [Ca2+]o  was recorded accordingly.  
Using CalcuSyn for analyzing the synergistic effect: 
Choose “Drug wizard” for adding effects for individual drugs; choose “Drug manually” for input 
combined effects.  
Because the software requires that the input drug effects shall be < 1, so the average intracellular 
calcium readout is subtracted from the basal fluorescence ratio value. For example, if the average 
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intracellular calcium level is 1.3 under 4 mM [Ca2+]o , and the initial readout for calcium level is 
1.03, the number for inputting into the software as the drug effects shall be 1.3-1.03 = 0.27.  
  
 
Results: 
 
 
Figure E-1 Representative [Ca2+]i oscillation pattern from single-cell study. WT: calcium 
concentration increased stepwise. Control: typical [Ca2+]i  response of non-CaSR 
transfected HEK293 cells upon the stimulation with extracellular calcium. Similar 
phenomena will be seen with increase of L-Phe in the absence of calcium.   
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Figure E-2 Representative [Ca2+]i oscillation pattern from single-cell study. WT: L-Phe 
concentration increased stepwise in the presence of 2.0 mM Ca2+.  
 
0.8
1
1.2
1.4
1.6
1.8
2
0 2 4 6 8 10 12 14 16
WT
R
at
io
 3
40
/3
80
Time (Min)
2 mM Ca2+
1.0 mM
0 mM 2.0 mM
3.0 mM
4.0 mM
5.0 mM 8.0 mM
10.0 mM6.0 mM
0.8
1.2
1.6
2.0
0 5 10 15 20 25
1.5 4.02.0 5.0 7.52.5 3.0
5 mM L-Phe
WT with L-Phe
Time (min)
R
at
io
 (3
40
/3
80
 n
m
)
351 
 
Figure E-3 Representative [Ca2+]i oscillation pattern from single-cell study. WT: calcium 
concentration increased stepwise in the presence of 5.0 mM L-Phe. 
 
Similar experiments have been done for the CaSR mutants.  
  
 
Figure E-4 Representative [Ca2+]i oscillation pattern from single-cell study. E297I: L-Phe 
concentration increased stepwise in the presence of 7.5 mM Ca2+.  
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Figure E-5 Representative [Ca2+]i oscillation pattern from single-cell study. E297I: Ca2+ 
concentration increased stepwise in the presence of 5.0 mM Ca2+.  
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Figure E-6 Intracellular calcium response curve upon titration with calcium or L-Phe. 
Plots are fitted using Hill equations. A. WT CaSR transfected cellular response to the 
extracellular calcium concentration change in the presence of 5.0 mM of L-Phe. B. WT 
CaSR transfected cellular response to the extracellular L-Phe concentration change in the 
presence of 2.0 mM of calcium. C. E297I CaSR transfected cellular response to the 
extracellular calcium concentration change in the presence of 5.0 mM of L-Phe. D. E297I 
CaSR transfected cellular response to the extracellular L-Phe concentration change in the 
presence of 7.5 mM of calcium. 
Hill number = 5.2 ± 0.2 Hill number = 3.0 ± 0.1
Hill number = 2.5 ± 0.1Hill number = 1.8 ± 0.1
A
B
C
D
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a                                                                 b 
 
 
Table E-1. Analysis of possible synergy using CalcuSyn in the sensing of calcium and L-Phe 
to WT CaSR and mutant E297I. After transfection with WT CaSR for 48 hours, [Ca2+]i 
was recorded upon incremental increases in [Ca2+]o in the presence of 1 mM L-Phe or upon 
incremental increases in L-Phe in the presence of 2 mM [Ca2+]o. A similar experiment 
carried out in cells transfected with mutant E297I in the presence of 1 mM, 5 mM or 10 
mM L-Phe. A CI number > 1.0 indicates lack of a synergistic effect of the two ligands in 
WT CaSR and mutant E297I.   
 
Test for Synergistic Effect on WT
F(mM) Ca(mM) CI
1.0 2.0 271.3
1.0 3.5 121.8
1.0 4.0 6296.7
1.0 5.0 8737.2
1.0 7.5 20400.0
1.0 8.0 27100.0
1.0 10.0 135000.0
5.0 1.0 2.5
5.0 1.5 2.1
5.0 2.0 1.8
5.0 3.0 1.5
5.0 3.5 1.5
5.0 4.0 1.5
5.0 5.0 1.2
5.0 7.5 1.4
5.0 8.0 1.7
5.0 10.0 1.8
Test for Synergistic Effect on E297I 
F (mM) Ca (mM) CI
1 5.0 886.3
1 7.5 6.9
1 10.0 6.3
1 15.0 3.6
1 20.0 1.6
1 25.0 1.5
5 5.0 1.3
5 7.5 1.2
5 8.0 1.1
5 10.0 1.0
5 15.0 1.0
5 20.0 0.9
5 25.0 0.7
